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Objetivos  
 
 
 El objetivo global de esta investigación fue desarrollar estrategias de 
análisis metabolómico global y orientado para la identificación y cuantificación 
de metabolitos con potencial como biomarcadores en análisis clínico, para lo que 
se utilizó una técnica de detección clave como es la espectrometría de masas —
que destaca por su gran versatilidad y excelentes niveles de sensibilidad, 
selectividad, precisión, exactitud y resolución. Se trata pues de un objetivo que 
engloba una disciplina en auge como es la metabolómica y un área de 
investigación como es la identificación de biomarcadores en análisis clínico. Este 
objetivo se dividió a su vez en tres objetivos generales en función de la temática 
del estudio en cuestión: Objetivo 1, desarrollar estrategias innovadoras en 
análisis metabolómico global con aplicación en clínica: (a) en una muestra 
escasamente estudiada como es el sudor, (b) en la preparación de la muestra y, 
(c) en la detección por espectrometría de masas para conseguir una mejora 
significativa en los métodos globales. Objetivo 2, identificar metabolitos con 
potencial como biomarcadores mediante el análisis global de biofluidos para su 
aplicación en estudios clínicos nutricionales o en el diagnóstico de enfermedades 
como la aterosclerosis y el cáncer de pulmón. Objetivo 3, optimizar métodos de 
análisis orientado confirmatorio y cuantitativo (absoluto y relativo) para la 
determinación de compuestos con potencial como marcadores en biofluidos y su 
aplicación en el diagnóstico de enfermedades. 
De estos tres objetivos generales derivaron los siguientes objetivos 
concretos: 
i) Realizar un estudio de optimización para la evaluación en análisis 
metabolómico de un biofluido obtenido de forma no invasiva como 
es el sudor. Se pudieron así comparar diferentes alternativas de 
preparación de muestra con las que proponer un método adecuado 
para la utilización analítica de este biofluido. Este estudio permitió la 
identificación mediante análisis por espectrometría de masas de 
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metabolitos presentes en sudor del que existe escasa información 
sobre su composición. Esta investigación ha dado como resultado un 
artículo (Capítulo 1) que recoge los aspectos derivados del análisis de 
esta muestra poco frecuente. 
ii) Evaluar la utilidad de una plataforma analítica totalmente automa-
tizada basada en el acoplamiento en línea de la extracción en fase 
sólida (SPE) y la cromatografía de líquidos con la espectrometría de 
masas en tándem (LC–MS/MS). Para ello se usó una gran diversidad 
de materiales sorbentes y la espectrometría de masas de alta 
resolución mediante un detector híbrido cuadrupolo–tiempo de 
vuelo (QTOF), para su aplicación al análisis global de suero humano, 
según recoge el Capítulo 2. 
iii) Demostrar una nueva faceta de la detección por espectrometría de 
masas mediante una modalidad conocida como Fraccionamiento en 
Fase Gaseosa (GPF) para su implementación en análisis global, tal 
como muestra el Capítulo 3. 
Un objetivo general y amplio como es la identificación de metabolitos 
biomarcadores mediante el análisis global de biofluidos se ha dividido en función 
del área de aplicación: Intervenciones dietéticas y diagnóstico de enfermedades 
como la aterosclerosis y el cáncer de pulmón, lo que ha dado lugar a una división 
en los siguientes objetivos concretos: 
iv) Estudiar mediante análisis metabolómico global basado en LC–
QTOF las diferencias existentes en el perfil metabólico del suero de 
individuos sometidos a cuatro intervenciones dietéticas basadas en 
diferente contenido energético y graso (Capítulo 4). De esta forma, se 
pretende establecer mediante análisis metabolómico diferencias me-
tabólicas asociadas a diferentes patrones dietéticos.  
v) Elucidar las diferencias metabólicas entre individuos con 
aterosclerosis diagnosticados con angina estable, infarto de 
miocardio sin elevación del segmento ST e infarto agudo de 
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miocardio (Capítulo 5). El papel de la espectrometría de masas de 
alta resolución es clave para la identificación de metabolitos con 
contribución significativa a la discriminación.  
vi) Buscar un panel formado por metabolitos con potencial como bio-
marcadores para monitorizar individuos diagnosticados con ateros-
clerosis y predecir un episodio de infarto agudo de miocardio. La 
inclusión de factores clínicos en la búsqueda de los modelos 
predictivos mediante la combinación de marcadores estadísticos es 
clave en numerosos estudios, tal y como se detalla en el Capítulo 6. 
vii) Aplicar el protocolo derivado de i) a la discriminación de individuos 
diagnosticados con cáncer de pulmón frente a individuos sanos 
(incluyendo fumadores y no fumadores). La utilización de un 
biofluido no invasivo como el sudor y el desarrollo de un panel de 
metabolitos con potencial marcador son la base para la consecución 
de este objetivo planteado y resuelto en el Capítulo 7. 
El objetivo general 3, relacionado con el análisis orientado para el 
desarrollo de métodos de análisis confirmatorio y cuantitativo de compuestos con 
potencial como marcadores clínicos, tuvo como campo de aplicación el análisis de 
compuestos polares tales como ácidos tricarboxílicos y aminoácidos esenciales, 
compuestos lipídicos como fosfolípidos y un péptido de interés clínico como la 
catelicidina. Con estas premisas, los objetivos concretos fueron: 
viii) Utilizar el perfil de fosfolípidos en suero humano para la búsqueda 
de un panel con potencial predictivo para discriminar individuos 
diagnosticados con aterosclerosis. La selección de una etapa de SPE 
para la separación selectiva de los fosfolípidos y la espectrometría de 
masas de alta resolución constituyen dos herramientas claves de esta 
investigación junto al tratamiento de datos diseñado para configurar 
el panel de fosfolípidos marcadores, según se muestra en el Capítulo 
8. 
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ix) Establecer diferencias en concentración de aminoácidos esenciales 
en suero humano mediante SPE–LC–MS/MS en pacientes con 
aterosclerosis afectados por angina estable o por infarto agudo de 
miocardio. Para ello, la utilización de la configuración instrumental 
basada en un detector de triple cuadrupolo aporta una herramienta 
óptima en análisis cuantitativo orientado con posibilidad de analizar 
suero humano sin tratamiento previo (Capítulo 9). 
x) Determinar las diferencias metabólicas en pacientes con determi-
nados factores de riesgo cardiovascular respecto a la concentración 
en suero de metabolitos implicados en el ciclo de los ácidos 
tricarboxílicos. Identificar interacciones de factores de riesgo con la 
presencia de lesiones coronarias fue un objetivo adicional planteado, 
que también se recoge en el Capítulo 10. 
xi) Desarrollar un método basado en el análisis directo de suero humano 
para el análisis confirmatorio y cuantitativo de péptidos de interés 
clínico como es la catelicidina. La aplicación de este método al 
análisis de suero de pacientes de la unidad de cuidados intensivos 
puede ser de interés, tal como se describe en el Capítulo 11.  
La formación de la futura doctora, que constituye el objetivo último de 
toda tesis doctoral, ha incluido el máster en “Química Fina” con el número de 
créditos correspondientes, así como todas las etapas necesarias para cumplir los 
requi-sitos exigidos para optar a la mención de Doctorado Internacional. En 
paralelo con lo anterior y con la investigación recogida en la parte principal de la 
Memoria, se ha pretendido una formación más amplia de la doctoranda mediante 
la realización de otras actividades que se recogen como anexos, a saber: 
Anexo I: Investigación simultánea con la de la Tesis y supervisión de trabajos 
realizados por otros miembros del Grupo, que han dado lugar a 5 artículos 
publicados o en fase de publicación. 
Anexo II: Revisión bibliográfica sobre el interés y el potencial de la determinación 
de histatinas (péptidos antimicrobianos) en muestras biológicas. 
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Anexo III: Capítulos de libro sobre temas relacionados o no con la Tesis, como las 
aplicaciones de la metabolómica o las técnicas empleadas para determinar la 
acción de una bacteria sobre ciertos metabolitos en leche. 
Anexo IV: Patente de un panel de marcadores para el diagnóstico de cáncer de 
pulmón mediante análisis del sudor humano.  
Anexo V: Comunicaciones orales y en cartel en 8 conferencias nacionales o 
internacionales.  
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Objectives  
 
 
 The basic objective of the research in this book was to develop strategies 
based on targeted and untargeted metabolomics analysis for identification and 
qualitative/quantitative analysis of metabolites with biomarker capability in 
clinical analysis by using mass spectrometry as analytical technique —because of 
its versatility and excellent levels of sensitivity, selectivity, precision, accuracy 
and resolution. This is, therefore, an objective that encompasses the current 
impact of metabolomics and research on the search for clinical biomarkers. This 
objective was divided into three general objectives according to the different 
topics in this research: Objective 1, to develop innovative strategies in untargeted 
metabolomics analysis with clinical application: (a) by characterization of one 
sample scarcely studied as does human sweat, (b) in sample preparation and, (c) 
in detection by mass spectrometry in order to enhance the detection capability of 
untargeted methods. Objective 2, to identify metabolites with biomarker 
potential by global analysis of both a conventional biofluid such as serum and a 
unconventional biofluid such as sweat for application in dietetic clinical studies 
or in the diagnostic of diseases such as atherosclerosis or lung cancer. Objective 
3, to optimize confirmatory and quantitative (absolute and relative) methods for 
targeted analysis of metabolites with biomarker potential in biofluids and their 
application for diagnostic of pathological states. 
 From the general objectives derived the following concrete objectives: 
i) To perform an optimization study for assessment in metabolomics 
analysis of a non-invasive biofluid such as sweat. Thus, it was pos-
sible to compare different sample preparation alternatives to propose 
a suited method for analytical application of this biofluid. This study 
allowed identification of metabolites present in this biofluid by mass 
spectrometry, which provided an added value to this study supported 
on the lack of publications dealing with the characterization of 
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human sweat. The result was a research article containing results 
obtained by analysis of this sample (Chapter 1). 
ii) To evaluate the usefulness of an automated analytical platform based 
on on-line coupling of solid phase extraction (SPE) and liquid 
chromatography with mass spectrometry (LC–MS/MS) in untar-
geted analysis. For this purpose, a great diversity of sorbent 
materials and high resolution mass spectrometry by a hybrid 
quadrupole–time of flight (QTOF) detector were two crucial aspects 
in this research. The application area was the global analysis of 
human serum, as Chapter 2 details. 
iii) To demonstrate the potential of Gas-Phase Fractionation (GPF) as 
mass spectrometry detection mode in global metabolomics analysis 
(see Chapter 3). 
 A wide general objective as the identification of biomarker metabolites 
through global analysis of biofluids has been divided into the following concrete 
objectives according to the application field: dietetic interventions and diagnostic 
of diseases such as atherosclerosis and lung cancer: 
iv) To study, by untargeted metabolomics analysis based on LC–QTOF 
MS/MS, the differences in the metabolic profile of serum from 
individuals subjected to four dietetic interventions characterized by 
the energetic content and fatty composition (Chapter 4). The study 
was oriented to find metabolic differences associated to the different 
dietetic patterns through metabolomics analysis.  
v) To elucidate metabolic differences among atherosclerotic individuals 
diagnosed with: stable angina, non-ST elevation myocardial 
infarction (NSTEMI) and acute myocardial infarct (Chapter 5). The 
role of high resolution mass spectrometry is crucial for identification 
of metabolites with significant contribution to explain the observed 
discrimination.  
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vi) To find a panel formed by metabolites with biomarker potential to 
monitor individuals diagnosed with atherosclerosis and predict a 
possible episode of myocardial infarct. The inclusion of clinical 
factors in the search for predictive models by iterative combination 
of statistical biomarkers is key in this type of studies, as Chapter 6 
describes. 
vii) To apply the protocol optimized in i) to discriminate individuals 
diagnosed with lung cancer against healthy individuals (including 
smokers and non-smokers). The utilization of a non-invasive biofluid 
and development of a metabolites panel with biomarker potential are 
the basis to achieve this objective developed in Chapter 7. 
 General objective 3, related to targeted analysis and development of 
confirmatory and quantitative analytical methods for determination of meta-
bolites with clinical marker capability, was focused on the analysis of polar 
compounds such as carboxylic acids and essential amino acids, lipids such as 
phospholipids, and a peptide with clinical interest such as cathelicidin. With 
these premises, the concrete objectives were: 
viii) To use the phospholipids profile of human serum to find a panel of 
compounds with predictive capability to discriminate indi-viduals 
diagnosed with atherosclerosis. The selection of a SPE step for 
isolation of phospholipids and the selection of high-resolution mass 
spectrometry constitute two basic tools in this research, together 
with the data treatment designed to propose the panel of marker 
phospholipids, as can be seen in Chapter 8. 
ix) To differentiate the concentrations of essential amino acids in human 
serum by SPE–LC–MS/MS in patients with atherosclerosis also 
affected either by stable angina or acute myocardial infarction. The 
use of analytical equipment involving a triple quadrupole detector 
consti-tutes an optimal tool for quantitative targeted analysis, 
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capable of analyzing human serum without sample preparation 
(Chapter 9). 
x) To establish metabolic differences among patients with given 
cardiovascular risk factors related to serum concentration of 
metabolites involved in the tricarboxylic acids cycle. To identify 
interaction of risk factors with coronary lesions was an additional 
objective also included in Chapter 10. 
xi) To develop a method based on direct analysis of human serum for 
confirmatory and quantitative analysis of peptides of clinical interest 
as is the case with cathelicidin, as described in Chapter 11. 
 The formation of the future PhD, which is the final objective of a Doctoral 
Thesis, has also included the master on “Fine Chemistry”, in which the PhD 
student developed the mandatory courses. Also, the necessary steps to fulfill the 
requirements to achieve the mention to the Internacional Doctorate were 
developed by the PhD student. In parallel to the above mentioned tasks and to 
the research in the main part of the Book, a wider formation of the PhD student 
has been sought  by development of other activities summarized below as 
annexes: 
- Annex I: Research simultaneous with that of the Thesis and 
supervision of research carried out by other members of the Group, 
which have provide 5 articles published or in some step prior to 
publication. 
- Annex II:  Review about the interest of the determination of a certain 
group of antimicrobial peptides, called histatins, in biological 
samples. 
- Annex III: Book chapters on subjects related and non-related to the 
Thesis, such as the applications of metabolomics or the techniques 
employed to study the effect of a bacteria on certain metabolites in 
milk. 
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- Annex IV: A patent of a markers panel for the diagnosis of lung 
cancer by sweat analysis. 
- Annex V: Oral and poster communications in 8 national or 
international meetings. 
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Introduction  
 
 
 This introduction section is intending to offer an overview of the two 
main topics considered in this research that constitutes this PhD Book: 
Metabolomics and qualitative and quantitative analysis of biomarkers. 
 
1. Location, definition and characteristics of metabo-
lomics 
 From the Latin suffix “ome”, the term “omics” means mass or many and 
is used to differentiate studies which involve large number of measurements per 
endpoint. The measured parameters can be DNA, mRNA, proteins, and 
metabolites, giving place to primary omics (genomics, transcriptomics, 
proteomics and metabolomics, respectively), or they can be specific families such 
as lipids, glycans, toxics, foreign substances, or even interactions among them, 
providing the secondary omics (lipidomics, glycomics, toxicomics, xeno-
metabolomics, and interactomics, respectively), all them as parts of primary 
omics. The evolution and discovery of omics complementarity yielded the term 
systems biology, coined by Nicholson and Wilson [1], and also expressed as high-
dimensional biology, global systems biology or integrated systems biology. The 
term intended, in principle, to integrate multivariate biological information to 
better understand gene–environment interactions. Figure 1 schematizes both the 
traditional central dogma of molecular biology, where the flow of information 
goes from genes to transcripts to proteins, finishing with the site where enzymes 
act on metabolism (Figure 1.A), and also the omics organization, where the flow 
of biological information ends in the metabolites which finally is reflected in the 
phenotype (Figure 1.B).  
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Figure 1. A) Traditional central dogma of molecular biology. B) General scheme of 
systems biology. 
 Through the study of metabolomics it is possible to define the current 
status of the system, as a result of environmental conditions and genetic 
potential, that is more difficult to be predicted by genomic and/or proteomic 
characterizations. For this reason, regardless of the sequential relationship in 
which the omics are introduced, metabolomics provides information directly in 
line with the new approach of systems biology that considers living systems as 
dynamic and complex and assumes that their behavior originates from 
interactions; therefore, it is difficult to make predictions when exclusively 
considering the properties of individual parts [2–4]. 
 In any case, the subject of metabolomics is the metabolome, which 
includes all organic substances naturally occurring from the metabolism of the 
studied living organism, also including xenobiotics (i.e., chemicals that are 
present in an organism, but not produced by it) and their biotransformation 
products. Polymerized structures such as proteins and nucleic acids are excluded 
from the metabolome. Actually, one may consider that a metabolite correspond 
to any organic compound that does not directly come from gene expression. 
According to this view, small peptides —synthesized through an enzymatic 
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process and forming part of a metabolic pathway, as is the case of tripeptide 
glutathione— are considered metabolites.  
Endogenous metabolites can be classified into primary and secondary 
metabolites. The former are ubiquitous (i.e., they may occur in bacterial, plant, 
and animal kingdoms) and are directly involved in processes essential to life, 
such as growth, development, and reproduction. This is, for example, the case for 
amino acids or intermediates of glycolysis. At the opposite, secondary metabolites 
have a restricted distribution (often at the species level) and are synthesized for a 
particular biological function. This is, for example, the case with alkaloids in 
plants or hormones in mammals. At present, approximately 2.900 endogenous 
metabolites can be identified, but if we consider their total number, estimated at 
6.500 molecules, this is lower than the 25.000 genes, the 300.000 tRNAs and the 
more than 106 proteins present in the human organism [5,6].  
 Despite the term metabolomics has been traditionally attributed to 
Fiehn, who in 2002 defined this discipline as “an overall and exhaustive analysis 
by which all the metabolites in a biological system are identified and quantified” 
[7], a previous definition by Oliver (in 1998) established metabolomics as “the 
analysis of the metabolome under a given biological condition and referred to a 
high-scale detection and quantitation of metabolites in biological media” [8]. 
Presently, the definition of metabolomics as a more or less complex analysis is 
very poor and a wider and well documented definition as “the discipline that 
provides comprehensive and sistematic information on temporal changes in the 
profiles of metabolite levels in biofluids and tissues, which can arise from control 
by the host genome, extended genomes and effect of other enviromental or 
promoted factors” is better adjusted to metabolomics. Implicitely included in the 
definition, without expliciting their concourse are transcripts and proteins, thus 
involving the top-down pathways established by the central dogma of molecular 
biology, and the bottom-up positive and negative feedback control established by 
systems biology (Figure 1).  
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Distinction between metabolomics and metabonomics, the two terms 
used to design the discipline, has been differently interpreted by the authors 
working in this field. While some of them consider metabolomics as the complete 
analysis of plants metabolome, and metabonomics as the analysis of the 
metabolic reaction to medication, environment and/or diseases; others establish 
that the goal of metabolomics is holistic quantitative and qualitative analysis of 
all metabolites in a given biological system, whereas the goal of metabonomics is 
the comparison of metabolite levels in a given system in response to a particular 
stimulus of treatment [9,10]. Nevertheless, one or the other distinction is each 
time more infrequent and the term metabolomics tends to be used in all 
instances.  
 The present state of metabolomics endows this discipline with positive 
and negative technical characteristics that are in the way of being in depth 
studied by researchers in the field for even improving the former and, of course, 
overcoming the latter. Therefore, positive characteristics of metabolomics that 
promote its use and establish a difference with other omics are as follows:  
- The existence of robust and stable analytical platforms for a number of 
metabolites, as a result of the research on this area during the last two 
decades of the twenty century, before omics as such appeared. 
- The excellent analytical and biological precision of the existing platforms 
that allows their accurate use. 
- The analysis cost per sample and analyte, which is, in general, low as 
compared with genomics and transcriptomics analyses. This fact 
facilitates application to a high number of samples, and extensive studies 
in cohorts with a significant biological variability; thus providing wider 
and well-supported information. 
- The analysis time, much shorter than that required in genomics, 
transcriptomics and proteomics, especially for fingerprinting, footprint-
ing or qualitative metabolomics profiles, which are obtained in few min. 
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- The capability to integrate data from different techniques (integrated 
metabolomics) applied to samples from different body compartments. 
 Negative or non-resolved aspects of metabolomics are as follows: 
- The necessity for multiple analytical platforms as a result of the 
enormous variety of metabolites that ranges from non-polar lipids to 
ionic compounds; from relatively high molecules such as cholesterol to 
very small ions such as ammonium. 
- The wide range of concentrations within which metabolites appear in the 
organisms, which encompasses more than nine orders of magnitude 
(from pmol to mmol), and makes mandatory the use of dilution and 
preconcentration steps, as well as analytical equipment with different 
dynamic range. 
- The absence of enough standardized methods, as a consequence of being 
the last of the primary omics. 
- The number of metabolites constituting the metabolome, which in a 
vegetal system can reach 200.000 (in a human individual lower than 
10.000); and the diversity within a single family. 
 
2. Complementarity of omics 
 Despite metabolomic approaches have been trialing somewhat behind 
transcriptomics and proteomics approaches, key metabolomics contributions 
demonstrated more than a decade ago, and continue demonstrating, the 
complementary and sometimes decisive role of metabolomics in the omics-world. 
For example: 
- by demonstrating that metabolic pathways can be determined kinetically 
by monitoring correlative behaviors between only a handful of metabo-
lites [4], 
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- by proofs of functionality in the identification of signal transduction 
cascades [5], 
- by using the analysis of intracellular metabolites to reveal phenotypes for 
mutations of proteins active in metabolic regulation [6], 
- by quantifying the change of several metabolite concentrations relative to 
the concentration change of one selected metabolite to reveal the site of 
action, in the metabolic network, of silent genes [7], 
- by developing metabolite profiling studies to identify hyperbolically 
related pairs of metabolites that were consistent with known feedforward 
and feedback mechanisms of regulation [8]. 
 Metabolomics, as the complement to transcriptomic and proteomics, has 
its own advantages as compared with them, such as that there are fewer 
metabolites than genes and proteins (as example, the human genome contains 
25.000 genes, the expression and alternative splicing of the mRNAs indicate that 
human may be able to produce 106 different proteins, while a recent prediction in 
2013 suggests that there are only 40.000 metabolites (6.500 in humans) [9]); 
thus reducing processing complexities. Additionally, the technology involved in 
metabolomics is generic, as a given metabolite —unlike a transcript or protein— 
is the same in every organism that contain it. 
 One other benefit is that, although some environmental perturbations or 
genetic manipulations may not cause changes in transcriptomic and proteomic 
levels, they will have significant effects on the concentrations of numerous 
individual metabolites due to the “downstream” character of metabolomics. Even 
more, metabolomics lends itself readily to functional genomic and other analyses, 
as changes in the cell physiology as a result of gene deletion or over-expression 
are amplified, both in theory [10] and in practice [11], through the hierarchy of 
the transcriptome and the proteome and are, therefore, more easily measurable 
through the metabolome, even when changes in metabolic fluxes are negligible. 
Finally, the dynamic levels of metabolites in organisms must reflect the exact 
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metabolic phenotypes under different cultural and genetic conditions due to the 
direct interaction between metabolome and phenotype. 
 Nevertheless, there is in metabolomics a typical complexity derived from 
the chemical diversity of the metabolome due to the large number of different 
families of metabolites that hinders to obtain a complete view of the metabolome 
by using a unique analytical method. Therefore, the combination of orthogonal 
methods is practically mandatory. Additionally, there is a number of intrinsic and 
extrinsic factors affecting metabolic pathways, as Figure 2 shows. In addition, 
measurement of a complete set of metabolites not only requires rapid quenching 
of metabolism, in the case of intracellular metabolites, but also the development 
of a method suitable for detecting and quantifying large numbers of metabolites 
depending of the intrinsic and extrinsic factors of the given individual. It is worth 
emphasizing the rapid timescale for the turnover (the turnover times is 
approximately equal to the concentration of the metabolite divided by the flux 
through the pathway on which it is a member) of an intracellular metabolite, 
which in microbial systems can be under 1 s, even for metabolites at mM 
concentrations. 
  
Figure 2. Intrinsic and extrinsic factors that affect the human metabolic status and can 
be studied using metabolomics. 
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3. Analytical strategies in metabolomics and their main 
objectives 
 Metabolomics analysis encompasses different strategies which depend on 
the information required from the system under study [12], namely: (a) targeted 
analysis [13], which aims at qualitative and quantitative study of one or, more 
frequently, a small group of chemically similar metabolites; (b) global 
metabolomics profiling [14], which allows detection of a broad range of 
metabolites by using a single analytical platform or a combination of 
complementary analytical platforms —mainly based on nuclear magnetic 
resonance (NMR) or mass spectrometry (MS), coupled to gas chromatography 
(GC), liquid chromatography (LC) or capillary electrophoresis (CE)— to obtain a 
comprehensive profile of the metabolome; (c) metabolomics fingerprinting [15], a 
high throughput, fast methodology for analysis of biological samples that 
provides fingerprints for sample classification and screening; and, (d) 
metabolomics footprinting [16], which aims at the study of metabolites in 
extracellular fluids, also known as exometabolome or secretome. Obviously, the 
complexity of sample preparation for each strategy is different increasing from 
(c) to (a).  
 The most recent trend leans to simplification by establishing distinction 
only between targeted and untargeted analysis, including profiling, which require 
quite different sampling and sample preparation approaches [17]. Each of these 
strategies has its own inherent advantages and disadvantages, but they can be 
highly complementary when used in combination.  
 Untargeted metabolomics is the attempt to measure all the analytes in a 
sample, including chemical unknowns. Due to its comprehensive nature, analysis 
of untargeted metabolomic data must be conducted with advanced chemometric 
techniques, such as multivariate analysis, designed to reduce the extensive data 
sets generated into smaller and more manageable signals. These unidentified 
signals then require annotation using either available experimental libraries, 
structural elucidation by in silico fragmentation tools or experimental identi-
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fication with standards. From the perspective of biomarkers discovery, 
untargeted analysis offers the tantalizing opportunity for novel species discovery 
and, therefore, the identification of unique, specific, and accurate biomarkers. In 
untargeted analysis, coverage of the metabolome is unbiased and only restricted 
by the methodologies of sample preparation and the inherent sensitivity and 
selectivity of the analytical techniques employed. However, the untargeted 
approach does suffer from a number of limitations: the protocols and time 
constraints required to process the extensive raw data sets generated, the 
analytical chemistry challenges of identifying and characterizing unknown 
metabolites, the time demands for identifying unknown metabolites that can run 
weeks and months, the overreliance on the innate analytical coverage of the 
profiling technique utilized, and a strong bias toward detection of highly 
abundant small molecule species can all have detrimental effects. 
 Targeted metabolomics, on the other hand, is supported on the 
measurement of distinct sets of characterized and chemically annotated small 
molecules within a biological sample. Absolute quantification of metabolite levels 
using mass spectrometry can be performed via the standard addition method. 
Internal standards, typically isotopically labeled versions of the endogenous 
metabolites, are spiked into the matrix across a range of concentrations to 
generate a standard curve. The labeled standards, which often contain 13C or 2H 
isotopes, can be easily differentiated from the endogenous metabolite of interest 
due to the isotopic difference in mass. It is also imperative that the isotope-
labeled standard is pure to avoid interference with, and modulation of, the 
endogenous metabolite signal. The targeted approach exploits the extensive a 
priori knowledge of a vast array of metabolites and the metabolic pathways to 
which they belong in order to select specific species for analysis. By analyzing 
specific key metabolites across all characterized metabolic pathways, these 
metabolites can function as sentinels to identify perturbations in the pathways, 
highlighting them for further analysis. When performing targeted metabolomics 
on a mass spectrometer, the instrument is more sensitive since it is measuring 
fewer compounds. Furthermore, the sample preparation step can be modified to 
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reduce the overrepresentation of abundant molecules in the analyses. From a 
biomarker perspective, this can facilitate the association of low-abundance 
metabolites with disease states. While their unambiguous identification is known 
a priori, their association with a given phenotype may be novel. If a particular 
pathway appears to be highlighted in the analyses, additional metabolites in the 
pathway can be added to the mass spectrometric metabolomics assay for a more 
detailed interrogation. In addition, since all analyzed species are clearly defined, 
analytical artifacts are not carried through to downstream analyses, and 
laborious chemical classification steps are not required. 
 
4. Analytical tools in metabolomics 
 Regarding the general workflow of an analytical process (Figure 3) that 
starts from sampling and goes to sample preparation, to detection and, finally, to 
data treatment; different analytical tools can be used in each step of the process. 
As data treatment tools are described in the next point, this section is mainly 
focused on the analytical tools employed in the sample preparation and detection 
steps.  
 
Figure 3. General workflow of an analytical process. 
 
4.1. Analytical tools for sample preparation 
 Taking into account that sample preparation comprises in most of the 
cases extraction of the metabolites into a suitable solvent, preconcentration, clean 
up and, in some cases, derivatization, different methodologies for sample 
preparation can be used in this step of the analytical process. 
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 Metabolites extraction is a key step in the metabolomics analytical 
process and its effectiveness directly affects the quality of the final data. The 
required selectivity of the extraction step will depend on the aim of the study. 
Therefore, while targeted metabolomics calls for a highly selective extraction that 
provides clean and concentrated extracts, extraction is eminently non-selective in 
metabolic profiling; so, only salts and macromolecules are considered potential 
interferents to be removed in this step. The extraction protocol is mainly 
conditioned by the target biological sample, which, in the case of solids, is 
performed by solid–liquid extraction. On the other hand, metabolites from liquid 
samples are mainly extracted by liquid–liquid extraction (LLE), SPE or solid-
phase microextraction (SPME). 
 The necessity for additional sample preparation steps is marked by the 
analytical platform that follows this procedure. As an example, the low volatility 
of many metabolites makes necessary derivatization prior to GC–MS analyses, 
which is usually performed by silylation [12]. 
 The use of chromatographic techniques prior to detection is of great 
importance in metabolomics. Despite traditional GC, CE and LC separations have  
so far been extensively used in metabolomics, new chromatographic approaches 
have also been implemented with promising perspectives in metabolomics. This 
is the case of new chromatographic phases like monolithic capillary columns or 
phases with smaller particle size and higher pressures to increase resolution and 
sensitivity [18]. 
4.2.  Analytical tools employed in the detection step 
Concerning the detection step, as the large number of molecules that 
constitute the metabolome display a high diversity of chemical structures and 
abundances, it is impossible to cover the whole metabolome using a single 
analytical platform. The selection of the detection technique most adequate for 
each situation is directly dependent on the final purpose of the experiment. 
Concretely, in targeted metabolomics, where very selective sample treatment 
procedures must be employed, optical detection techniques such as UV/visible 
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absorption —using conventional or diode array detectors— or electrochemical 
techniques such as voltammetry, potentiometry or conductimetry can be used, as 
well as more selective alternatives such as MS, fluorescence spectrometry or 
Fourier transform infrared (FT-IR). On the other hand, the most recommended 
techniques for untargeted metabolomics are NMR spectroscopy and MS due to 
their sensitivity and resolution capabilities. The latter technique usually requires 
to be hyphenated to another technique such as GC or LC for separation of the 
metabolic components [19,20]. Whilst NMR spectroscopy is particularly 
appropriate for the analysis of bulk metabolites and GC–MS for the analysis of 
volatile organic compounds and derivatised primary metabolites, LC–MS is 
highly applicable to the analysis of a wide range of semi-polar compounds 
including many secondary metabolites of interest.  
 Benefits and downsides of NMR and MS with respect to their use in 
metabolomics are depicted in Table 1. These strengths and weaknesses justified 
that both techniques are needed for metabolome analysis. However, NMR is 
more suitable for fingerprinting analysis, being MS suitable for all targeted and 
untargeted metabolomics (profiling and fingerprinting).  
As can be seen in the table, one of the strongest points of MS as 
compared to NMR is its sensitivity. In fact, mass spectrometry-based meta-
bolomics offers quantitative analyses with high selectivity and sensitivity and the 
potential to identify metabolites with high mass accuracy, taking into account 
that sensitivity in MS is affected by both ionization and type of detector but, in 
general terms, it is much more sensitive than NMR.  
 On the other hand, quantification requires suitable internal standards 
with similar ionization and fragmentation efficiencies. Concretely, quantitative 
information on a metabolite peak can be obtained in one of three ways: (i) by 
integrating it against a reference sample of the same compound (this requires the 
identity of the metabolite to be known and compared between separate runs, 
which can introduce error); (ii) by comparing the relative ratios of a set of peaks 
across a series of spectra; and, (iii) by addition to the sample of a stable-isotope 
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version of the metabolite of interest. Concerning qualitative analysis, tandem MS 
fragmentation patterns can give clues as to the connectivity and the presence of 
specific functional groups in an unknown metabolite. Identification of meta-
bolites is often expedited by comparison to internal standards and searching 
against mass spectral libraries. Fragmentation of compounds under a certain 
applied voltage is very reproducible, thus MS/MS measurements are highly 
selective. 
 Although MS measurements are fast, the overall run time depends on the 
chromatographic step, that may vary from minutes to hours (but never to days, as 
in 2D-NMR). However, combination with chromatographic or electrophoretic 
equipment reduces the complexity of mass spectra due to metabolite separation 
in a time dimension, besides delivering additional information on the physico-
chemical properties of metabolites. 
 Among the weakest points, mass spectrometry-based techniques usually 
require sample preparation, which can cause metabolite losses. The complexity of 
sample preparation depends on the type of mass spectrometer but, in general, it 
is more tedious than in NMR. However, sample preparation can be automatized 
in the case of MS. 
  On the other hand, global profiling may be limited by the ionization type, 
due to the fact that specific metabolite classes may be discriminated based on the 
sample introduction system and the ionization efficiency. Despite of this fact, 
mass spectrometry is currently the most reliable platform for identification as 
there are a wide variety of libraries with MS and MS/MS information for known 
components of biological samples.  
All those strengths of mass spectrometry against NMR can be verified as 
mass spectrometry-based metabolomics is characterized by a number of annual 
publications exceeding those based on NMR.  
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Table 1. Strengths and weaknesses of NMR and MS in metabolomics. 
Nuclear Magnetic Resonance Spectroscopy Mass Spectrometry 
STRENGTHS WEAKNESSES STRENGTHS WEAKNESSES 
 Rapid and simple 
sample preparation 
protocols. 
 
  Possibility of 
coupling to sample 
preparation 
automated systems. 
 Laborious sample 
preparation 
protocols needed in 
some cases. 
  Difficult automatization 
despite robotized 
systems. 
 Easy automatization  
 No requirement for 
chromatographic 
separation. 
 Relatively poor 
resolution in complex 
samples. 
 Excellent resolution 
(improved by 
separation). 
 
 Useful for 
identification 
purposes. 
 Difficult to unequivo-
cally assign signals. 
 Accurate m/z 
measurements ideal 
for identification of 
metabolites. 
 Structural 
information 
throughout 
fragmentation 
patterns (MSn). 
 
 High 
reproducibility. 
 Poor sensitivity and 
selectivity. 
 Highly sensitive in its 
different modes. 
 Very selective 
(especially in MSn). 
 Detection depends 
on ionization 
efficiency. 
 Non-destructive.    Destructive, 
particularly 
complicated for 
analysis of valuable 
samples. 
 Versatility. 
Possibility of direct 
analysis of solids 
and in-vivo studies. 
 
  Low sample volume 
(0.5 to 500 µL). 
 Limited to liquid 
samples or extracts 
isolated from solid 
samples. 
  Useful for fingerprinting, 
less suitable for global 
profiling and targeted 
analyses. 
 Suitable for 
quantitative targeted 
analysis, global 
profiling and 
fingerprinting. 
 Quantification 
requires chemically-
related internal 
standard. 
 Relatively high 
throughput in 1D-
NMR experiments. 
 Very low throughput in 
2D-NMR experiments. 
 
 High throughput.  More efficient when 
coupled to 
separation 
techniques. 
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4.3. Mass spectrometry systems employed in metabolomics 
 Mass spectrometry is a detection technique based on the differential 
displacement of ionized molecules through vacuum by applying an electrical 
field. Simplistically, a mass spectrometer consists of an ion source, a mass 
analyzer, a detector and a data system. Sample molecules are inserted to the ion 
source, where they become ionized. The ions, which are in the gas phase, are 
separated according to their mass-to-charge ratio (m/z) in the mass analyzer and 
finally detected. 
 There are different types of ionization sources to generate the gas-phase 
ions: electron impact ionization and chemical ionization, commonly used in GC–
MS, and electrospray ionization and atmospheric pressure chemical ionization, 
frequently employed in LC–MS. For the purpose of this research, electrospray 
ionization analyzers have been used when coupling LC to MS, and electron 
impact ionization in the GC to MS coupling. Electrospray ionization (ESI) is 
particularly useful to be coupled to LC as ionization occurs at atmospheric 
pressure. Polar and ionic compounds are best suited for this type of ionization. In 
ESI, the chromatographic eluate is sprayed from a metal or fused silica capillary. 
An electrospray is achieved by raising the potential on the spray capillary to 4 kV 
in positive or negative ionization modes. The resulting spray of charged droplets 
is directed toward a counter-electrode at a lower electrical potential, where the 
droplets lose solvent leading to ionic species into the gas phase. The counter-
electrode contains an orifice through which ions are transmitted into the vacuum 
chamber of the mass spectrometer, traversing differentially pumped regions via 
skimmer lenses [21]. 
 On the other hand, electron impact ionization (EI) is produced by the 
interaction between energetic electrons and molecules in gas phase to induce 
ionization and fragmentation of the molecule, producing radical cations. 
 Once the sample has been ionized, it is transported to the mass analyzer 
via an electric or magnetic field. The most relevant to the research developed in 
this Thesis are here briefly described: 
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i) Triple quadrupole mass spectrometer (QqQ) 
A diagram of the design of a triple quadrupole MS is shown in Figure 4 [22]. 
 
Figure 4. General scheme of a triple quadrupole mass spectrometer. 
 The triple quadrupole mass spectrometer consists of an ion source 
followed by ion optics that transfer the ions to the first quadrupole —this device is 
formed by four parallel rods to which specific direct current and radio frequency 
voltages are applied. The rods filter out all ions except those of one or more 
particular m/z values as determined by the voltages applied. The applied voltage 
is variable, so that ions with other m/z values are allowed to pass through. 
Afterwards, selected ions reach a collision cell where they are fragmented. The 
collision cell is typically called the second quadrupole, but it is actually a 
hexapole, filled with an inert gas such as nitrogen or argon. The fragment ions 
formed in the collision cell are then sent to the third quadrupole for a second 
filtering stage to enable a user to isolate and examine multiple precursor to 
product ion transitions. This is called selected reaction monitoring mode (SRM). 
Since the fragment ions are pieces of the precursor, they represent portions of the 
overall structure of the precursor molecule. 
 Due to the low-mass accuracy achieved with respect to other mass 
analyzers, triple quadrupole spectrometers are preferably used for targeted 
analyses, as they allow quantification with high sensitivity and selectivity in SRM 
mode, actually the most sensitive operational mode for the triple quadrupole MS 
instrument.  
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ii) Quadrupole-time of flight (QTOF) mass spectrometer 
 Figure 5 shows the diagram of the instrument used in the research in this 
Thesis [23].  
 
 
Figure 5. General scheme of a quadrupole time-of-flight mass spectrometer. 
 The QTOF mass analyzer is based on the same configuration as the QqQ 
but replacing the last quadrupole by an acceleration tube as mass analyzer 
(usually in orthogonal configuration) to filter out ions according to the equation 
of kinetic energy. The QTOF can operate in MS mode with the TOF as scanning 
tool by taking benefit from the high mass accuracy or in MS/MS mode for 
structural elucidation. 
 This hybrid mass analyzer offers better selectivity than triple 
quadrupoles, meanwhile sensitivity is considerably lower. On the other hand, 
thanks to its great mass accuracy (below 2 ppm) highly reliable identification can 
be achieved, thus allowing its use for global metabolic profiling.  
iii) Ion trap (IT) 
 The ion trap is the three dimensional analogue of the linear quadrupole 
mass filter. In this device, ions are subjected to electrical and magnetical forces 
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not only in two dimensions as in the simple quadrupole, but also in the third 
dimension, trapping ions. This feature gives the ion trap the possibility of tandem 
mass spectrometry experiments and even of performing multiple stage mass 
spectrometry (MSn). 
 
Figure 6. General scheme of an ion trap mass spectrometer. 
 Figure 6 shows the diagram of the ion trap device [24]. It is composed by 
a ring electrode and two end-cap electrodes. As can be seen in the diagram, the 
ions trapped describe orbits inside the trap. The voltage applied in the end-caps 
(V cap) enables fragmentation of the ions by collisions with the helium damping 
gas rather than ejection. So, this voltage is used to induce resonance excitation 
and resonance ejection. On the other hand, the potential applied to the ring 
electrode determines the range of m/z values that can be trapped and the 
modification of this voltage produces the ejection of the ions for their detection. 
 
5. Data analysis in metabolomics  
 Statistical considerations play a vital role in the whole process of a 
metabolomics experiment affecting upon data output quality, analysis and 
subsequent biological interpretation. Statistical analysis strategies employed in 
metabolomics are designed according to the approach selected, being slightly 
different for targeted and untargeted analysis (Figure 7). 
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Figure 7. General statistical analysis workflow for targeted and untargeted analysis in 
metabolomics. 
 
5.1. Statistical analysis for targeted metabolomics 
 Targeted metabolomics analysis often requires statistical methods to be 
used during the development of the optimized analytical methodology for the 
determination of the compounds of interest. Thus, statistical procedures as 
response surface or screening design are employed to optimize experimental 
parameters to obtain the best conditions for the determination of the target 
compounds [25–27]. The rest of statistical analyses employed in the process of 
developing a new methodology for targeted metabolomics are based on simple 
statisticals such as simple regression, employed to obtain the calibration curves 
for metabolites quantitation, or simple calculations, used to characterize the 
analytical method (reproducibility and repeatability, mainly). 
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 After method application and data generation, common pre-processing 
strategies as normalization or scaling can be used before interpretation of the 
results or further statistical studies. These are: 
- Normalization: the main objective of this approach is to remove the 
unwanted systematic bias in ion intensities between measurements, 
while retaining biological variation. Different normalization techniques 
can be applied, from normalization using a single metabolite level or 
standard to logarithmic transformation and more complex alternatives 
such as probabilistic quotient normalization and quantile normalization 
[28].  
- Scaling: the scaling methods are data pre-treatment approaches that 
divide each variable by a different factor in order to treat all variables 
equally, regardless of their intensity. One of the most common factors 
employed is the mean of each variable, although Z-transform can also be 
used in case of combining data obtained from different platforms or 
methodologies [29]. 
 
5.2. Statistical analysis for untargeted metabolomics  
 This kind of metabolomics analysis is focused on covering the maximum 
number of metabolites using one or more analytical platforms. Thus, generic 
experimental conditions are mostly employed for sample analysis that is usually 
done by a separation technique prior to detection. Because of that, after data 
acquisition, two steps are required: alignment of the chromatograms and 
extraction of the potential metabolites (usually called potential molecular 
features) [30]. Owing to the complexity of steps in which many factors need to be 
considered (adducts, peak shape, noise removal, etc.), different bioinformatics 
tools have been designed for this purpose. 
 This type of metabolomics experiments generates large multivariate data 
sets that constitute a great challenge from a statistical point of view. Thus, 
                                                                                                                         
39 
Introduction  
reliable and robust approaches to handle and extract the relevant information 
from the vast amount of data generated are needed. The outputs of a 
metabolomics data analysis may differ greatly depending on the purpose of the 
research. Current metabolomics untargeted studies can be placed into two 
general categories —those that aim at developing and discovering biomarkers and 
those that aim at understanding biological processes [31]. In the former case, 
very few highly dependable metabolites can be sufficient for diagnostic purposes; 
while in the second case, an extended set of compounds may be desirable when a 
biochemical network is under examination. Despite the differences between the 
two strategies, there are also some similarities between them, as in both cases the 
huge amount of available data requires some filters to facilitate further statistical 
analysis by reducing the number of potential molecular features. Thus, only 
potential entities with high intensity, high significance with respect to a factor of 
interest, or entities that appear with high frequency in the samples batch would 
pass the filter. As a result, different filters have been created to fulfill the different 
requirements:  
- Fold change analysis: this tool compares the level of each potential 
 molecular feature among the groups under study and retains only 
 the entities that show a minimum change.  
- Filter based on univariate hypothesis test: only entities with a p-value 
below 0.05 or 0.01 pass this filter. 
- Filter by Volcano plot: this approach is a combination of analysis of 
variance and fold change analysis.  
- Filter by abundance: this tool allows removing all potential molecular 
features below a certain abundance.  
- Filter by frequency: the application of this filter eliminates entities only 
present below a certain percentage of samples from each group. 
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i) Untargeted analysis to understand biological processes  
 Different strategies can be used to study the influence of a known factor 
(disease, diet, time, genotype, etc.) in a batch of samples and identify the most 
affected molecular features. 
 Common chemometric tools [32,33] such as principal component 
analysis (PCA) [34] are generally used for display and exploratory analysis 
purposes, whereas univariate statistical tests such as the Student’s t-test are used 
to identify the relevant variables after exploratory analysis. 
- Exploratory analysis by unsupervised learning: unsupervised methods 
attempt to analyze a set of observations without measuring or observing 
any related outcome. As there is not specified class label or response, the 
data set is considered as a collection of analogous objects. Unsupervised 
learning uses procedures that attempt to find the natural partitions of 
patterns to facilitate the understanding of the relationship between the 
samples and to highlight the variables that are responsible for these 
relationships. By providing means for visualization, unsupervised 
learning aids in the discovery of unknown but meaningful categories of 
samples or variables that naturally fall together. The success of such 
approaches is frequently subjectively evaluated by the interpretability 
and usefulness of the results with respect to a given problem. 
PCA is the most common unsupervised method, to the detriment of 
others such as hierarchical cluster analysis. PCA is an orthogonal 
transformation of multivariate data first formulated by Pearson [35] 
mostly used for exploratory analyses by extracting and displaying 
systematic variations. PCA attempts to uncover hidden internal 
structures by building principal components describing the maximal 
variance of the data [36]. This method represents a very useful tool for 
display purposes as it provides a low-dimension projection of the data 
(i.e., a window into the original K-dimensional space) by transformation 
into a new coordinate system. The basic concept relies on areas of signal 
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variance in the data where underlying phenomena can be observed. This 
principle leads to a focus on a small number of uncorrelated independent 
signals that explain a large part of the total variance in a compact and 
insightful manner. In practice, PCA builds hyperplanes in the original 
space that are linear combinations of the original variables and describes 
the data in a least squares view. The inspection of PCA scores and 
loadings plots highlights the relationships among the distribution of 
samples that may reveal grouping, trends or outliers and the 
corresponding variables. Moreover, more effective data analyses can be 
performed on the reduced dimensional space, such as clustering, pattern 
recognition or classification. The vast majority of metabolomics studies 
involves PCA as a first exploratory step [37–43]. 
- Classification by supervised multivariate analysis: supervised learning 
considers each object with respect to an observed response and includes 
regression and classification problems depending on the output type 
under consideration (i.e., a numerical value in the first case and a class 
label in the second). This classification aims at producing general 
hypotheses based on a training set of examples that are described by 
several variables and identified by known labels corresponding to the 
existing classes. The task is to learn the mapping from the first to the last. 
Numerous techniques, based either on statistics or on artificial 
intelligence, have been developed for that purpose. Within the variety of 
supervised statistical techniques, which includes decision trees, artificial 
neural networks and support vector machines, the most employed is 
partial least squares (PLS). This technique is particularly adapted to 
situations where less observations (N) than measured variables (e.g. 
detected features, K) are available. Its use has become very popular 
thanks to its ability to deal with many correlated and noisy variables 
forming megavariate data structures (K>>N) [44, 45]. PLS builds a low 
dimensional sub-space based on linear combinations of the original X-
variables and makes use of the additional Y information by adjusting the 
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model to capture the Y-related variation in X. A PLS-based classification 
therefore has the property that it builds data structures with an intrinsic 
prediction power, by maximizing the covariance between the data and 
the class assignment. The decomposition relies on latent variables that 
are computed sequentially to provide a good correlation with the 
remaining unexplained fraction of Y. In the context of classification, PLS 
discriminant analysis (PLS-DA) is performed to sharpen the partition 
between groups of observations, in such as way that a maximum sepa-
ration among classes is obtained. The model can then be analyzed to 
understand which variables carry the class-separating information [46]. 
PLS-DA was demonstrated to be a potent tool for classification of 
metabolomics data [47].  
- Univariate hypothesis testing: the Student’s t-test, the one-way analysis 
of variance or the non-parametric equivalents can be used to identify 
statistical differences between samples of distinct classes [48]. The 
predictive power of each variable is assessed by finding statistically 
significant differences between the mean intensity values of a given 
signal, of which the calculated p-value is a straightforward indicator. 
Such procedures are easily understandable but their use is rather limited 
in dealing with thousands of highly correlated variables. False positives 
(type I error) are likely to occur when performing multiple comparisons. 
Procedures such as the Bonferroni of the Benjamini correction have been 
introduced to address this issue [49]. The vast majority of metabolomics-
dedicated software provides statistical hypothesis testing [50,51]. 
ii) Untargeted analysis to discover biomarkers 
The statistical analyses described above are not sufficient to acquire 
detailed biological understanding, needed for biomarker discovery. In contrast to 
metabolomics studies focused on deciphering biological processes, where 
interesting metabolites are found post hoc, in biomarker studies metabolite 
selection should be performed a priori rather that post hoc. That is, biomarker 
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selection must be performed before deriving a definitive multivariate predictive 
model. Furthermore, whereas long lists of metabolites or large multivariate 
models are quite useful for understanding pathways and biological processes, 
they are not ideal for developing cost-effective biomarker tests. Rather, a short 
list of 1–10 biomarkers is mathematically much more robust and far more 
practical for clinical testing purposes. While pattern discovery methods such as 
unsupervised clustering or PCA are useful for discovering novel biological 
processes, they are not ideal for biomarker discovery. Instead, supervised 
machine learning algorithms (PLS), or multivariate regression models are used 
for modelling the discriminatory relationship between a binary dependent 
variable and one or more explanatory variables. 
 Regarding the selection of potential biomarkers, performing it by 
univariate statistical significance test is equally inappropriate, as often meta-
bolites that are not significant in isolation can, when combined into a single 
multivariate model, produce clear and reproducible discrimination. For this 
reason, iterative methodologies for biomarker panel development, like the 
employed in the PanelomiX bioinformatics tool or in the ROCCET on line tool, 
are recommended. 
 On the other hand, biomarker panels are designed to discriminate with 
an optimal sensitivity/specificity but in most of the cases the parameter em-
ployed for measuring the clinical utility of a panel developed by PLS, for example, 
is the R2 (multiple correlation coefficient). Despite R2 of the model and R2 of its 
cross-validation can certainly be used as part of the biomarker selection process, 
they provide very little transparency and are not a readily interpretable indication 
of the clinical utility of a given model. Additionally, most clinicians are not 
familiar with this style of model evaluation, being the ROC (receiver operating 
characteristic) curve analysis the standard method for describing and assessing 
the performance of medical diagnostic tests with binary classification [52].  
 ROC curves consider the frequency with which the test produces true 
positives, true negatives, false positives and false negatives. These values are 
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summarized into the proportion of actual positives that are correctly classified as 
positive (sensitivity) and the proportion of actual negatives that are correctly 
classified as negative (specificity). An example of ROC curve is shown in Figure 8. 
 
Figure 8. ROC curve representation including the curve described for an ideal test, and a 
test without predictive value. 
 For ease of interpretation, sensitivity can be considered as the probability 
of true positives (the positive result of the test from a subject that has an actual 
positive outcome), and specificity can be considered as the probability of false 
positives (the negative result of the test from a subject that has an actual negative 
outcome). As the sensitivity and specificity of a test can vary depending on the 
biomarker decision boundary, the best way to observe how this decision 
threshold affect sensitivity and specificity is through a ROC curve. Furthermore, 
the ROC curve is a non-parametric measure of biomarker utility, being widely 
considered the most objective and statistically valid method for biomarker 
performance evaluation [52,53]. 
 There are different informatics tools for ROC curve generation and the 
parameter that often summarized the curve is the area under the curve (AUC). 
This parameter can be interpreted as the probability that a diagnostic test or a 
classifier will rank a randomly chosen positive instance higher than a randomly 
chosen negative one. If all positive samples are ranked before negatives ones 
(example of a perfect classifier), the AUC is 1.0. An AUC of 0.5 is equivalent to 
randomly classifying subjects as either positive or negative (classifier without 
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utility). However, using the whole area under a ROC curve may not be 
appropriate in some cases and the partial AUC is most useful when only certain 
regions of the ROC space (high sensitivity or high specificity) are of particular 
interest [54]. 
 
6. Present role of metabolomics in clinical research: 
personalized medicine 
 Despite metabolomics is the most recent of the primary omics, its 
significant contribution to the clinical field deserves to be discussed as well as its 
key role in the incipient personalized medicine (PM). The secondary omics in 
which the most salient contributions have been developed are lipidomics and 
nutrimetabolomics.  
 In the omics world, lipids have long been in the shadows, while nucleic 
acids and proteins hogged the limelight. Recent improvements in LC and MS, 
together with the recognized role of lipids functions in most of the so-called 
“diseases of the industrialized societies”, have provided the rapid expansion of 
lipid research. Lipids fulfill a variety of vital functions, as they are central 
constituents of biological membranes, serve as energy storage compounds, and 
act as second messengers or as covalent modifiers governing the localization of 
proteins and favoring effectiveness of protein–protein and lipid–protein 
interactions. In addition, bioactive lipids generated during remodeling of 
membrane lipids by activated lipases serve as intra and extracellular mediators in 
cell signalling, in cell–cell communication, inflammation, host-defence mecha-
nisms and ischemia-reperfusion, apoptosis and response to stimulus [55]. 
 Lipidomics, defined as a comprehensive analysis of all lipids in a 
biological system (lipidome), is, through lipid profiling, a fast-growing area of 
research due to the involvements of lipids in human diseases such as obesity, 
atherosclerosis, high-pressure and diabetes (known as “metabolic syndrome”), 
Alzheimer’s disease, and as well as in drug discovery [56–62].  
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 Nutrimetabolomics or nutritional metabolomics is one of the most firm 
supports of the intended PM. The close relationship between nutrition and health 
—each time more defended by clinicians— is clearly demonstrated by meta-
bolomics studies.  
 Particularly important in this field is the role of metabolomics to decipher 
gut microbial metabolic influence on health and disease, as the consortium of 
symbiotic gut microorganisms can be viewed as a metabolically adaptable, 
rapidly renewable, and metabolically flexible ecosystem varying in addition with 
the host’s age, diet, and health status. Because metabolites are the products and 
by-products of the many intricate biosynthetic and catabolic pathways existing in 
all living systems, monitoring the resulting metabolic variations provides a 
unique insight into intra- and extra-cellular regulatory processes involved in our 
metabolic homeostasis. By the study of low molecular weight compounds in 
biofluids (blood and urine), stools, and tissues (intact biopsies or extracts), 
metabolomics assures the characterization of metabolic fingerprints that can be 
associated with individual phenotypes, which encompass dietary or disease 
status. 
 The intestinal tract is one of the most important interfaces between 
mammalian metabolism and the environment along which the varying metabolic 
activities of the gut microbiota not only determine absorption, digestion, 
metabolism, and excretion of dietary nutrients but also shape regio-specifically 
the surrounding and distant host cell biochemical processes [63]. Advances in 
metabolomics applications are providing novel insights into the molecular 
foundations of these host–microbial relationships and their influence onto health 
and disease risks [64, 65]. In particular, a series of investigations in humans [66], 
rats [67], and gnotobiotic mice [68] have provided a set of reference metabolic 
profiles of gut intestinal biopsies that can be used not only to assess compartment 
structure and function but also the gut microbial impact at the tissue level [69]. 
Therefore, these studies indicated that the type of gut microbiota may be a key 
factor in the determination of the intestinal homeostasis, osmo-protection, 
motility, and calorie recovery from the diet. 
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 Food products are nowadays more and more commonly employed to 
modulate the composition of the gut microbiota with the main objective to 
prevent disease development and contribute to the health status’ maintenance. 
The effects of consuming live microbial supplements (probiotics) on the 
microbial ecology, and on human health and nutritional status have been 
extensively investigated over the past years [70]. Probiotic supplementation aims 
at replacing or reducing the number of potentially pathogenic bacteria in the 
intestine by enriching the populations of beneficial strains that ferment carbo-
hydrates and have little proteolytic activity. As an alternative, prebiotics, non-
digestible food ingredients, generally oligosaccharides, modify the balance of the 
intestinal microbiota by stimulating the activity of health beneficial bacteria, such 
as lactobacilli and bifidobacteria. Eventually, the combined use of prebiotics and 
probiotics, also called “synbiotics”, may offer superior effects in health main-
tenance through modulating the microbial functional ecology [70]. 
  The influence of the gut microorganisms on the progression of human 
diseases is nowadays a main concern in the etiology and/or maintenance of gut 
dysfunctions, such as irritable bowel syndrome (IBS) [71] or inflammatory bowel 
disease (IBD) [72]. The incidence and prevalence of these diseases make 
mandatory more research on the gut–metabolomics binomial [73].  
 Metabolomics was also proven to be a valuable diagnostic tool to 
differentiate Crohn’s disease (CD) from ulcerative colitis (UC), but also active and 
quiescent UC, as per the analysis of intact gut biopsies and colonocytes [74].  
 A recent study associates consumption of black tea with reduced 
cardiovascular risk. Black tea polyphenols (BTPs), high-molecular-weight species 
that predominantly persist in the colon, can undergo a wide range of 
bioconversions by the resident colonic microbiota and can in turn also modulate 
gut microbial diversity. Novel metabolomics platforms, coupled to de novo 
identification currently available, have been used to cover the large diversity of 
BTP bioconversions by the gut microbiota. Evidence for cardiovascular benefits 
of BTPs points toward anti-inflammatory and blood pressure-lowering properties 
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and improvement in platelet and endothelial function for specific microbial 
bioconversion products. It has also been of interest to assess how phenotypic 
variation in gut microbial BTP bioconversion capacity relates to gut and 
cardiovascular health predisposition [75]. 
 A salient comment deserves an in development study that, under the 
acronym NU–AGE (from “new dietary strategies addressing the specific needs of 
elderly population for a healthy aging in Europe) involved a number of European 
researchers. The NU-AGE rationale is that a one-year Mediterranean whole diet 
(considered by UNESCO a heritage of humanity), newly designed to meet the 
nutritional needs of the elderly, will reduce “inflammaging” in about 3.000 fully 
characterized subjects aged 65–79 years of age, and will have systemic beneficial 
effects on health status (physical and cognitive). Within the comprehensive set of 
analyses that will be performed to identify the underpinning molecular 
mechanisms metabolomics profiling and targeted analyses play a key role [76].  
 Clinical metabolomics has different purposes, including disease diagnosis 
and follow-up, therapeutic drug monitoring and PM development. Within the 
different applications for disease diagnosis, the most common medical areas in 
metabolomics are cardiology, human reproduction, diabetes, central nervous 
system diseases and oncology. Studies for disease diagnosis involve mainly the 
discovery of new biomarkers and their characterization. The search for and use of 
biomarkers in metabolomics is described in deep in the next section. However, 
there are also metabolomics clinical studies, the objective of which is to 
understand or find which metabolic pathways are perturbed by the presence of a 
given disease. This research has allowed to know, as an example, how lipid 
metabolism is highly perturbed by Alzheimer’s disease [77]. 
 As mentioned before, diabetes and cardiovascular diseases are two of the 
most studied diseases by metabolomics. The worldwide pandemic rise of obesity 
prevalence is strongly linked to incidence of type2 diabetes (T2D) and 
cardiovascular disorders. Recently, a branched chain amino acids (BCAAs) 
related metabolic signature contributing to insulin resistance in obese human 
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subjects has been described [78]. Furthermore, metabolomic analyses have been 
applied to the study of an epidemiological cohort in which diabetes-related 
complications could be detected already under sub-clinical conditions [79]. In 
addition to previously reported T2D biomarkers, including sugar metabolites, 
ketone bodies, and BCAA, metabolites resulting from perturbations of metabolic 
pathways linked to kidney dysfunction (3-indoxyl sulfate), lipid metabolism 
(glycerophospholipids, free fatty acids), and bile acid metabolism have been 
considered.  
 Moreover, metabolomics was employed to decipher indicators of early 
onsets of pre-diabetes status, marked by alterations in fatty acid, tryptophan, uric 
acid, bile acid, and gut microbial metabolism [80]. This information can be easily 
obtained by using the sampling in the oral glucose tolerance test (OGTT) that, as 
it is well known, only provides the evolution of glucose and insuline along the 
test. In addition to the evolution of these parameters, monitoring the metabolic 
evolution of the OGTT provides information on the lactate, hyppurate and 
glycerol, and, more interesting, on the changes of levels of three bile acids —
glycocholic acid, glycochenodeoxycholic acid, and taurochenodeoxycholic acid— 
which provides information on key parameters related to cholesterol levels [81, 
82]. Increases in lysophosphatidylcholine [80] and decreases in amino acids 
[83], acylcarnitines [80] and fatty acids [80,83] have also been reported. 
Although the levels of fatty acids declined during an OGTT, the levels of saturated 
(SFA) and monounsaturated fatty acids (MUFA) were more significantly 
decreased than those of polyunsaturated fatty acids (PUFA). Moreover, a 
substantial reduction in the SFA/MUFA ratio was observed, consisting of a shift 
from MUFA towards SFA. These findings indicate a change in fatty acid 
composition following an OGTT [83].  
 Metabolomics studied related to respiratory disorders have been 
increased in the last few years through the study of organic volatile compounds 
contained in the exhaled breath. As an example, comparison of exhaled air 
profiles from individuals with impaired respiratory function revealed differences 
between participants with and without chronic obstructive pulmonary disease 
   
50 
Mass spectrometry for the identification and  
quantitation of metabolomic biomarkers in clinical analysis 
 
[84]. However, the identification of the compounds responsible of these 
differences has not been done.   
 In dealing with PM, it may be said that the current revolution in 
metabolomics will at term offers new opportunities for preventive medicine, 
prognostic strategies and provides a new step towards PM. The importance of any 
branch of metabolomics in the search for PM is demonstrated by the presence of 
this omics in all present definitions of PM [85]:  
- Personalized Medicine seeks to improve tailoring and timing of 
preventive and therapeutic measures by utilizing biological information 
and biomarkers on the level of molecular disease pathways, genetics, 
proteomics as well as metabolomics. 
- Personalized Medicine seeks to improve stratification and timing of 
health care by utilizing biological information and biomarkers on the 
level of molecular disease pathways, genetics, proteomics as well as 
metabolomics. 
 Some recent contributions also deserve to be commented just to show the 
wide variety of clinical (or close to clinical) aspects where metabolomics can be a 
useful tool. Complementary and alternative medicine has also taken advantage 
from metabolomics. As an example, aromatherapy that uses essential oils 
through inhalation had not evidenced its efficacy in treating medical conditions 
owing to a particular lack of studies employing rigorous analytical methods that 
capture its identifiable impact on human biology. Recently, a comprehensive 
metabolomics study has revealed changes in people, after exposed to aroma 
inhalation for 10 continuous days, consisting of metabolic alterations in urine 
from people with anxiety symptoms. The samples, analyzed by GC–TOF and ultra 
performance liquid chromatography (UPLC) coupled to QTOF, showed a 
significant change of the metabolic profile of the individuals before and after 
subjected to aromatherapy. The change was characterized by the increased levels 
of arginine, homocysteine, and betaine, as well as decreased levels of alcohols, 
carbohydrates, and organic acids in urine. Notably, the metabolites from 
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tricarboxylic acids cycle and gut microbial metabolism were significantly altered. 
This study demonstrates that the metabolomics approach can capture the subtle 
metabolic changes resulting from exposure to essential oils, which may lead to an 
improved mechanistic understanding of aromatherapy [86]. 
 
7. The search for and use of metabolomic biomarkers 
7.1. Definition and features of biomarkers 
 Cells, either directly or indirectly (via extracellular fluid), communicate 
with body fluids. Cell metabolites, peptides and proteins are released from cells 
or are taken up from body fluids via normal excretion, trans-membrane diffusion 
or transport, and throughout the death process during which cells release all of 
their contents. Thus, at least to a certain extent, biochemical and protein changes 
in cells and organs are reflected in body fluids. While tissue samples, biopsies, 
and certain fluids such as urine (kidney), bile (liver), and cerebrospinal fluid 
mainly reflect changes in specific organs and thus are considered “proximal 
matrices”; plasma samples reflect systemic changes that often cannot be traced 
back to a certain organ [87]. Such changes of metabolites, peptides and proteins 
in body fluids, if mechanistically linked to disease processes and drug effects in 
tissues and organs, have the potential to serve as surrogate markers or 
biomarkers. 
 In 2001, a consensus panel at the National Institute of Health defined the 
term biomarker as “a characteristic that is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenesis processes, or 
pharmacologic responses to a therapeutic intervention” [88]. Despite biomarkers 
are not new in the field of medicine [89], they have gained immense scientific 
and clinical interest in recent years thanks, in many aspects, to omics disciplines. 
 Biomarkers are useful along several points of a disease continuum. Thus, 
they are useful in the context of primary prevention, for preventing disease itself. 
Also, they can facilitate secondary prevention for the early detection of disease via 
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screening, detection of subclinical disease and by aiding the monitoring of 
disease progression. Finally, biomarkers are also useful for the purpose of tertiary 
prevention, helping guide treatment to avoid morbidity owing to established 
disease [90]. 
 One avenue for the identification of novel risk markers is being opened 
by the global analysis of the human metabolome. While decades of research in 
biochemistry, nutrition, and physiology have revealed specific metabolic 
pathways, systematic surveys of pathways altered in human disease states are 
now possible. An emerging set of metabolite profiling capabilities, based on 
techniques such as MS and NMR spectroscopy, enable the monitoring of 
hundreds of analytes from biological samples. These technologies promise to 
transform our ability to profile samples, with the goal of illuminating biology and 
discovering valuable clinical biomarkers.  
 Today’s clinical diagnostics is typically based on a limited set of 
biomarkers, often only one parameter that is associated with the functional 
aspect of an organ or a specific disease process (for example creatinine in serum 
as a marker of kidney function). However, there are no single molecular entity 
markers, and there will never be one that captures the function of organs such as 
the kidney, liver or vascular endothelium in all its complexity. 
 Biomarkers are useful as research and clinical tools in most major 
medical fields, as shown in Table 2. 
The characteristics of an ideal biomarker are the following:  
1) Safe and easy to measure, in such a way that the measurement could be 
repeated, if required, without danger for the patient and be performed by 
not very specialized personnel. 
2) Low cost to measure, not only that of the test, but also the cost of follow-
up testing should be low to monitor future levels of the biomarker and 
treatment efficacy. 
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3) The occurrence of a moderate proportion of the disease in the 
community should be explained by the biomarker. 
4) High predictive accuracy for detecting a disease. The sensitivity (the 
detection of a disease when that disease is truly present) and specificity 
(recognition of true absence of disease) of the biomarker should be 
relatively high, thus reducing false-positive and false-negative rates.  
5) Consistent across sexes and ethnic groups. 
 
Table 2. Examples of biomarkers currently used in different fields of medicine. 
 
Specialization Disease 
Screening to 
identify at-risk 
patients 
(primary 
prevention) 
Diagnostic for 
existing disease 
states 
(secondary 
prevention) 
Prognostic for 
treatment and 
outcomes (tertiary 
prevention) 
Cardiovascular 
Cardiovascular 
disease 
Serum LDL 
cholesterol 
Coronary artery 
computed 
tomography 
screening 
Echocardiographic 
left ventricular 
ejection fraction as a 
prognosticator for 
sudden cardiac death 
Endocrinology 
Diabetes 
mellitus 
Fasting blood 
glucose 
Microalbuminuria 
screening for 
diabetic 
nephropathy 
Hemoglobin A1c% and 
long-term glucose 
control 
Gastroenterology Colon cancer 
Family history of 
premature colon 
cancer 
Colonoscopy 
Carcinoembryonic 
antigen for 
postsurgical colon 
cancer recurrence 
Rheumatology 
Systemic lupus 
erythematous 
- 
Anti-Smith 
antibody specific 
for detecting lupus 
Andi-dsDNA for 
diagnosis of lupus 
nephritis 
Oncology Breast cancer 
BRCA-1 gene 
BRCA-2 gene 
Mammography 
Tumor estrogen 
receptor, 
progesterone receptor 
and HER2-neu 
receptor status for 
decisions about 
tamoxifen therapy 
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 It should be noted that a biomarker may be very useful even if it does not 
meet all the criteria of an ideal biomarker. For example, high density lipoprotein 
(HDL) cholesterol protects against cardiovascular disease (CVD); however, 
raising HDL cholesterol has not been proven to decrease CVD risk. On the other 
hand, positive and negative predictive values are dependent on the prevalence of 
disease in a given population: as the prevalence of disease within a given 
population declines, the positive predictive value gets smaller and the negative 
predictive values gets larger for the same test. Predictive values of biomarkers 
with regards to specific outcomes are also important to consider. For instance, 
troponin is a highly sensitive biomarker of early acute myocardial infarction 
mortality [91]; therefore, both the diagnostic and predictive aspects of troponin 
make it an ideal biomarker for detecting this disease.  
 Even if a biomarker meets several criteria that make it “ideal”, this does 
not imply that the biomarker will necessarily be useful in a clinical setting. 
Specifically, if a novel biomarker cannot add a value in clinical settings, then it 
may never pass the sizeable hurdle that separates clinical practice from clinical 
research. 
7.2.  The analytical platforms for biomarkers implementation 
 Multiplexing analytical technologies, including but not limited to, arrays, 
bead immunoassays and mass spectrometry, allow for the assessment of 
molecular marker panels ideally in a single run. Among these technologies MS is 
attractive due to its sensitivity, specificity and flexibility, and it allows for 
absolute quantification. Whereas antibodies are derived from biological sources, 
MS-based multiplexing assays lack the manufacturing and batch-to-batch 
reproducibility challenges of many antibody-based assays. While in antibody-
based assays the type and number of compounds detected is always limited by 
the antibodies included in the assay, mass spectrometry provides the basis for 
non-targeted approaches and, therefore, the means for detection of an open 
number of previously undefined signals [92]. Non-targeted assays constitute the 
extreme of multiplexing assays and, in an ideal world, would capture the 
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complete human metabolome or proteome. The major difference between an 
untargeted and targeted assay is that in a truly untargeted analysis, the 
compounds underlying the signals are not known. Thus, such assays are semi-
quantitative at best and can only be validated to a limited extent. In contrast to 
untargeted assays, targeted multiplexing assays simultaneously measure several 
well-defined compounds, which are validated and are quantitative. Targeted 
multiplexing assays avoid some of the analytical and statistical uncertainties 
associated with completely untargeted data sets in terms of the quality of data, 
quantification, interferences as well as false negatives and positives. 
 Both the platform used to obtain the raw analytical data and the 
chemometric tools used for data treatment, together with the corresponding data 
bases are keys to success in the search for biomarkers [93].   
7.3.  The process for biomarker development 
 Regulatory agencies have established review structures as well as 
guidelines that outline the biomarker qualification process [94]. Based on these 
guidelines, the biomarker development process can be divided into three stages: 
discovery, verification and qualification.  
 Discovery, as the first stage, can be divided into two sub-stages, as Fig. 9 
shows: identification of the candidate biomarker, and analytical validation. The 
former is an untargeted analysis to identify the potential biomarkers. This 
procedure is commonly carried out by high resolution mass spectrometry as 
QTOF. After extraction and identification of the potential markers, analytical 
validation involves a targeted step in which the predictive behavior of the 
markers is properly established by using more sensitive methods generally 
involving the use of QqQ. 
 Verification mechanistically links the molecular marker to the 
biochemical process underlying a disease or drug effect. The qualification process 
bridges the results of molecular marker measurements, symptomatic drug effects 
and disease outcomes.  
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Figure 9. Analytical platform for identification/validation of biomarkers. 
 
 Qualification has been defined as “a graded, fit-for purpose evidentiary 
process linking a biomarker with biology and clinical endpoints” [95]. 
Qualification has been differentiated from validation, which focuses on the 
reliability and performance characteristics of the analytical assay used to measure 
molecular markers [94,96]. Translation of a molecular marker from the discovery 
stage into pre-clinical testing and clinical development greatly depends on the 
availability of robust, precise and sensitive assays for the measurement of a larger 
number of samples [97]. While during the discovery phase a partial validation 
following “fit-for-purpose” principles will be sufficient, the validation must 
become more stringent if drug development strategies, regulatory approval and 
clinical decisions will depend on such a molecular marker. During later clinical 
development, and especially when developed as a clinical diagnostic tool, which 
typically involves comparison of individual results with normal values, absolute 
quantification of the analytes and complete validation following applicable 
regulatory guidelines is critical. If appropriately qualified and based on 
adequately validated assays, molecular markers can support primary outcomes, 
they may help to understand and monitor mechanisms of toxicity, drug 
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interactions, disease-drug interactions and the effects of genotypes, sex and age. 
They can be used to stratify patient populations, guide subgroup analyses to 
bridge safety and efficacy data between different populations such as adults to 
pediatric patients, and among different ethnic groups. Molecular markers may 
also be developed into clinical diagnostic tests and, finally, they must comply with 
a set of rules and regulations for premarketing clearance or premarket approval 
oversight by the corresponding organism in the application country [98–101].  
7.4.  Metabolomics biomarkers  
 Because the vast number of diseases and the number of biomarkers 
reported for each, two (viz., CVD and cancer) have been the diseases selected to 
comment metabolomic biomarkers reported either for them or for related risk 
factors. 
 Metabolomics has been used to study various forms of cardiovascular 
risk factors such as diabetes mellitus, obesity, and metabolic syndrome [102–
104]. There is no doubt that the growing prevalence of obesity has skyrocketed 
the interest in identifying biomarkers of this disease, as obesity is considered a 
major risk factor for CVD [105]. A large number of potential obesity biomarkers 
that correlate with traditional cardiovascular risk factors or predict subsequent 
cardiovascular events have been reported (usually involving in vitro and in vivo 
studies in animals, then in humans), but they require an in-depth validation in 
humans [106].  
 The also growing prevalence of type 2 diabetes mellitus (T2DM) is a 
consequence of obesity and sedentary life habits, which correlate with CVD. 
Plasma fatty acids metabolic profile coupled to uncorrelated linear discriminant 
analysis has been reported as biomarker screening of T2DM and type 2 diabetic 
coronary hearts diseases [107].  
 Present research on biomarkers associated with common pathologies in 
CVD [108] ranges from markers for myocardial ischemia [109–111] and 
cardiogenic shock [112], risk of developing atherosclerosis or future 
cardiovascular events [113–115], chemotherapy-induced cardiotoxicity [116], and 
   
58 
Mass spectrometry for the identification and  
quantitation of metabolomic biomarkers in clinical analysis 
 
pulmonary hypertension related to advanced heart failure [117]. Nevertheless, at 
present, only biomarkers for the consequences of ischemia (i.e., myocardial 
necrosis) are available. Abnormal levels were found for -aminobutyric acid, uric 
acid, citric acid, and several yet to be identified metabolites [111]. To extend 
beyond ischemia, the plasma signature of aconitic acid, hypoxanthine, 
trimethylamine-N-oxide, and threonine differentiated with high diagnostic 
accuracy between infarcted subjects and patients undergoing coronary 
angiography [110]. Despite the studies on the role of NO in the pathogenesis of 
cardiogenic shock [118], the metabolomic insights of disregulated NO metabolism 
links to cardiogenic shock has not been demonstrated. No conclusive meta-
bolomics studies to identify risk in patients with atherosclerosis and its 
associated adverse events have involved from phosphatidylcholine and choline 
metabolism to disregulation of the arginine-NO metabolic pathways [114].  
 On the other hand, lung cancer is the leading cause of cancer-related 
death in most developed countries [119], as a consequence of the fact that 60% of 
patients are diagnosed at advanced stages when a cure is unlikely [120]. The 
annual mortality rate for lung cancer exceeds the annual rate for breast, prostate, 
and colon cancer combined, all of which have successful clinical screening tools 
for the detection of early-stage disease [121]. Therefore, the search for diagnostic 
strategies for early lung cancer detection has intensified in the last decade. Early 
detection involves a high-risk population, a screening test, and a testing schedule. 
 Within this context, one must distinguish populations of individuals at-
risk before or after the disease becomes measurable (Figure 10).  
 
Figure 10. Clinical contexts for biomarker development in early detection of lung cancer. 
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 The search for early detection of lung cancer biomarkers has involved the 
following candidate samples–omics:  
(i) Tissues, and genomics —hypermethylation of a number of tumor sup-
pressor genes [122–124)—, transcriptomics —regions of chromosomal 
amplification [125], mRNA expression variation [126,127], the dif-
ferential expression of several microRNAs [128]—, proteomics —the 
proteomic signature of invasive [129] and pre-invasive lesions in lung 
tissues [130]— and, of course, metabolites, which are considered in more 
detail.  
Metabolomic profiles of lung and prostate tissues, obtained by CE–
TOF/MS, comprised 114 and 86 metabolites, respectively, and the 
profiles not only well distinguished tumor from normal tissues, but also 
squamous cell carcinoma from the other tumor types in lung cancer and 
poorly differentiated tumors from moderately differentiated tumors in 
prostate cancer. Concentrations of most amino acids, especially 
branched-chain amino acids, were significantly higher in tumor tissues, 
independent of organ type, but of essential amino acids were particularly 
higher in poorly differentiated than in moderately differentiated prostate 
cancers. Organ-dependent differences were prominent at the levels of 
glycolytic and tricarboxylic acids cycle intermediates and associated 
energy status. Significantly high lactate concentrations and elevated 
activating phosphorylation levels of phospho-fructokinase and pyruvate 
kinase in lung tumors confirmed hyperactive glycolysis [131].  
(ii) Biofluids including peripheral blood and its components (circulating 
cells, plasma, and serum), exhaled breath condensate, urine, and sputum 
offer non-invasive access to large quantities of samples available for 
analysis. Alterations can lead to the generation of disease-specific 
molecular species such as altered or methylated DNA, overexpressed 
mRNA, miRNA, or proteins that can potentially be released into the 
extracellular microenvironment. Therefore, molecular analyses of early 
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stage lung cancer-related biofluids represent an attractive choice for the 
discovery and validation of diagnostic biomarkers [132,133].  
Exhaled breath condensate (EBC) is the cooling of exhaled gas to gain 
insight into the composition of extracellular lining fluid and soluble 
exhaled gases. Compounds that have so far been measured include, in 
addition to proteins and DNA [134], lipid peroxidation products, 
products of nitrogen oxide metabolism, hydrogen ions, hydrogen 
peroxide, and cytokines. EBC represents the non-invasive sampling for 
diagnosing lung cancer, which offers a wider potential on metabolomics 
research. The analysis of volatile organic compounds (VOC) that 
underlying rationale of this sampling approach is based on the 
observation that tumor cell growth is accompanied by the alteration of 
protein expression pattern that may lead to peroxidation of the cell 
membrane and thus to the emission of VOCs [135]. Several recent studies 
have used GC–MS analysis  of VOCs as both discovery and validation 
platforms [136–138]. Other groups made use of the analytical power of 
GC–MS and the sensitivity of custom designed nanosensors in which 
changes in electrical resistance from organic compounds contained in 
exhaled breath of patients can be detected by these sensors and recorded. 
For example, in a study by Peng and colleagues, a VOC signature that 
distinguished patients with lung, colorectal, and breast cancers from 
healthy individuals was recently identified from exhaled alveolar breath 
[139–141]. Other studies attempted to identify volatile proteins and 
peptides present in EBC and used them as potential markers for the early 
detection of lung cancer [140, 141]. The results of these studies provide 
evidence for feasibility of this strategy to isolate and identify proteins 
useful for early detection of lung cancer. Further studies are still needed 
to standardize a collection device, to further show specificity of any test, 
and to determine the use of this approach in clinical practice. Some 
achievements of metabolomics in the search for lung cancer biomarkers 
are as follows: 
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- Decreased concentrations of alkanes in the breath of patients with lung 
cancer as compared to samples obtained from controls have been 
detected [142]. The explanation for this finding has been that, during 
carcinogenesis, cytochrome P450 enzymes (CYP) are induced resulting in 
the enhanced catabolism of several VOCs. The test for these biomarkers 
has a sensitivity of 85% and a specificity of 80% in selecting patients.  
- Inhibition of proliferation of human lung, colon and pancreatic cancer 
cells by prostaglandin E3 (PGE3) —derived from cyclooxygenase 2 (COX-
2) metabolism of the omega-3 fatty acid eicosapentaenoic acid (EPA)— 
has also been reported [143]. However, how PGE3 metabolism is 
regulated in cancer cells, particularly in human non-small cell lung 
cancer (NSCLC) cells, had not been fully understood, until identification, 
using MALDI, of differences in lipid metabolism between two human 
NSCLC cell lines, A549 and H596. This identification could contribute to 
their differential response to EPA treatment, which showed that the level 
of EPA incorporated into phospholipids in H596 cells was 4-fold higher 
than A549 cells. Intriguingly, H596 cells produced much less PGE3 than 
A549 cells even though the expression of COX-2 was similar in these two 
cell lines.  
- Lipids peroxidation, a well-known index of free radical activity, occurs as 
a result of auto-oxidation of polyunsaturated fatty acids and it has been 
implicated in the pathogenesis of lung cancer [144]. Khyshiktyev et al. 
have reported that, without stating the actual marker, levels of lipid 
peroxidation were lower in EBC of patients with lung cancer than in 
controls [145]. 
- Significant differences in EBC hydrogen peroxide levels were 
demonstrated between groups: lung cancer subjects (23.68±9.15 µM); 
smokers (5.21±0.69 µM); ex-smokers (14.35±3.79 µM); and non-smokers 
(17.59±6.53 µM) [146]. 
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- Different samples such as serum (from 29 healthy volunteers and 33 lung 
cancer patients with adenocarcinoma, n = 12; squamous cell carcinoma, 
n = 11; or small cell carcinoma, n = 10 ranging from stage I to stage IV 
disease), and lung tissue (from 7 lung cancer patients including the 
tumor tissue and its surrounding normal tissue) were analyzed and a 
total of 58 metabolites (57 individual metabolites) were detected in 
serum, and 71 metabolites were detected in the lung tissue. The levels of 
23 of the 58 serum metabolites were significantly changed in all lung 
cancer patients compared with healthy volunteers, and the levels of 48 of 
the 71 metabolites were significantly changed in the tumor tissue 
compared with the non-tumor tissue. Partial least squares discriminant 
analysis, applied to the serum sample data, showed characteristic 
alterations in each histological subtype and disease stage [147].  
 Special mention deserves the recent use of sweat as sample to search for 
lung cancer biomarkers, as discussed in Chapters 1 and 7 of this PhD book [148–
150].  
  Finally, two general aspects in dealing with present research on bio-
markers deserve to be emphasized:  
(i) The general mandate for orthogonal (i.e., uncorrelated) disease bio-
markers that provide additional clinical information along new biological 
axes. A robust set of predictors for identifying at risk individuals is of 
particular importance because of the delay or prevention of diseases such 
as atherosclerosis. Therefore, existing biomarkers can be combined with 
present ones to offer higher sensitivity and/or selectivity and, in short, 
more accuracy in the resulting biomarker.  
(ii) The indubitable certainty that systems biology may provide the best and 
closest to ideal biomarkers. Attempts in this sense by combining pro-
teomics and metabolomics enable to link alterations of cellular proteins 
to metabolism and function [151]. 
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 En este apartado de la Memoria se describen sucintamente los diferentes 
instrumentos y aparatos usados durante el desarrollo experimental de la Tesis. 
En los capítulos se incluye una explicación más detallada de los que se han 
utilizado en cada uno de ellos. 
 
1. Sistemas automáticos y/o continuos de preparación de 
muestra 
 En el Capítulo 2 de la Memoria se ha tratado de enfatizar la aplicabilidad 
de los sistemas continuos al tratamiento de muestra en el análisis no orientado 
(untargeted analysis) para aumentar el número de metabolitos detectados. Por 
otro lado, en el bloque 3 de la Memoria se recoge el uso de un sistema automático 
para la preparación de muestra en análisis orientado (targeted analysis). Estos 
sistemas automáticos permiten llevar a cabo de manera reproducible, parcial o 
totalmente automatizada —y a veces con drástica reducción del volumen de 
muestra y reactivos— esta etapa crucial del proceso analítico, que es una de las 
principales fuentes de error de los métodos de análisis cuantitativo. 
  Se emplearon dos sistemas comerciales similares para llevar a cabo la 
SPE de forma automatizada: el Prospekt-2, que se usó para el pretratamiento de 
muestra en el análisis de catelicidina, como se recoge en el Capítulo 11; y el 
Symbiosis, que se usó para el pretratamiento de muestra en el análisis de 
aminoácidos (Capítulo 9) y para maximizar el número de metabolitos detectados 
en análisis no orientado (Capítulo 2). Ambos sistemas, además de trabajar en 
modo dinámico, permiten la elución directa con la fase móvil cromatográfica o 
con un pequeño volumen de disolvente que se incorpora a la fase móvil. Trabajar 
a alta presión posibilita la conexión en línea de este sistema con el conjunto 
cromatográfo/detector, consiguiéndose así la automatización completa del 
método analítico. El sistema Prospekt-2 está compuesto por tres módulos: Un 
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muestreador (MIDAS), una unidad de extracción en fase sólida (ACE) y una 
bomba de alta presión dispensadora de disolventes de 2 mL de capacidad (HPD). 
Por su parte, el sistema Symbiosis cuenta con 5 módulos: Un muestreador 
refrigerado (AS), de enorme interés para muestras termoinestables;  una unidad 
de extracción en fase sólida (ACE), dos bombas de alta presión dispensadoras de 
disolventes (HPD1 y HPD2), de 2 mL de capacidad,  y una bomba de HPLC.   
 
2. Sistemas discontinuos de preparación de muestra 
 Al igual que los del apartado anterior, los sistemas discontinuos se han 
empleado tanto en análisis orientado como no orientado.  
 Dada la naturaleza no selectiva, semi- o no cuantitativa de las 
plataformas analíticas empleadas a lo largo de la Tesis para análisis metabólico 
global, se hizo especial hincapié en el desarrollo de métodos con mínima o nula 
preparación de muestra, evitándose, por tanto, los sistemas continuos de 
pretratamiento de muestra (salvo en el estudio recogido en el Capítulo 2). En 
general, el pretratamiento de muestra se basó en etapas de extracción, 
centrifugación, hidrólisis o extracción en fase sólida usando µ-SpinColumn (un 
sistema de SPE diseñado para pequeños volúmenes de muestra y en el que se 
utiliza la fuerza centrífuga para hacer pasar los disolventes a través del cartucho). 
Por otro lado, para la extracción y preconcentración de fosfolípidos se usaron 
cartuchos de SPE convencionales, empaquetados con un sorbente específico para 
esta familia de compuestos (HybridSPE), según se recoge en el Capítulo 8.  
 La determinación de los compuestos implicados en el ciclo de los ácidos 
tricarboxílicos mediante GC-IT/MS requirió un pretratamiento de muestra 
basado en la precipitación de las proteínas del suero, la extracción y la 
derivatización por sililación de estos metabolitos (ver Capítulo 10). 
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3. Detección con o sin separación cromatográfica previa 
 Los métodos desarrollados en la parte experimental de esta Tesis 
Doctoral abarcan tanto los que requieren separación cromatográfica (LC o GC)  
previa a la detección mediante espectrometría de masas, como los que la 
detección se lleva a cabo sin separación. 
 En los Capítulos 9 y 11, dedicados al análisis orientado de aminoácidos y 
catelicidina, la separación mediante LC y posterior detección por MS en tándem 
por triple cuadrupolo se llevó a cabo con un cromatógrafo Agilent 1200 Series LC 
equipado con una bomba binaria, un desgasificador, un automuestreador y un 
compartimento de columna termostatizados, y un espectrómetro de masas 
Agilent 6410 de triple cuadrupolo con una fuente de ionización por electrospray 
(ESI). El software Agilent MassHunter Workstation se usó para la toma de datos 
y el análisis cuali- y cuantitativo. El Capítulo 9 recoge el uso de una fase 
estacionaria de interacción hidrófila –HILIC–, especialmente diseñada para 
compuestos polares o iónicos que tienen poca o ninguna retención en columnas 
de fase reversa, tal como requiere la separación de aminoácidos.  
 En las plataformas dedicadas a la obtención del perfil metabolómico 
(metabolomics profiling) de muestras de sudor (Capítulos 1 y 7) y suero 
(Capítulos del 2 al 6), y en las desarrolladas para la identificación y cuantificación 
de fosfolípidos en suero (Capítulo 8), se utilizó un equipo HPLC Agilent 1200 
Series acoplado a un detector de masas de tiempo de vuelo de alta resolución, 
Agilent 6540. Las columnas para la separación cromatográfica fueron en su 
mayoría C18 (fase reversa), salvo en el caso de las plataformas de los Capítulos 1 y 
2 en los que también se ensayaron columnas con fase estacionaria HILIC. En 
todos los casos se usó el software MassHunter para la adquisición de espectros y 
el análisis cualitativo. 
 Para el análisis de los compuestos implicados en el ciclo de los ácidos 
tricarboxílicos se empleó un cromatógrafo de gases Varian CP-3800 acoplado a 
un detector de masas de trampa iónica (Varian Saturn 2200), que consta de un 
automuestreador (Varian 8400).  Se utilizó el software de Varian de control de 
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sistema e integración de señales (Star Chromatography Workstation 6.0) para la 
obtención y el tratamiento de los datos. 
 
4. Técnicas quimiométricas 
 De acuerdo con la importancia que ha adquirido la quimiometría en los 
métodos usados en metabolómica, en la Tesis Doctoral que se recoge en esta 
Memoria se han utilizado extensamente herramientas quimiométricas, tanto para 
el desarrollo y optimización de métodos analíticos como para el tratamiento de 
datos multivariantes. La metodología del diseño de experimentos se ha utilizado, 
cuando ha sido posible, en la optimización de algunas condiciones 
experimentales como las implicadas en la ionización de analitos previa a su 
detección por espectrometría de masas. La precisión de los métodos propuestos 
para el análisis cuantitativo (targeted analysis) de familias de compuestos se 
estudió como reproducibilidad dentro del laboratorio y repetibilidad mediante 
series de experimentos por triplicado usando análisis de varianza (ANOVA) a 
diferentes niveles de concentración de los analitos.  
 El tratamiento de datos se realizó con distintos programas informáticos 
según el objetivo: 
a) Alineamiento de entidades moleculares en análisis no orientado 
(profiling):  
- Por un lado se usó la combinación de dos paquetes del lenguaje de 
programación R de uso libre: XCMS y CAMERA. El primero permite 
extraer y alinear las entidades moleculares potenciales de un análisis 
no orientado, y el segundo reconoce aductos e isótopos y los agrupa 
para eliminar falsos positivos y crear la lista definitiva de entidades. 
- Por otro lado se empleó la combinación de dos softwares de Agilent: 
Qualitative Workstation y MassProfiler Professional (Agilent). El 
primero permite extraer las entidades teniendo en cuenta aductos e 
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isótopos, mientras que el segundo posibilita el alineamiento de las 
entidades potenciales. 
- Finalmente, se usó el software MassProfinder, de Agilent, que permi-
te realizar las etapas de extracción de entidades (teniendo en cuenta 
aductos e isótopos) y el alineamiento en un único paso.  
b) Análisis estadístico:  
- El paquete estadístico “stats” del lenguaje de programación R, que 
permite realizar una amplia gama de análisis estadísticos tanto 
paramétricos como no paramétricos, así como la representación de 
los datos.  
- Statgraphics y Unscrambler: Ambos softwares también permiten 
realizar distintos análisis estadísticos univariantes y multivariantes, 
así como el diseño y evaluación de modelos de screening y superficies 
de respuesta. 
- MassProfiler Professional: Permite la aplicación de diferentes 
algoritmos de análisis estadístico especialmente adecuados para el 
análisis metabolómico. 
c) Evaluación de la capacidad de predicción de metabolitos o paneles con 
potencial marcador: Esta evaluación se ha realizado a través de las curvas 
ROC, que representan especificidad frente a sensibilidad. Para su 
obtención se ha usado tanto la herramienta gratuita de acceso online 
ROCCET (http://www.roccet.ca/ROCCET/), como el paquete “pROC” 
del lenguaje de programación R. 
d) Diseño de modelos de predicción y creación de paneles de marcadores: 
En este caso se han empleado tanto el MassProfiler Professional que 
permite la creación de modelos por PLS-DA, como la herramienta en 
línea ROCCET o el software PanelomiX, que permiten crear paneles de 
marcadores y evaluar su capacidad de predicción/discriminación. 
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5. Bases de datos 
 Aunque queda un gran camino por recorrer, existen varias bases de datos 
de metabolitos a disposición del usuario que contienen información para la 
identificación y caracterización de muchos de los compuestos presentes en 
diversas matrices biológicas. Entre ellas, las bases de datos ‘Metabolites and 
Tandem MS Database’ (METLIN), ‘Human Metabolome Database’ (HMDB) y 
‘MassBank’ se han empleado para la identificación de compuestos presentes en 
biofluidos (suero y sudor) a partir de los datos espectrales obtenidos mediante 
espectrometría de masas en las partes 1, 2 y 5 de esta Memoria. Además, la 
información biológica disponible en la HMDB y las rutas biosintéticas de la base 
de datos ‘Kyoto Encyclopedia of Genes and Genomes’ (KEGG) se han utilizado 
para la interpretación de resultados obtenidos en los capítulos 4, 5 y 6.   
 Para la identificación de lípidos existen otras bases de datos que, si bien 
no están constituidas por datos espectrales experimentales, contienen 
información útil sobre la rotura in silico de las distintas familias, como es el caso 
de LipidMaps. Esta base de datos se empleó, en las partes 3 y 5 de esta Memoria, 
para la identificación de fosfolípidos en base a los datos espectrales obtenidos por 
espectrometría de masas. 
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 Section I of this PhD Book is devoted to methodological development and 
innovation on metabolomics with the main aim of helping to overcome some of 
the weak aspects of profiling analysis in clinical metabolomis. The target aspects 
are related both with clinical sample preparation of different biofluids involving 
different tools, and with coverage  enhancement of metabolomics profiling.  
Chapter 1 is devoted to the development of a method to analyze human 
sweat, an odd clinical sample, with clear potential in metabolomics. The method, 
based on LC–QTOF MS/MS, provided identification of 41 metabolites after 
sample preparation either by only dilution or clean-up by SPE to increase 
sensitivity and reduce interferents. The pathways in which most of the identified 
metabolites are involved open a door to the use of this sample to searching for 
biomarkers. 
 The limited detection coverage of the approaches for global meta-
bolomics profiling of serum has intended to be overcome in Chapter 2, in which 
an automated approach was configured by online coupling of SPE involving 
sorbents with different retention mechanisms to LC–QTOF. The SPE protocols 
allowed 3445 molecular entities to be detected by serial configurations of the 
automated SPE system. 
 One other limitation of metabolomics profiling is the necessity for 
MS/MS information to achieve unequivocal metabolite identification. The 
general procedure in most analytical platforms requires a first injection of the 
sample batch to know the potential metabolites to be identified, and a second 
injection to obtain the MS/MS information of the ion precursors. To avoid dual 
injection, Chapter 3 deals with the study of the GPF strategy advantages in 
profiling metabolomics analysis. 
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Castro* 
 
Abstract 
 Sweat has recently gained popularity as a potential tool for diagnostics 
and biomarker monitoring as it is a non-invasive biofluid the composition of 
which could be modified by certain pathologies, as is the case with cystic fibrosis, 
which increases chloride levels in sweat. The aim of the present study was to 
develop an analytical method for analysis of human sweat by liquid chroma-
tography–mass spectrometry (LC–QTOF MS/MS) in high resolution mode. Thus, 
different sample preparation strategies and different chromatographic modes 
(HILIC and C18 reverse modes) were compared to check their effect on the 
profile of sweat metabolites. Forty one compounds were identified by the MS/MS 
information obtained with a mass tolerance window below 4 ppm. Amino acids, 
dicarboxylic acids and other interesting metabolites such as inosine, choline, uric 
acid and tyramine were identified. Among the tested protocols, direct analysis 
after dilution was a suited option to obtain a representative snapshot of sweat 
metabolome. In addition, sample clean up by C18 SpinColumn SPE cartridges 
improved the sensitivity of most identified compounds and reduced the number 
of interferents. As most of the identified metabolites are involved in key 
biochemical pathways, this study opens new possibilities to the use of sweat as a 
source of metabolite biomarkers of specific disorders. 
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1.  Introduction 
  Sweat is an aqueous electrolyte solution excreted by the eccrine and 
apocrine sweat glands originated in the skin dermis of mammals and terminated 
in the secretory canals that flow into the skin surface and hair follicles. The 
primary function of sweating is thermoregulation to control body temperature by 
evaporative cooling. In addition, sweat is a defence mechanism of skin, the 
excretion fluid of chemosignals such as androstadienone —which acts as 
hormonal stimuli in females—, and waste of metabolites such as uric acid [1]. 
Sweat is mainly composed by water, but it contains several minor components 
including electrolytes, ammonia, urea, small molecules such as carboxylic acids 
and amino acids as well as more complex biomolecules such as proteolytic 
enzymes and antimicrobial peptides, among others [2]. Therefore, the varied 
composition of sweat supports its clinical interest to be potentially exploited for 
diagnostic.  
 The scant application of sweat in clinical analysis is explained by the lack 
of studies to relate sweat composition and pathological states. In fact, few clinical 
tests use sweat samples. One of these tests is for diagnosis of cystic fibrosis in 
new-borns based on determination of chloride in sweat [3–5]. However, the 
advances both in sweat collection devices and sensitive analytical techniques 
increased the interest on sweat testing of drugs over the past few years [6–10]. 
Sweat may offer a non-invasive alternative to present sampling for continuous 
monitoring of drugs exposure as sweat can be collected for a programmed period 
with minimal disturbance for the sampled individual. Sweat sampling can be 
performed with the aid of sweat wipes as liquid perspiration or over time using 
sweat patches [11]. The experience gained in sweat collection procedures for the 
analysis of xenobiotics could be used to implement this biofluid in clinical 
diagnostics [12,13].  
 Major limitations in the analysis of sweat are the low volume of sweat 
secreted and the variability in secretion among individuals [14,15]. Also, sampling 
is a complex process since the collected sweat should be representative and 
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unaffected by interferents. Non-invasiveness and the absence of requirements in 
terms of health personnel care are the main benefits from sweat as clinical 
sample. 
 Despite the scant studies on the clinical perspectives of sweat, the 
potential of this biofluid in omics disciplines has been pointed out. In proteomics, 
a current research developed by Raiszadeh et al. revealed that sweat proteome is 
rather different from serum proteome [16]. Therefore, human sweat could be 
considered an additional source of unique disease-associated biomolecules. In 
fact, Raiszadeh et al. found differential abundances of selected proteins between 
schizophrenia patients and control individuals. This preliminary test should be 
validated to prove the applicability of human sweat in the diagnostic of 
schizophrenia. In the metabolomics field, a recent study of sweat by high-
resolution NMR spectroscopy has revealed that some of the components present 
in human sweat are involved in primary and secondary biological functions [17]. 
Among them, amino acids, sugars, lactate, glycerol, and compounds involved in 
the citric acid cycle (e.g. pyruvate, fumarate or aconitate) have been detected. 
NMR is especially suited to metabolomics profiling of human sweat as this is a 
relatively non-complex biofluid. Nevertheless, more research on sweat 
composition is demanded to assess the potential of this biofluid for clinical 
diagnostic. The aim of the present study was to develop a method for analysis of 
human sweat by LC–QTOF MS/MS. Different sample preparation strategies such 
as sample dilution, acid/alkaline hydrolysis and solid-phase extraction (SPE) 
were compared to check their influence on the profile of the detected metabolites. 
Taking into account the polar character of human sweat, two analytical 
chromatographic columns, C18 and HILIC, were tested to study their suitability 
to analyze human sweat. Identification of metabolites by LC–QTOF MS/MS in 
high resolution mode was carried out to obtain a snapshot of the composition of 
sweat metabolome. 
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2. Experimental 
2.1. Reagents 
 MS-grade formic acid, ammonium formate and acetonitrile (ACN) to 
prepare the chromatographic mobile phases and sodium hydroxide and 
hydrochloric acid were purchased from Scharlab (Barcelona, Spain). Deionized 
water (18 mΩ • cm) from a Millipore Milli-Q water purification system was used. 
2.2. Instruments and apparatus 
 An Agilent 1200 Series LC system (consisting of a binary pump, a vacuum 
degasser, an autosampler and a thermostated column compartment) coupled to 
an Agilent 6540 UHD Accurate-Mass QTOF hybrid mass spectrometer equipped 
with dual electrospray ionization (ESI) source (Santa Clara, CA, USA) was used. 
The chromatographic eluate was thus monitored in high resolution mode. 
2.3. Cohort selected for the study 
 A cohort of 96 individuals with an average age of 59±11 years and a 
proportion of 75% male individuals participated in this study. All steps from 
sweat sampling to analysis were performed in compliance with the guidelines 
dictated by the World Medical Association Declaration of Helsinki of 2004. The 
study was approved by the ethics committee of the Reina Sofia University 
Hospital. The individuals selected for this study were previously informed to 
obtain consent.  
2.4.     Sweat producer and collector: procedure 
 All samples were collected from 9 to 11 am after breakfast ingestion to fix 
the most common conditions of clinical practice. A Macroduct® Sweat Analysis 
System (Wescor, Utah, USA), consisting of a Webster sweat inducer and a 
Macroduct sweat collector (US Patent 4,542,751), was used. Pilogel® 
iontophoretic discs (US Patent 4,383,529) (Wescor, Utah, USA), a gel reservoir of 
pilocarpinium ions, were used in the iontophoretic stimulation of sweat.   
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 The sweat inducer provided a current intensity of 1.5 mA for 5 min 
through two pilogel discs as electrodes located on the forearm. After removing 
the discs the skin where the positive disc had been located was cleaned with 
distilled water and the Macroduct collector covered this skin to collect sweat for 
15 min. The collected sweat was transferred to a micro Eppendorf and stored at –
80 ºC until use. 
 One individual was randomly selected to collect seven sweat samples in 
different days which were used to study sample variability and methodological 
reproducibility.  
2.5. Sample treatment 
 A pool was prepared taking 5 µL of samples from all participants. Then, 
different experimental protocols were compared to select that providing 
maximum metabolite coverage. Firstly, 10 µL of sample was diluted with 20 µL of 
0.1% v/v formic acid in water to analyze directly sweat without treatment. Then, 
two different strategies were tested.  
 (i) Sweat hydrolysis under acid or alkaline conditions to release 
 metabolites conjugated to proteins or peptides. With this aim, 100 µL 
 aliquots were 1:1 mixed with 0.1 M either NaOH or HCl in water and 
 vortexed at room temperature for 30 min, then evaporated to dryness 
 and reconstituted by 100 µL of chromatographic mobile phase A.  
 (ii) Sweat clean up and preconcentration by solid phase extraction using 
 C18 and hydrophilic centrifugal Micro SpinColumnTM systems (Harvard 
 Apparatus, MA, USA) and following the protocol recommended by the 
 manufacturer depending on the sorbent material.  
 The protocol for C18 Micro SpinColumnTM was as follows: 150 µL of 
water for solvation, 150 µL of 50% (v/v) acetonitrile for sorbent conditioning, 150 
µL of 5% (v/v) acetonitrile for sorbent equilibration, 25 µL of sample, 150 µL of 
5% (v/v) acetonitrile to obtain thesample free from the undesirable retained 
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compounds, which were subsequently eluted by 150 µL of 50% (v/v) acetonitrile. 
Centrifugation for 25 s at 1000 × g was used for each step.  
 The protocol for hydrophilic Micro SpinColumnTM system was: 150 µL of 
water for solvatation, 150 µL of 50% (v/v) acetonitrile for sorbent conditioning, 
150 µL of 5% (v/v) acetonitrile for sorbent equilibration, 25 µL of sample, 150 µL 
of acetonitrile to remove undesired non retained compounds, and 150 µL of 50% 
(v/v) acetonitrile to elute the retained target compounds. The centrifugation 
conditions were as those used for the C18 sorbent.  
 Both the eluate and the nonretained fraction (collected after sample 
application) obtained in each SPE protocol were analyzed separately after 
evaporation and reconstitution by 20 µL of water acidified with 0.1% formic acid. 
2.6. LC–QTOF MS/MS analysis  
 Two chromatographic columns were tested for separation. A C18 reverse-
phase analytical column (Mediterranean, 50 mm×0.46 mm i.d., 3 μm particle 
size) from Teknokroma (Barcelona, Spain) was used at constant temperature of 
25 °C. The mobile phases were water (phase A) and ACN (phase B) both with 
0.1% formic acid as ionization agent. The LC pump was programmed with a flow 
rate of 0.8 mLmin–1 and the following gradient elution was developed: 3% phase 
B was kept constant from min 0 to 1; from 3 to 80% of phase B from min 1 to 10.5 
and from 80 to 100% of phase B from min 10.5 to 11.5. A post-time of 5 min was 
set to stabilize the initial conditions.  
 A Luna hydrophilic interaction chromatography column (HILIC)  
(100 mm × 0.46 mm i.d., 3 μm particle size) from Phenomenex (Torrance, CA, 
USA) was used in the other method. In this case, the mobile phases were 5% (v/v) 
of ACN (phase A) and 95% (v/v) of ACN (phase B), both with 5 mM of 
ammonium formate (pH 6) as ionization agent. The LC pump was programmed 
with a flow rate of 0.6 mLmin–1 and the following gradient elution was developed: 
90% phase B was kept constant for 5 min; then, the percentage of phase B 
decreased to 70% since min 5 to 17 and finally decreased to 50% from min 17 to 
20. A post-time of 5 min was set to stabilize the initial conditions. 
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 In both cases the injection volume was 3 µL and the injector needle was 
washed for 10 times between injections with 70% methanol. Furthermore, the 
needle seat back was flushed for 15 s at a flow rate of 4 mLmin–1 with 70% 
methanol to avoid cross contamination. 
 The parameters of the electrospray ionization source, operating in 
negative and positive ionization mode, were as follows: the capillary and 
fragmentor voltage were set at ±3.5 kV and 175 V, respectively; N2 in the 
nebulizer was flowed at 40 psi; the flow rate and temperature of the N2 as drying 
gas were 8 L min–1 and 350 °C, respectively. The instrument was calibrated and 
tuned according to the procedures recommended by the manufacturer. Data were 
collected in both centroid mode at a rate of 1 spectrum per second in the 
extended dynamic range mode (2 GHz).Accurate mass spectra in MS scan and 
MS/MS mode were acquired in the m/z range 60–1100. The instrument gave 
typical resolution 15000 FWHM (Full Width at Half Maximum) at m/z 118.0862 
and 30000 FWHM at m/z 922.0098. To assure the desired mass resolution, 
continuous internal calibration was performed during analyses by using the 
signals at m/z 121.0509 (protonated purine) and m/z 922.0098 [protonated 
hexakis (1H, 1H, 3H-tetrafluoropropoxy) phosphazine or HP-921] in the positive 
ion mode; while in the negative ion mode, ions with m/z 119.0362 (proton 
abstracted purine) and m/z 966.0007 (formate adduct of HP-921) were used. 
 The samples were first injected in full scan acquisition mode and then in 
auto MS/MS acquisition mode to obtain information on the product ion of the 
most relevant compounds. The maximum number of precursors selected per 
cycle was set at 2 with an exclusion window of 0.3 min after 2 consecutive 
selections of the same precursor. Three collision energies (10, 20 or 40 eV) were 
used to obtain the maximum information from fragmentation. At least three 
replicates of each sample preparation test were analyzed to improve the quality of 
the results. Blanks were inserted in the analysis sequences between sets of 5 
samples. 
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2.7. Data processing and statistical analysis 
 MassHunter Workstation software (version B5.00 Qualitative Analysis, 
Agilent Technologies, Santa Clara, CA, USA) was used to process all data 
obtained by LC–QTOF in full scan MS mode. Treatment of raw data file was 
initiated by extraction of potential molecular features (MFs) with the suited 
algorithm included in the software. For this purpose, the extraction algorithm 
considered all ions exceeding 500 and 1000 counts with a single charge state for 
chromatograms obtained with C18 and HILIC column, respectively, as the 
background noise was different for the two cases. Additionally, the isotopic 
distribution to consider a molecular feature as valid should be defined by two or 
more ions (with a peak spacing tolerance of 0.0025 m/z, plus 10.0 ppm in mass 
accuracy). Adducts formation in the positive (+H, +Na, +NH4) and negative 
ionization (-H, +HCOO) modes, as well as neutral loss by dehydration were 
included to identify features corresponding to the same potential metabolite. 
Thus, ions with identical elution profiles and related m/z values (representing 
different adducts or isotopes of the same compound) were extracted as entities 
characterized by their retention time (RT), intensity in the apex of the 
chromatographic peaks and accurate mass. Background contribution was 
removed by subtraction of MFs linked to plasticizers, solvent impurities and 
other contaminants after analysis of a blank (0.1% formic acid) under identical 
operational conditions for each sample treatment procedure tested. In this way, 
raw data files were created in compound exchange format files (.cef files) for each 
sample and exported into the Mass Profiler Professional (MPP) software package 
(version 12.1, Agilent Technologies, Santa Clara, CA, USA) for further processing.  
 In the next step, the data were processed by alignment of retention times 
and m/z values across the data matrix using a tolerance window of 0.6 min and 
10 ppm mass accuracy, respectively. Data pretreatment was based on baselining 
to remove background noise and normalization by logarithmic transformation to 
reduce relatively large differences among the respective MF abundances. The 
molecular features extracted from the analysis of blanks were removed from the 
data set formed by molecular features extracted from sweat samples. The 
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extraction algorithm confirmed the efficiency of this filtering step. This correction 
was applied to all the sample treatments tested. Stepwise reduction of the MFs 
number was performed based on frequency of occurrence by comparing 
repetitions of the same fraction or hydrolysis procedure. A filter by frequency was 
set at 100%, which ensured the detection of each molecular feature in all the 
injected replicates . 
 Identification of the most relevant entities was based on MS and MS/MS 
information and searching in the METLIN MS and MS/MS database 
(http://metlin.scripps.edu) and Human Metabolome Database (HMDB, 3.5 
version).  
 
3. Results and discussion 
 As mentioned before, sweat should be considered a potential biofluid for 
clinical diagnostic of great interest because its non-invasive sampling. With this 
aim, development of methods for analysis of sweat by LC–QTOF MS/MS are 
demanded to define suited protocols for characterization of this biofluid by 
coverage of as much as possible sweat metabolome. 
3.1. Comparison of the two chromatographic modes for direct analysis of 
human sweat 
 Most metabolites present in sweat are polar because of the aqueous 
nature of this excreted biofluid. For this reason, the separation capability of two 
chromatographic modes, HILIC and C18 reverse mode, were compared. In both 
cases the sweat pool was 1:1 diluted with 0.1% (v/v) formic acid and directly 
analyzed by LC–TOF MS in positive and negative ionization modes. Molecular 
features were extracted from raw data files obtained by the four chromatographic 
methods (C18 and HILIC methods in positive and negative ionization modes). 
For this purpose, an extraction algorithm was used by setting the minimum peak 
abundance at 500 counts for C18 reverse mode analyses and 1000 counts for 
HILIC analyses. These cut-off values were established taking into account the 
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chromatographic background noise, which was higher in the HILIC chroma-
tograms. Supplementary Fig. 1 shows the distribution of the retention times for 
the molecular features detected by each chromatographic method and ionization 
mode. As can be seen, most of the molecular features detected in the methods 
based on the C18 analytical column were associated to retention times in the first 
part of the chromatogram, while resolution in the case of HILIC allowed a more 
homogeneous elution of potential metabolites. Therefore, the polar character of 
the metabolite composition of sweat is confirmed. Fig. 1 shows the base peak 
chromatograms (BPCs), which included the intensity of the highest ion per scan, 
obtained by the HILIC (Fig. 1a) and C18 (Fig. 1b) analytical columns in both 
ionization modes. As can be seen, the two chromatograms reporting wider 
information in terms of number of peaks were obtained with the method based 
on the HILIC column in the negative ionization mode and with that on C18 
column in the positive ionization mode. On the other hand, the chromatograms 
provided by HILIC in the positive ionization mode and C18 in the negative mode 
were not characterized by high resolution. It is worth emphasizing that BPCs 
were influenced by the presence of components of the gel discs. Among gel discs 
components to stimulate sweat secretion, the contaminant giving the highest 
peak in sweat samples was pilocarpine, which is mostly detected in the positive 
ionization mode. Other components of the gel formulation such as methyl-
paraben and propylparaben were also detected in the analysis of sweat by both 
ionization modes.  
 Direct analysis of sweat enabled detection of 67 and 57 molecular 
features in positive ionization mode for the C18 and HILIC analytical methods, 
respectively; meanwhile, 29 and 37 molecular features, respectively, were 
detected in negative ionization mode for both columns. Although C18 reverse 
mode seems not to be appropriate for separation of sweat polar metabolites 
according to the chromatographic profile, this mode should not be discarded at 
least in positive ionization mode due to the number of molecular entities 
detected. 
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 Despite the high number of potential entities detected in positive 
ionization mode, sample preparation could improve metabolite coverage. With 
this aim, different steps encompassing hydrolysis or cleaning by centrifugal SPE 
were tested after a quality control study to assess the performance of the analysis 
equipment. 
 
Fig. 1. Base peak chromatograms (BPCs) obtained for sweat analysis in positive and 
negative ionization using two chromatographic modes: (a) HILIC, (b) RP-C18. 
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3.2. Quality control (QC) study 
 A quality control (QC) test was carried out by analysis of sweat as an 
attempt to assess the instrumental precision of the detection step and the 
stability of the samples. The QC test was performed by repetitive injection  
(n = 14) of the human sweat pool prepared in this research, by inserting a blank 
each 5 injections to evaluate carry-over effects. The autosampler temperature was 
set at 6 ºC to minimize potential degradation and methylparaben was used as 
internal standard as a normalization strategy to minimize intra-individual 
variability. Methylparaben is always present in sweat and its concentration would 
depend on the sweat volume collected. Due to the number of molecular features 
found in the samples (67 in the positive ionization mode), a multivariate analysis 
based on Principal Component Analysis (PCA) was used to assess variability 
associated to instrumental precision and sample integrity. Supplementary Fig. 2 
shows the PCA resulting from normalization in which significant variations were 
observed after 4 h at 6 ºC (sample number 9 of the programmed sequence in the 
QC test). Therefore, sequences of analysis included only 8 samples to minimize 
variability sources associated to sample stability. The normalization procedure 
was considered for programming sequences in further experiments. Under these 
conditions, instrumental precision estimated as RSD percentage ranged from 3 to 
11%. 
 Additionally, the intra-individual variability was assessed by analysis of 7 
samples collected from the same individual in different days, which were 
analyzed in duplicate within a five days interval. This study also allowed 
evaluating the methodological reproducibility since the variability estimated as 
RSD ranged from 2 to 21%. These values indicated that the collection system was 
reproducible enough for metabolomics research. 
3.3. Comparison of acidic and basic hydrolysis 
 Sweat hydrolysis protocols under acidic and alkaline conditions were 
tested to maximize metabolite identification in sweat as some metabolites could 
thus be released from proteins or other conjugates. For this purpose, sweat was 
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incubated with NaOH or HCl aqueous solutions as described in the Experimental 
section. Fig. 2a and 2b shows the chromatograms from sweat without hydrolysis 
and after basic and acid hydrolysis in positive and negative ionization modes, 
respectively, using the C18 analytical column. As can be seen, the number of 
chromatographic peaks increased significantly by analysis of hydrolyzed samples 
as compared to direct analysis of sweat. Fig. 2c and 2d compares the number of 
features detected in all the repetitions in each analysis in negative and positive 
ionization modes, in which the number of features increased significantly in the 
negative ionization mode for sweat hydrolyzed under alkaline conditions, while in 
the positive mode the features increased under acidic conditions. Thus, the 
analysis of sweat subjected to alkaline hydrolysis allowed detection of 155 
potential entities in negative ionization mode, while direct analysis of sweat led to 
29 entities. On the other hand, acidic hydrolysis enabled detection of 83 entities 
in positive ionization mode, while direct analysis led to detection of 67 entities. 
One fact to be emphasized is that 79 and 76% of the molecular features detected 
by direct analysis of sweat were also detected in the hydrolyzed samples in 
negative and positive ionization modes, respectively. Despite the high number of 
potential metabolites detected in hydrolyzed sweat, many of them were identified 
as pilocarpine adducts (sodium, dimers and fragments), the main contaminant 
interferent detected in human sweat, which is used to stimulate sweat secretion 
by the Macroduct® system. In fact, 8 out of 11 molecular features exclusively 
detected in the analysis of sweat subjected to alkaline hydrolysis in positive 
ionization mode were identified as pilocarpine adducts, and 15 out of 26 entities 
exclusively detected in sweat subjected to acid hydrolysis in positive ionization 
mode were identified as pilocarpic acid adducts or fragments. However, only 7 
out of 122 molecular features exclusively detected in sweat after alkaline 
hydrolysis were identified as pilocarpine adducts in negative ionization mode. In 
this case, peptide fragments and artifacts were among the numerous molecular 
features detected in sweat hydrolyzed under alkaline conditions. Attending to 
these results, sweat hydrolysis would not be recommended since the sample 
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integrity is altered by detection of numerous artifacts associated to metabolites 
and peptides. 
  
Fig. 2. BPCs obtained by analysis of human sweat without hydrolysis and after alkaline 
and acid hydrolysis in positive (a) and negative (b) ionization modes. Venn diagrams 
comparing the molecular features detected in the three analyses in negative (a) and 
positive (b) ionization modes. 
3.4.  Sample cleaning by centrifugal solid phase extraction 
 The Macroduct® sweat collection system is commercialized for the 
determination of chloride in sweat as a diagnostic tool for cystic fibrosis. It is easy 
to use, reproducible, and sample collection does not require an additional 
extraction procedure. However, this system is based on stimulation of sweat by 
pilocarpine iontophoresis and collection of the sweat in a disposable plastic 
device containing a water soluble colorant. Consequently, the gel components 
employed for sweat stimulation were identified in human sweat either by direct 
analysis or after sample hydrolysis. Therefore, it would be interesting to reduce 
the presence of these interferents in collected sweat by implementation of sample 
hydrolysis 
hydrolysis 
hydrolysis 
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preparation steps. For this reason, the possibility of including centrifugal SPE 
using C18 or hydrophilic Micro SpinColumnTM was studied. The protocol based 
on hydrophilic SpinColumnTM was proved by analysis of both the non-retained 
fraction and the eluate using the HILIC chromatographic mode in both polarities. 
The resulting chromatograms, shown in Supplementary Fig. 3, were quite similar 
to those obtained by direct analysis in the case of the eluate and gave no 
information in the case of the non-retained fraction. Thus, no improvement in 
terms of metabolite coverage was observed using this SPE protocol. 
 Concerning sweat preparation by C18 SpinColumnTM, analysis of the non-
retained metabolites and those in the eluate was independently carried out by 
both chromatographic columns (C18 and HILIC). Fig. 3 shows the 
chromatograms obtained in both ionization modes from the non-retained 
fraction (non-retained metabolites and those washed out in the cleaning step) 
analyzed using the C18 (Fig. 3a) or HILIC analytical column (Fig. 3b). The 
chromatograms reveal the degree of efficiency of this SPE step for pilocarpine 
removal, while methylparaben and propylparaben were completely removed from 
the sample. The metabolites in the eluate —use of 50% (v/v) acetonitrile for 
elution—, with a higher non polar character, were analyzed by the 
chromatographic C18 column for optimum retention. Supplementary Fig. 4 
illustrates the chromatograms provided by both ionization modes, in which 
intense peaks identified as pilocarpine, methylparaben and propylparaben 
appear. Other exogenous metabolites such as caffeine and theophylline were also 
identified in the eluate by positive ionization mode. Therefore, this strategy could 
add interest for sweat cleaning by removal of undesired exogenous metabolites.  
 Fig. 4a and 4b shows the Venn diagrams comparing the detection 
coverage in sweat analysis by the C18 analytical column using two different 
approaches: direct analysis with only dilution, and centrifugal SPE with C18 
SpinColumnTM (non-retained and eluted fractions). In negative ionization mode, 
the most remarkable aspect is the detection of 78 molecular entities in the non 
retained fraction after SPE versus 29 entities detected by direct analysis. 
Pilocarpine, methylparaben and propylparaben were only detected in the analysis 
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after sweat dilution and in the SPE eluate. This effect was similarly observed in 
positive mode since detection of 69 molecular entities by centrifugal SPE (which 
included 91% of the entities detected in diluted human sweat) was possible. 
 
Fig. 3. BPCs obtained in positive and negative ionization modes for the non-retained 
fraction after centrifugal SPE of human sweat with C18 SpinColumnTM using both 
chromatographic modes: RP-C18 (a) and HILIC (b). 
 Fig. 4c and 4d shows the Venn diagrams that compare the detection 
coverage in the analysis of human sweat by the HILIC analytical column with 
sample dilution and after centrifugal SPE with the C18 SpinColumnTM (eluate). In 
this case, more differences were observed between direct analysis and after SPE 
by the hydrophilic sorbent both in positive and negative ionization modes. In 
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fact, approximately 40% molecular features detected by analysis of diluted sweat 
were exclusive of this approach. 
 
 
Fig. 4. Venn diagrams comparing the detection coverage in direct sweat analysis and after 
centrigual SPE using C18 SpinColumnTM (retained and non-retained fractions) using  
RP-C18 chromatographic mode in negative (a) and positive (b) ionization modes, and 
using HILIC mode in negative (c) and positive (d) ionization modes. 
 Attending to these results, the C18 centrifugal SPE approach is 
appropriate as cleaning strategy by analysis of the non retained fraction since the 
main interferents associated to the sampling device and exogenous metabolites 
are retained and subsequently eluted after collection of the non retained target 
analytes. 
3.5. Identification of potential entities detected by MS/MS 
 Few studies on metabolic composition of sweat have been carried out 
since the systematic investigations of sweat composition started in the last part of 
the past century [17]. A recent research by Kutyshenko et al. provided a list of 43 
compounds identified by NMR in human sweat including amino acids, sugars 
and carboxylic acids, among others [12]. However, NMR offers limited sensitivity 
as compared to MS; therefore, identification of sweat metabolites by MS could 
increase the metabolomics coverage. 
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 In this research, 41 sweat compounds were identified and confirmed 
including amino acids, sugars, dicarboxilic acids, fatty acids and derivatives as 
well as exogenous compounds. Only compounds with high quality of MS/MS 
spectra at different collision energies were considered in this step. Identification 
was supported on mass accuracy of precursor ions and that of the most 
representative fragments, searching for them in the METLIN database. Table 1 
lists the 43 identified metabolites, which are classified by families. Information 
on identification in terms of MS precursor ion and the two most representative 
product ions is also included. As most of the compounds are detected in both 
positive and negative ionization polarities, only the ionization mode with the 
highest sensitivity is included. In all cases, the mass accuracy error, expressed as 
ppm for precursor ions, ranged from 0 to 4 ppm. The retention time for each 
compound in both tested chromatographic systems is also included. As exposed 
above, chromatographic resolution by HILIC methods is better than that by C18 
methods as the latter led to coelution of many metabolites in the first part of the 
chromatogram. 
 Comparison of the relative intensities for the identified metabolites by 
the different sample treatments revealed that sample clean up by C18 
SpinColumnTM provided the best results in terms of efficiency for most families. 
Furthermore, most exogenous compounds are almost completely removed from 
the sample when this strategy is adopted. On the other hand, fatty acids and 
derivatives were better detected after sample preparation by the hydrophilic 
SpinColumnTM.  
 The variety of metabolites identified in sweat emphasizes the interest of 
sweat to be assessed for clinical analysis. Most of the identified metabolites were 
amino acids and dicarboxylic acids, which are representative of crucial 
biochemical pathways that could be related to pathologies or dysfunctions. Thus, 
19 amino acids, including essential and non essential amino acids, were identified 
in sweat by combining positive and negative ionization modes. Two amino acids 
derivatives such as tyramine (tyrosine derivative) and pyroglutamic acid 
                                                                                                                         
119 
J. Chromatogr. A, 1333 (2014) 70–78 Section I. Chapter 1 
 
(glutamic acid derivative) and a dipeptide such as prolylhydroxyproline were 
unequivocally identified in sweat. 
Table 1. List of metabolites identified in human sweat classified by families. Retention 
time in both chromatographic modes are included as well as the MS identification 
information (precursor and product ions) and the error (expressed in ppm) of the 
precursor ion detected. 
Family Metabolite 
MS spectra 
(m/z) 
[adduct] 
MSMS 
spectra 
(m/z) 
RT (min) 
C18 HILIC 
Amino acids 
Arginine 
175.1188 
[M+H]+ 
130.0969 
116.0709 
0.67 - 
Aspartic acid 
132.0302 
[M-H]- 
88.0434 
71.0134 
0.70 17.64 
Carnitine 
116.1124 
[M+H]+ 
103.0391 
60.0804 
0.67 13.62 
Citrulline 
176.1029 
[M+H]+ 
159.0767 
113.0702 
0.72 15.93 
Glutamate 
148.0601 
[M+H]+ 
130.0485 
84.0454 
0.72 17.26 
Glutamine 
147.0759 
[M+H]+ 
130.0504 
84.0454 
0.69 - 
Histidine 
156.0764 
[M+H]+ 
110.0712 0.68 19.19 
Leucine/Isoleucine 
132.1017 
[M+H]+ 
86.0966 
44.0499 
1.43 7.00 
1.61 6.45 
Methionine 
150.0581 
[M+H]+ 
133.0310 
104.0527 
1.14 - 
Ornithine 
131.0826 
[M-H]- 
83.0606 0.72 15.91 
Phenylalanine 
166.0860 
[M+H]+ 
120.0806 
103.0541 
3.55 5.92 
Proline 
116.0706 
[M+H]+ 
70.0655 0.78 9.25 
Serine 
104.0353 
[M-H]- 
74.0248 0.67 14.32 
Taurine 
124.0074 
[M-H]- 
79.9565 0.71 7.93 
Threonine 
120.0655 
[M+H]+ 
102.0548 
74.0606 
0.70 17.76 
Tryptophan 
205.0971 
[M+H]+ 
188.0705 
159.0915 
4.67 6.34 
Tyrosine 
180.0666 
[M-H]- 
163.0404 
72.0097 
1.80 8.34 
Valine 
118.0862 
[M+H]+ 
72.0812 0.92 7.56 
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Amino acid 
derivatives 
Pyroglutamic acid 
128.0353 
[M-H]- 
82.0292 1.56 10.25 
Tyramine 
120.0806 
[M+H-H2O]+ 
103.0542 
77.0393 
3.53 6.10 
Prolyl 
hydroxyproline 
227.1041 
[M-H]- 
112.0398 4.68 6.42 
Amino acid 
breakdown product 
Urocanic acid 
137.0357 
[M-H]- 
93.0459 
66.0342 
1.16 7.76 
Metabolites 
involved in purine 
nucleosides 
degradation 
Inosine 
267.0728 
[M-H]- 
135.0310 - 4.99 
Uric acid 
167.0211 
[M-H]- 
124.0157 1.54 10.32 
Dicarboxylic acids 
Azelaic acid 
187.0976 
[M-H]- 
125.0970 
97.4887 
6.96 4.22 
Butanedioic acid 
117.0191 
[M-H]- 
163.0250 
[M+FA-H]- 
71.0139 
101.0246 
73.0302 
0.91 6.52 
Sebacic acid 
201.1134 
[M-H]- 
183.1038 
139.1131 
7.62 - 
Suberic acid 
173.0824 
[M-H]- 
111.0809 
83.0503 
6.21 - 
Exogenous 
compounds 
Caffeine 
195.0879 
[M+H]+ 
138.0655 
110.0708 
5.31 2.87 
Methylparaben 
151.0413 
[M-H]- 
136.0172 
92.0278 
7.56 2.50 
Pilocarpic acid 
225.1246 
[M-H]- 
163.1218 
 
2.93 10.63 
Pilocarpine 
209.1279 
[M+H]+ 
163.1227 
95.0608 
3.35 3.01 
Propylparaben 
179.0714 
[M-H]- 
136.0153 
92.0262 
9.33 2.51 
Theophylline 
181.0712 
[M+H]+ 
124.0498 
69.0444 
4.76 3.18 
Nutrients 
Choline 
104.1070 
[M+H]+ 
60.0819 
45.0340 
0.64 6.36 
Coumaric acid 
165.0554 
[M+H]+ 
119.0499 1.79 8.32 
Fatty acids 
derivatives 
MG (18:0) 
359.3148 
[M+H]+ 
341.3042 
85.1008 
- 2.48 
MG (16:0) 
331.2831 
[M+H]+ 
313.2711 
123.1155 
10.44 2.50 
MG (22:2) 
431.3127 
[M+Na-2H]- 
89.0247 10.12 2.60 
Sphingolipids C16 Sphinganine 
274.2742 
[M+H]+ 
257.2480 8.76 - 
Sugars 
Maltotriose 
503.1636 
[M-H]- 
161.0463 
341.1094 
0.79 16.58 
Tetrasaccharide 
689.2113 
[M+Na]+ 
325.1123 
487.1625 
0.81 18.78 
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 Concerning dicarboxylic acids, azelaic acid, butanedioic acid, sebacic acid 
and suberic acid were confirmed in negative ionization mode. The identification 
of four dicarboxylic acids reveals the importance of this group of endogenous 
metabolites in human sweat. 
 Two metabolites involved in the degradation of purine nucleosides such 
as inosine and uric acid were also detected in human sweat. Therefore, the 
activity of this pathway is also reflected in this non invasive sample. Urocanic 
acid, a breakdown product of histidine, was identified as excreted metabolite in 
human sweat. This compound is accumulated in the epidermis where it acts as a 
UV protector and as immunoregulator. One other low molecular weight 
metabolite identified in sweat was choline, which can be either ingested as free 
form in the diet or produced by degradation of glycerophosphocholines. Previous 
studies have described the presence of this metabolite in sweat [12,13]. 
 Finally, it is worth mentioning the identification of one sphingolipid and 
three fatty acid derivatives with non polar character —viz. C16 sphinganine and 
three monoacylglycerols such as MG(18:0), MG(16:0) and MG(22:2)—, which 
emphasize the presence of non polar metabolites in sweat, despite the aqueous 
nature of this biofluid. 
 Among the 43 compounds identified in this research using LC–QTOF  
some of them (viz. coumaric acid, uric acid, dicarboxylic acids, carnitine, taurine, 
tyramine, tyrosine and fatty acid related compounds) were not identified by a 
previous study based on NMR [12]. In addition, some of the identified 
metabolites had been evaluated as potential biomarkers in other biofluids [18-
20]; aspect that may be of interest to study sweat as potential biofluid for 
biomarker searching. 
 
4. Conclusions 
 Different sample preparation protocols as well as different chroma-
tographic modes have been compared for global metabolomics profiling analysis 
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of sweat. Although sweat is scarcely used in metabolomics studies, its potential 
for discrimination of metabolic profiles correlated with different pathologies 
would make this biofluid interesting to explore. Among the tested protocols, 
sweat hydrolysis would not be recommended for metabolite profiling since the 
sample integrity is altered by detection of numerous artifacts. Direct analysis 
after dilution was a suited option to obtain a representative snapshot of sweat 
metabolome. On the other hand, the clean up step with C18 SpinColumn SPE 
cartridges improves sensitivity and reduces the number of exogenous 
compounds. Only for fatty acids the clean up step should be developed by 
hydrophilic SpinColumn SPE cartridges. 
 Identification of a high number of sweat components from a wide variety 
of families demonstrated that LC–QTOF MS/MS is a good strategy to analyze this 
biofluid. It should be mentioned that almost 50% of the identified compounds 
were amino acids, being the compounds more abundant in sweat. 
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Supplementary material 
 
Supplementary Fig. 1. Distribution of the retention times for the molecular features 
detected by LC–MS/MS analysis of human sweat with each chromatographic mode and 
ionization mode. 
 
 
Supplementary Fig. 2. Principal Component Analysis (PCA) as quality control study to 
evaluate instrumental precision by analysis of human sweat pool using the signal of 
methylparaben as normalization strategy. 
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Supplementary Fig. 3. BPCs obtained after centrigugal SPE of human sweat with 
hydrophilic SpinColumnTM by analysis of the retained fraction (a) and non-retained 
fraction (b). 
 
Supplementary Fig. 4. BPCs obtained by analysis of the retained fraction in 
centrifugal SPE of human sweat with C18 SpinColumnTM in positive (a) and negative 
(b) ionization modes. 
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Enhancing detection coverage in global 
metabolomics profiling by automated solid-phase 
extraction on-line coupled to LC–MS/MS 
M. Calderón-Santiago, F. Priego-Capote*,  M. D. Luque de Castro 
Abstract 
 One of the main shortcomings of global metabolomic profiling is a 
limited detection coverage that, however, can be improved by a combination of 
analytical techniques such as NMR spectroscopy, LC–MS or GC–MS. An 
automated approach was configured by on-line coupling of solid-phase extraction 
(SPE) to LC–MS. The approach was applied to the metabolomic analysis of 
human serum based on sample fractionation by this SPE–LC–MS coupling. With 
this purpose, sorbents acting either via non-mixed or mixed retention 
mechanisms were assessed for their ability to provide selective fractions of serum 
metabolites. A combination of the results provided by the SPE protocols for the 
different sorbents allowed 3445 molecular entities to be detected —more than 
73% in the fractions eluted from at least two sorbents. Also, more than 81% of 
this detection coverage was obtained by a combination of analyses carried out in 
the eluates from four sorbents: polydivinylbenzene resin, C18 sorbent, and 
anionic and cationic mixed-mode polymeric sorbents. Also, pairs of SPE 
protocols were serially conducted in automated SPE–SPE–LC–MS confi-
gurations to boost their selectivity in single analyses and hence maximize 
throughput, which can be especially useful with scarce or highly valuable 
samples. The serial configurations afforded single-analysis detection coverages of 
79.5–99.7% for molecular features via two separate analyses with the same 
sorbents.  
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1.  Introduction 
 The primary purpose of metabolomics is to analyze the complement of 
low-molecular weight compounds present in a biological fluid, cell or organism 
under a given set of physiological conditions or different perturbations. 
Metabolomics essentially relies on three major strategies depending on whether 
analyses are to be comprehensive, qualitative and/or quantitative [1]. So-called 
“targeted analyses” involve the qualitative and quantitative study of one or, more 
frequently, a small group of chemically similar metabolites. On the other hand, 
metabolomics fingerprinting uses a global screening approach to classify samples 
in terms of metabolite patterns (fingerprints) that change in response to a 
specific factor. Finally, global metabolomics profiling or “untargeted analysis” 
involves the detection of a broad range of metabolites by using a single analytical 
platform or a combination of complementary analytical platforms to obtain a 
comprehensive profile of the metabolome. The greatest challenge of 
metabolomics is maximizing detection and accurate identification of thousands 
of metabolites, which is currently a utopian goal in dealing with complex 
organisms. For instance, viral and bacterial metabolomes contain around a 
thousand or even fewer metabolites [2,3], whereas the human metabolome 
consists of approximately 7900 metabolites [4] and plant metabolomes can easily 
contain up to 100 000–200 000 metabolites [5,6]. The determination ability of 
platforms for metabolomics analysis can be measured in terms of “metabolomics 
coverage”, that is, the number of metabolites an individual platform such as GC–
MS/MS, LC–MS/MS, CE–MS/MS or NMR spectroscopy, or a combination 
thereof, can detect. 
 The main limitation of existing metabolomics profiling methodologies is 
a result of the high complexity of the metabolome, which includes a wide range of 
compounds with different physico–chemical properties at concentrations 
spanning several orders of magnitude [7,8]. Specifically, metabolite levels can 
range from a few picomoles to a few millimoles per litre, which complicates the 
detection of low-concentrated metabolites in the presence of metabolites existing 
at high concentration levels.  
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 The most effective strategy for the comprehensive analysis of 
metabolomes currently available involves integrating information obtained with 
different analytical platforms (mainly NMR spectroscopy [9,10] and MS coupled 
to a separation technique such as GC, LC or CE [11–13]) or using direct infusion 
[14,15]. One other way of maximizing metabolomic coverage is by optimizing 
existing fractionation protocols for sample preparation [16,17]. These protocols 
are intended to enable the analysis of metabolites according to physico-chemical 
properties such as polarity, acid–base character, affinity or molecular size. 
Sample preparation in metabolomics usually includes liquid–liquid extraction 
(LLE) [18–20] or solid–liquid extraction with different solvents with special 
emphasis on solid-phase extraction (SPE) with selective sorbents [21,22]. 
However, the poor automatability of these strategies makes protocols time-
consuming. For example, the metabolomics profiling of Escherichia coli has been 
addressed by integrating the analysis of extracts obtained with different solvent 
compositions [23]. This strategy, however, cannot be automated, so it is 
impractical for analyzing large numbers of samples. Unlike liquid–liquid 
extraction and solid–liquid extraction, SPE can be easily automated to extract 
metabolites from biological fluids with a wide variety of sorbents capable of 
retaining compounds with different properties [24-26]. Integrative SPE with 
selective sorbents for subsequent LC–MS analysis can be expected to improve 
metabolomics coverage.  
 In this work, an automated platform was used for integrative SPE 
coupled on-line to LC–MS/MS analysis of human serum in high resolution mode 
with a view to enhancing metabolomics coverage in relation to conventional 
protocols currently used to characterize the serum metabolome. In addition, the 
proposed platform allows complementary SPE protocols to be combined in 
purposely constructed SPE–SPE–LC–MS configurations for more compre-
hensive analysis of biofluids. The ultimate aim was to increase the number of 
metabolites detected in order to acquire more biological information for 
subsequent processing. 
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2. Experimental section 
2.1. Chemicals 
 MS-grade acetonitrile (ACN), formic acid, ammonia and ammonium 
formate were purchased from Scharlab (Barcelona, Spain) and used to prepare 
chromatographic mobile phases and the solutions used in the SPE protocol. 
Deionized water (18 m · cm) from a Millipore Milli-Q water purification system 
was used throughout. 
2.2. Instruments and apparatus 
 An Agilent 1200 Series LC system coupled to an Agilent Accurate-Mass 
QTOF hybrid mass spectrometer equipped with a dual source for electrospray 
ionization (ESI) (Santa Clara, CA, USA) was used to construct the analytical 
platform (Fig. 1). The chromatographic eluate was monitored in the accurate 
mass mode. 
 SPE was done in a Symbiosis Pharma automated workstation from Spark 
Holland (Emmen, The Netherlands) equipped with a Reliance autosampler, also 
from Spark Holland, and a refrigerated stacker sample compartment. The 
autosampler was furnished with a 0.2 mL sample loop. The workstation 
contained two high-pressure syringe dispensers (HPD) for solvent delivery and 
four 6-port valves connected with Peek tube of 0.25 mm i.d. (VICI, Houston, 
Texas, USA), which was used for all system connections. The SPE workstation 
was equipped with a unit for cartridge exchange —automatic cartridge exchanger 
(ACE)— holding up to 100 cartridges which were clamped in the loop of two of 
the valves (Clamp I and Clamp II) for each analysis. A 1 mL × 1.0 mm i.d. 
stainless tube from Análisis Vínicos (Tomelloso, Spain) was used to connect the 
two valves of the SPE workstation (viz. Valve 2 and Clamp II). This configuration 
allowed the eluate from the first cartridge (Clamp I) to be conditioned for a 
second SPE step (Clamp II), if required, by mixing with other solution prior to 
loading in a complementary second cartridge. Cartridges (10 × 2 mm) packed 
with the following sorbents were tested: Hysphere C2 (silica-based ethyl phase), 
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Hysphere C8 (EC) (end-capped silica-based octyl phase), Hysphere C18 (silica-
based octadecyl phase), Hysphere Resin GP (polymeric polydivinylbenzene 
phase), Hysphere Resin SH (strong hydrophobic-modified polystyrene–
divinylbenzene), Hysphere MM anion (mixed-mode anionic), Hysphere MM 
cation (mixed-mode cationic, Spark Holland) and Oasis HLB (hydrophilic–
lipophilic balance, Waters, Milford, MA, USA). The fourth valve, located behind 
the column compartment, was used to select the chromatographic fraction to be 
monitored in LC–MS/MS.. 
2.3. Blood collection and serum isolation 
 Venous blood was collected in evacuated sterile serum tubes (Vacutainer, 
Becton Dickinson, Franklin Lakes, NJ, USA) containing no additives and 
incubated at room temperature for 10 min to facilitate coagulation. Then, the 
tubes were centrifuged at 2000 g at 4 °C for 15 min to isolate the serum fraction 
(processing within 2 h after collection). A serum pool prepared by mixing 
different serum samples and stored at –80 °C until analysis was used in all 
optimization tests.  
2.4.     LC–TOF/MS analysis 
 Chromatographic separation was performed at 25 °C, using a C18 
reversed phase analytical column (Mediterranean, 100 mm × 4.6 mm i.d., 3 m 
particle size) from Teknokroma (Barcelona, Spain). The mobile phases used were 
water (phase A) and ACN (phase B), both containing 0.1% formic acid as 
ionization agent or 5 mM ammonium formate (pH 6.1) when using cationic 
cartridges. The LC pump was programmed to operate at a flow rate of 0.8 
mL/min in accordance with the following gradient elution sequence: 3% phase B 
for 1 min; phase B ramp from 3 to 100% from min 1 to min 25; and hold at 100% 
for 3 min. 
 The electrospray ionization source was operated in the positive and 
negative ionization modes, using the following settings: capillary and fragmentor 
voltage ±3.5 kV and ±175 V, respectively; N2 nebulizer gas pressure 40 psi; and 
N2 drying gas flow rate and temperature 10 L/min and 325 °C, respectively. The 
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instrument was calibrated and tuned as recommended by the manufacturer. Data 
were collected in the centroid mode, using a rate of 1.0 spectrum per second in 
the extended dynamic range mode (2 GHz). Accurate mass spectra were acquired 
over the m/z range 100–1100. The instrument gave typical resolution 15 000 
FWHM (Full Width at Half Maximum) at m/z 118.086255 and 30 000 FWHM at 
m/z 922.009798. Mass accuracy in recorded ions was assured by continuous 
internal calibration via the signals at m/z 121.0509 (protonated purine) and m/z 
922.0098 [protonated hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine or 
HP-921] in the positive ionization mode; and those at m/z 112.9856 
(trifluoroacetate anion) and m/z 1033.9881 (HP-921) in the negative mode.  
2.5. Single cartridge automatic SPE configuration and protocol 
 The retention capabilities of the different cartridges were assessed 
separately, using a single cartridge configuration (Fig. 1). For this purpose, four 
standard SPE protocols (see Table 1) were programmed for application in terms 
of the characteristics of each sorbent, namely: two reversed phase protocols 
differing only in the loading solution, a cationic protocol and an anionic protocol. 
In all cases, retained metabolites were eluted by using a suitable mobile phase in 
the programmed gradient of the chromatographic method. Variability in the 
process was assessed by using three replicates per sorbent (see Supplementary 
Fig. 1). 
Table 1. Solid phase extraction protocols used with the different sorbents. 
Step 
Reversed phase 
protocol 1 
Reversed phase 
protocol 2 
Cationic 
protocol 
Anionic 
protocol 
Solvation 1 mL ACN 1 mL ACN 1 mL ACN 1 mL ACN 
Equilibration 1 mL water 
1 mL 
20% ACN 
1 mL 
20% ACN  
1% formic acid 
1 mL 
20% ACN  
2% ammonia 
Sample 
loading 
1 mL water 
1 mL 
40% ACN 
1 mL 
20% ACN  
1% formic acid 
1 mL 
20% ACN  
2% ammonia 
Elution 
Mobile phase with 
formic acid 
Mobile phase with 
formic acid 
Mobile phase 
with ammonium 
formate 
Mobile phase 
with formic 
acid 
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Figure 1. Instrumental configurations for single- and double-cartridge SPE on-line 
coupled to LC–TOF/MS including an autosampler (AS), two high-pressure dispensers 
(HPDs), two clamps and five two-position valves (one with a T-rotor). 
 
2.6. Double cartridge automatic SPE configuration and protocol  
 The double cartridge configuration used to combine complementary 
cartridges is also shown in Fig 1. The SPE protocols were similar (see Table 1) and 
differed only in equilibration or in the solution loaded into the second cartridge. 
HPD 2 was used to directly pump an appropriate solution to equilibrate the 
second cartridge or for mixing with the eluate from the first cartridge. The eluates 
from both cartridges were sequentially led to the chromatographic column for 
independent, consecutive analysis. 
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2.7.  Data processing and statistical analysis 
 MassHunter Workstation software (version 3.01 Qualitative Analysis, 
Agilent Technologies, Santa Clara, CA, USA) was used to process all data 
obtained by LC–TOF/MS in the full scan MS mode. Processing of raw data files 
started by extracting potential molecular features (MFs) with the applicable 
algorithm included in the software. The extraction algorithm considered all ions 
exceeding 5000 counts (above background noise) with a single charge state. In 
addition, the isotopic distribution for a valid feature had to be defined by two or 
more ions (with peak spacing tolerance of 0.0025 m/z, plus ±7.0 ppm). Adduct 
formation in the positive (+Na, +K, +NH4) and negative ionization mode (+Cl, 
+HCOO), and neutral losses by dehydration and the loss of phosphate, 
glucuronide or methyl groups, were also included to identify features of the same 
metabolite. Thus, ions with identical elution profiles and related m/z values 
(representing different adducts or isotopes of the same compound) were 
extracted as entities characterized by their retention time (RT), intensity at the 
apex of each chromatographic peak and accurate mass. In this way, raw data files 
were created in compound exchange format (.cef files) for each sample and 
exported into the Mass Profiler Professional (MPP) software package (version 
2.0, Agilent Technologies, Santa Clara, CA, USA) for further processing. In a 
subsequent step, the data were preprocessed by aligning retention times and m/z 
values across the data matrix, using a tolerance window for retention time and 
mass accuracy of 0.5 min and 7 ppm, respectively. Venn diagrams were then 
constructed to compare the number of entities found with each cartridge or 
configuration. 
 
3. Results and discussion 
 As stated before, the selectivity of the retention mechanisms for SPE 
sorbents can provide an interesting analytical tool for assisting fractionation of 
complex metabolomes. 
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 This research was entirely conducted with a pool serum prepared from 
several healthy donors to ensure comparability of tests, all of which were 
performed in triplicate. Also, all chromatographic separations were done by using 
a C18 phase column in the reversed gradient mode. HILIC chromatographic 
columns were not included in this study since the elution step was carried out in 
gradient mode for all tested sorbents. Thus, HILIC-gradient methods were not 
compatible with this elution mode. Retention capabilities were optimized for 
comparison of the sorbents based on non-mixed retention mechanisms first and 
those relying on mixed mechanisms then. Sorbents providing wider coverage 
were also assayed, using the above-described serial configurations 
3.1. Retention capabilities of SPE reversed phase sorbents based on non-
mixed mechanisms 
 The materials acting via non-mixed retention mechanisms studied here 
included C18, C8 and C2, in increasing polarity —a function of the hydrocarbon 
chain length. The retention ability of each material was assessed by inserting on-
line the eluted fraction from the column into the LC–TOF/MS system to 
determine the number of metabolites retained in the sorbent. The results are 
shown as a Venn diagram in Fig. 2.A. As can be seen, the C2, C8 and C18 sorbents 
allowed a quite similar number of molecular features to be determined (viz. 1421, 
1524 and 1593, respectively; and up to 2178 entities in combination). Also, a 
minimum of 1459 common molecular features, which represented 67.0% of the 
total detection potential, were detected in at least two of the tests. Based on these 
results, the C18 sorbent was seemingly the best for obtaining a representative 
view of the metabolome of human serum judging by its detection capabilities. 
However, C8 and C2 should not be discarded as they enabled the detection of a 
substantial number of molecular entities not covered by C18. Supplementary Fig. 
2.A shows the base peak chromatograms (BPCs) in the positive ionization mode 
obtained by LC–TOF/MS analysis of the eluates from the three SPE sorbents. 
The analysis of the fractions extracted with C18, C8 and C2 gave BPCs with wide 
common chromatographic zones and a few different zones. The differences 
between the results obtained in the negative and positive ionization modes were 
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quite similar (see BPCs in Supplementary Fig. 2.B); also, the eluates from the C8 
and C2 sorbents exhibited decreased retention efficiency relative to C18. Figure 
2.B shows the extracted ion chromatograms (EICs) for m/z 518.3217 
corresponding to LysoPC(18:3), which represents to a characteristic family of 
serum metabolites detected in the eluted fraction of the three sorbents. As can be 
seen, the retention efficiency of LysoPC(18:3) in C18 sorbent was clearly higher 
than that observed for the other two tested materials. 
 
Figure 2. A) Venn diagram comparing molecular features (MFs) determined with a 
single-cartridge SPE–LC–TOF/MS configuration and sorbents based on non-mixed 
retention mechanisms (C18, C8 and C2) in the positive ionization mode.  B) Extracted ion 
chromatogram (EIC) for precursor ion at m/z 518.3217 corresponding to lysoPC (18:3). 
 
3.2. Retention capabilities of SPE sorbents based on mixed mechanisms 
 Materials simultaneously acting via mixed retention mechanisms are 
frequently used to expand the applicability of SPE. In this work, we used five 
types of sorbents based on different retention mechanisms, namely: polymeric 
resins GP (polymeric polydivinylbenzene phase) and SH (strong hydrophobic-
modified polystyrene-divinylbenzene); Oasis HLB (a sorbent with balanced 
hydrophilic and lipophilic interactions); and two sorbents exhibiting ionic 
interactions (an anionic and a cationic MM sorbent). These sorbents were tested 
with the reversed phase protocol previously used for sorbents involving non-
mixed retention mechanisms. As can be seen in Fig. 3.A, the eluate from resin GP 
provided greater coverage of metabolites in human serum than the other 
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sorbents acting via a combined retention mechanism (viz. 1596 entities versus 
1215 with resin SH and 1119 with HLB). In fact, 78% of the entities detected in the 
eluate from resin GP were also detected with HLB and SH. Based on these results 
resin GP is seemingly especially suitable for obtaining a representative profile of 
metabolites in human serum under the tested conditions. Supplementary Fig. 2.C 
shows the BPCs obtained by analyzing the eluates from the resing GP, resin SH 
and Oasis HLB; as can be seen, there were critical differences consistent with the 
Venn diagrams. Figure 3.B and C illustrate EICs for m/z 203.0526  
corresponding to a sodium adduct of a hexose such as glucose, fructose or 
mannose and m/z 132.1019 associated to leucine. Both metabolites are 
representative examples of high and low concentrated metabolites in serum, 
detected in the eluted fraction of the three sorbents. The retention efficiency of 
these compounds in resin GP sorbent was clearly higher than that observed in the 
other two polymeric materials.   
 
Figure 3. A) Venn diagram comparing molecular features (MFs) determined with a 
single cartridge SPE–LC–TOF/MS configuration and sorbents based on mixed retention 
mechanisms (resin GP, resin SH and HLB Oasis). B) EIC for precursor ion at m/z 
203.0526 associated to a sodium adduct of a hexose. C) EIC for a precursor ion at m/z 
132.1019 corresponding to leucine. 
 
 Ionic MM sorbents were studied by using a protocol similar to that for 
the reversed SPE procedures but at a different pH in two key steps: sample 
loading and elution. In this way, ionic interactions were enhanced via the 
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formation of formic acid and ammonium formate, which facilitated retention of 
cationic and anionic compounds in both cartridges (see Table 1). The two car-
tridges contained the same polymeric support and differed only in their cationic 
or anionic nature; therefore, their differences in retention capabilities can be 
exclusively ascribed to ionic interactions and the influence of an acid or base on 
the loading and elution steps. As can be seen from Fig. 4, a high proportion of 
molecular features (60% with the anionic MM sorbent and 80% with the cationic 
MM sorbent) were detected in the eluates from both cartridges. Also, the 
sorbents proved quite selective: independent experiments with the ionic MM 
sorbents allowed 316 and 122 features to be uniquely detected. These differences, 
resulting from the selectivity of the sorbents, reflected in marked overlap between 
the BPCs for the two sorbents (see Supplementary Fig. 2.D). Figure 4 also shows 
EICs of two metabolites, thromboxane A2 (m/z 353.2322) and 1-
methyladenosine (m/z 282.1196), which were preferably retained in one of the 
ionic MM sorbents. Thus, thromboxane A2 was well-retained in the anionic 
polymeric sorbent while 1-methyladenosine was properly retained in the cationic 
polymeric sorbent. These examples support the complementary behavior of both 
SPE cartridges. 
 
 
 
Figure 4. A) Venn diagram comparing molecular features (MFs) determined with a single 
cartridge SPE–LC–TOF/MS configuration and sorbents based on mixed retention 
mechanisms (anionic and cationic MM sorbents). B) EICs for precursor ions at m/z 
353.2322 and 282.1196 corresponding to thromboxane A2 and 1-methyladenosine, 
respectively. 
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3.3. Detection coverage of SPE–LC–TOF/MS with the studied sorbents 
 Once assessed for retention, the sorbents were compared in terms of the 
number of molecular features detected in their eluates. Table 2 lists the number 
of entities detected by SPE–LC–TOF/MS in each fraction. Aligning the TOF 
chromatograms via the retention time and mass accuracy afforded the detection 
of 3445 molecular entities in combination —more than 73% in the eluates from at 
least two sorbents. Supplementary Fig. 3 shows the extracted ion chromatograms 
obtained in the analysis of different eluates for three of the metabolites present in 
human serum. In view of these results, sample fractionation by SPE could be an 
approach for maximizing the detection capabilities of some analytical 
methodologies.  
Table 2. Molecular features detected in the SPE–LC–TOF/MS analysis of the fractions 
eluted from each sorbent in the single-cartridge configuration. The total number of unique 
molecular features detected, and the proportion detected with each individual sorbent, are 
also shown. 
Sorbent Number of MFs Detection coverage (%) 
C18 1593 46.2 
C8 1524 44.2 
C2 1421 41.2 
Resin GP 1596 (801)* 46.3 
Resin SH 1215 (603)* 35.3 
Oasis HLB 1119 (403)* 32.5 
MM anion 795 23.1 
MM cation 601 17.4 
Total 3445  
* The number of entities detected with the nonpolar protocol is given in brackets. 
 
 Psychogios et al. in the framework of the Human Metabolome Database 
Consortium [27] succeeded in detecting and identifying 3564 metabolites by 
using a combination of five different methodologies based on LC–MS/MS, NMR, 
GC–MS, direct infusion–MS and TLC prior to GC–FID. In the research proposed 
here no overall identification was carried out by tandem mass spectrometry since 
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the main objective was to show that the selectivity of these sorbents can be 
exploited jointly in on-line SPE–LC–MS analysis of biological samples to 
substantially increase the metabolite coverage of this detection technique. 
The detection capability of the SPE–LC–TOF/MS approach with 
combination of sorbents was also assessed by comparison with the analyses of 
fractions obtained by serum liquid–liquid extraction with a methanol–
chloroform system. To this end, a 300 μL aliquot of the serum pool was mixed 
with an identical volume of a 1:2 chloroform–methanol solution to precipitate 
proteins. The methanolic and chloroform fractions were separated by 
centrifugation and analyzed by LC–TOF/MS. As can be seen, the combined 
analysis of the two fractions enabled detection of 1444 entities, which is below the 
detection capability of the automated SPE approach. Figure 5 compares the 
results obtained by the SPE–LC–TOF/MS approach and the precipitation 
method involving a binary mixture of methanol and chloroform.  
 
 
Figure 5. Venn diagram comparing molecular features (MFs) determined by SPE–LC–
TOF/MS combining all sorbents tested in comparison with a method based on liquid–
liquid extraction with methanol–chloroform mixture and independent analysis of the two 
fractions. 
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 The potential of sorbents individually exhibiting the highest detection 
coverage in SPE–LC–TOF/MS was assessed with a view to their joint, 
complementary use. The target sorbents were C18 and resin GP, which were used 
with conventional reversed phase protocols, as well as cationic and anionic MM 
sorbents, which were used with pH-modified protocols. Supplementary Fig. 4 
shows a Venn diagram comparing the metabolite coverage achieved by analyzing 
the respective eluates. As can be seen, only 10 molecular features were shared by 
the four eluates; this underlines the fractionation capabilities of the selected 
materials. Using the four eluates in combination allowed the detection of a total 
of 2812 molecular entities —a much higher figure than that provided by 
independent analyses with the individual sorbents. Many of the features (62%) 
were detected in the eluates from at least two sorbents. In addition, the results of 
these joint analyses were complementary. Thus, 881 unique features were 
detected in the eluates from the ionic MM sorbents, with 459 common entities 
detected with the anionic and cationic protocols. On the other hand, 1895 
molecular features were exclusively detected with the protocols based on SPE in 
the reversed mode (C18 and resin GP). Finally, the analyses with C18 and resin 
GP as sorbents allowed the detection of 1240 common features. 
3.4.  Serial configurations for improved metabolomics coverage (double 
cartridge) 
 Once the complementarity of the fractions obtained with different 
cartridges was demonstrated, technical configurations based on two serially 
arranged SPE cartridges were designed to exploit the benefits of orthogonal SPE 
protocols. This allowed metabolites not retained in the first cartridge to be 
trapped in the second. As shown earlier, cationic and anionic MM sorbents 
provided highly selective metabolite profiles by virtue of their ionic interactions. 
Therefore, the most suitable combinations for the intended purpose should be 
those using a reversed mode sorbent such as C18 or GP resin with an ionic MM 
sorbent in order to maximize metabolomic coverage. Figure 6 shows Venn 
diagrams illustrating the detection capabilities of the double cartridge approach 
with a single serum aliquot. As can be seen, the number of molecular features 
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detected in the eluates from the ionic MM sorbents used in the second cartridges 
was much smaller than that afforded by separate analysis with ionic sorbents in a 
single cartridge configuration. The orthogonal protocols allowed detection of a 
substantial number of molecular entities (1884 to 2176). Such high detection 
ability arises from the supplemental selectivity provided by these compatible SPE 
protocols. Supplementary Fig. 5 shows one of the orthogonal BPCs obtained by 
sequential elution from the two cartridges used in one of the configurations. 
Table 3 compares the detection capabilities of the serial configurations in a single 
analysis with those of a combination of two separate analyses with the same two 
sorbents. As can be seen, the detection coverage with the serial SPE system 
ranged from 79.5 to 99.7% of the molecular features detected with a combination 
of the two separate analyses.  
 
 
 
Figure 6. Venn diagram comparing molecular features (MFs) determined with a  
double cartridge SPE–SPE–LC–TOF/MS configuration with discrimination between  
the first and second cartridge for C18–anionic MM, C18–MM cationic, resin 
 GP–anionic MM and resin GP–cationic MM. 
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Table 3. Molecular features detected in the SPE–SPE–LC–TOF/MS analysis with the 
serial configurations. The number of molecular features detected in each cartridge and the 
total number detected in each test are also listed. The last column represents the number 
of features detected with the double cartridge configuration in relation to the use of two 
cartridges. 
Sorbent 
MFs 
cartridge 1 
MFs 
cartridge 2 
Total 
MFs 
Detection coverage 
(%) 
C18–anionic MM 1612 897 2016 85.4 
C18– cationic MM 1642 811 2007 92.2 
Resin GP–anionic MM 1553 758 1884 79.5 
Resin GP–cationic MM 1677 899 2176 99.8 
 
 
 Basic tentative identifications based on precursor ion are listed in 
Supplementary Table 1 for the different SPE–SPE couplings. This list gives an 
idea of the potential of this double-cartridge configuration for serum 
fractionation according to SPE selectivity. 
 
4. Conclusions 
 The potential of SPE–LC–MS in combination with sorbents of different 
physico–chemical properties was assessed with a view to maximizing detection 
coverage in the analysis of the human serum metabolome. Sample fractionation 
by SPE was found to provide an effective means for enhancing the detection 
capabilities of a single analytical platform (LC–TOF/MS) relative to a 
combination of several (e.g. LC–MS, GC–MS, CE–MS, NMR spectroscopy). Also, 
the selectivity of SPE sorbents allowed serial configurations to be developed to 
use a combination of protocols applied in two different cartridges for the analysis 
of the same sample aliquot. The need for little operator intervention in the 
process is an additional benefit to be considered in adopting the proposed 
configuration for metabolomic studies involving large numbers of samples. 
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Supplementary material 
 
 
Supplementary Figure 1. Experimental variability in retention time found by analyzing 
three replicates of human serum by SPE–LC–TOF/MS with different sorbents. 
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Supplementary Figure 2. Base peak chromatograms (BPCs) obtained by SPE-LC-
TOF/MS analysis with the next cartridges: (A) Cartridges based on non-mixed retention 
mechanisms in the positive ionization mode.  (B) Cartridges based on non-mixed retention 
mechanisms (C18, C8 and C2) in the negative ionization mode. (C) Cartridges based on 
mixed retention mechanisms in the positive ionization mode. (D) The two ionic sorbents 
in the positive ionization mode. 
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Supplementary Figure 3. A) Extracted ion chromatograms (EICs) obtained by SPE–
LC–TOF/MS with different sorbents for lysophosphatidylcholine C18:1 in human serum. 
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Supplementary Figure 3. C) Extracted ion chromatograms (EICs) obtained by SPE–
LC–TOF/MS with different sorbents for glutamine in human serum. 
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Supplementary Figure 3. D) Extracted ion chromatograms (EICs) obtained by SPE–
LC–TOF/MS with different sorbents for uric acid in human serum. 
                                                                                                                         
159 
Sent to J. Chromatogr. A Section I. Chapter 2 
 
 
Supplementary Figure 4. Venn diagram comparing molecular features (MFs) 
determined with a single cartridge SPE–LC–TOF/MS configuration for resin GP, C18, 
anionic MM and cationic MM sorbents. 
 
 
Supplementary Figure 5. Base peak chromatograms (BPCs) obtained by SPE–SPE–
LC–TOF/MS analysis with resin GP–cationic MM cartridges. 
 
 
 
Supplementary Table 1 is included in the cd-rom: “Chapter 2 – Supplementary Table 
1.xls”. 
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Enhanced detection and identification in 
metabolomics by use of LC–MS/MS untargeted 
analysis in combination with gas phase 
fractionation 
M. Calderón-Santiago, F. Priego-Capote*,  M. D. Luque de Castro 
Abstract 
 Liquid chromatography coupled to tandem mass spectrometry is one of 
the most widely used analytical platforms for profiling analysis in metabolomics. 
One weakness of untargeted metabolomic analysis, however, is the difficulty of 
identifying metabolites. In fact, the process typically involves mass-based 
searching of LC–MS and LC–MS/MS data, and requires using MS/MS data for 
unequivocal identification. Current strategies use LC–MS analysis in the scan 
mode prior to acquiring MS/MS information about targeted metabolites or the 
“auto MS/MS” mode to fragment high-abundance compounds mainly —which 
requires additional injections to obtain MS/MS data for minor sample 
components. Because an additional procedure is needed to enhance the fraction 
of metabolites with MS/MS data, in this work, the effectiveness of acquiring 
different MS/MS parameters across an analytical batch or repetitions of the same 
sample by using exclusion or inclusion criteria to select precursor ions is 
assessed. The procedure, known as “Gas Phase Fractionation (GPF)”, was used 
here for untargeted analysis of serum. The joint use of four methods with a 
different mass range for selection of precursor ions each provided useful MS/MS 
information for at least 80% of all molecular entities detected in the MS scan 
replicates. By contrast, the conventional “auto MS/MS” mode of data acquisition 
provided MS/MS data for only 48–57% of entities and was therefore less effective 
toward identifying metabolites. The additional use of GPF improved the detection 
and identification of metabolite families such as phospholipids, amino acids, bile 
acids, carnitines, and fatty acids and their derivatives. 
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1.  Introduction 
 The main objective of metabolomics is to identify and/or quantify small 
molecules or metabolites (<1500 Da) present in biofluids, cells or organisms.1 
Metabolomics uses three different strategies mainly (viz., fingerprinting, targeted 
and untargeted or profiling analysis),2 but especially the latter two. Since the 
fingerprinting strategy is aimed primarily at the analysis of specific families or 
groups of metabolites, the underlying analytical methodology can be easily 
adapted to obtain the sensitivity and specificity levels required for each individual 
application. On the other hand, untargeted (profiling) analysis is aimed at 
identifying the greatest possible number of metabolites with a single, high-
throughput analytical protocol or a combination of complementary protocols if 
needed. Although no single analytical tool encompassing the whole metabolome 
is currently available,3 recent advances in liquid chromatography coupled to mass 
spectrometry (LC–MS) have turned this analytical tool into an effective platform 
for the unbiased detection of a large number of metabolites from biological 
samples.4–8 In fact, LC–MS/MS has considerably facilitated metabolite 
identification and quantitation by improving MS sensitivity and precision.9 
  By virtue of its role as a primary carrier of metabolites in the human 
body, serum/plasma is the most common target biofluid of clinical and 
nutritional metabolomics analyses. Serum/plasma provides a liquid highway for 
all molecules secreted, excreted or discarded by different tissues in response to 
different physiological needs or stresses. However, the high complexity of serum 
hinders obtaining a complete metabolite profile in a single analysis. In fact, 
characterizing the serum metabolome has required using a combination of five 
different instrumental platforms.3 
 At present, metabolite identification by untargeted analysis is 
accomplished mainly via mass-based searches of LC–MS and LC–MS/MS data, 
the latter being essential for unequivocal identification. In fact, successful 
identification of metabolites requires managing comprehensive MS/MS spectral 
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libraries and MS/MS information for each potential molecular entity detected in 
a metabolomic analysis. 
 The MS/MS information needed can be obtained by manual selection of 
precursors based on LC–MS data or by use of the “auto MS/MS” acquisition 
mode, which is much less time-consuming.10 This mode combines MS scan cycles 
with programmed MS/MS scans of selected precursor ions depending on their 
relative abundance in the MS scan, thereby allowing both MS and MS/MS data to 
be acquired in a single analysis. However, not all metabolites detected by MS 
scanning will be fragmented and give an MS/MS spectral signal, so frag-
mentation of the most abundant metabolites —or those with high ionization 
capabilities— is to be preferred over that of less concentrated metabolites. 
 Applying different MS/MS acquisition parameters based on preset 
exclusion or inclusion criteria for selection of precursor ions to an analytical 
batch or to replicates of a sample can increase the fraction of metabolites 
providing useful MS/MS data. This procedure, termed “Gas Phase Fractionation” 
(GPF), which has been validated for proteomics applications,11-13 has substantially 
enhanced the identification of proteins. GPF has been introduced in 
metabolomics by developing an algorithm that provides the set of methods 
needed to obtain MS/MS spectra for a ranked list of interesting precursor 
features compiled by automated selection of quasi-molecular ions after LC–MS 
profiling.14 The underlying methodology requires injection of the sample in the 
MS and MS/MS modes. 
 The aim of this work was to assess the usefulness of GPF to increase the 
level of information obtained by LC–MS/MS analysis of serum. For this purpose, 
a combination of methods based on different inclusion criteria for selection of 
precursor ions to undergo MS/MS fragmentation was programmed in order to 
assess the influence of GPF on metabolomic coverage. Since accurate meta-
bolomic profiling requires using at least three replicates per sample,15 using GPF 
in combination with appropriate replicates is an effective approach to enhancing 
identification capabilities without the need for further sample injections. 
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2. Experimental section 
2.1. Chemicals 
 Chromatographic mobile phase B was prepared in LC–MS grade 
acetonitrile from Sigma–Aldrich (Madrid, Spain). MS grade formic acid  from 
Scharlab (Barcelona, Spain) was used as ionization agent in LC–QTOF analyses, 
and deionized water (18 MΩ·cm) supplied by a Millipore Milli-Q water 
purification system from Millipore (Bedford, MA, USA) was used to prepare the 
chromatographic aqueous phase. All samples were prepared in LC grade 
methanol from Scharlab. 
2.2. Instruments and apparatus 
 A Sorvall Legend Micro 21R centrifuge from Thermo Scientific (Waltham, 
MA, USA) was used to centrifuge serum samples after protein precipitation. An 
Agilent 1200 Series LC system consisting of a binary pump, a vacuum degasser, 
an autosampler and a thermostated column compartment, and coupled to an 
Agilent 6540 UHD Accurate-Mass QTOF hybrid mass spectrometer equipped 
with a dual electrospray (ESI) source (Santa Clara, CA, USA), was used to obtain 
MS spectra. Chromatographic eluates were monitored by tandem mass 
spectrometry in the high resolution mode. 
2.3. Blood collection and serum isolation 
 All steps from blood sampling to analysis were performed in compliance 
with the guidelines dictated by the World Medical Association Declaration of 
Helsinki (2004) and supervised by specialist staff of the Maimonides Biomedical 
Research Institute (Cordoba, Spain). 
 Venous blood was collected from ten healthy individuals into evacuated 
sterile serum tubes containing no additives (Vacutainer, Becton Dickinson, 
Franklin Lakes, NJ, USA) and incubated at room temperature for 30 min to 
facilitate coagulation. Then, the tubes were centrifuged at 4 °C at 2000 g for 15 
min to isolate the serum fraction, which was pooled (200 µL per participant) 
prior to placing in plastic tubes and storage at –80 °C until analysis.  
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2.4.     Sample preparation 
 Aliquots of 100 µL of serum pool were immersed in an ice bath and 
deproteinized with 200 µL of methanol.16 The mixture was shaken for 1 min and 
the resulting precipitate removed after centrifugation at 4 °C at 13 800 g for 5 
min. Then, the upper phase was collected in a vial and the vial placed on the 
chromatograph autosampler for subsequent analysis.  
2.5. LC–QTOF MS/MS analysis 
 Chromatographic separation was performed by using a Mediterranean 
C18 reversed phase analytical column (50 mm × 0.46 mm i.d., 3 µm particle size) 
from Teknokroma (Barcelona, Spain) which was thermostated at 25 °C. The 
mobile phases were water (phase A) and ACN (phase B), both containing 0.1% 
formic acid as ionization agent. The LC pump was programmed to use a flow rate 
of 0.8 mL/min and the following elution gradient: 3% phase B as initial mobile 
phase (2 min), ramp to 100% phase B (12 min) and holding (3 min). A post-time 
of 3 min was used to regain the initial conditions for the next analysis. The 
injected volume was 5 µL and the injector needle was washed 10 times with 80% 
methanol between injections. Also, the needle seat back was flushed with 80% 
methanol at 4 mL/min for 12 s to avoid cross contamination. The autosampler 
was kept at 4 °C to increase sample stability. 
 The settings of the electrospray ionization source, which was operated in 
the negative and positive ionization modes, were as follows: capillary voltage 
±4.0 kV, fragmentor voltage 175 V, N2 pressure in the nebulizer 40 psi; N2 flow 
rate and temperature as drying gas 10 L/min and 350 °C, respectively. The 
instrument was calibrated and tuned as recommended by the manufacturer. 
MS/MS data were acquired in both polarities, using the centroid mode at a rate of 
2.5 spectra/s in the extended dynamic range mode (2 GHz). Accurate mass 
spectra over the m/z range 100–1000 were acquired in the MS scan mode, and 
MS/MS was performed with automated selection of 2 precursor ions per cycle 
and an exclusion window of 0.25 min after 2 consecutive selections of the same 
precursor. The collision energy was set at 20 V for the whole run. 
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 Five experimental protocols were designed by restricting the inclusion 
range for selection of precursor ions in the MS/MS acquisition range as shown in 
Table 1. A total of 12 replicates of deproteinized serum were analyzed in each 
experimental protocol. The first experimental protocol used a conventional “auto 
MS/MS” method and the inclusion m/z range from 100 to 1000. The second 
experimental protocol was based on a combination of two MS/MS methods 
differing in the inclusion range used to select precursor ions. Thus, 6 replicates 
were analyzed over the m/z range 100–550 and another 6 over the range 550–
1000. The third and fourth experimental protocols used a combination of 3 and 4 
methods, respectively, and 3 and 4 different inclusion ranges (viz., m/z 100–400, 
400–700 and 700–1000 with the third protocol; and m/z 100–325, 325–550, 
550–775 and 775–1000 with for the fourth), respectively. Finally, the fifth 
protocol involved a combination of six methods with different inclusion ranges. A 
total of 60 analyses were thus conducted on the set of replicates. 
 The QTOF spectrometer provided a typical resolution of 15 000 FWHM 
(Full Width at Half Maximum) at m/z 118.086255 and 30 000 FWHM at m/z 
922.009798. In order to assure the required mass accuracy for recorded ions, the 
spectrometer was subjected to continuous internal calibration during analyses by 
using the signals at m/z 121.0509 (protonated purine) and 922.0098 [protonated 
hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazine or HP-921] in the positive 
ion mode; and those at m/z 119.0362 (proton abstracted purine) and 966.0007 
(formate adduct of HP-921) in the negative ion mode. 
2.6. Data processing and statistical analysis  
 The MassHunter Workstation software package (B.05.00 Qualitative 
Analysis and B.06.00 Profinder, Agilent Technologies, Santa Clara, CA, USA) was 
used to process all data obtained by LC–QTOF in the MS/MS mode. The 
recursive feature extraction algorithm in the software MassHunter Profinder was 
used to extract and align potential molecular features in all injections. This 
algorithm initially deconvolutes chromatograms and aligns features across the 
selected sample files in terms of mass and retention time; then, it uses the mass 
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and retention time of each feature for recursive targeted feature extraction. This 
two-step procedure reduces the number of both false negatives and false positives 
in feature extraction. The target parameters for feature extraction included a 
threshold of 1500 counts and a maximum charge state of 2. In addition, the 
isotopic distribution for a valid feature had to be defined by two or more ions —
with a peak spacing tolerance of 0.0025 m/z, plus 10.0 ppm. Adduct formation in 
the positive (+H, +Na) and negative ionization mode (–H, +HCOO) was also used 
to identify features of the same molecule. Features were aligned by using a 
tolerance window of 0.30 min and a mass accuracy of 10 ppm for retention times 
and m/z values across all data files, respectively. The minimum absolute height 
required for feature extraction was set at 3000 counts, which was also used for 
100% of samples in the recursive step. 
 Once all features were extracted and aligned, the software MassHunter 
Qualitative was used for the targeted extraction of MS/MS information from all 
molecular features in the whole set of analyses. The most salient entities were 
identified by using MS and MS/MS information, and searching the METLIN MS 
and MS/MS database (http://metlin.scripps.edu) and the Human Metabolome 
Database (HMDB, version 3.5). 
 
3. Results and discussion 
3.1. Common LC–MS serum elution profiles 
 As noted earlier, only the molecular features detected in the 60 replicates 
of serum analyses were considered. Following molecular feature extraction and 
alignment, two data sets consisting of 139 and 158 molecular entities in the 
negative and positive ionization mode, respectively, were obtained. Serum is a 
complex biofluid containing water-soluble metabolites and a significant lipid 
fraction as shown by the LC–MS/MS elution profiles obtained in the positive and 
negative ionization mode (see Figure 1). As can be seen, the elution profiles 
revealed the presence of molecular features with variable m/z values and 
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retention times. MS and MS/MS information allowed most of the metabolites 
detected in each ionization mode to be identified. Those identified were grouped 
into chemical families, some of which were detected in both ionization modes. 
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Figure 1. Chromatographic profiles obtained by LC–MS/MS analysis of serum in the 
positive (a) and negative ionization mode (b). 
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Table 1. Experimental protocols for the LC–MS/MS analysis of human serum. 
Protocol Method 
MS scan 
(m/z) 
Inclusion 
range (m/z) 
Number of 
replicates 
1 1 100–1000 100–1000 12 
2 
2.1 
100–1000 
100–550 6 
2.2 550–1000 6 
3 
3.1 
100–1000 
100–400 4 
3.2 400–700 4 
3.3 700–1000 4 
4 
4.1 
100–1000 
100–325 3 
4.2 325–550 3 
4.3 550–775 3 
4.4 775–1000 3 
5 
6.1 
100–1000 
100–250 2 
6.2 250–400 2 
6.3 400–550 2 
6.4 550–700 2 
6.5 700–850 2 
6.6 850–1000 2 
 
Worth special note among the metabolites identified in the negative 
ionization mode were nonpolar compounds such as phospholipids, which contain 
ionizing functional groups or tend to form adducts with formic acid. Compounds 
containing carboxyl groups such as fatty acids, bile acids and dicarboxylic acids 
were also prevalent in the elution profile for the negative ionization mode. On the 
other hand, the elution profile for the positive ionization mode was consistent 
with typical polar metabolites such as amino acids and purines, and also with 
their derivatives —the amino group is easily ionized in acid media. Bile acids and 
some phospholipids were also unequivocally identified in the elution profile for 
the positive ionization mode by virtue of most having some amino group. 
Interestingly, single-chain phospholipids (particularly phosphatidylcholines and 
phosphatidylethanolamines) were successfully identified in the positive 
ionization mode thanks to their characteristic fragmentation pattern. On the 
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other hand, double-chain phospholipids required using MS/MS spectra in the 
negative ionization mode to confirm their chain length. Table S-1 lists most of the 
metabolites identified in serum as classified into chemical families. 
 Both elution profiles contained a large number of metabolites coeluting 
over the range 10–16 min, which was confirmed by the times in the positive 
ionization mode: 0–8 min. Thus, a significant fraction of metabolites had similar 
retention times but differed in signal intensity by effect of their different 
concentrations and/or ionization capabilities. In fact, most of the tentative 
metabolites detected from low signals coeluted with metabolites giving higher 
signals. One can therefore assume that the precursor selection process used in 
Protocol 1 (“auto MS/MS” mode, Table 1) favored the detection of abundant 
metabolites or compounds with a high ionization power over that of metabolites 
with a low concentration or ionization capability, which were not fragmented. 
3.2. Comparison of MS/MS detection coverage in terms of the acquisition 
method 
 The purpose of this test was to compare MS/MS detection coverage by 
using a single acquisition method in combination with GPF methods involving 
different inclusion ranges for selection of precursor ions. The reference method 
used for this purpose was that based on a single MS/MS inclusion range (m/z 
100–1000). Figure 2 shows the distribution of tentative metabolites obtained by 
using this method with MS/MS information in the positive and negative 
ionization mode as a function of m/z. 
 Although a total of 158 and 139 molecular entities were detected and 
aligned in the positive and negative ionization mode, respectively, only 90 and 67 
tentative metabolites, respectively, present in all replicates were fragmented by 
MS/MS with the reference method. Therefore, only 57% of all entities were 
detected in the positive mode and 48% in the negative mode. As can be seen from 
Figure 2, a high proportion of molecular features was detected over the m/z range 
400–550 —which corresponds to lysophospholipids mainly— in the positive 
mode and over the range 400–700 —potentially associated with phospholipids, 
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which possess easily ionized functional groups and are highly concentrated in 
serum— in the negative mode. Figure 3 shows the number of tentative 
metabolites fragmented by MS/MS with each method used in the five protocols 
according to the inclusion ranges for precursor selection. As can be seen, the 
results were similar in both ionization modes; in fact, the number of tentative 
metabolites detected by MS/MS increased with that of methods used by the GPF 
protocol, but was slightly smaller with the protocol using a combination of 6 
MS/MS inclusion ranges.  
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Figure 2. Distribution of tentative metabolites with MS/MS information in serum in the 
positive (a) and negative ionization mode (b) as a function of m/z. 
 
 Thus, the proportion of tentative metabolites detected from MS/MS 
information by using the 2-method GPF protocol increased to 73 and 63% of the 
total number of entities identified after alignment. The maximum coverage was 
obtained with the 4-method GPF protocol, which allowed MS/MS information for 
about 80% of all tentative metabolites included in the original data set to be 
extracted. A comparison of the protocols using a combination of 2 and 4 methods 
revealed that the latter allowed a greater number of tentative metabolites to be 
identified over the m/z range 100–325 in the positive ionization mode 
(particularly amino acids, purines and their derivatives, which are very easily 
ionized in this mode). By contrast, the greatest increase in MS/MS acquisitions 
with the negative ionization mode was obtained in the m/z range 550–1000, 
which was assigned to phospholipids. Based on these results, GPF protocols for 
   
176 
Enhanced detection and identification in metabolomics by use of  
LC–MS/MS untargeted analysis in combination with gas phase fractionation  
metabolomic analysis provide an effective tool for expanding metabolite coverage 
(particularly with coeluting compounds). 
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Figure 3. Number of tentative metabolites fragmented with different LC–MS/MS 
protocols using a single method or GPF protocols based on a combination of 2–6 methods. 
(a) Positive ionization mode. (b) Negative ionization mode. 
 
3.3. Identification of metabolites in the positive ionization mode 
 As noted earlier, some metabolite families (particularly amino acids, 
acylcarnitines, purines, lysophospholipids and sphingomyelins) are preferentially 
detected in the positive ionization mode with LC–MS/MS. As stated in the 
previous section, metabolites with m/z < 550 were the most benefited by the use 
of precursor ion restricted fragmentation in GPF. Figure 4 shows the specific 
metabolites identified in each compound family as a function of the GPF 
acquisition method used. Several amino acids were easily identified in all 
replicates with the five protocols, namely: betaine, carnitine, phenylalanine, 
phenylglycine and tryptophan. Creatine was detected with all other protocols and 
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the amino acids (iso)leucine and tyrosine were only detected with combinations 
of 2, 3 and 4 GPF methods. As can be seen from Figure S-1, the extracted ion 
chromatograms (EICs) for these amino acids overlapped over a narrow elution 
interval [0.8–1.1 min for (iso)leucine/and 1.8–2.2 min for tyrosine]; as a result, 
they could only be detected with some GPF methods. A similar behavior was 
observed in purine and its derivatives. Thus, purine was clearly identified with 
both GPF and the conventional acquisition method, but two derivative 
metabolites giving higher peak areas (viz., uric acid and hypoxanthine) were only 
detected with the GPF protocol using 2, 3 and 4 MS/MS acquisition methods in 
combination (see EICs in Figure S-2). 
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Figure 4. Number of compounds with MS/MS information for the most important 
families identified in positive ionization mode as a function of the tested protocol.   
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 Lysophospholipids constitute one other family of compounds that is 
easily identified in the positive ionization mode. Lysophosphatidylcholines 
(LPCs) and lysophosphatidylethanolamines (LPEs), which are the most common 
lysophospholipids, exhibit a characteristic fragmentation pattern in the positive 
ionization mode.17 This family was detected over the mass range m/z 400–700 in 
the elution window from 11 to 14 min; a total of 13 lysophospholipids including 
the most common or abundant LPCs and LPEs were thus identified by using the 
conventional MS/MS acquisition method. Using 2 GPF methods in combination 
increased the number of lysophospholipids detected to 18, and using 3 or 4 
methods expanded coverage to 20 compounds of this family. Finally, using 6 GPF 
methods allowed the identification of 22 LPCs and LPEs including less common 
LPCs such as LPC(O-16:2) and the plasmalogen LPC(P-16:0), which form by 
condensation with an alkyl alcohol (C16:2) and by etherification with glycerol, 
respectively.  
 One other example of the benefits of GPF methodology was that of 
sphingolipids. Thus, sphingosine was clearly identified in all replicates, both with 
GPF and with the conventional method. However, sphingosine-1-phosphate was 
only identified by GPF. Carnitine, present in free and esterified forms in human 
serum, is essentially involved in the metabolism of free fatty acids. As stated 
above, carnitine in free form was successfully detected irrespective of the MS/MS 
acquisition method used. However, only acetylcarnitine and decanoylcarnitine 
among acylcarnitines were identified with the conventional acquisition method —
by contrast, GPF enabled identification of two additional acylcarnitines. Thus, 
octanoylcarnitine was identified with all GPF protocols, and isobutyrylcarnitine 
with 6 MS/MS acquisition ranges only (see Figure S-3). In this particular case, 
the narrower were the mass ranges used for selection of precursor ions, the better 
was identification of low-molecular weight carnitine analogues. 
3.4.  Identification of metabolites in the negative ionization mode 
 The main effect of using GPF in the negative ionization mode was 
increasing the number of metabolites identified at m/z values above 550. This 
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spectral region corresponds mainly to phospholipids (particularly phosphatidyl-
cholines and phosphatidylethanolamines, which are the two most concentrated 
subclasses of glycerophospholipids in human serum). Figure 5 compares the 
number of metabolites identified with different methods in the negative 
ionization mode. No phospholipids could be identified with the conventional 
MS/MS acquisition method. By contrast, GPF allowed several 
phosphatidylcholines to be identified (particularly by use of 6 different mass 
ranges to select precursor ions). Identification of fatty acids and related 
compounds was similarly affected by the use of GPF, which allowed 3–9 
compounds in this family to be identified. The conventional MS/MS acquisition 
method enabled the identification of 12-HETE, 9-HODE and leukotriene B4, 
which form by oxidation of essential fatty acids and contain easily ionized 
functional groups. Using GPF methodology allowed many other major fatty acids 
such as oleic, linoleic, linolenic acid, arachidonic and docosahexanoic, in addition 
to the minor metabolite 13-HpODE —which eluted near 9-HODE and 12-HETE— 
to be identified. As can be seen from the extracted ion chromatograms for fatty 
acids in Figure S-4, all free fatty acids identified eluted at times from 15 to 17 min, 
which is consistent with the fragmentation pattern observed by using GPF 
methodology.  
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Figure 5. Number of compounds with MS/MS information for the most important 
families identified in negative ionization mode as a function of the tested protocol.   
 
 One other family of metabolites identified in the negative ionization 
mode was that of bile acids. Thus, taurocholic, glycocholic and deoxycholic acid 
were identified with both GPF and the conventional MS/MS acquisition method. 
By contrast, cholic acid could only be identified with the GPF protocols based on 
a combination of 3 or more mass ranges for selection of precursor ions because 
its peak was shorter than those for the other bile acids (see Figure S-5). The 
dicarboxylic acids citric and nonanedioic were also identified in human serum. 
Finally, citric acid was identified with all methods, but the MS/MS spectrum for 
nonanedioic acid could only be acquired with GPF. 
 
4. Conclusions 
 Poor metabolite identification is one of the main current weaknesses of 
profiling analysis in metabolomics owing to the absence of a comprehensive 
MS/MS database and the difficulty of obtaining MS/MS information for most 
detected metabolites. 
 Using GPF methodology for serum analysis by LC–MS/MS in 
metabolomics has proved an effective strategy for increasing the amount of 
MS/MS information available about some compounds. A combined method 
splitting the range of precursor ion masses into four intervals was found to be 
best the choice among all studied here as it provided MS/MS information for at 
least 80% of all detected entities. By contrast, the conventional auto MS/MS 
mode of data acquisition provided information for only 48–57% and was 
therefore less effective for unequivocal identification of metabolites.  
 Because samples are usually injected at least in triplicate in metabolomic 
analyses, the proposed methodology can be easily applied to sample batches 
without the need for a previous LC–MS injection. A combination of three 
methods with different exclusion intervals for selection of precursor ions can be 
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used to expand MS/MS information without the need for repeated injection of 
samples. Also, a combination of appropriate exclusion intervals suited to the 
target compounds can be used to maximize the number of potential molecular 
features extracted from MS/MS data. 
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Supplementary material 
 
 
Figure S-1. Extracted ion chromatograms (EICs), in positive ionization mode, of the 
identified amino acids: betaine (118.0867 m/z), carnitine (162.1124 m/z), creatine 
(132.0769 m/z), leucine/isoleucine (132.1016 m/z), tyrosine (182.0812 m/z), 
phenylalanine (166.0856 m/z), phenylglycine (152.0706 m/z), and tryptophan (205.0964 
m/z). 
 
 
Figure S-2. Extracted ion chromatograms (EICs), in positive ionization mode, of purine 
(121.0509 m/z) and its identified derivatives: uric acid (169.0354 m/z) and hypoxanthine 
(137.0457 m/z). 
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Figure S-3. Extracted ion chromatograms (EICs), in positive ionization mode, of the 
identified acylcarnitines: acetylcarnitine (204.1234 m/z), isobutyrylcarnitine (232.1536 
m/z), octanoylcarnitine (288.2164 m/z) and decanoylcarnitine (316.2486 m/z). 
 
 
 
Figure S-4. Extracted ion chromatograms (EICs) of fatty acids and relative metabolites 
identified in negative ionization mode: leukotriene B4 (335.2244 m/z), 13-HpODE 
(311.2246 m/z), 9-HODE (295.2305 m/z), 12-HETE (319.2295 m/z), linoleic acid 
(279.2354 m/z), docosahexaenoic acid (327.2354 m/z), arachidonic acid (303.2336 m/z), 
linolenic acid (277.2173  m/z), and oleic acid (281.2517 m/z). 
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Figure S-5. Extracted ion chromatograms (EICs) of identified bile acids in negative 
ionization mode: glycocholic acid (464.3039 m/z), cholic acid (407.2812 m/z), taurocholic 
acid (514.2877 m/z), and deoxycholic acid (391.2877 m/z). 
 
 
Table S-1. List of all metabolites identified in serum classified by families and including 
the information that led to their identification: the MS and MS/MS information (only two 
of the product ions are shown), as well as the retention times. 
Family Compound 
Precursor 
ion (m/z) 
Adduct 
Product ions 
(m/z) 
Rt 
(min) 
Acylcarnitines 
Acetylcarnitine 204.1234 [M+H]+ 145.0493 85.0287 1.0 
Isobutyrylcarnitine 232.1536 [M+H]+ 173.0758 144.1036 5.4 
Octanoylcarnitine 288.2164 [M+H]+ 229.1509 144.1036 7.9 
Decanoylcarnitine 316.2486 [M+H]+ 155.1428 257.1738 8.9 
Amino acids and 
derivates 
Betaine 118.0867 [M+H]+ 58.0658 59.0735 0.7 
Carnitine 162.1124 [M+H]+ 103.0387 - 0.8 
Creatine 132.0769 [M+H]+ 114.0635 90.0540 0.8 
Leucine/isoleucine 132.1016 [M+H]+ 86.0960 - 2.0 
Leucine/isoleucine 132.1016 [M+H]+ 86.0960 - 2.2 
Tyrosine 182.0812 [M+H]+ 165.0557 136.0776 2.5 
Phenylalanine 166.0856 [M+H]+ 120.0803 103.0545 5.2 
Phenylglycine 152.0706 [M+H]+ 107.0477 135.0371 5.4 
Tryptophan 205.0964 [M+H]+ 188.0703 146.0596 5.9 
Hippuric acid 178.0510 [M-H]- 134.0576 77.0410 6.9 
Indoxylsulfuric acid 212.0025 [M-H]- 132.0440 79.9582 8.7 
Bile acids 
Glycocholic acid 464.3039 [M-H]- 402.2986 74.0210 9.5 
Cholic acid 407.2812 [M-H]- 241.0738 - 10.5 
Taurocholic acid 514.2877 [M-H]- 124.0242 - 11.2 
Deoxycholic acid 391.2877 [M-H]- 345.2739 - 12.3 
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Dicarboxilic acids 
Citric acid 191.0201 [M-H]- 111.0108 87.0032 1.9 
Nonanedioic acid 187.0977 [M-H]- 169.0871 125.1049 8.2 
Fatty acids and 
derivates 
Leukotriene B4 (LTB4) 335.2244 [M-H]- 195.0960 129.0533 11.7 
13-HpODE 311.2246 [M-H]- 293.2173 113.0918 13.0 
9-HODE 295.2305 [M-H]- 277.2173 171.1036 13.1 
12-HETE 319.2295 [M-H]- 301.2180 135.1174 13.7 
Linolenic acid (C18:3) 277.2173 [M-H]- 259.2017 - 15.2 
Docosahexaenoic acid 
(C22:6) 
327.2354 [M-H]- 283.2446 229.1943 15.3 
Arachidonic acid (C20:4) 303.2336 [M-H]- 259.2481 205.1933 15.5 
Linoleic acid (C18:2) 279.2354 [M-H]- - - 15.8 
Oleic acid (C18:1) 281.2517 [M-H]- - - 16.5 
Lysophospholipids 
LPC(20:5) 542.3241 [M+H]+ 184.0708 104.1025 11.1 
LPC(18:3) 518.3206 [M+H]+ 184.0772 104.1068 11.2 
LPC(16:1) 494.3241 [M+H]+ 184.0735 104.1060 11.4 
LPE(18:2) 478.2922 [M+H]+ 337.2728 - 11.5 
LPE(20:4) 502.2924 [M+H]+ 361.2726 - 11.6 
LPE(22:6) 526.2917 [M+H]+ 385.2662 - 11.7 
LPC(22:6) 568.3398 [M+H]+ 184.0747 104.1148 11.8 
LPC(18:2) 520.3365 [M+H]+ 184.0727 104.1045 11.9 
LPC(20:4) 544.3376 [M+H]+ 184.0683 104.1075 12.0 
LPE(16:0) 454.2926 [M+H]+ 313.2745 - 12.0 
LPC(22:5) 570.3551 [M+H]+ 184.0693 104.1049 12.1 
LPC(20:3) 546.3525 [M+H]+ 184.0743 104.1097 12.2 
LPE(20:3) 504.3102 [M+H]+ 363.2936 - 12.2 
LPC(16:0) 496.3397 [M+H]+ 184.0668 104.1048 12.4 
LPE(18:1) 480.3080 [M+H]+ 339.2881 - 12.5 
LPC(O-16:1) 480.3448 [M+H]+ 184.0681 104.1032 12.6 
LPC(18:1) 522.3549 [M+H]+ 184.0730 104.1048 12.6 
LPC(22:4) 572.3689 [M+H]+ 184.0760 104.1032 12.8 
LPC(O-16:0) 482.3604 [M+H]+ 184.0762 104.1064 12.8 
LPC(17:1) 508.3751 [M+H]+ 184.0724 104.1064 13.0 
LPE(18:0) 482.3237 [M+H]+ 341.3035 - 13.6 
LPC(18:0) 524.3716 [M+H]+ 184.0723 104.1068 13.8 
Phospholipids 
PC(18:2/20:4) 850.5559 [M+HCOO]- 790.5390 303.2291 14.5 
PC(18:1/18:2) 828.5747 [M+HCOO]- 768.5515 281.2811 14.7 
PC(19:1/20:2) 870.5686 [M+HCOO]- 810.5444 295.2865 14.7 
PC(16:0/18:2) 802.5586 [M+HCOO]- 255.2295 279.2294 14.8 
PC(18:1/18:1) 830.5884 [M+HCOO]- 770.5730 281.2818 14.9 
PC(18:1/20:4) 852.5688 [M+HCOO]- 792.5429 281.2830 14.9 
PC(18:0/18:1) 832.6003 [M+HCOO]- 772.5957 281.2821 15.0 
PC(16:0/18:1) 804.5804 [M+HCOO]- 255.2350 281.2434 15.0 
PC(16:0/19:1) 818.5521 [M+HCOO]- 758.5389 295.2645 15.1 
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Purines and 
derivates 
Purine 121.0509 [M+H]+ 113.9757 104.0199 1.3 
Uric acid 169.0354 [M+H]+ 152.0090 141.0371 2.1 
Xanthine 151.0266 [M-H]- 108.0332 - 2.5 
Hypoxanthine 137.0457 [M+H]+ 119.0378 110.0465 2.6 
Sphingolipids 
Sphingosine 300.2895 [M+H]+ 282.2781 252.2649 9.8 
Sphingosine-1-phosphate 380.2569 [M+H]+ 282.2733 264.2723 10.9 
Vitamins Choline 104.1074 [M+H]+ 60.0803 - 0.7 
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 Section II of this PhD Book is devoted to two research areas with high 
development in clinical metabolomics at present: nutrimetabolomics and 
biomarkers search. The research on both is under the umbrella of profiling 
analysis.  
 In dealing with nutrimetabolomics, to which the research in Chapter 4 is 
dedicated, metabolome alterations caused in individuals subjected to four 
intervention diets demonstrate, once again, the importance of diet on health. The 
role of this omics on the search for a personalized diet is one of the key steps 
towards a personalized medicine. 
 Two types of samples (serum and sweat) from patients with two very 
different types of diseases (atherosclerosis and lung cancer) were the basis for 
the developed research together with proper analytical approaches such as LC–
QTOF MS/MS, sample preparation, if required, and application of the most 
convenient data treatment.  
 Serum from patients diagnosed with atherosclerosis and affected by 
stable angina or myocardial infarction (acute myocardial infarction or non-ST 
elevation myocardial infarction) were the target samples to be analyzed in 
Chapter 5 and 6. The profiles of given serum metabolites were compared to 
search for potential biomarkers for early prediction of an ischemic event, which 
could lead to a drastic reduction of mortality. Change in the concentration of 
statistically significant metabolites allowed discrimination of individuals who 
suffered acute or non-ST elevation myocardial infarction from those suffering 
stable angina, as can be seen in Chapter 5. On the other hand, a three-variable 
panel for infarct prediction was created, thus discriminating between individuals 
affected by acute myocardial infarct and those diagnosed by stable angina with 
sensitivity and specificity values higher than 80%, as shown in Chapter 6. 
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 Sweat from patients with lung cancer and control individuals were 
analyzed by the analytical platform in Chapter 1, and the individual capability of 
the identified metabolites to discriminate between the two groups in terms of 
sensitivity and specificity was successfully established. Additional individual or 
combined panels of metabolites allowed reducing false negative and false positive 
rates, as discussed in Chapter 7.  
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Comparative nutrimetabolomic study of the 
influence of fat intervention diets on serum 
metabolic profiles by LC–MS/MS 
M. Calderón-Santiago, F. Priego-Capote, M. D. Luque de Castro* 
 
Abstract 
 A nutrimetabolomic study to assess the influence of fat intervention diets 
on serum metabolic profiles in 76 patients diagnosed with metabolic syndrome is 
here presented. Four isoenergetic diets but with different fat content [two with 
high-fat content (38%) and two with low-fat content (28%)] were administered to 
the selected cohort. Metabolite profiles were obtained before and after the 
intervention period for 12 weeks by serum fractionation into polar and non-polar 
metabolites and LC–QTOF analysis in high resolution mode. Multivariate 
statistical analysis allowed discrimination among the post-intervention samples 
and between pre- and post-intervention stages for the four diets. Within the lipid 
fraction, phospholipids were the family of metabolites more influenced by the 
intervention diets. Concretely, three common glycerophospholipids 
[PC(18:0/16:2), PC(16:0/18:2) and PC(18:0/18:2)] were affected by the diets. 
High-fat diets led to 19 altered phospholipids, while 16 phospholipids showed 
changes by low-fat diets. Concerning the polar fraction, high-fat diets altered 
more metabolites (14–15) than low-fat diets (6–9). In this fraction, amino acids 
were mostly influenced after the high-fat diets, and only ornithine was altered 
with one of the low-fat diets. Bile acids and acylcarnitines levels were also altered 
after diet intake. A common behavior was found for some of the identified 
compounds; thus, octenoyl-L-carnitine and lysophosphatidylcholine (16:0) levels 
appeared increased after intake of any of the diets. 
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1.  Introduction 
 Nutritional studies play a key role in the identification of essential 
nutrients needed for human growth and health. Nowadays, nutritional scientists 
are challenged to find new ways to treat or prevent diseases brought on by 
nutritional oversufficiency such as obesity, diabetes, chronic inflammation 
and/or cardiovascular diseases. One of the main approaches to face up these 
studies is nutrimetabolomics, which is aimed at: (1) food component analysis; (2) 
food quality/authenticity detection; (3) consumption biomarkers; and, (4) 
elucidation and detection of effects and pathology-risk biomarkers in nutritional 
and epidemiological studies. The last approach has been used to assess metabolic 
changes caused by intake of certain nutrients with an impact on human health. 
The starting hypothesis is that the majority of metabolism alterations are 
detected in biological fluids such as serum/plasma or urine. One of the most 
common analytical strategies to detect and discriminate metabolic changes is 
metabolomics fingerprinting, which is aimed at developing classification models 
based on snapshots or fingerprints from samples by suited detection techniques 
[1]. However, data quality in these approaches is limited as low discrimination 
among metabolites is attained. Data quality is drastically enhanced by application 
of a global metabolomics approach focused on detection and identification of 
those metabolites with the highest contribution to the observed variability. This 
strategy seems to be especially suited to detect and discriminate metabolic 
changes caused by nutritional states. 
 Considering the chemical diversity and number of metabolites in human 
biofluids (a conservative estimation of human serum reported 4229 metabolites 
and a wide range of concentrations —up to 11 orders of magnitude— observed in 
human serum [2–4]), different analytical platforms in combination are needed to 
approach full coverage of the metabolome. In fact, a variety of techniques can be 
employed to maximize metabolite detection coverage, with nuclear magnetic 
resonance (NMR) and mass spectrometry (MS) being the most used. The 
coupling of MS to either LC (LC–MS) or gas chromatography (GC–MS) has been 
widely used to study metabolic changes associated with pathological states and 
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nutritional studies [5–10]. The choice of a separation technique prior to MS 
detection is primarily dictated by the properties of the given analyte, with GC–
MS as more suitable for volatile and semi-volatile analytes and capillary 
electrophoresis (CE) as an alternative to LC for charged analytes [11,12]. 
 Comparing the use of LC–MS to NMR for metabolomics studies [7,13,14], 
the sensitivity of the former is significantly higher than that characterizing NMR, 
thus providing the possibility to monitor metabolic changes that remained 
unnoticed when working with the latter. LC–MS allows analysis of a wide range 
of metabolite classes. The widespread availability of robust LC–MS methods in 
many research laboratories has increased enormously its use for metabolic 
profiling over the past few years. In fact, many studies have provided higher 
metabolome coverage (approximately 55–70% of total metabolites detected using 
multiple platforms) by a single experiment using LC–MS than by GC–MS or CE–
MS [4] (an estimated 10–15% overlap is usual between LC–MS and GC–MS 
platforms [8]). Therefore, LC–MS can provide comprehensive metabolite 
coverage by untargeted analyses using a single platform [15]. LC–MS 
metabolomics studies generally involve differential comparison of several 
subjects or treatment groups (e.g. normal versus treated individuals, healthy 
versus ill individuals) without a priori identification of all detected metabolites. 
 The Lipgene project is a large European multi-centre project which 
includes a human intervention trial (486 volunteers at baseline) conducted to 
compare the impact of different types and amounts of dietary fatty acids on 
insulin sensitivity. This human intervention study is supported on a food-
exchange model involving four diets for alteration of dietary fat quantity and 
quality in participants. The key aspects of this strategy for correlation and 
discrimination of metabolic patterns with the supplied diets were: (i) diets differ 
significantly in overall fat intake but remain isoenergetic; (ii) the two high-fat 
diets are significantly higher in the content of saturated fatty acids (SFAs) or 
monounsaturated fatty acids (MUFAs) as compared with the two low-fat diets; 
(iii) the effect of long-chain n-3 polyunsaturated fatty acids (PUFAs) 
supplementation was tested in a low-fat background diet. Supported on this 
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study, an LC–QTOF MS/MS platform has been applied to obtain metabolic 
profiles of serum from individuals subjected to four isoenergetic intervention 
diets under controlled conditions for twelve weeks. The aim was to detect and 
evaluate serum metabolic differences according to the administered diets.  
 
2. Materials and methods 
2.1. Chemicals 
 LC-MS grade acetonitrile (Sigma-Aldrich, Madrid, Spain) was used for 
preparation of chromatographic mobile phases. MS-grade formic acid (Scharlab) 
was used as ionization agent in LC-QTOF analyses, while deionized water (18 
MΩ·cm) from a Millipore Milli-Q water purification system (Millipore, Bedford, 
MA, USA) was used to prepare the chromatographic aqueous phases. 
Chromatographic-grade methanol and chloroform (Scharlab, Barcelona, Spain) 
were used for sample treatment. 
2.2. Instruments and apparatus 
 A Sorvall Legend Micro 21R centrifuge (Thermo Scientific, Waltham, MA, 
USA) was used to centrifuge samples after deproteination. An Agilent 1200 Series 
LC system (consisting of a binary pump, a vacuum degasser, an autosampler and 
a thermostated column compartment) coupled to an Agilent 6540 UHD 
Accurate-Mass QTOF hybrid mass spectrometer equipped with a dual elec-
trospray (ESI) source (Santa Clara, CA, USA) was used. The chromatographic 
eluate was monitored in high-resolution mode. 
2.3. Diets composition 
 Four isoenergetic diets that differed in fat quantity and quality were 
planned for this study. Two diets were designed to provide 38% energy (E) from 
fat and the other two with 28% E from fat with the following assigned names and 
compositions: 
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(1) HSFA: high-fat content (38% energy) with high proportion of saturated 
fatty acids (16% SFA), while monounsaturated and polyunsaturated fatty 
acids (MUFAs and PUFAs, respectively) were present at 12% and 6%, 
respectively. 
(2) HMUFA: high-fat content (38% energy) with high proportion of MUFAs 
(20%), while SFA and PUFAs were 8% and 6%, respectively. 
(3) LFHCC: low-fat content (28% energy) with high-complex carbohydrate 
diet (8% SFA, 11% MUFA, 6% PUFA), supplemented with 1 g/d high 
oleid acid sunflower oil supplement. 
(4) LFHCCn-3: low-fat (28% energy), high-complex carbohydrate diet (8% 
SFA, 11% MUFA, 6% PUFA), supplemented with 1.24 g/d very long chain 
n-3 PUFA supplement. 
 2.4.     Cohort under study 
 This research was conducted within the framework of the LIPGENE 
integrated project [diet, genomics and metabolic syndrome (MetS): an integrated 
nutrition, agro-food, social and economic analysis]. A total of 76 patients with 
MetS from the LIPGENE cohort were accepted to participate in this study aimed 
at evaluating metabolic alterations by LC-QTOF MS/MS. All participants gave 
written informed consent and underwent a comprehensive medical history, 
physical examination and clinical chemistry analysis before enrolment. None of 
the subjects was taking medication or supplementary vitamins with influential 
effect on serum metabolome. 
 Patients were randomly divided into four groups to receive one of the 
four dietary interventions for 12 weeks under controlled conditions. Both the 
design and protocol of the intervention study have been described in detail by 
Shaw et al. [16]. Serum control samples were obtained in basal state prior to the 
intervention as control samples (PRE). Patients arrived at clinical centres after 12 
weeks of the intervention study following a 12-h fast refrained from smoking 
during the fasting period and abstained from alcohol intake during the preceding 
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7 days. In the laboratory and after cannulation a fasting blood sample was taken 
for each individual (POS).  
2.5. Blood extraction and serum isolation 
 Sampling was performed following the Recommendations on Biobanking 
Procedures for serum processing and management recently published by the 
European Consensus Expert Group [17]. The subsequent aspects were taken into 
account: (i) sample storage at 80°C; (ii) recording of the time from collection 
through processing; (iii) experimental definition of the time limits appropriate 
for analytes measurement. All steps from blood to analysis were performed in 
compliance with the guidelines dictated by the World Medical Association 
Declaration of Helsinki (2004), which were supervised by specialized personnel. 
 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, USA) and in-
cubated for 30 min at room temperature to allow coagulation. Then, the tubes 
were centrifuged at 2000 × g for 15 min at 4 °C to isolate the serum fraction that 
was placed in plastic tubes and stored at –80 °C until analysis. 
2.6. Sample treatment  
 Serum samples (100 µl) immersed in a bath ice were treated with 300 µl 
of 1:2 methanol–chloroform. The mixture was shaken for 2 min and centrifuged 
for 5 min at 4 °C and 20200 × g. Both phases (aqueous and organic) were 
collected in different vials, then placed in the LC autosampler for subsequent 
analysis. 
2.7. LC–QTOF MS/MS analysis 
 Chromatographic separation was performed using a C18 reverse-phase 
analytical column (Mediterranean, 100 mm x 0.46 mm i.d., 3 µm particle size) 
from Teknokroma (Barcelona, Spain), which was thermostated at 25°C. The 
mobile phases were 5% ACN (phase A) and 95% ACN (phase B) both with 0.1% 
formic acid as ionization agent. Two chromatographic modes were programmed 
according to the two phases obtained from the sample. In both cases the LC 
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pump was programmed with a flow rate of 0.8 mL/min. For the aqueous fraction, 
the following elution gradient was set: 9% phase B was fixed as initial mobile 
phase, increased to 100% of phase B from min 0 to 10, and kept at 100% for 5 
min. On the other hand, the elution gradient established for the non-polar 
fraction was: 40% phase B was fixed as initial mobile phase, increased to 100% of 
phase B from min 0 to 10, and kept at 100% for 5 min. In both cases, a post-time 
of 5 min was set to equilibrate the initial conditions for the next analysis. The 
injection volume was 8 µL and the injector needle was washed for 10 times 
between injections with 80% methanol. Furthermore, the needle seat back was 
flushed for 12 s at a flow rate of 4 mL/min with 80% methanol to avoid cross 
contamination. 
 The parameters of the electrospray ionization source, operating in 
negative and positive ionization mode (negative mode for non-polar fraction and 
positive mode for polar fraction), were as follows: the capillary and fragmentor 
voltage were set at ±3.5 kV and 110 V, respectively; N2 in the nebulizer was flowed 
at 40 psi; the flow rate and temperature of the N2 as drying gas were 10 L/min 
and 350°C, respectively. The instrument was calibrated and tuned according to 
procedures recommended by the manufacturer. MS and MS/MS data were 
collected in both polarities using the centroid mode at a rate of 2.5 spectrum per 
second in the extended dynamic range mode (2 Ghz). Accurate mass spectra in 
auto MS/MS mode were acquired in MS m/z range 100–1100 and MS/MS m/z 
range 31–1100. The auto MS/MS mode was configured with 2 maximum 
precursors per cycle and an exclusion window of 0.25 min after two consecutive 
selections of the same precursor. The collision energy selected was 20 eV. 
 The instrument gave typical resolution 15000 FWHM (Full Width at Half 
Maximum) at m/z 118.086255 and 30000 FWHM at m/z 922.009798. To assure 
the desired mass accuracy of recorded ions, continuous internal calibration was 
performed during analyses by using the signals at m/z 121.0509 (protonated 
purine) and m/z 922.0098 [protonated hexakis (1H, 1H, 3H-tetrafluoropropoxy) 
phosphazine or HP-921] in positive ion mode; while in negative ion mode ions 
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with m/z 119.0362 (proton abstracted purine) and m/z 966.0007 (formate 
adduct of HP-921) were used. 
2.8.   Data processing and statistical analysis 
 MassHunter Workstation software package (B.05.00 Qualitative Analysis 
and B.06.00 Profinder, Agilent Technologies, Santa Clara, CA, USA) was used to 
process all data obtained by LC-QTOF in auto MS/MS mode. The MassHunter 
Profinder software was employed to extract and align potential molecular 
features in all the injections by using the recursive feature extraction algorithm. 
This algorithm performs firstly a chromatographic deconvolution and aligns the 
features across the selected sample files using mass and retention time. Secondly, 
it uses the mass and retention time of each feature to perform a recursive 
targeted feature extraction. This two-step procedure reduces the number of false 
negatives as well as false positives in feature extraction. Parameters considered 
for feature extraction included a threshold of 1500 counts and a maximum charge 
state of two. Additionally, the isotopic distribution for a valid feature had to be 
defined by two or more ions (with a peak spacing tolerance of 0.0025 m/z, plus 
10.0 ppm). Adducts formation in the positive (+H, +Na) and negative ionization 
(-H, +HCOO) modes were also included to identify features corresponding to the 
same molecule. Features alignment was done with a tolerance window of 0.45 
min and 10 ppm mass accuracy for retention time and m/z values across all the 
data files, respectively. The minimum peak area required for the feature 
extraction was fix on 3000 counts, and this value was also set at 3000 counts for 
at least the 75 percent of the samples of each group considered in the cohort in 
the recursive step. 
 After features extraction and alignment, data files in compound exchange 
format (.cef files) were created for each sample and exported into the Mass 
Profiler Professional (MPP) software package (version 12.1, Agilent Technologies, 
Santa Clara, CA, USA) for further processing. Data pretreatment was based on 
baselining to remove background noise and normalization by logarithmic 
transformation to reduce relatively large differences among molecular feature 
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abundances. Supplementary Figure 1 shows the normalization effect of the 
logarithmic transformation. As can be seen, the resultant matrix fits a normal 
distribution both in the polar and non-polar fraction. 
 MPP software allows both supervised and unsupervised analysis of the 
data by PLS-DA and PCA. In the former case, the validation model selected was 
N-Fold, by which the classes in the input data were randomly divided into N 
equal times; N-1 parts were used for training, and the remaining one part was 
used for testing. The process was repeated N times, with a different part used for 
testing in each iterative step. Then, repetitions and a fold number of 3 were 
selected for all validations. 
 Once the difference between the groups under study were verified, an 
analysis of variance (ANOVA) was executed using the ROCCET online tool 
(http://www.roccet.ca/ROCCET/) to know the entities significantly differenced 
between sampling times PRE and POS in each diet. The full process was done 
separately with each fraction: aqueous and organic phases. 
 
3. Results and discussion 
3.1. Serum metabolite differences according to the intervention diets 
 A common factor associated to metabolomics analysis in clinical and 
nutritional studies dealing with humans is the biological variability among 
individuals, which frequently mask the effects of other variability sources 
associated to internal factors (diseases, metabolic disorders) or external factors 
(diet, lifestyle). In this research, data acquisition was carried out to observe the 
biological variability not ascribed to diets intake as compared to the variability 
after diets intake. For this purpose, the chromatograms acquired in basal state 
(PRE) were compared with those acquired after the intervention period for 12 
weeks (POS) of each diet. After obtaining a global profile of metabolites present 
in polar and non-polar phases representing individuals subjected to every diet, 
the comparison among the different profiles would allow evaluation of 
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similarity/dissimilarity patterns according to administered diets. Supplementary 
Figure 2 shows the base peak chromatograms (BPCs) obtained in both ionization 
modes from an individual prior the intervention study (PRE) and after the 
intervention diets (POS). 
 As mentioned under ‘Materials and methods’, only those molecular 
entities detected in at least 75% of the samples belonging to one of the groups 
considered under study (PRE and POS for each diet) were considered. This 
procedure allows reducing the presence of tentative metabolites related to inter-
individual variability sources such as anthropometric factors. With these 
premises, the number of molecular features detected in the non-polar fraction 
(negative ionization mode) was 170, while in the polar fraction (positive 
ionization mode) 41 tentative compounds were detected.  
 After data pretreatment, Principal Component Analysis (PCA) was 
employed in the first stage of data treatment to evaluate if the variability 
associated to the intervention study allowed discriminating POS samples from 
PRE samples. For this purpose, samples in the PCA scores plot were labelled by 
the sampling time but no attention was paid to the type of diet. Supplementary 
Figure 3 shows the PCA scores plot in a 3D graph. As can be seen, no clear 
discrimination was observed between PRE and POS states although certain 
trends can be visualized. The variability explained with PC1, PC2 and PC3 was 
33.9% for the organic phase and 27.3% for the aqueous phase, which clearly 
means that the variability associated to the intervention diets was not the major 
cause of variability present in the samples cohort. Taking into account this fact, a 
PLS-DA was carried out to find discrimination according to the intervention diet. 
In this case, five classes were considered: PRE samples and POS samples for the 
four intervention diets. Figure 1 shows the PLS-DA loadings plot obtained both 
for polar and non-polar fractions, which clearly allowed differentiating 
individuals prior to the intervention diets (PRE sampling time) from individuals 
after the intervention period (POS sampling time). Additionally, no complete 
discrimination was observed among individuals subjected to the four diets. 
Nevertheless, certain groupings were detected in both fractions according to the 
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intervention diet and, additionally, individuals after the low-fat diet 
supplemented with long chain n-3 PUFAs (LFHCCn-3) provided the highest 
variability versus control individuals (PRE sampling time) in comparison to the 
resting diets. If the PRE sampling time is not considered for PLS-DA, separation 
of individuals after the four intervention diets was appreciated, as Figure 2 
shows. As can be seen, discrimination of individuals according to the intervention 
diet was observed in both the polar and the non-polar fractions. In both analyses 
the maximum separation was observed for individuals subjected to the LFHCCn-
3 diet, who were assigned with the most discriminant metabolic pattern. 
Concerning the diet influence, the main variability source was not associated to 
the fat content but the diet composition. No similarity groupings were observed 
between pairs of diets. At this point, the effects found for the polar and non-polar 
fractions as a result of the intervention diets were independently evaluated 
 
Figure 1. Scores graphs obtained after multivariate analysis by PLS-DA of the polar and 
non-polar fraction, considering POS and PRE time for each diet. 
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Figure 2. Scores graphs obtained after multivariate analysis by PLS-DA of the polar and 
non-polar fractions, considering POS time for each diet. 
 
Figure 3. Scores graphs obtained after multivariate analysis by PLS-DA of non-polar 
fraction for each diet, considering in each case PRE and POS times. 
 
3.2. Non-polar metabolic effects associated to the intervention diets 
  The influence of each diet on non-polar metabolites in serum was 
independently evaluated by comparing the PRE sampling time versus the POS 
sampling time for each diet. For this purpose, a PLS-DA model was created for 
each diet as Figure 3 shows. Complete discrimination was observed between 
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individuals before and after the intervention diets. The discrimination capability 
obtained in the training step was above 94% for the four diets. 
 Taking into account the existing metabolic differences caused by each 
intervention diet, a fold change analysis was executed to identify the tentative 
metabolites with the highest contribution capability to explain the observed 
variability. In all cases, a number of molecular features between 17 and 19 
experienced a fold change higher than 1.25, which implies an increase or decrease 
of 25% of the MS detector response in relative terms. Identification of these 
tentative metabolites by using MS and MS/MS allowed detecting a significant 
number of phospholipids, essentially, glycerophosphatidylcholines and 
glycerophosphatidylethanolamines including different fatty acids chains. Table 1 
lists the lipids identified after fold change analysis. The significance level 
according to an ANOVA test is also shown. As can be seen metabolic changes 
occurring in the non-polar fraction of serum after four intervention diets for 12 
weeks were targeted at phospholipids. Apart from these two families of 
phospholipids, several sphingomyelins and two essential fatty acids —linoleic 
acid and docosahexanoic acid— were also detected with a concentration change 
due to intervention diets. Table 1 shows all the non-polar metabolites that 
experienced a fold change of at least 1.25 by comparing physiological states 
before or after the intervention diets. They are grouped as a function of the diet 
but also according to the magnitude of change. The first aspect to be emphasized 
is regarding the number of glycerophospholipids or sphingomyelins with two 
substituents that experienced a concentration change above 1.25 (increase or 
decrease in individuals after the intervention diets). Thus, two diets, HSFA and 
LFHCC, presented increased levels of 7 and 8 glycerophospholipids, and sphingo-
myelins with two substituents, respectively. On the other hand, only three or one 
metabolites of these families decreased their concentration due to the intake of 
these two intervention diets. The opposite behavior was observe for the LFHCCn-
3 diet since only three of these compounds increased their concentration in 
serum due to the intervention, while 7 of them decreased their concentration. The 
fourth diet —HMUFA diet— caused an increase of four disubstituted 
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glycerophospholipids or sphingomyelins and a decrease of the same number of 
lipidic metabolites. Therefore, the effect of the intervention diet on the lipid 
profile, which was mostly manifested on phospholipidic structures, depended on 
the diet. Nevertheless, some common effects were observed in individuals after 
any intervention diet. The most representative example was found for 
lysophospholipids, with special emphasis on lysoPC(O-16:1), that experienced an 
increase of serum concentration  in all individuals (>2.0) after the intervention 
diets. In fact, this change was statistically significant according to the ANOVA 
test for individuals subjected to HSFA, LFHCC and LFHCCn-3 diets. 
Table 1. Non-polar metabolites that experienced a fold change above 1.25 by comparing 
physiological states before or after intervention diets. Isomers of the same 
lysophosphatidylcholine are differenced by (1) and (2). 
 HSFA HMUFA LFHCC LFHCC(n-3) 
>2 SM(d22:0/20:3)** 
LysoPC(O-16:1)** 
PC(16:0/18:2) 
LysoPE(O-16:1) 
PC(18:0/16:2) 
PC(O-18:0/18:2)* 
LysoPC(18:2) (1) 
LysoPC(18:2) (2) 
LysoPC(16:0) (2) 
LysoPC(O-16:1) 
PC(16:0/18:2)*** 
PC(18:0/18:2)* 
SM(d20:1/16:1) 
LysoPC(O-16:1)*** 
PC(38:5)1 
PC(18:0/20:4) 
LysoPC(O-16:1)** 
1.75-2 LysoPE(18:0) 
LysoPC(18:0) (1) 
PC(18:0/18:2) 
SM(d18:2/24:0) 
LysoPC(16:1) 
SM(d20:1/16:1) 
SM(d22:0/20:3) 
LysoPC(18:0) (1) PC(16:0/18:2) 
Docosahexaenoic 
acid (C22:6) 
1.5-1.75  PC(18:0/20:4) 
PC(16:0/20:3) 
LysoPC(17:0) 
PC(18:0/16:2) 
PC(O-18:0/18:2) 
1.25-1.5 LysoPC(16:0) (1) 
LysoPC(16:0) (2) 
PC(18:2-OH/16:0) 
LysoPE(18:1) 
LysoPC(18:2) (2) 
LysoPC(18:0) (1) 
LysoPC(18:0) (2) 
LysoPC(16:0) (1) 
PC(16:0/20:3) 
SM(d18:0/18:1) 
LysoPC(16:0) (1) 
SM(d20:1/16:1) 
LysoPC(20:4) 
(-1.25)-(-1.5)  Docosahexahenoic 
acid (C22:6) 
PC(18:0/16:2) 
LysoPE(18:1) 
Linoleic acid 
(C18:2) 
PC(18:0/18:1) 
(-1.5)-(-1.75)    PC(18:0/18:2) 
PC(38:5)1 
(-1.75)-(-2) PC(22:6/18:0) 
PC(O-15:1/18:1) 
LysoPC(18:2) (1) 
  PC(16:0/20:3) 
<(-2) PC(16:0/20:4) PC(18:0/18:2)*** 
PC(16:0/18:2) 
LysoPC(16:0) (1) 
PC(O-18:0/18:2) 
LysoPC(17:0) 
PC(16:0/20:4) 
LysoPC(20:4) 
LysoPE(20:4) 
LysoPC(18:2) (2)** 
PC(18:2-OH/16:0) 
LysoPE(20:4) 
SM(d22:0/20:3) 
PC(18:0/16:2) 
 *** p-value < 0 .01 
**  0.01<p-value<0.025 
*    0.025<p-value 
1 PC(38:5) is the sum of PC(18:0/20:5) and PC(16:0/22:5)   
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 Apart from these overall changes, some particular modifications in 
families of phospholipids were observed as a function of the diet. Thus, the main 
difference among diets was observed for three of the most common 
glycerophospholipids, PC(16:0/18:2), PC(18:0/16:2) and PC(18:0/18:2). These 
three metabolites reported different levels depending on the diet, as Figure 4 
shows. Thus, the concentrations of these three PCs were increased in individuals 
after HSFA and LFHCC interventions, while the same compounds were 
decreased in individuals subjected to HMUFA diet. On the other hand, 
individuals after the LFHCCn-3 intervention diet were marked by a different 
effect since PC(16:0/18:2) increased its relative concentration in serum, while 
PC(18:0/18:2) and PC(18:0/16:2) levels were decreased. Attending to these 
results, a direct influence of the intervention diet on three of the most important 
blood phospholipids was found. 
 
Figure 4. Mean values and 95% confidence levels of the normalized area for 
PC(18:0/16:2), PC(16:0/18:2) and PC(16:0/18:2). 
 Additional effects associated to the intervention diets can be deduced by 
comparing the compounds that change their concentration in relative terms. 
Thus, the two diets characterized by high-fat content (38% energy) led to an 
opposite effect in the concentration of glycerophospholipids combining essential 
PUFA substituents and relevant saturated FAs such as palmitic and stearic acids 
(C16:0 and C18:0). Thus, PC(22:6/18:0) and PC(16:0/20:4), which include 
docosahexaenoic acid and araquidonic acid, decreased their concentration in 
serum after intake of the HSFA diet. On the other hand, PC(18:0/20:4) and 
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PC(16:0/20:3) increased their levels in serum after the HMUFA diet. Concerning 
the lysophospholipids profile, these two diets described a common pattern since a 
quite similar trend was found for the most important lysophospholipids —
particularly, lysoPC(16:0) and lysoPC(18:0)— except for one of the isomers of 
lysoPC(18:2) that described an opposite effect. This metabolite (eluting at 8.0 
min) increased its concentration in HMUFA individuals, and decreased in 
individuals subjected to HSFA diet. One other difference detected in individuals 
controlled by these two diets was that affecting lysoPE(18:1). This compound 
increased its concentration in HSFA individuals, while this was decreased in 
HMUFA cases. 
 Concerning the two diets based on low-fat content (LFHCC and LFHCCn-
3), a similar trend was observed for most phospholipid structures, except for 
glycerophospholipids. Glycerophosphocholines, including PUFA substituents, 
clearly increased their concentration in LFHCC individuals, while LFHCCn-3 
individuals were marked by a decreased of this PC structure. Also, one other 
difference between individuals subjected to these two diets was observed for 
lysoPC(20:4), which includes arachidonic acid. This lipidic metabolite was found 
at minor concentration in individuals after LFHCC diet as compared to 
individuals after LFHCCn-3 diet. Taking into account that both diets were based 
on the same fat composition, the mentioned changes can be associated to the 
supplement included, high oleic acid sunflower oil or long chain n-3 PUFA. The 
LFHCCn-3 diet also promoted a change in the profile of sphingomyelins as 
compared to the two diets based on high-fat content. Thus, the SM(d22:0/20:3) 
decreased its concentration in individuals after the LFHCCn-3 diet, while this SM 
increased its concentration in serum after the HSFA and HMUFA diets. One 
other representative effect was observed by comparing individuals after the 
LFHCCn-3 and HSFA diets since an oxidized PC(18:2-OH/16:0) increased its 
serum concentration in HSFA individuals (1.48 fold change), while this oxidized 
phospholipid decreased its serum level (<–2 fold change) after the PUFA 
supplemented diet.   
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 It is also worth mentioning that two essential fatty acids — docosa-
hexaenoic acid and linoleic acid— reported concentration changes in three diets. 
Thus, docosahexaenoic acid was found at increased concentration in LFHCCn-3 
individuals, which included an n-3 PUFA supplement, while that was decreased 
in HMUFA cases. On the other hand, linoleic acid was detected at lower 
concentration in those controlled by the LFHCC diet as compared to control 
individuals.  
3.3. Polar metabolic effects associated to the intervention diets  
 By analogy with the non-polar fraction, the influence of each diet on the 
polar metabolites in serum was evaluated by comparing the PRE sampling time 
versus the POS sampling time. Supervised analysis by multivariate comparison of 
polar tentative metabolites based on PLS-DA allowed establishing metabolic 
differences in serum profiles analyzed in individuals after the four intervention 
diets. In this fraction, prediction capability values were above 94% for the 
training set for the four diets, which supported the discrimination effect observed 
in each PLS scores plot (Figure 5).  
 
Figure 5. Scores graphs obtained after multivariate analysis by PLS-DA of the polar 
fraction for each diet, considering in each case PRE and POS times. 
 A fold change analysis was then executed to know the entities with 
capability to contribute to a higher extent to the separation between PRE and 
POS sampling times in each diet. Identification based on MS and MS/MS 
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information allowed elucidating the compounds that were altered in terms of 
relative concentration due to the intervention diet, as shows Table 2. The 
identified metabolites are classified by the fold change value, positive or negative, 
and diet. The significance level according to an ANOVA test is also shown. As can 
be seen, a common trend was observed in serum from all individuals subjected to 
the diets as compared to the pre-intervention state. Thus, octenoyl-L-carnitine 
resulted increased after the 12-weeks control period. Additionally, this effect was 
highly significant (99%) in the four groups of individuals. Common metabolites 
were found modified after the intake of one of either the low-fat diets or the high 
fat diets. Concretely, several amino acids, excepting ornithine, were only 
modified by intake of a high-fat diet, where the number of metabolites altered 
was higher (14–15) than in the case of the low fat diets (6–9). Apart from that, 
other relevant changes were observed for each diet. Thus, two critical differences 
were observed in the two high-fat content diets, HSFA and HMUFA. The first 
difference affects to levels of certain amino acids such as proline, creatine, 
betaine, valine and ornithine. These amino acids showed a different trend in the 
two groups of individuals. Ornithine was found at increased concentration in 
individuals after the HSFA diet, while those subjected to HMUFA diet decreased 
its concentration as compared to the pre-intervention state. The opposite effect 
was observed for the rest of amino acids, which means that valine, betaine and 
proline significantly increased their concentrations in HMUFA individuals, while 
proline, valine and creatinine decreased their concentration in HSFA diet. In 
addition to the phenomenon observed for ornithine, the same behavior was 
found for inosine, which increased its serum concentration in HSFA individuals 
(with statistical significance) while the HMUFA diet led to a relevant lowering 
effect (–1.82) in the concentration of this purine nucleoside. The mean area with 
the 95 percent of confidence levels for proline, methionine and valine for each 
time and diet are shown in Supplementary Figure 4. 
 Minor relevant changes were found in the polar fraction of serum from 
individuals subjected to the two low-fat content diets, LFHCC and LFHCCn-3. As 
previously emphasized, both diets resulted in increased concentration of 
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octenoyl-L-carnitine, but only in the LFHCC individuals were detected relevant 
effects for other two carnitine derivatives: hexanoyl-L-carnitine and 
acetylcarnitine,. Particularly, both carnitine analogues decreased their serum 
concentration due to the LFHCC diet. This diet also increased the concentration 
of ornithine as the HSFA diet.  
Table 2. Polar metabolites that experienced a fold change above 1.25 by comparing 
physiological states before and after intervention diets. 
 HSFA HMUFA LFHCC LFHCC(n-3) 
>2 Inosine* 
Paraxanthine 
L-ornithine 
Octenoyl-L-
carnitine*** 
Octenoyl-L-
carnitine*** 
Cholic acid CMPF*** 
Octenoyl-L-
carnitine*** 
1.75-2   Octenoyl-L-
carnitine*** 
 
1.5-1.75  Valine*   
1.25-1.5 LysoPC(16:0) 
CMPF 
Hippuric acid 
Bilirubin (1) 
Betaine* 
Proline 
Paraxanthine 
CMPF 
Hippuric acid 
2-Phenylacetamide 
Ornithine LysoPC(16:0) 
(-1.25)-(-1.5) Proline 
Creatinine 
Methionine* 
Glycocholic acid 
Bilirubin (2) 
Aconitic acid 
Bilirubin (1) 
Methionine 
Hexanoyl-L-
carnitine* 
Acetylcarnitine*** 
Bilirubin (2) 
Aconitic acid 
Inosine 
Hippuric acid 
Caffeine 
Hypoxanthine* 
(-1.5)-(-1.75) Caffeine 
Valine 
Caffeine  Bilirubin (2) 
(-1.75)-(-2)  Ornithine 
Inosine 
  
<(-2)     
***p-value < 0 .01 
**  0.01<p-value<0.025 
*    0.025<p-value 
(1) and (2) bilirubin corresponds to bilirubin and bilirubin IXa, two indistinguishable isomers by 
mass spectrometry.  
 
 Two bile acids were also in the list of metabolites altered in terms of 
concentration: cholic acid and glycocholic acids, which are connected by a 
pathway regulated by choloylglycine hydrolase. The concentration of cholic acid 
was considerably increased (2.02) in individuals subjected to LFHCC, while 
glycocholic acid was decreased (–1.33) in HSFA diet. Finally, the LFHCCn-3 class 
was characterized by a decrease in the concentration of inosine, hippuric acid and 
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hypoxanthine (with a statistical significant decrease in the last case). On the other 
hand, the levels of some metabolites were increased or decreased only after 
intake of some of the diets under study. As an example, methionine decreased by 
diets with high-fat content (HSFA and HMUFA). 
3.4.  Pathways analysis 
  After identification of polar and non-polar metabolites that experienced 
changes in concentration due to the 12-weeks intervention period, an 
interpretation of the obtained results was carried out attending to the connection 
of biochemical pathways. Despite concentration changes of polar metabolites 
such as amino acids or carnitines were observed in relative terms, most 
alterations occurred on the metabolism of lipids, which was identified as the 
main variability source. Thus, the main metabolic impact caused by the 
intervention diets is reflected in the metabolism of glycerophospholipids and 
sphingolipids, which are the main components of cellular membranes, but also of  
blood lipoproteins, bile and lung surfactant. The influence of fatty acids intake on 
the qualitative and quantitative behavior of phospholipids had previously been 
reported [18]. In fact, concerning the three most abundant families of lipids 
present in serum, changes of the fatty acids composition in the diet have affected 
to phospholipids in a higher extent than to triglycerides and cholesteryl esters. 
The phenomenon seems to be logical since phospholipids constitute a family of 
compounds necessary for the absorption, transport and storage of lipids. With 
these premises, serum phospholipids could be proposed as sensitive markers of 
the fatty acid composition of diets. Among the metabolic changes altering the 
glycerophospholipids profile, it is worth mentioning that the serum levels of three 
of the most important phospholipids —PC(16:0/18:2), PC(18:0/16:2) and 
PC(18:0/18:2— have been affected by the diet; therefore they were able to set 
differences in individuals after diet intake. Additionally, the relative changes 
occurring in the profile of glycerophospholipids were not dependent on the fat 
energetic contribution that characterizes the diets. Thus, HSFA and LFHCC diets 
promoted a representative increase in relative concentrations of glycerophos-
phatidylcholines with two substituents, while the opposite effect was observed in 
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individuals subjected to LFHCCn-3 diet, which also evidenced a decrease in the 
level of sphingomyelins. The supplement of long chain n-3 PUFAs seems to be 
critical to explain these differences in metabolism. 
 Glycerophospholipids are synthetized from acyl-CoA, a group of 
coenzymes involved in fatty acids metabolism. The presence of PUFAs as 
substituents of glycerophosphatidylcholines contributed to set one other 
metabolic difference between groups of individuals: increased levels in HMUFA 
and LFHCC individuals versus decreased levels in HSFA and LFHCCn-3 
individuals. Also, two PUFAs such as docosahexaenoic acid and linoleic acid, 
which are implicated in the metabolism of essential fatty acids, experienced 
differences among individuals subjected to different diets. The connection 
between the metabolism of fatty acids and glycerophospholipids establishes a 
global effect of intervention diets on the metabolism of lipids.  
 Choline, one other metabolite involved in the metabolism of glycerol-
phospholipids, also revealed a statistical significant change in concentration due 
to the HSFA diet, while in HMUFA diet, betaine, which is synthesized by choline 
oxidation through conversion to betaine aldehyde, was that experiencing a 
change in concentration with statistical significance. Betaine is an intermediate in 
the biosynthesis of essential and non-essential amino acids. Thus, betaine plays a 
crucial role in the synthesis of L-carnitine that is the precursor of carnitines, the 
alteration of which was detected as one of the most representative metabolic 
effects caused by diets. Carnitine is an infrequent amino acid but an essential 
factor in the metabolism of fatty acids. This compound metabolizes fatty acids 
through the formation of acylcarnitines that generate acetyl-CoA and carnitine, 
thus completing the cycle of lipid degradation. Acetylcarnitine levels have also 
shown to be signiticantly decreased after LFHCC intake. 
 One other amino acid that was altered as a result of dietetic interventions 
was valine, whose degradation leads to leucine and, finally, to acetyl-CoA, which 
regulates the biosynthesis of fatty acids. In relation to valine, a variation was 
observed in individuals subjected to HSFA and HMUFA diets, since the levels of 
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this amino acid were increased in HMUFA individuals, while HSFA individuals 
described the opposite result. 
 Other two amino acids implicated in a common pathway, proline and 
ornithine, reported different results for LFHCC and HSFA individuals, since 
ornithine was increased in LFHCC individuals and decreased in HSFA 
individuals. Ornithine is produced in the urea cycle through arginine, but also it 
is the substrate to produce proline by the activity of the ornithine 
cyclodeaminase.  The urea cycle is also connected to the citrate cycle, which could 
explain the decreased concentration of aconitic acid in LFHCCn-3 individuals as 
no modification of the metabolites involved in the urea cycle was observed. 
Methionine presented the same behavior in the two high-fat content diets as its 
concentration was decreased after the intervention period. However, its variation 
was only statistically significant in the case of the HSFA diet. Methionine is an 
intermediate of transmethylation reactions, being the methyl acceptor for the 
catabolism of betaine. 
 Two bile acids (cholic and glycocholic) were also affected by some diets. 
Bile acids facilitate the absorption, transport and excretion of fats and sterols in 
the intestine and liver. Therefore, it seems to be relevant that the type of fat 
administered to individuals could have an important effect on the metabolism of 
bile acids. Two diets revealed changes in the levels of bile acids: LFHCC, which 
increased the concentration of cholic acid, and HSFA, which promoted a relative 
decrease of glycocholic acid, the precursor of cholic acid.    
 Regarding purine base derivatives, inosine and hypoxanthine levels 
resulted modified after the intake of some of the diets. Concretely, inosine levels 
resulted significantly increased after HSFA intake, and decreased unsignificantly 
after HMUFA or LFHCCn-3 intake. Inosine is directly related to hypoxanthine, 
whose levels resulted significantly decreased after LFHCCn-3 intake. Hypo-
xanthine has demonstrated to induce oxidative stress related to lipid oxidation. 
In fact, the only oxidized phospholipid identified in the non-polar fraction —
PC(18:2-OH/16:0)— decreased its concentration in individuals after LFHCCn-3 
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intervention, the same diet by which hypoxanthine was significantly decreased. 
On the other hand, hypoxanthine levels were significantly increased in 
individuals after HSFA intervention, the diet based on high content of SFA and 
the same diet by which inosine and the oxidized phospholipid were significantly 
and slightly increased, respectively.  
 Other compound with concentration modified after intake of some diets 
was hippuric acid, involved in the metabolism of phenylalanine. The concen-
tration of hippuric acid was slightly increased after intake of high-fat content 
diets —HSFA and HMUFA— and slightly decreased after LFHCCn-3 diet. 
Hippuric acid has been associated to the metabolism of phenolic compounds, 
thus it could be associated to oxidation inhibition activity. Additionally, bilirubin 
1 and bilirubin 2 (see Table 2) were found to increase and decrease, respectively 
their concentrations after HSFA intervention; bilirubin 1 experienced a decrease 
by HMUFA intake, while in LFHCC and LFHCCn-3 diets the decrease affected to 
bilirubin 2. Both bilirubin analogues are as potent physiological antioxidants. A 
less well-known metabolite, 3-carboxy-4-methyl-5-propyl-2-furanpropionic acid 
(CMPF), experienced a slight concentration increase in individuals subjected to 
one of the two high-fat content diets and the LFHCCn-3 diet. The occurrence of 
this metabolite in blood is associated to the consumption of fish, vegetables and 
fruits, being related with the metabolism of phospholipids [9]. Nevertheless, its 
origin is not clear and an endogenous presence by metabolism of furan fatty acids 
cannot be excluded.  
 
4. Conclusions 
 A global nutrimetabolomics study has been developed to compare 
metabolic effects caused by four intervention diets differentiated in fat quantity 
and quality. The serum samples obtained before and after diet intake were 
fractioned by a mixture methanol–chloroform, and the polar and non-polar 
fractions evaluated separately. The comparison of serum metabolite profiles 
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obtained by LC–QTOF in high resolution mode has shown to be a suitable 
strategy to identify the most influenced metabolites after intervention diets. 
 Multivariate statistical analysis by PLS-DA revealed a slight 
discrimination among metabolic profiles representing the four post-intervention 
states, being the low fat content diet supplemented with n-3 fatty acids that 
providing the most discriminant metabolic pattern. A clear discrimination 
between the pre-intervention and post-intervention times for each diet was also 
observed.  
 The evaluation of the non-polar fraction led to know that phospholipids 
are the major fraction altered in the non-polar fraction after the intervention 
diets. On the other hand, the evaluation of the polar fraction revealed some 
amino acids, bile acids and acylcarnitines as some of the most affected 
metabolites in serum. In fact, the high fat content diets presented more amino 
acids with levels modified after diets, while only ornithine was slightly increased 
in one of the low fat content diets. 
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Supplementary Figure 2. Base peak chromatograms obtained by LC–MS/MS analysis 
of: A) the polar fraction of a pre-intervention sample in positive ionization mode; B) the 
polar fraction of a post-intervention sample in positive ionization mode; C) the non-polar 
fraction of a pre-intervention sample in negative ionization mode; and D) the non-polar 
fraction of a post-intervention sample in negative ionization mode. 
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Supplementary Figure 3. Scores plot obtained for PRE and POS times considering all 
the diets after multivariate principal component analysis (PCA) for polar fraction (a) and 
non-polar fraction (b).  
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Supplementary Figure 4. Mean values and 95% confidence levels of the normalized 
area for proline, valine and methionine. 
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Metabolomic discrimination between patients 
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Abstract 
 The ischemic cascade starts when atherosclerotic plaques decrease the 
supply of oxygen and substrates to cells and ﬁnalizes with myocardial infarction. 
These states have been here studied at metabolite level by optimization of a 
metabolomics proﬁling approach based on high-accuracy MS. For this purpose, 
serum samples from patients diagnosed with coronary artery disease and affected 
by stable angina or myocardial infarction (acute myocardial infarction or non-ST 
elevation myocardial infarction) were analyzed by LC–QTOF MS/MS after 
deproteinization to compare the proﬁle of serum metabolites. The data set, 
composed by tentative molecular features detected in MS analyses, was ﬁltered 
with statistical algorithms to remove entities resulting in redundant information. 
Tentative molecules were identiﬁed ﬁnding mainly lipids as statistically 
signiﬁcant metabolites in the discrimination study due to their change in 
concentration. Lipids such as bile acid derivatives, phospholipids, and 
triglycerides were identiﬁed as relevant compounds for discrimination of 
individuals who suffered acute or non-ST elevation myocardial infarction from 
those suffering stable angina. The results achieved by this research could support 
the capability of metabolomics to go inside the study of artery diseases, and in 
addition to other omics disciplines could help to detect the occurrence of these 
disorders at initial stages or even to prognosticate their appearance. 
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1.  Introduction 
 Nowadays, cardiovascular diseases (CVDs) are the leading cause of death 
worldwide with supremacy in low-and middle-income countries (80%) and with 
high significance in European countries (50%). Therefore, CVDs are a major 
cause of disability and contribute significantly to increase health care costs [1]. 
Cardiovascular diseases usually originate in atherosclerosis, a coronary artery 
disease characterized by the formation of lipid plaques in arteries restricting 
blood circulation to the heart. Atherosclerosis is the main cause of angina 
pectoris, a perceived symptom resulting from a mismatch of myocardial supply 
and demand caused by the partial obstruction of the artery. When the anaerobic 
threshold is crossed, the patient develops symptomatic angina pectoris (chest 
pain) which can appear after a physical effort or activity (angina stable) [2]. If 
this symptom is perceived with minimum activity and higher frequency, the 
suited term is unstable angina.  
 A rupture in the atherosclerotic plaque can generate a thrombus which 
can occlude normal blood flow. Complete thrombotic occlusion of a coronary 
artery causes myocardial necrosis and is termed acute ST-elevation myocardial 
infarction also known as acute myocardial infarction (AMI), whereas incomplete 
occlusion does not cause myocardial necrosis and is termed non-ST elevation 
myocardial infarction (NSTEMI). It is worth mentioning that unstable angina 
and NSTEMI are often considered together because they can be indistinguishable 
upon first appearance [3]. 
 One of the main problems in clinical practice is the diagnosis of 
cardiovascular dysfunctions, which are commonly detected in a relatively 
advanced stage of the disease course [4]. The initial diagnostic approach for 
coronary artery disease encompasses a detailed patient history, a complete 
physical examination and an electrocardiogram. After this preliminary 
evaluation, laboratory blood tests, stress testing and invasive cardiac 
catheterization may be necessary to obtain further insight diagnostic and confirm 
the presence of atherosclerotic problems. 
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 Different studies on atherosclerosis have been developed in the “omics” 
scene mainly aimed at the search for biomarkers and elucidation of the 
mechanisms through which myocardial infarction occurs. In fact, different 
proteomic databases of cardiac proteins have so far been constructed and 
alterations of several cardiac proteins in human myopathies have been described 
[5–7]. In the genomic area, research has been mainly focused on looking for 
genetic factors that may be associated with this disease susceptibility [8]. On the 
other hand, transcriptomics has also been used to identify specific patterns on 
myocardial tissue with different cardiovascular diseases (e.g. heart failure or 
cardiac transplants) [9, 10]. The latest developed omics, metabolomics, has 
contributed in a lesser extent to the study of atherosclerosis despite the metabolic 
changes that occur as a consequence of ischemia (e.g. accumulation of glucose, 
increased synthesis of prostacyclin and thromboxane, production of nitric oxide) 
[11]. Despite these well-known evidences, the metabolic impact associated to 
myocardial infarction is still unknown. 
 To date, there have been few metabolomics studies devoted to 
cardiovascular diseases. One of the first studies to uncover the potential of 
unbiased metabolomic profiles in predicting atherosclerosis patients was based 
on NMR spectroscopy analysis of blood samples [12]. This study included 
patients with unstable atherosclerosis or prior myocardial infarction. The model 
resulted in a 90% predictive capability for atherosclerosis patients on a major 
lipid region of the NMR spectra. However, a follow-up study was unable to keep 
this prediction results due to variability sources supported on gender and the use 
of3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors 
between the two populations under study [13]. These results emphasize the 
clinical variability of patient cohorts. 
 Other study utilized GC–MS to evaluate major changes in plasma 
metabolites between 9 patients with NSTEMI, 10 patients with stable 
atherosclerosis and 10 patients without coronary lesions [14]. Citric acid,  
4-hydroxyproline, aspartic acid, and fructose levels were decreased, whereas 
lactate, urea, glucose, and valine levels were increased in atherosclerosis patients 
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as compared with the control group. Thus, metabolic changes were limited to 
polar metabolites. 
 Presently, no many biomarkers are used in the diagnosis of cardio-
vascular diseases —e.g. creatinin phosphokinase (CPK) or troponin for acute 
myocardial infarction. There are an ischemic cascade with elevation of specific 
markers at different stages of cardiovascular diseases, from plaque formation to 
necrosis and left ventricle remodeling, but most of the markers proposed so far 
are proteins, lipids or factors (e.g. placental growth factor, tissue factor) [15]. 
Nowadays, it is interesting to use metabolomics as a discrimination tool for 
disease diagnosis, given that many of the analytical tools used in metabolomics 
are automatable and on the whole high throughput, they lend themselves to 
screening populations of individuals for disease. There are still work to be done to 
fully elucidate the metabolic processes and changes occurring as a consequence 
of atherosclerosis. The objective of the present research was to find overall 
metabolic changes which could be used to differentiate three cardiovascular 
pathologies such as stable angina, NSTEMI and AMI by LC–QTOF/MS. This 
instrumental platform provides great advantages in metabolomics studies. The 
use of LC–MS/MS for identification and confirmatory analysis was also planned. 
 
2. Materials and methods 
2.1. Reagents 
 LC-grade methanol and MS-grade formic acid and acetonitrile (ACN) 
were purchased from Scharlab (Barcelona, Spain). Deionized water (18 mΩ • cm) 
from a Millipore Milli-Q water purification system was used. 
2.2. Instruments and apparatus 
 A Sorvall Legend Micro 21R centrifuge (Thermo Scientific, Waltham, MA, 
USA) was used to centrifuge samples after deproteinization.  
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 An Agilent 1200 Series LC system coupled to an Agilent 6540 UHD 
Accurate-Mass QTOF tandem mass spectrometer equipped with a Jetstream® 
ESI source (Santa Clara, CA, USA) was used. The chromatographic eluting 
solution was monitored in high resolution mode. 
2.3. Cohort selected for the study 
 A total of 189 patients affected by significant coronary artery lesion as 
atherosclerosis were included in the study. The main characteristics of the 
patients are shown in Supplementary table 1. As can be seen, the selected cohort 
was composed of 73 and 74 individuals diagnosed with stable angina and 
NSTEMI, respectively, while 42 of them had suffered previously an acute 
myocardial infarct. The average age of the cohort was 67±14, 79.0% of them male 
individuals, 51.6% smokers, 25.8% diabetic, 37.8% obese, 61.4% hypertense and 
52.7% with hypercholesterolemia. Despite the variability of these factors, their 
proportion in the three considered sub-groups was quite similar. In fact, 
independence of clinical factors and cardiovascular pathologies was proved 
according to the Pearson’s Chi Squared test with a 95% of confidence level. 
Atherosclerosis was diagnosed to all patients after evaluation through cardiac 
catheterization (angiographic stenosis revealed a reduction of the arterial lumen 
≥ 70%). Blood extraction immediately preceded catheterization. Most patients 
were taken medication as follows: β-blocking agents (78%), statins (92%), 
antiplatelet agents (88%) and aspirin (98%). 
 2.4.     Blood extraction and serum isolation 
 All steps from blood extraction to analysis were performed in compliance 
with the guidelines dictated by the World Medical Association Declaration of 
Helsinki (2004), which were supervised by specialized personnel from Miguel 
Servet Hospital (Zaragoza, Spain) that approved the experiments. Informed 
consent was obtained from all participants prior to sample collection. 
 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, USA) and 
incubated for 30 min at room temperature to allow coagulation. Then, the tubes 
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were centrifuged at 2000 g for 15 min at 4°C to isolate the serum fraction (which 
was put in an ice bath prior to freezing within 2 h after collection). Serum was 
placed in plastic ware tubes and stored at –80 °C until analysis.  
2.5. Sample treatment 
 Serum samples (100 µL) immersed in an ice bath were treated for 
deproteinization with methanol (200 µL), the most common solvent used for 
metabolomics profiling without sample fractionation. The mixture was shaken 
for 1 min and the precipitate removed after centrifugation for 5 min at 4 °C and 
13800 g. The upper phase was collected in a vial that was placed in the LC 
autosampler for subsequent analysis. 
2.6. LC–QTOF MS/MS analysis  
 Chromatographic separation was performed using a Mediterranea 
reversed phase C18 analytical column (100 mm x 0.46 mm i.d., 3 μm particle 
size) from Teknokroma (Barcelona, Spain) kept at 25 °C. Mobile phases were 
water (phase A) and ACN (phase B), both with 0.1% formic acid as ionization 
agent. The LC pump was programmed with a flow rate of 0.8 mL/min and the 
following gradient elution was carried out: 3% phase B was kept constant from 
min 0 to 2; from 3 to 100% of phase B from min 2 to 27; finally, 100% of phase B 
was kept from min 27 to 33. 
 The injection volume was 10 µL and the injector needle was rinsed with 
70% methanol for 10 times between injections. Furthermore, the needle seat back 
was flushed for 15 s at a flow rate of 4 mL/min with 70% methanol to avoid cross 
contamination. 
 Jetstream ESI source parameters, operating in negative and positive 
ionization mode, were as follows: nozzle, capillary and fragmentor voltage were 
set at +/– 2 kV, +/– 3.5 kV and 175 V, respectively; N2 nebulizer gas was flowed 
at 40 psi; N2 drying gas flow rate and temperature were 8 L/min and 325°C; N2 
sheath gas flow rate and temperature were 11 L/min and 350°C. The instrument 
was calibrated and tuned according to procedures recommended by the 
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manufacturer. The data were collected in both centroid and profile modes at a 
rate of 2 spectrum per second in the extended dynamic range mode (2GHz). 
Firstly, the samples were analyzed in full scan MS mode in the m/z range 60–
1100 for metabolite profiling. The reported data set was statistically processed to 
detect molecular features with a high significance to explain the observed 
variability. Once the most significant entities were recognized, the samples were 
analyzed in targeted MS/MS mode (m/z range 60–1100) to obtain structural 
information with identification purposes. To assure the desired mass accuracy of 
recorded ions, continuous internal calibration was performed during analyses 
with the use of signals at m/z 121.0509 (protonated purine) and m/z 922.0098 
[protonated hexakis(1H, 1H, 3H-tetrafluoropropoxy)phosphazine or HP-921] in 
positive ion mode; in negative ion mode ions with m/z 119.0362 (proton 
abstracted purine) and m/z 966.000725 (formate adduct of HP-921) were used. 
Resolution provided by the instrument ranged from 15000 FWHM (Full Width at 
Half Maximum) at low masses (purine) and 30000 FWHM at high mass values 
(HP-921). 
 Samples were randomized injected twice to obtain chromatograms in 
both ionization modes. A blank sample was injected every 10 samples and the ESI 
source was cleaned every day to avoid carry over. A stability study was planned by 
repetitive injections of samples to avoid variability associated to disturbances in 
the metabolic profile. As can be seen in Supplementary figure 1, variability was 
found from the 13th injection, which sets the maximum period that samples can 
be at the autosampler without affecting their stability. 
2.7. Data processing and statistical analysis 
 Raw data files were converted to mzData files using MassHunter 
Workstation software (version 3.01 Qualitative Analysis, Agilent Technologies, 
Santa Clara, CA, USA) and then the data from each polarity were separately 
processed in R statistical language (version 2.15.0, http://www.r-project.org/) 
using the open-free XCMS R-package (version 1.24, http://metlin.scripps.edu/ 
xcms/index.php) [16,17] and the also open-free CAMERA R-package (version 
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1.12.0, http://www.bioconductor.org/packages/2.10/bioc/html/CAMERA.html). 
First, the XCMS package was used for processing mzData files of each ionization 
mode by extraction of potential molecular features (MFs) considering only ions 
exceeding 1000 counts peak height with a peak width between 10 and 60 s, a 
signal to noise threshold of 10 and 5 ppm of error in mass accuracy. Then, a non-
linear alignment was executed using the “retcor” function with a degree of 
smoothing for local polynomial regression fitting of 0.5 and a symmetric fitting, 
process that used a re-descending M estimator with Tukey’s biweight function. 
Then, the CAMERA package was used to correlate potential adducts (in positive 
ionization mode [M+Na]+ and [M+H]+;in negative ionization mode [M+HCOO]–, 
[M+Cl]– and [M-H]–) and isotopic peaks of the same molecular entity. Adducts 
formed by dehydration neutral loss were also considered.  Thus, ions with 
identical elution profiles and related m/z values (representing different adducts 
or isotopes of the same compound) were grouped as a unique feature to remove 
redundant information. This process resulted in a data set containing the 
intensity values in the apex of chromatographic peaks for all molecular entities 
characterized by accurate mass and retention time (RT). Background 
contribution was removed by subtraction of MFs linked to plasticizers, solvent 
impurities and other contaminating compounds after analysis of blank sample 
(methanol) under identical instrument operation conditions. 
 The data set from each polarity was then imported to the Mass Profiler 
Professional (MPP) software package (version 2.0, Agilent Technologies, Santa 
Clara, CA, USA) for further processing. Data pretreatment was based on 
baselining to median across samples to remove background noise and 
normalization by logarithmic transformation to reduce relatively large differences 
among MF abundances. A fold-change algorithm was applied as filter to retain 
those molecular entities that experienced a change in relative concentration of 
2.0 between pairs of classes. MPP software also allowed unsupervised and 
supervised analysis by PCA and PLS-DA of the data. In the case of PCA, data 
scaling by mean centering was used as pretreatment. Auto-scaling was selected in 
the case of PLS-DA. The validation model selected was N-Fold. With this model 
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the classes in the input data are randomly divided into N equal parts; N-1 parts 
are used for training, and the remaining one part is used for testing. The process 
repeats N times, with a different part being used for testing in an iterative 
process. Thus, each row is used at least once in training and once in testing, and a 
confusion matrix is generated. This whole process can then be repeated as many 
times as specified by the number of repetitions. For all validations 10 repetitions 
and a fold number of 3 were selected. 
 Finally, an ANOVA test was executed for each metabolite to know the 
discrimination capability of each one among the three groups of patients 
considering significant a p-value lower than 0.05. 
 
3. Results and discussion 
3.1. Optimization of the LC–QTOF MS/MS analysis 
 Profiling analysis of serum metabolome from cardiovascular patients was 
carried out with a global approach based on non-targeted analysis. A simple 
deproteinization step with methanol was selected in this study to avoid sample 
fractionation which would increase the number of analysis. Chromatographic 
resolution was optimized with three different elution gradients, 22, 33 and 55 
min, from aqueous solution (phase A) to acetonitrile (phase B) in both ionization 
modes. For the three methods tested, a 3% of phase B was kept for 2 min and, 
then, a gradient to 100% of B was programmed for 14, 25 and 47 min with a final 
step for 6 min of 100% B. Figure 1 includes base peak chromatograms (BPCs) 
provided by analysis of three aliquots of serum pool with the three 
chromatographic methods using negative ionization mode. According to the 
number of features extracted (3 replicates), the longest chromatographic method 
did not improve chromatographic resolution in any ionization modes. Therefore, 
theintermediate gradient method was adopted for analysis of samples from the 
complete cohort of individuals. 
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Figure 1. Base peak chromatograms obtained by the three chromatographic methods 
tested in negative ionization mode from three aliquots of serum pool. The number of 
molecular features obtained by each chromatogram are also included.  
 
3.2. Data mining and pre-treatment 
 The alignment of molecular features is a crucial step prior to statistical 
analysis. The tolerance window for alignment employed was 0.2 min and 5 ppm 
for elution time and mass accuracy, respectively. Supplementary figure 2.A 
illustrates the curves for retention time deviation with elution time for all 
molecular entities after alignment. As can be seen chromatographic profiles were 
well-aligned demonstrating that chromatographic precision was quite good. One 
outlier was detected according to retention time deviation and, for this reason, 
this entity was removed. After data pretreatment, the data set obtained in the 
negative ionization mode contained 289 molecular entities. Supplementary figure 
2.B shows the frequency histogram as a bars diagram plotting the number of 
entities with a certain frequency. The bars diagram reveals that most entities 
(92.7%) were detected in at least 90% of samples considered in this study, which 
supports a data set representative of the selected cohort. The data set obtained in 
the positive ionization mode did not reported significant differences among the 
groups under study, so these data were removed. 
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3.3. Statistical analysis by unsupervised and supervised methods 
 As mentioned above, myocardial infarction or heart attack implies 
myocardial cell death as a consequence of prolonged ischemia (impairment of 
blood flow with inadequate oxygen delivery to the heart muscle). Some heart 
attacks strike suddenly but it is also frequent to experience symptoms (angina) 
some hours, days or weeks in advance.  
 Despite some metabolic changes occurring in a myocardial infarction 
have been described [15,18], it may be of interest to compare metabolic profiles of 
different atherosclerosis stages to elucidate metabolic pathways of the process. 
For this purpose, a fold-change filter was applied to simplify the data set and 
eliminate redundant information. The filter removed those molecular features 
that did not experience a relative change in concentration of 2.0 between pairs of 
groups. The fold-change algorithm reduced the data set from 289 to 13 molecular 
features, which should explain a relevant part of the variability associated to the 
three groups. With this new data set, a principal component analysis was 
executed but no discrimination of the three groups was observed (Supplementary 
figure 3) due to overlapping of patients pertaining to the three groups. For this 
reason, PCAs were split into three studies: stable angina versus NSTEMI, stable 
angina versus AMI and NSTEMI versus AMI. Figure 2 illustrates the three-
dimensional scores plot for the three independent studies. As can be seen, the 
two PCAs involving individuals diagnosed with stable angina clearly 
differentiated the two groups considered (Figure 2.A and 2.B). Therefore, 
relevant metabolic changes allowed differentiating patients diagnosed with the 
less severe diagnostic in atherosclerosis (stable angina) versus those diagnosed 
with NSTEMI and those who suffered an AMI episode. On the other hand, no 
discrimination was observed between individuals with NSTEMI and after an AMI 
episode (Figure 2.C). With these premises, prediction models based on PLS-DA 
were developed for the three studies to estimate the discrimination capability 
supported on the clinical diagnostic. Figure 3 shows the three-dimensional plots 
for each PLS model with the first three latent variables. As can be seen, PLS-DA 
plots confirmed the results obtained by PCA since clear discrimination was 
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observed in those cases involving individuals diagnosed with stable angina but 
not for the NSTEMI/AMI study. Prediction capability values expressed in 
percentage for training and validation sets of each PLS-DA are shown in Table 1. 
 
 
Figure 2. PCA scores plot obtained for AMI versus stable angina (A), stable angina 
versus NSTEMI (B), and AMI versus NSTEMI (C). 
 
 
Figure 3. PLS-DA scores plot of the three models: AMI versus stable angina (A), stable 
angina versus NSTEMI (B), and AMI versus NSTEMI (C). 
 
 Therefore, supervised analysis by PLS-DA confirmed the capability of the 
panel of molecular features obtained after simplification of the data set to 
discriminate patients diagnosed with stable angina versus those who suffered 
more severe diagnostics: NSTEMI or AMI. 
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Table 1. Prediction capability for the three PLS-DA models considered. 
 Model 1 Model 2 Model 3 
 AMI 
Stable 
angina 
NSTEMI 
Stable 
angina 
AMI NSTEMI 
Model validation 
Sensitivity (%) 76.2 72.6 74.0 79.7 56.7 59.5 
Specificity (%) 72.6 76.2 79.7 74.0 59.5 56.7 
Recognition ability (%) 75.68  76.9  57.7 
Model Training 
Sensitivity (%) 74.0 71.4 78.0 83.8 66.2 69.0 
Specificity (%) 71.4 74.0 83.8 78.0 69.0 66.2 
Recognition ability (%) 73.0  80.9  67.2 
 
3.4.  Identification of significant metabolites contributing to explain 
diagnostics 
 Targeted analysis of significant molecular features was carried out by 
tandem mass spectrometry with the QTOF spectrometer for identification of 
metabolites, which would allow interpreting the connection between metabolic 
changes and clinical diagnostic. The HMDB and the METLIN databases were 
used to support the identification step. The identified metabolites are listed in 
Table 2 with analytical information such as retention time, m/z value of the 
detected adduct, error expressed in ppm and the main fragment ions used for 
identification. According to the fold-change algorithm, cholic acid was the most 
significant metabolite to discriminate patients affected by AMI from those 
diagnosed with stable angina. On the other hand, lysophosphocholine (16:0) was 
the metabolite with the highest relative change in terms of concentration for 
discrimination of patients diagnosed with NSTEMI from those with angina 
stable. 
 Cholic acid is one of the major bile acids biosynthesized from cholesterol 
and transformed into other secondary bile acids, one of them being deoxycholic 
acid [19]. Bile acids are usually the form in which the excess of cholesterol in the 
body is eliminated, so low levels of bile acids are generally related to high levels of 
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cholesterol, one of the CVD risk factors. The levels of cholic and deoxycholic acids 
were not significantly related with the presence of hypercholesterolemia (p-
values 0.5986 and 0.1005, respectively). Nevertheless, a positive relationship 
between hypercholesterolemia and deoxycholic levels was observed as 
Supplementary figure 4 shows.  Furthermore, it has been demonstrated   that 
coronary artery disease patients have significantly decreased bile acid excretion 
levels as compared with normal population [20]. Supplementary figure 5 shows 
that patients with AMI presented the lowest level of both bile acids, while 
patients with stable angina presented the highest levels; however, a low 
discrimination capability is obtained by both metabolites. 
 One other identified bile metabolite was bilirubin which is the end-
product of porphyrin rings degradation catalyzed by hemeoxygenase (HO). This 
enzyme generates free redox active iron, carbon monoxide and biliverdin, which 
is metabolized to bilirubin. One of the two HO isoforms, the HO-1, is a stress-
responsive enzyme highly induced by many agents such as cytokines, endotoxin, 
heavy metals, nitric oxide and the own hemesubstrate [21]. An excess of nitric 
oxide released during occlusion of artery lumen could be responsible for the 
increase of bilirubin concentration in AMI and NSTEMI patients (Figure 4.A), 
which endows this metabolite with high discrimination capability (p-value 
0.001). HO-1 represents a key defensive mechanism against further oxidative 
injury by virtue of the anti-inflammatory and antioxidant capacities of CO, 
biliverdin and bilirubin.  
 On the other hand, lysophosphocholines are produced by hydrolysis of 
lysophophatidylcholines, resulting from cholesterol by the action of cholesterol 
acyltransferases. LysoPC (16:0) is one of the most common lysoPCs formed by a 
chain of palmitic acid, which is present in animal fats, in vegetable and fish oils. 
 Apart from lysoPC(16:0), other phospholipids were identified in the 
resulting panel, which emphasizes the role of phospholipids in the development 
of the coronary artery disease. The metabolism of phospholipids has previously 
been related to cardiovascular disorders [22]. In fact, lysoPCs play a key role in 
   
246 
Metabolomic discrimination between  
patients with stable angina, NSTEMI, and AMI  
plaque inflammation and vulnerability, whereas oxidized phospholipids tend to 
accumulate at sites where oxidative stress is especially involved. Among them, it 
is worth mentioning areas with atherosclerotic lesions, hyperlipidemic plasma or 
with low concentration of high-density lipoproteins. Additionally, the reverse 
cholesterol transport is inhibited, thus contributing to the development of 
hypercholesterolemia and atherosclerosis [23]. Other relevant lysoPC identified 
in the panel of significant metabolites were lysoPC(18:2) and lysoPC(18:1) which, 
together with lysoPC(16:0), constitute three of the main phospholipids present in 
human plasma. Supplementary figure 6 illustrates the average levels obtained for 
the three lysoPCs in the three groups considered in this research. An oxidized 
phosphocoline —PC(16:0/5:0(CHO)—  was also detected with a relative change in 
concentration in NSTEMI patients versus stable angina patients, supporting the 
importance of phospholipids oxidation in the atherosclerotic cascasde [24]. 
Supplementary figure 6.D describes the average levels of this oxidized 
phospholipid in the three groups included in the study. 
 Two additional phospholipids were identified as contributing meta-
bolites: a phosphatidylserine (compound 1), and PA(10:1/18:1). Phosphatidyl-
serines are located mainly on the inner monolayer surface of the plasma cell 
membrane and are the most abundant anionic phospholipids contributing to 
interfacial effects in membranes involving non-specific electrostatic interactions. 
The main cause of their presence in serum is connected to cellular apoptosis, 
which takes place after a myocardial infarction or during platelet activation [25]. 
In this case, two identification options were possible for m/z 734.4243: the 
[M+FA–H]– adduct of either methyl ester PS(14:1/14:1) or PS(14:1/15:1), the 
latter related with an exogenous factor such as diet. Thus, detection of C:15 fatty 
acid is based on the intake of dairy products and milk [26]. On the other hand, 
phosphatidic acids (PAs) are main components of cellular membranes and 
intermediates in the biosynthesis of triacylglycerols and phospholipids. PAs are 
involved in many processes: platelet aggregation, smooth muscle contraction, in 
vivo vasoactive effects, chemotaxis, expression of adhesion molecules, increased 
tight junction permeability of endothelial cells, induction of stress fibres, 
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modulation of cardiac contractility, and many others [27]. As can be seen in 
Figure 4.B and Supplementary figure 7.A, PA(10:1/18:1) and PS(compound 1) 
levels were lower in patients with stable angina than in those with AMI episode or 
NSTEMI diagnostic, but only PA(10:1/18:1) is endowed with high discrimination 
capability (p-value 0.002). 
 
Figure 4. Means and 95% least significance difference (LSD) intervals for each group of 
patients for the metabolites: bilirubin (A), PA(10:1/18:1) (B), phosphatidylserine (C), m/z 
497.27492 (D) and m/z 355.15819 (E). P-value of ANOVA test for those metabolites, and 
the cardiovascular disease as categorical factor are also shown. 
 The triglyceride TG(18:3/20:4/18:3) was also identified with a lower 
concentration in individuals who suffered an AMI episode or were diagnosed 
with NSTEMI as compared with individuals suffering from stable angina (see 
Supplementary figure 7.B). Triglyceride concentrations have been widely 
proposed as predictors of myocardial infarction as their levels seem to be related 
with the probability of cardiovascular events [28]. 
 One other interesting lipid metabolite was 25-hydroxy metabolite of 
vitamin D3, which is the main circulating form of vitamin D3. Deficiency of this 
vitamin has been linked to an increased risk of hypertension, congestive heart 
failure, peripheral arterial disease, myocardial infarction, stroke, and related 
mortality, even after adjustment for traditional cardiovascular risk factors. 
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Clinical and epidemiological studies have evidenced that vitamin D may also be 
associated with several indices of vascular function, including the development 
and progression of atherosclerotic cardiovascular disease [29]. This fact could 
partially explain the significance of the monohydroxy metabolite of vitamin D3. 
Supplementary figure 8 shows the main levels of this metabolite in the three 
groups of patients. 
 Finally, two additional metabolites were not identified according to their 
MS/MS spectra. In this case, the objective was to calculate the molecular formula 
with the best isotopic distribution adjustment for the precursor ion and also for 
the most representative product ions. Thus, the precursor ion m/z 497.27492 
eluted at 16.4 min was assigned to two potential molecular formulas (C26H42O9 
and C22H45NO9P) with accuracy error of 1.42 and 2.04 ppm, respectively. Figure 
4.E illustrates the high discrimination capability (p-value 0.0009) of this 
metabolite for the three classes under study. On the other hand, the precursor ion 
at m/z 355.15819 was eluted at 29.4 min and, for this reason, it should be a lipid 
metabolite. The tentative molecular formula for this metabolite was C18H28O5S 
with accuracy error of 0.78 ppm, which could fit to a sulfate derivative. The 
concentration levels for this metabolite in the three classes considered are shown 
in Figure 4.D, which explains its high discrimination capability (p-value 0.0005). 
 
4. Conclusions 
 A group of 13 metabolites able to discriminate between different stages of 
atherosclerosis has been identified, most of them lipids and some bile acids as 
cholic or deoxycholic acids. Bilirubin has shown to be one of the most influential 
metabolites as it is able to discriminate between patients with stable angina and 
patients with AMI or NSTEMI with a p-value of 0.0012. Some of those 
compounds had previously been related to cardiovascular diseases or oxidative 
stress, which has shown to be very influential on atherosclerosis. It would be 
interesting to use other techniques as NMR or GC–MS to identify the unknown 
metabolites, thus assessing the results of this study. 
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 Metabolomics has shown to be a very useful strategy to study metabolic 
changes relevant in cardiovascular disease and to propose new biomarkers to 
discriminate between different stages of atherosclerosis. 
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Supplementary figure 1. PCA comparing metabolic profiles associated to serum by 
repetitive injections of one aliquot in LC–MS in positive ionization mode. 
 
Supplementary figure 2. A. Retention time deviation curves obtained for all molecular 
entities after alignment as a function of the elution time. B. Bars diagram of frequency 
histogram plotting the number of entities with a certain frequency. 
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Supplementary figure 3. PCA scores plot obtained for the three groups of patients 
(AMI, NSTEMI and stable angina) 
 
Supplementary figure 4. Means and 95% least significant difference (LSD) intervals 
for patients with hypercholesterolemia and those with normal cholesterol level for 
metabolites cholic acid (A) and deoxycholic acid (B). 
 
Supplementary figure 5.Means and 95% least significance difference (LSD) intervals 
for each group of patients for the metabolites cholic acid (A) and deoxycholic acid (B). p-
Value of ANOVA test for all metabolites, and the cardiovascular disease as categorical 
factor are also shown. 
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Supplementary figure 6. Means and 95% least significance difference (LSD) intervals 
for each group of patients for the metabolites LysoPC(16:0)  (A), LysoPC (18:1) (B), 
LysoPC (18:2) (C) and PC (16:0/5:0(CHO)) (D). p-Vvalue of ANOVA test for all 
metabolites, and the cardiovascular disease as categorical factor are also shown. 
 
 
 
Supplementary figure 7.TG(18:3/20:4/18:3) peak area means and 95% least 
significance difference (LSD) intervals for each group of patients. p-Value of ANOVA test  
for this metabolite, using the cardiovascular diagnostic as categorical factor is also shown. 
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Supplementary figure 8. Hydroxyvitamin D3 peak area means and 95% least 
significance difference (LSD) intervals for each group of patients. p-Value of ANOVA test  
for this metabolite using the cardiovascular diagnostic as categorical factor is also shown. 
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Osuna, J. C. Sanchez, M. D. Luque de Castro* 
 
Abstract 
 Atherosclerosis is one of the most frequent aetiology for myocardial 
infarction and death. Therefore, the early prediction of an ischemic event can 
lead to a drastic reduction of mortality. In this research, serum marker 
metabolites from atherosclerotic patients who either had suffered from acute 
myocardial infarction or had been diagnosed with stable angina were analyzed by 
LC–QTOF MS/MS. Clinical factors such as age of the patients and body mass 
index (BMI), and biochemical factors such as urine levels of urea and creatinine 
were also considered as potential markers for the development of discriminative 
models. Individual markers with discrimination capability between individuals 
affected by myocardial infarct and those diagnosed by stable angina have been 
used to create a three-variable panel for infarct prediction. The panel consists of 
two lipid metabolites: 13-HpODE (a metabolite connected to the inflammatory 
cascade), lysophosphatidylcholine PC(22:6) (with an essential omega-3 fatty acid, 
docosahexanoic acid) and BMI. Sensitivity and specificity values were 85.1 and 
80.8%, respectively, while positive and negative predictive values were 75 and 
88.9%. Monitoring these markers could allow the early detection and risk 
stratification of myocardial infarct episodes with subsequent reduction of 
cardiovascular damages.  
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1.  Introduction 
 One of the most frequent causes of death worldwide is related to 
cardiovascular diseases (CVDs) with over 80% of deaths in low- and middle-
income countries and almost 50% of deaths in Europe (Petersen et al. 2005). 
CVDs are also a major cause of disability that significantly contributes to increase 
health care costs (Gaziano et al. 2006). These diseases usually have their origin in 
atherosclerosis, a coronary artery disease (CAD) that occurs when lipid plaques 
formed along the artery walls cause a subsequent thickening effect, which results 
in partial artery stenosis. In this stage, the symptomatic diagnostic is called 
angina. Then, the formation of thrombi (blood clots) on plaques surface can 
cause total occlusion of the artery leading to insufficient supply of oxygen and 
substrates to the cells (ischemia) that is produced as acute myocardial infarction 
(AMI). 
 Early diagnosis and risk stratification of myocardial infarction can lead to 
a reduction of mortality by initiation of the reperfusion treatment. Nowadays, 
this cardiovascular episode can be clinically diagnosed by an electrocardiogram 
(ECG), the main limitation of which is its alteration by other cardiopathies such 
as acute pericarditis or left ventricular hypertrophy resulting in false positives 
(Wang et al. 2003). Apart from ECG, measurement of some markers like creatine 
kinase isoenzymes, cardiac myoglobin, Human Fatty Acid Binding Protein (H-
FABP) and troponins can help in the detection of AMI and risk stratification (Wu 
et al. 1996). Among them, troponins have been widely considered as the best 
cardiac markers, but conventional troponin assays lack sensitivity and precision 
at the low serum concentrations observed in the early hours after the onset of 
chest pain (Baker et al. 2011).The new ultra sensitive troponin assays may soon 
offer improved certainty in this early period with capability of reliable detection 
in patients with chronic stable heart disease and even in asymptomatic healthy 
individuals (Omland et al. 2009). One of the main limitations in using troponins 
as AMI markers is that acute and chronic conditions distinct from acute coronary 
syndromes (ACS) commonly lead to small elevations in troponin levels, with few 
available data regarding management of care for patients under such conditions 
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(de Lemos, 2013). Therefore, new statistical tools combined with highly sensitive 
assays, incorporating baseline troponin values and changes in concentration over 
1 to 2 h may allow rapid exclusion of myocardial infarction and help to address 
specificity concerns, but they must be validated in appropriate target cohorts 
(Cullen et al. 2013). 
 Currently research on cardiac markers is also focused on the 
transcriptome and metabolome levels. Thus, the study of cardiac-specific micro-
RNAs, one of the most active research areas, has resulted in a new marker, miR-
208a, with a prediction model characterized by 90.9% sensitivity and 100% 
specificity (Devaux et al. 2012). However, additional investigations with large 
cohorts need to be done to validate microRNAs as cardiac markers and obtain the 
false positive rate. Furthermore, a more exhaustive research is required to make 
rapid detection of microRNAs possible and support their viability (Wang et al. 
2010). 
 Metabolomics markers have also been proposed to study atherosclerosis 
events. Wang et al. identified choline, betaine,trimethylamine N-oxide, aconitic 
acid, threonine or hypoxanthine as metabolites with statistical relevance to aid in 
the atherosclerotic diagnostics (Wang et al. 2011).In other recent study, Shah et 
al. identified metabolite profiles (medium-chain acylcarnitines, short-chain 
dicarboxylacylcarnitines, long-chain dicarboxylacylcarnitines, branched-chain 
amino acids and fatty acids) for independent prediction of death/myocardial 
infarction (Shah et al. 2012). This study provided an opportunity to refine 
cardiovascular risk assessment and elucidate novel mechanisms of the disease. 
The specificity and sensitivity of these markers have been determined in only a 
short number of cases, but they have not been evaluated in multimetabolite 
panels.  
 The aims of this research were to find and configure panels of markers to 
increase the predictive power of myocardial infarction. Statistical models sup-
ported the selection of markers with discrimination capability between a group of 
atherosclerotic patients diagnosed with stable angina and another group affected 
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by acute myocardial infarct (AMI). The main risk factors considered in atheros-
clerosis and AMI were combined with metabolite markers as a strategy to 
evaluate their predictive capability either independently or in multiparametric 
diagnostic panels.  
 
2. Materials and methods 
2.1. Reagents 
 LC-grade methanol and MS-grade formic acid and acetonitrile (ACN) 
were from Scharlab (Barcelona, Spain). Deionized water (18 mΩ • cm) was from a 
Millipore Milli-Q water purification system. 
2.2. Instruments and apparatus 
 A Sorvall Legend Micro 21R centrifuge (Thermo Scientific, Waltham, MA, 
USA) was used to centrifuge samples after deproteinization.  
 An Agilent 1200 Series LC system coupled to an Agilent 6540 UHD 
Accurate-Mass QTOF tandem mass spectrometer equipped with a Jetstream® 
electrospray (ESI) source (Santa Clara, CA, USA) was used. The chromatographic 
eluate was monitored in high-resolution mode (2 GHz). 
2.3. Cohort selected for the study 
 A total of 73 patients diagnosed by significant CAD were included in the 
study. CAD was diagnosed after evaluation through cardiac catheterization with a 
reduction of the arterial lumen ≥ 70% by angiographic stenosis. The main 
characteristics of the patients are shown in Table 1. As can be seen, the selected 
cohort was composed of 47 individuals diagnosed with stable angina and 26 
individuals who had previously been affected by AMI (around 3 days prior to 
catheterization). The average age and body mass index (BMI) of the cohort was 
66±13 years old and 28±4 kg/m2, respectively. The cohort was composed by 
86.3% male individuals and 50.7% smokers. Concerning clinical parameters, the 
CAD cohort was formed by 23.3% diabetic, 38.4% obese, 62.0% with 
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hypertension and 43.8% with hypercholesterolemia. These distributions were 
equilibrated in the two groups considered in this study: stable angina and AMI 
patients. Independence of these clinical factorsas well as smoking habit was 
proved according to the Pearson’s Chi Squared test for categorical variables with 
a 95% of confidence level (p-values are shown in Table 1). Non-categorical factors 
were included for statistical analysis with potential metabolite markers. 
Table 1 Main features of the cohort selected for this study. Independence of categorical 
variables was checked by P-Pearson Chi Squared test.  
Characteristic 
Atherosclerosis 
patients 
(n=73) 
Patients 
with AMI 
(n=26) 
Patients with 
stable angina 
(n=47) 
p-value 
Age (mean± SD, years) 66±13 68±12 65±13 - 
Male, n (%) 63 (86.3) 23 (88.5) 40 (85.1) 0.690 
Smoking, n (%) 37 (50.7) 12 (46.1) 25 (53.2) 0.565 
Diabetes, n (%) 17 (23.3) 8 (30.7) 9 (19.1) 0.278 
Obesity, n (%) 28 (38.4) 9 (34.6) 19 (40.4) 0.436 
Hypertension, n (%) 44 (62.0) 14 (53.8) 30 (66.7) 0.284 
Hypercholesterolemia, n (%) 32 (43.8) 11 (42.3) 21 (44.7) 0.845 
BMI (kg/m2) 28±4 27±4 29±3 - 
 
 Clinical examination was completed by quantitative analysis of urea and 
creatinine levels in urine following conventional protocols (using the auto-
analyzers AU2700 and AU5400 from Beckman Coulter, Marseille, France). Most 
patients included in the cohort were under controlled medication as follows: β-
blocking agents (78%), statins (92%), antiplatelet agents (88%) and aspirin 
(98%). Therefore, drugs administration was not considered in this study.  
2.4.     Blood drawing and serum isolation 
 Blood drawing immediately preceded catheterization. All steps from 
blood to analysis were performed in compliance with the guidelines dictated by 
the World Medical Association Declaration of Helsinki (2004), which were 
supervised by specialized personnel from Miguel Servet Hospital (Zaragoza, 
Spain) that approved the experiments. Individuals selected for this study were 
informed to obtain consent prior to sample collection. 
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 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, USA) and 
incubated for 30 min at room temperature to allow coagulation. Then, the tubes 
were centrifuged at 2000 g for 15 min at 4 °C to isolate the serum fraction that 
was placed in plastic tubes and stored at –80 °C until analysis.  
2.5. Sample treatment 
 The vials containing the serum samples (100 µL) were immersed in an ice 
bath and treated for deproteinization with methanol (200 µL) (Bruce et al. 2009). 
The mixture was shaken for 1 min and the precipitate removed after 
centrifugation for 5 min at 4 °C and 13800 g. The upper phase was collected in a 
vial, then placed in the autosampler of the chromatograph for subsequent 
analysis. 
2.6. LC–QTOF MS/MS analysis  
 Chromatographic separation was performed using a Mediterranea 
reversed phase C18 analytical column (100 mm×0.46 mm i.d., 3 μm particle size) 
from Teknokroma (Barcelona, Spain) kept at 25 °C. Mobile phases were water 
(phase A) and ACN (phase B) both with 0.1% formic acid as ionization agent. The 
LC pump was programmed at a flow rate of 0.8 mL/min and the following 
gradient elution was carried out: 3% phase B was kept constant from min 0 to 2; 
from 3 to 100% of phase B since min 2 to 27; finally, 100% of phase B was kept 
since min 27 to 33. 
 The injection volume was 10 µL and the injector needle was rinsed with 
70% methanol for 10 times between injections. Furthermore, the needle seat back 
was flushed for 15 s at a flow rate of 4 mL/min with 70% methanol to avoid cross 
contamination. Electrospray source parameters, operating in both positive and 
negative ionization mode, were as follows: nozzle, capillary and fragmentor 
voltage were set at ±2 kV, ±3.5 kV and 175 V, respectively; N2 nebulizer gas was 
flowed at 40 psi; N2 drying gas flow rate and temperature were 8 L/min and  
325 °C, respectively; N2 sheath gas flow rate and temperature were 11 L/min and 
350 °C, respectively. The instrument was calibrated and tuned according to 
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procedures recommended by the manufacturer. The data were collected in both 
centroid and profile modes at a rate of 2 spectra per second. Firstly, the samples 
were analyzed in full scan MS mode in the m/z range 60–1100 for metabolite 
profiling. The reported data set was statistically processed to detect molecular 
features with a high significance to explain the observed variability. Once the 
most significant entities were recognized, the samples were analyzed in targeted 
MS/MS mode (m/z range 60–1100) to obtain structural information with 
identification purposes at three collision energies 10, 20 and 40 eV. To assure the 
desired mass accuracy of recorded ions, continuous internal calibration was 
performed during analyses by using the signals at m/z 119.0362 (proton 
abstracted purine) and m/z 966.0007 (formate adduct of hexakis (1H, 1H, 3H-
tetrafluoropropoxy)phosphazine or HP-921) in negative ionization mode; while 
in positive ion mode ions with m/z 121.0509 (protonated purine) and m/z 
922.0098 [protonated HP-921] were used. Resolution provided by the 
instrument ranged from 15000 FWHM (Full Width at Half Maximum) at low 
masses (purine) and 30000 FWHM at high mass values (HP-921). 
2.7. Data processing and statistical analysis 
 Raw data files were converted to mzData files using MassHunter 
Workstation software (version 3.01 Qualitative Analysis, Agilent Technologies, 
Santa Clara, CA, USA) and then processed in R statistical language (version 
2.15.0, http://www.r-project.org/) using the two open-free XCMS R-package 
(version 1.24, http://metlin.scripps.edu/xcms/index.php) (Carpenter and Bithell, 
2000; Robin et al. 2011) and CAMERA R-package (version 1.12.0, 
http://www.bioconductor.org/packages/2.10/bioc/html/CAMERA.html). First, 
the XCMS package was used for processing mzData files by extracting potential 
molecular features (MFs) considering only ions exceeding 1000 counts peak 
height with a peak width between 10 and 60 s a signal-to-noise threshold of 10 
and 5 ppm of error in mass accuracy. Secondly, a non-linear alignment was 
executed using the “retcor” function with a degree of smoothing for local 
polynomial regression fitting of 0.5 and a symmetric fitting, process which used a 
re-descending M estimator with Tukey’s biweight function. Then, the CAMERA 
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package was used to correlate potential adducts ([M-H]–, [M+Cl]– and 
[M+HCOOH-H]– in negative ionization mode; and [M+H]+ and [M+Na]+ in 
positive ionization mode) and isotopic peaks of the same molecular entity. Ions 
with identical elution profiles and related m/z values (representing different 
adducts or isotopes of the same compound) were grouped as a unique feature to 
remove redundant information. This process resulted in a data set for each 
polarization mode containing the intensity values in the apex of chromatographic 
peaks for all molecular entities characterized by accurate mass and retention time 
(RT). Background contribution was removed by subtraction of MFs linked to 
plasticizers, solvent impurities and other contaminating compounds after 
analysis of blank sample (methanol) under identical instrument operation 
conditions. Data sets were then imported to the Mass Profiler Professional (MPP) 
software package (version 2.0, Agilent Technologies, Santa Clara, CA, USA) for 
further processing. Data pretreatment was based on baselining to median across 
samples to remove background noise and normalization by logarithmic 
transformation to reduce relatively large differences among MF abundances. A 
fold-change algorithm was applied as filter to retain those molecular entities, 
which experienced a change in relative concentration of 1.75 between the two 
classes. Significance of the remaining entities was studied by Kruskal-Wallis test, 
after verifying their non-normal distribution by Kolmogorov-Smirnov test. 
 MPP software also allowed unsupervised analysis of the data set by PCA. 
Mean centering as pretreatment scaled the data set. 
 The p-ROC R-package (1.5.1 version, URL http://web.expasy.org/ 
pROC/) was used to build ROC curves as statistical tool to study the influence of 
risk factors related to CAD. This study was carried out by using multiparametric 
pROC to differentiate groups formed by combination of diagnostic (stable angina 
or AMI) and risk factor with categorical yes/no response. Thresholds of 
individual predictors were set to provide specificity above 90% considering that 
an efficient predictor in clinical practice should be able to detect clearly at least 
nine out of ten patients having a favorable prognosis when the test was negative. 
Partial ROC AUCs (pAUC) (Fawcett, 2006; Robin et al. 2011) were calculated 
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using an adaptation of algorithms previously reported (Carpenter and Bithell 
2000). PanelomiX toolbox, which is supported on the iterative combination of 
biomarkers and thresholds, was used to combine biomarkers and other scores by 
selecting thresholds that provide optimal classification performance in terms of 
sensitivity and specificity (Robin et al. 2013). Panels of markers were built by 
setting sensitivity and selectivity cut-off values >80%.  
 Identification of the most relevant entities was done using MS and 
MS/MS information and searching in the METLIN MS and MS/MS database 
(http://metlin.scripps.edu) and Human Metabolome Database (HMDB, v. 3.5).  
 
3. Results and discussion 
3.1. Data pre-treatment and statistical analysis 
 Serum samples were analyzed by LC–QTOF MS/MS both in positive and 
negative ionization modes. Nevertheless, the data set obtained in the positive 
ionization mode did not report significant differences between the two groups 
under study. For this reason, this section is entirely focused on the results 
obtained by LC–QTOF MS/MS in negative ionization mode. 
 As previously mentioned, MFs were extracted from the raw data files 
obtained after LC–TOF MS analysis of serum taking into account alignment of 
chromatograms to correct small differences in retention time and mass accuracy. 
The resulting data set was composed by 73 samples×289 molecular entities, 
92.7% of which were detected in at least 90% of the total number of samples. This 
fact ensures representativeness of the study since no molecular entities 
associated to particular individuals, which could divert the resulting statistical 
models, were included in the data set. Once the data set was built, a fold change 
algorithm with cut-off 1.75 was applied to reduce the data set to those molecular 
entities that exhibited a change of relative concentration ascribed to both CAD 
events. The application of this filter reduced the number of entities up to 26 
tentative metabolites defined by the pair m/z value and retention time. 
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 This data set was completed by clinical parameters obtained after routine 
urine analysis which reported information on levels of creatinine and urea. Both 
parameters have shown to be linked to risk cardiovascular factors (Alderman et 
al. 1995; Kapitulnik 2004). Anthropometric information through body mass 
index (BMI), expressed as kg/m2, and patients age were also included in the data 
set, which was finally formed by 30 variables (26 potential metabolites, BMI, age, 
creatinine and urea).The Kolmogorov-Smirnov test was used to check if these 30 
variables showed normal distributions in the cohort under study. As these 
variables did not show a normal distribution, the non-parametric Kruskal-Wallis 
test was applied to identify the most influential variables to explain the CAD 
diagnostic. Thirteen molecular features and the BMI reported significance with p-
value below 0.1, which was selected to keep a suited number of variables for 
multivariate analysis. Supplemental Table S1 shows the values of parameters 
describing the significance of variables. These 14 variables (13 MFs and BMI) 
formed a new data set that was analyzed by principal component analysis (PCA) 
to find discrimination trends according to the CAD diagnosis: stable angina or 
AMI. As shown by the PCA plots (Fig. 1), there is a discrimination trend that gives 
partial separation between patients diagnosed with stable angina and those who 
had suffered an AMI episode. Separation was visualized by plotting PC1, PC2 and 
PC3 components that explained 61.6% of the total variability. 
 
Figure 1. PCA scores plot to find discrimination patterns between CAD patients 
diagnosed with stable angina or after an AMI episode. 
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3.2. Influence of risk factors in the diagnosis of CAD events 
 There are numerous risk factors associated to cardiovascular diseases. 
Among them, it is worth mentioning diabetes, obesity, hypertension, smoking 
habit, hypercholesterolemia, lack of physical activity, unhealthy diet, stress or 
genetic factors. In this study, obesity, hypercholesterolemia and smoking habit 
were selected to evaluate their prediction capability. For this purpose, statistical 
analysis by the Kruskal-Wallis test raising significance with p-value<0.05 as cut-
off was applied to identify the most influential metabolites contributing to 
differentiate both groups of individuals (Table 2). Five molecular features were 
detected as highly significant together with the BMI. Search of MS/MS spectra in 
databases led to the identification of biliverdin and bilirubin, two eicosanoids (5-
HETE and 13-HpODE) and the 1Z-alkenylacylglycerolDG (P-14:0/18:1n9). 
Bilirubin is an excretion product formed in normal heme catabolism, which can 
be found in human serum (Kapitulnik 2004). However, biliverdin is an 
intermediate formed in the same pathway but rapidly reduced to bilirubin by the 
activity of biliverdin reductase. This metabolite has not been detected in human 
serum and, therefore, its presence could be justified by partial oxidation of 
bilirubin from sampling to analysis. Concerning 5-HETE and 13-HpODE 
metabolites, their identification was supported on the selective product ions 
formed by MS/MS fragmentation, which allows discriminating them from their 
structural isomers (Ferreiro-Vera et al. 2011). The fifth metabolite, 1Z-alkenyl-
acylglycerol DG (P-14:0/18:1n9), is an intermediate in the biosynthesis of ether 
phospholipids, which are known as plasmalogens. These metabolites have been 
detected in cardiovascular tissues where they are supposed to exert antioxidative 
functions as scavengers of reactive oxygen species (Stenvinkel et al. 2004). 
Plasmalogen oxidation products as α-hydroxyaldehydes and epoxides accumulate 
in all chronic diseases as atherosclerosis and myocardial infarction as well as in 
different neuropathologies and aging. Table 2 shows the information used for 
identification of the target metabolites with the highest discrimination capability. 
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Table 2. List of identified metabolites including retention time (RT), monoisotopic 
molecular weight (Mw), m/z value of the detected adducts and product ions and the error 
expressed in ppm. 
Metabolite Mw 
RT 
(min) 
Parent ions (m/z) 
Product 
ions (m/z) 
Δppm 
Bilirubin 584.2818 31.5 
605.2380 [M+Na-2H]- 
583.2565 [M-H]- 
285.1301 0.2 
Biliverdin 582.2478 31.6 581.2405 [M-H]- 358.7100 0.1 
13-HpODE 312.2300 29.4 357.2263 [M+FA-H]- 
311.1689 
293.1795 
183.0120 
5.0 
5-HETE 320.2351 23.3 319.2289 [M-H]- 115.0396 3.0 
DG(P-14:0/18:1n9) 550.4961 29.4 595.4904 [M+FA-H]- 
225.0080 
281.2461 
535.0597 
6.0 
 
 
 Once identification of potential metabolites was completed, the next step 
was to study their prediction capability to discriminate the CAD diagnostic, stable 
angina or AMI in conjunction to the three risk factors: obesity, smoking and 
hypercholesterolemia. Biliverdin was excluded from this study since this 
metabolite seems to be produced by degradation of bilirubin. The study was 
carried out by using multiparametric pROC, as previously described (specificity 
above 90%). Under these conditions, the maximum partial area under the curve 
(pAUC) for a ROC curve was 10%. Table 3 lists the main parameters and 
performance of each metabolite fulfilling the specificity requirement, while Fig. 2 
shows the prediction performance (through ROC curves) of each metabolite for 
discrimination of the different indication/risk factor combinations. Smoking and 
obesity were the two risk factors that led to prediction capabilities with specificity 
above 90% and sensitivity values above 40% for DG(P-14:0/18:1n9), 13-HpODE 
and BMI. Particularly, the inclusion of obesity led to sensitivity values around 
44% for DG(P-14:0/18:1n9) and 13-HpODE, while the BMI pROC reported 58% 
for the same parameter. On the other hand, sensitivity reached 50% for the same 
two metabolites when smoking habit was considered. This fact suggested the 
evaluation of the prediction capability of the target metabolites by selecting only 
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patients defined by the risk factors: obese, hypercholesterolemic and smokers. In 
this context, the best prediction capability was for hypercholesterolemic patients, 
for which sensitivity values reached 48% for BMI, 57% for bilirubin and 5-HETE 
and 62% for 13-HpODE. Therefore, it is clear that the prediction capability of 
individual markers improved when hypercholesterolemic patients were 
evaluated. In the case of obese patients and smokers, the prediction capability did 
not lead to better sensitivity as compared to models including patients non 
defined by risk factors.  
 
 
 
 
Compound Parameter CVD 
CVD + SH 
(4 classes) 
CVD in 
smokers 
CVD + Obesity 
(4 classes) 
CVD in 
obese 
patients 
CVD + HC 
(4 classes) 
CVD in 
patients 
with HC 
Bilirubin 
Sensitivity 38 20 0 28 0 24 57 
Specificity 92 96 100 93 100 92 91 
pAUC 0.8 1.2 0.0 2.1 0.0 2.2 4.8 
13-HpODE 
Sensitivity 28 50 32 42 48 25 62 
Specificity 93 91 92 97 100 100 91 
pAUC 2.2 1.1 2.9 3.1 4.7 2.7 4.9 
DG(P-14:0/18:1n9) 
Sensitivity 28 50 42 42 31 26 32 
Specificity 93 91 92 96 100 100 91 
pAUC 1.7 0.5 1.4 2.6 3.2 2.7 2.9 
BMI 
Sensitivity 18 21 22 58 6 6 48 
Specificity 92 91 92 93 100 98 91 
pAUC 0.6 1.9 0.7 3.9 3.7 0.3 4.3 
5-HETE 
Sensitivity 20 8 3 11 38 0 57 
Specificity 92 91 92 93 100 100 91 
pAUC 0.8 0.1 0.1 0.7 0.5 0.0 4.4 
 
Table 3. Parameters of the ROC curves obtained for each identified metabolite 
by selecting a specificity range from 90 to 100% considering classes generated 
after combining cardiovascular disease (CVD) with risk factors (smoking habit 
(SH), obesity and hypercholesterolemia (HC)). Sensitivity, specificity and partial 
area under the curve (pAUC) parameters are expressed as percent. Curves 
reaching a sensitivity value higher than 40% are highlighted in grey. 
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3.3. Panel development 
 The development of a panel for discrimination between CAD patients 
diagnosed with stable angina and those affected by AMI was addressed using 
PanelomiX as computational toolbox. In this research, the initial data set was 
formed by 30 variables (26 metabolites and BMI, urea and creatinine levels and 
age). The configuration of the panel was supported on two statistical criteria: at 
least 80% sensitivity and at least 80% specificity. Thus, both false negative and 
positive rates would be considerably decreased. PanelomiX was applied to the 
cohort formed by 73 CAD patients to define a panel of three markers with the 
best classification parameters. Thereby, the best panel providing specificity and 
sensitivity above 80% was obtained with two variables corresponding to two 
metabolites and the BMI. This panel enabled a model with 85.1% specificity and 
80.8% sensitivity, while the pAUC at 95% CI was 9.7 (5.7–15.7)%. Furthermore, 
positive and negative predictive values were 75 and 88.9%, respectively. One of 
the metabolites involved in this panel was the 13-HpODE, which was previously 
detected as a highly significant metabolite to discriminate between 
atherosclerotic patients. The second metabolite was identified as 
lysophosphatidylcholine, particularly lysoPC(22:6). Identification of this 
metabolite is described in Fig. 3 that contains MS/MS spectra in positive and 
negative ionization modes. As can be seen, product ions from fragmentation of 
the phosphatidylcholine moiety were identified in positive ionization mode. On 
the other hand, the characteristic [M–CH3]– fragment, which is representative of 
phosphatidylcholines, and the product ions corresponding to the acyl chain R-
COO– (C22:6) and its decarboxylated fragment were identified in negative mode. 
This panel formed by two lipids and BMI is especially interesting since it 
combines two lipidic metabolites with an anthropometric variable directly related 
to obesity. Furthermore, the lipids included in this panel belong to two families 
that have been related to cardiovascular diseases through oxidative stress. Firstly, 
13-HpODE, one of the primary oxidation products of linoleic acid, is a significant 
component of oxidized LDL, which is implicated in the pathogenesis of 
atherosclerosis. The concentration of 13-HpODE has previously been linked to 
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atherosclerotic lesions (Natarajan et al. 2001). Secondly, anomalies in levels of 
lysophosphatidylcholines have been shown to be involved in cardiovascular 
complications (Matsumoto et al. 2007). 
 
Fig. 3 Fragmentation pattern and MS/MS spectra in positive and negative ionization 
modes for lysophosphatidylcholine PC(22:6). 
 
4. Conclusions 
 The analysis of serum samples by LC–QqTOF has shown to be a suitable 
strategy for biomarker discovery. The influence of risk factors has been studied 
by analyzing the prediction capability of potential markers in patients with a 
specific risk factor. In this context, a better prediction capability was obtained for 
hypercholesterolemic patients, for which specificity values of 91% and sensitivity 
values from 48 to 62% were obtained for bilirubin, 13-HpODE, BMI and 5-HETE.   
 A panel of markers for myocardial infarction prediction have been 
proposed with a specificity of 85.1 % and a sensitivity of 80.8 %, which gave rise 
to low false negative and positive rates. The metabolites that composed this panel 
are two lipids, 13-HpODE and lysoPC(22:6), and BMI, an anthropometric 
variable directly related to obesity. These results warrant a larger scale study to 
validate the proposed model. 
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Supplementary material 
Supplementary Table 1. Statistical p-value obtained after application of the Kruskall-
Wallis test considering the cardiovascular atherosclerotic disease diagnosis as dependent 
variable and individual potential metabolites or clinical factors as independent variables. 
Only those variables with p-value below 0.10 are shown. 
Independent variable p-value 
357.2263 0.003 
595.4904 0.004 
Body Mass Index (BMI) 0.006 
581.2405 0.007 
605.2380 0.008 
319.2289 0.036 
804.5745 0.051 
381.1743 0.056 
105.9603 0.060 
612.3289 0.087 
383.1896 0.090 
407.2794 0.090 
293.1793 0.099 
391.2851 0.099 
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Human sweat metabolomics for lung cancer 
prediction 
M. Calderón-Santiago, F. Priego-Capote*, N. Turck, X. Robin, B. Jurado-
Gámez, J. C. Sanchez, M. D. Luque de Castro* 
 
Abstract 
 Lung cancer is the carcinogenic disease with the highest mortality rate 
owing to the advanced stage at which it is usually detected. For this reason, 
methods for lung cancer detection at early stages are needed. In this context a 
method based on the metabolite analysis of sweat to discriminate between 
patients with lung cancer versus control individuals (smoker and non-smoker 
individuals) is proposed. The capability of the metabolites identified in sweat to 
discriminate between both groups was studied. Among them, a trisaccharide 
phosphate presented the best independent performance in terms of the 
specificity/sensitivity pair (80 and 72.7%, respectively). Additionally, two panels 
of metabolites were also configured using the PanelomiX tool as an attempt to 
reduce false negatives (at least 80% specificity) and false positives (at least 80% 
sensitivity). The first panel (100% specificity and 63.6% sensitivity) was 
composed by nonanedioic acid, γ-GluLeu dipeptide and maltotriose, while the 
second panel (88.6% specificity and 81.8% sensitivity) included nonanedioic acid, 
maltotriose and the monoglyceride MG(22:2). As both panels were supported on 
high sensitivity and specificity values, the proposed approach would be based on 
the analysis of the four implicated metabolites. The combined use of the two 
panels would allow reducing the number of cases subjected to confirmatory tests 
with the minimum rate of false negative and positive rates (0% and 18.2%, 
respectively). 
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1.  Introduction 
 Lung cancer is nowadays the neoplasic disease associated to the highest 
mortality worldwide. According to the American Cancer Society, lung cancer 
causes more deaths than the sum of the three most common cancers (colon, 
breast and prostate) (World Health Organization, 2012). Despite the advances in 
diagnostic, surgery and chemotherapy, overall survival rate 5 years after 
detection is below 15% (Howlander et al. 2010). The high mortality rate of lung 
cancer is mainly explained by the advanced stage at which it is usually detected as 
available diagnostic tests are invasive and, therefore, they cannot be used for 
general screening. 
 Presently, non-invasive techniques for cancer screening are the subject of 
wide clinical research. The use of diagnostic screening by sputum or thorax 
radiography has not succeeded in the reduction of mortality (Wegwarth et al. 
2012). Recently, the utilization of techniques such as low-dose computed 
tomography and chest X-ray radiography have achieved to decrease mortality 
rate around 20% (National Lung Screening Trial Research Team, 2012). 
Nevertheless, the main limitation of the present methods to diagnose lung cancer 
is ascribed to the high number of abnormalities potentially mimicking lung 
cancer (false positives) and the difficulty in applying diagnostic tools to the target 
population because of the high costs. 
 The above limitations have driven active research in omics disciplines 
with two main purposes: to understand the development and biology of lung 
cancer and identify potential biomarkers to detect initial stages in the 
development of the disease (Khadir and Tiss, 2013). Specifically, recent 
proteomic research has led to identification of potential biomarkers of lung 
cancer in saliva (Xiao et al. 2012) or plasma (Fan et al. 2009). On the other hand, 
recent genomic and transcriptomic studies have been focused on the detection of 
mutations related to cancer, as an attempt to understand the mechanism of 
tumour generation and the influence of risk factors such as smoking habit 
(Girard et al. 2000; Pleasance et al. 2009; Beane et al. 2011).    
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 Metabolomics has provided new technical approaches to enhance the 
capability of this discipline in biomarker discovery for clinical diagnosis, as many 
of the analytical tools used in metabolomics are automatable and, on the whole 
high throughput, they lend themselves to screening populations of individuals for 
disease. Recent research in this field has focused on biomarker discovery using 
different biological samples (tissue, urine, exhaled breath condensate or plasma) 
(Beger 2013). The most common strategy has been metabolic profiling, which has 
been applied to conventional biofluids such as urine and serum/plasma. 
However, the complexity of serum/plasma and urine matrices is a factor to be 
considered in the search for biomarkers since other pathological conditions could 
interfere, particularly when a panel of markers formed by metabolites involved in 
primary metabolism is found. This is the case with amino acids or compounds 
involved in energy metabolism (glycolysis or Krebs’ cycle) (Kami et al. 2013) as 
they have shown to be modified in tumour cells. Concretely, potential markers 
found in urine included modified nucleosides, sarcosine, creatinine or 
acetylglutamine (Beger 2013) (Carrolla et al. 2011). However, the measurement of 
modified nucleosides levels have not shown to be reproducible or robust and 
sarcosine has also shown to fail in prostate cancer detection (Jentzmik et al. 
2010). On the other hand, potential markers found in plasma/serum included 
mainly proteins and metabolites as lysophosphatidylcholines or 
phosphatidylinositols (Beger 2013), compounds previously related to other 
diseases (Karlsson et al. 2006). 
 Despite blood and urine are the most common human biofluids in 
clinical studies on lung cancer, other biofluids can be easily obtained and in a 
noninvasive manner. Sweat, saliva or tears, characterized by less complex 
matrices, could be evaluated in cohorts involving individuals affected by lung 
cancer (Kutyshenko et al. 2011). In contrast to the abundant research using 
serum/plasma or urine as target biofluids, sweat has received scant attention 
owing to the lack of homogenous sweat sampling protocols providing enough 
volume for analysis. However, the sensitivity of present available instrumentation 
makes possible obtaining metabolite profiles from small sample volumes (Wing 
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et al. 2013; Álvarez-Sánchez et al. 2010). Furthermore, sweat collection protocols 
have also been improved (Mena-Bravo and Luque de Castro 2014). In fact, there 
are already methods in which sweat is analyzed for disease discrimination such as 
in the analysis of chloride to diagnose cystic fibrosis (Gibson and Cooke 1959; 
Lynch 2010; Kirk et al. 1992). Sweat has also been used to detect the presence of 
toxics in the organism (Giovanni and Fucci 2013; Kintz et al. 1996; Taylor et al. 
1998; Uemura et al. 2004; Sears et al. 2012) or to control the hydro–electrolytic 
relationship during exercise in humans (Lee et al. 2010; Hew-Butler et al. 2010). 
All these findings, together with present cutting-edge analytical technologies, 
have led the authors to study sweat as a potential sample to diagnose lung cancer. 
 The aim of the present study was to evaluate sweat to discriminate 
individuals affected by lung cancer by metabolomics analysis using liquid 
chromatography–tandem mass spectrometry in high-resolution mode (LC–
QTOF MS/MS). Metabolite profiles obtained from diagnosed patients were 
compared to those provided by a control cohort and most significant metabolites 
identified were studied to evaluate their prediction capability. Statistical analysis 
of those metabolites supported the performance of a panel to reduce the rate of 
individuals to be subjected to invasive intervention for lung cancer diagnosis. 
 
2. Materials and methods 
2.1. Chemicals and reagents 
 MS-grade formic acid and acetonitrile (ACN) to prepare the chroma-
tographic mobile phases were from Scharlab (Barcelona, Spain). Deionized water 
(18 mΩ • cm) from a Millipore Milli-Q water purification system was used. 
2.2. Instruments and apparatus 
 An Agilent 1200 Series LC system (consisting of a binary pump, a vacuum 
degasser, an autosampler and a thermostated column compartment) coupled to 
an Agilent 6540 UHD Accurate-Mass QTOF hybrid mass spectrometer equipped 
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with a dual electrospray ionization (ESI) source (Santa Clara, CA, USA) was used. 
The chromatographic eluate was monitored in high-resolution mode. 
2.3. Cohort selected for the study 
 Forty one patients of the Respiratory Medicine Department diagnosed 
with lung cancer from May to December 2012 were included in this study. All 
patients with lung cancer were diagnosed after clinical tests based on 
bronchoscopy, fine-needle biopsy, or video-assisted thoracoscopy. These patients 
had an average age of 62±11 years and 78% of them were males. Their main 
characteristics —age, sex, body-mass index (BMI) and smoked pack-year— are 
shown in Supplementary Table 1. Independence of these factors among them and 
the control group was proved by analysis of variance (ANOVA) with a 95% of 
confidence level, except for the age that was proved by Kruskal-Wallis as it did 
not fit a normal distribution according to the Skewness and Kurtosis criteria for 
normality (p-values are  shown in Supplementary Table 1). 
 The present accepted guidelines for pathological and staging diagnosis of 
lung cancer were used (Sánchez de Cos et al. 2011). The most frequent diagnostic 
was squamous cell carcinoma (21 patients, 51%), followed by adenocarcinoma (8 
patients, 19.5%), small cell carcinoma (7 patients, 17 %) and large cell carcinoma 
(2 patients, 4.8%). Three individuals (7.3%) were diagnosed with non-small cell 
lung cancer without histological classification. Concerning stages, 5 cases were 
diagnosed as stage IA, 2 as stage IB, 2 as stage IIA, 2 as stage IIB, 12 as stage IIIA, 
4 as stage IIIB and 7 as stage IV. Clinical differences among the different stages 
are specified in Supplementary Table 1. The remaining 7 individuals were 
diagnosed with small cell lung cancer at advanced stage. The reduced number of 
patients for each diagnostic and stage did not enable the inclusion of these 
variability sources in the study. 
 The control group included 55 healthy individuals, 24 of which were 
active smokers. The existence of lung cancer or other severe pulmonary diseases 
(interstitial pneumonitis, pneumonia, tuberculosis, etc.) was excluded by 
fibrobronchoscopy and/or computed tomography scanning. Exclusion criteria 
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were: (i) coexistence of extrapulmonary neoplasia during the last five years or 
chemotherapy for other different neoplasias; (ii) severe organ disease with 
negative influence on prognostic or with influence on the application of the target 
protocol, including congestive heart failure, chronic liver disease (functional 
stage MELD >12), chronic kidney disease stage 5 with substitutive treatment 
(hemodialysis or peritoneal dialysis). The control group had an average age of 
55±10 years and 71% of them were males. 
 The study was approved by the ethical committee of the Reina Sofia 
University Hospital. The individuals selected for this study were previously 
informed to obtain complete consent. All steps from sweat extraction to analysis 
were performed in compliance with the guidelines dictated by the World Medical 
Association Declaration of Helsinki of 2004. 
 It should be emphasized that sweat collection was performed before 
finishing the clinical study, which means that patients were not subjected to 
cytostatic treatment. Therefore, medication was exclusively restricted to control 
the symptoms by analgesics (paracetamol or ibuprofen), cough suppressants 
(codeine) and similar drugs. Apart from that, both control individuals and 
patients were taking common treatments related to diseases associated to the age 
interval (statins, antihypertensives, analgesics, etc.).   
2.4.     Sweat extraction 
 A Macroduct® SweatAnalysis System (Wescor, Utah, USA), consisting of 
a Webster sweat inducer and a Macroduct sweat collector (US Patent 4,542,751), 
was used. Pilogel® Iontophoretic Discs (US Patent 4,383,529) (Wescor, Utah, 
USA), a gel reservoir of pilocarpinium ions, were used in the iontophoretic 
stimulation of sweat excretion. A total sweat volume around 50 µL was collected 
per individual. 
 The sweat inducer provided a current intensity of 1.5 mA for 5 min 
through two Pilogel discs as electrodes located on the forearm. After removing 
the discs the skin where the positive disc had been located was cleaned with 
distilled water and the Macroduct collector covered this skin to collect sweat for 
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15 min. The collected sweat was transferred to a microEppendorf tube and stored 
at –80 °C until use.  
2.5. Sample treatment 
 Sweat samples (10 µL) were diluted with 0.1% formic acid in 1:2 (v/v) 
ratio. The mixture was vortexed for 1 min and placed in the LC autosampler for 
subsequent analysis. All samples were prepared by duplicate. 
 A pool from each group under study (lung cancer and control patients) 
was prepared taking 5 µL aliquots from each participant. The two pools were 1:2 
diluted with water containing 0.1% formic acid, and vortexed for 
homogeneization before analysis. 
2.6. LC–QTOF MS/MS analysis  
 Chromatographic separation was performed using a C18 reverse-phase 
analytical column (Mediterranean, 50 mm × 0.46 mm i.d., 3 μm particle size) 
from Teknokroma (Barcelona, Spain), which was thermostated at 25°C. The 
mobile phases were water (phase A) and ACN (phase B) both with 0.1% formic 
acid as ionization agent. The LC pump was programmed with a flow rate of 0.8 
mL/min with the following elution gradient: 3% phase B as initial mobile phase 
was kept constant from min 0 to 1; from 3 to 80% of phase B from min 1 to 10.5, 
and from 80 to 100% of phase B from min 10.5 to 11.5. A post-time of 5 min was 
set to equilibrate the initial conditions for the next analysis. The injection volume 
was 3 µL and the injector needle was washed for 10 times between injections with 
70% methanol. Furthermore, the needle seat back was flushed for 15 s at a flow 
rate of 4 mL/min with 70% methanol to avoid cross contamination. 
 The parameters of the electrospray ionization source, operating in 
negative and positive ionization mode, were as follows: the capillary and 
fragmentor voltage were set at ±3.5 kV and 175 V, respectively; N2 in the 
nebulizer was flowed at 40 psi; the flow rate and temperature of the N2 as drying 
gas were 8 L/min and 350 °C, respectively. The instrument was calibrated and 
tuned according to procedures recommended by the manufacturer. MS and 
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MS/MS data were collected in both polarities using the centroid mode at a rate of 
1 spectrum per second in the extended dynamic range mode (2 GHz). Accurate 
mass spectra in MS scan and MS/MS mode were acquired in the m/z range 60–
1100. The instrument gave typical resolution 15000 FWHM (Full Width at Half 
Maximum) at m/z 118.086255 and 30000 FWHM at m/z 922.009798. To assure 
the desired mass accuracy of recorded ions, continuous internal calibration was 
performed during analyses by using the signals at m/z 121.0509 (protonated 
purine) and m/z 922.0098 [protonated hexakis (1H, 1H, 3H-tetrafluoro-propoxy) 
phosphazine or HP-921] in positive ion mode; while in negative ion mode ions 
with m/z 119.0362 (proton abstracted purine) and m/z 966.0007 (formate 
adduct of HP-921) were used. 
 Samples were first injected in full scan acquisition mode (two replicates 
per sample) and then in auto MS/MS acquisition mode with a preferred list to 
obtain the product ion information of metabolites with significant difference 
between the groups under study. The maximum number of precursors selected 
per cycle was set at 2, with an exclusion window of 0.3 min after 2 consecutive 
selections of the same precursor. Three collision energies (10, 20 or 40 eV) were 
used to obtain the maximum fragmentation information for each entity. 
2.7. Data processing and statistical analysis 
 MassHunter Workstation software (version 3.01 Qualitative Analysis, 
Agilent Technologies, Santa Clara, CA, USA) was used to process all data 
obtained by LC–QTOF in full scan MS mode. Treatment of raw data files started 
by extraction of potential molecular features (MFs) with the suited algorithm 
included in the software. For this purpose, the extraction algorithm considered 
all ions exceeding 500 counts with a single charge state. Additionally, the isotopic 
distribution for a valid feature had to be defined by two or more ions (with a peak 
spacing tolerance of 0.0025 m/z, plus 10.0 ppm). Adducts formation in the 
positive (+H, +Na) and negative ionization (–H, +HCOO) modes as well as 
neutral loss by dehydration were also included to identify features corresponding 
to the same molecule. Thus, ions with identical elution profiles and related m/z 
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values (representing different adducts or isotopes of the same compound) were 
extracted as entities characterized by retention time (RT), intensity in the apex of 
chromatographic peaks and accurate mass. Background contribution was 
removed by subtraction of MFs linked to plasticizers, solvent impurities and 
other contaminants after analysis of a blank (0.1% formic acid) under identical 
instrument operational conditions. In this way, raw data files were created in 
compound exchange format (.cef files) for each sample and exported into the 
Mass Profiler Professional (MPP) software package (version 2.2, Agilent 
Technologies, Santa Clara, CA, USA) for further processing.  
 In a next step, the data were preprocessed by alignment of retention 
times and m/z values across the data matrix using a tolerance window of 0.4 min 
and 10 ppm mass accuracy, respectively. The alignment was based on the 
iterative comparison of m/z and retention times values for all MFs detected in 
each sample with the resting samples. Data pretreatment was based on baselining 
for each variable across samples to treat all compounds equally regardless of their 
intensity. This involved a preprocessing method that subtract the median 
abundance of each variable from the corresponding values in each sample. 
Furthermore, a logarithmic transformation was used to reduce relatively large 
differences among the respective MF abundances. Stepwise reduction of MFs 
number was performed based on frequency of occurrence and abundance of the 
respective MFs in classes. This filter allowed retaining MFs detected in all the 
samples from each group (cancer and control), removing those entities only 
detected in reduced number of samples, which is due to individual variability. 
MPP software also allowed unsupervised and supervised analysis of the data by 
PCA and PLS-DA, respectively. In both cases, the data set used was the previously 
scaled. An N-Fold cross-validation model was selected for this research. With this 
model, the individuals of the input data are randomly divided into N equal parts; 
N-1 parts are used for model training, and the remaining part is used for testing. 
The process is repeated N times, with a different subset iteratively used for 
testing. Thus, each object is used at least once in training and once in testing, and 
a confusion matrix is generated. This whole process can then be repeated as 
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many times as specified by the number of repetitions. Ten repetitions and a fold 
number of 3 were selected in all PLS-DA models.  
 Identification of the most relevant entities was done using MS and 
MS/MS information and searching in the METLIN MS and MS/MS database 
(http://metlin.scripps.edu) and Human Metabolome Database (HMDB, 3.5 
version). Statistical significance of metabolites identified was done by Kruskall-
Wallis analysis. 
 The R (URL http://www.R-project.org) and pROC (1.5.1 version, URL 
http://web.expasy.org/pROC/) were used to evaluate the prediction perfor-
mances of each identified compound. PanelomiX toolbox, supported on the 
iterative combination of biomarkers and thresholds, was used to combine 
biomarkers by selecting thresholds that provide optimal classification perfor-
mance (Robin et al. 2013). Two panels of markers were built by setting either 
sensitivity or specificity cut-off values > 80%. In both cases, 5 repetitions and a 
fold number of 10 were selected. Cross-validation was executed using the 
PanelomiX computational toolbox, and no pre-filtering steps were included.  
 
3. Results and discussion 
3.1. Quality control and data pretreatment 
 The pool of sweat prepared from each group under study (lung cancer 
patients and control individuals) was injected 10 times in each polarity mode to 
obtain the global profile of molecular features associated to them. The initial data 
set was built after alignment of LC–TOF/MS chromatograms for efficient 
extraction of MFs according to retention time and mass accuracy. The tolerance 
window for both parameters was set at 0.4 min and 10 ppm for elution time and 
mass accuracy, respectively.  
 After data pretreatment, two data sets were obtained for positive and 
negative ionization modes. The experimental variability was minimized by 
applying a filter algorithm based on the detection frequency of MFs in the 
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replicates. In particular, the algorithm eliminates MFs no detected in at least all 
the replicates from each group —in this case, patients with lung cancer and 
control group. The application of the frequency filter simplified the data sets to 
209 and 35 MFs in negative and positive ionization modes, respectively. These 
sets were used to carry out a quality control (QC) study to evaluate the 
instrumental precision of the detection step. With this aim, a PCA was built for 
data sets (Supplementary Fig. 1) that revealed the absence of variability sources 
due to time injection. Under these conditions, the relative standard deviation for 
MS signals was below 20% in both positive and negative ionization modes. 
 The two sets of MFs obtained in both polarities using the pools were 
extracted in data files obtained by analysis of all individual samples and aligned 
with the same tolerance parameters used for pools. As samples were injected by 
duplicate, the average area of the two injections was calculated for each potential 
molecular feature. Then, the frequency filter was applied to remove those MFs no 
detected in at least a representative percentage of samples forming each 
predefined class. This representative percentage was set at 75%, selection 
supported on statistical criteria to build a fingerprinting representative of the 
sweat metabolome from the two target groups. It is worth mentioning that the 
pathology influences differently the serum metabolome of the individuals. For 
this reason, the filtering algorithm should not be completely restrictive. After this 
filter, 33 and 28 potential molecular entities were found in the positive and 
negative ionization modes. 
3.2. Identification and statistical analysis 
 Once the molecular entities with statistical significance were established, 
the MS/MS spectra of these entities were obtained by LC–QTOF MS/MS in 
automated mode to obtain the necessary information for identification. In this 
mode, the selection of precursor ions is automatically carried out in each MS 
scan, but a list of preferred ions can be included for selective fragmentation. The 
list of preferred precursor ions was formed by those associated to the molecular 
entities of the data set. The HMDB and METLIN database were used for 
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identification. To compare the MS/MS spectra of each entity with those recorded 
in the METLIN database, the information was collected using 10, 20 and 40 eV as 
collision energies with the purpose of obtaining different fragmentation levels. 
Table 1 shows the list of identified metabolites including the retention time and 
m/z values for precursor and product ions. Exogenous metabolites and 
interferents present in the Pilogel® to induce sweat production (e.g. pilocarpine 
or propylparaben) were removed from the data set. Most of the identified 
compounds were detected in negative ionization mode. As a result, only three 
metabolites (tryptophan, maltotetraose and 1-octen-3yl-glucoside) were 
confirmed in the positive ionization mode for inclusion in a preliminary panel. 
Table 1. Metabolites identified in sweat, including the retention time and m/z values for 
precursor and product ions as well as the error in precursor ion detection expressed as 
ppm. 
Negative ionization mode 
 Compound name RT (min) Precursor ion (m/z) Δppm Product ions (m/z) 
1 Citrulline 0.7 174.0883 0 
131.0818 
44.9974 
72.0078 
2 
Trisaccharide phosphate 
C18H34O20P 
0.8 601.1371  
547.0835 
96.9696 
161.0440 
259.0221 
3 Phenylalanine 3.5 164.0718 0 
147.0445 
103.0549 
91.0549 
72.0094 
4 Nonanedioic acid 7 187.0981 2 
125.0962 
187.0954 
97.0645 
123.0799 
57.0335 
5 Sulfonic lipid 8.5 577.1470  
170.0046 
391.1109 
497.1911 
6 Maltotriose 0.7 549.1672 0 
503.1598 
341.1085 
179.0553 
89.0241 
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7 Histidine 0.6 154.0624 1 
137.0358 
93.0457 
80.0385 
67.0307 
8 Taurine 0.7 124.0072 1 79.9567 
9 Urocanic acid 1.2 137.0360 2 
93.0445 
66.0349 
65.0206 
50.0050 
10 Muconic acid 7.5 123.0089 5 
53.0033 
95.0139 
68.9982 
11 Suberic acid 6.2 173.0824 2 
111.0809 
83.0503 
57.0349 
12 MG(22:2) 8.7 431.3127 3.6 89.0247 
Positive ionization mode 
 Compound name RT (min) Precursor ion (m/z) Δppm Product ions (m/z) 
1 Tryptophan 4.7 205.0970 0.7 
188.0699 
146.0593 
118.0647 
2 Maltotetraose 0.8 689.2103 1 
145.0488 
127.0385 
85.0283 
487.1640 
3 1-Octen-3yl-glucoside 8.4 291.1802 0.1 
273.1697 
127.1117 
57.0899 
 
 After metabolites identification, quantitative information (height of the 
chromatographic peaks obtained from extracted ion chromatograms, EICs) was 
extracted in all samples in the studied cohort. Statistical analysis by the Kruskal-
Wallis test between the two groups studied (lung cancer patients and control 
individuals) revealed that the trisaccharide phosphate, MG(22:2), nonanedioic 
acid, maltotetraose and maltotriose were the most significant metabolites (p-
value < 0.008), as Table 2 shows. Urocanic acid and γ-GluLeu dipeptide were 
also significant presenting a p-value between 0.01 and 0.05. The remaining 
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metabolites present in the data set did not report significant difference between 
the two groups under study. 
Table 2. Kruskal-Wallis statistical analysis to evaluate the significance of the identified 
metabolites in sweat to discriminate between lung cancer patients and control individuals. 
Marker p-Value 
Trisaccharide phosphate 0.00019 
Maltotriose 0.00177 
Nonanedioic acid 0.00194 
MG (22:2) 0.00411 
Maltotetraose 0.00728 
γ-GluLeu 0.03809 
Urocanic acid 0.04437 
Suberic acid 0.07485 
Sulfonic lipid 0.1828 
Citrulline 0.3254 
Tryptophan 0.3417 
Histidine 0.5015 
Phenylalanine 0.5648 
Muconic acid 0.6763 
GluVal 0.7430 
Taurine 0.8569 
 
3.3. Multivariate analysis for discrimination of lung cancer patients and 
control individuals 
 It is worth mentioning that the objective of this research was not to 
establish metabolite differences among histological types as presently the cyto-
histological diagnostic to confirm both tumour and hystological subtypes is 
irreplaceable. The same situation is found with the cancer stage. It would be very 
interesting to know if there are differences among the stages of the disease, which 
could be the subject of future research. Presently, distinction among stages 
requires x-ray computed tomography and endoscopic techniques to evaluate the 
endobronchial lesions and to study lymphadenopathies in the mediastinum.     
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 As commented above, one of the problems concerning lung cancer 
diagnosis is the stage at which the disease is detected and the characteristics of 
the existing available tests (cost and complexity), which hinders their application 
to all patients. Therefore, more economical tests with prognostic capability are 
demanded for a preliminary screening, which allows reducing the population 
under study by eliminating individuals in a categorical “rule-out” group. For this 
reason, the most important aspect in a prediction model for lung cancer is a low 
probability of false negatives, while the probability of false positives is not critical 
as the disease could be confirmed by other tests. 
 In this study a discrimination model based on PLS-DA was built using 
the dataset formed by identified metabolites (Table 1). The accuracy parameters 
for the validation and training sets of the resulting PLS-DA are listed in Table 
3,while the scores plot is shown in Fig. 1. As Table 3 shows, according to the 
training set the probability of false positives was 42.7%, which is high. However, 
the presence of the pathology for these target individuals could be confirmed with 
one other test. On the other hand, the probability of false negatives was only 
13.3%. Therefore, this discrimination model led to know that the identified 
metabolites could be combined to reduce the proportion of individuals 
demanding for a confirmatory test. 
 
Table 3. Accuracy parameters for the validation and training sets of the developed PLS-
DA model including sensitivity and specificity and the positive and negative predictive 
value. 
 
              Parameters 
Set 
Sensitivity 
(%) 
Specificity 
(%) 
Positive predictive 
value (%) 
Negative predictive 
value (%) 
Training 79.8 93.1 90.5 84.7 
Validation 78.6 86.1 82.5 82.8 
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Fig. 1. PLS-DA scores plot for discrimination of lung cancer patients and control 
individuals by sweat metabolomics analysis 
 
3.4. Statistical evaluation of the prediction capability by ROC curves 
 Assessment of sensitivity and specificity of the significant metabolites for 
lung cancer prediction was carried out by obtaining the ROC curves and 
estimating the partial area under the curve (pAUC). Evaluation of a predictor by 
the total AUC is not recommended when the performance test only takes place in 
high specificity or high sensitivity regions (Robin et al. 2011). For this reason, the 
pAUC parameter is more suited since it is restricted to specific regions of the 
curve. In this case the region selected encompassed from 80 to 100 % of 
specificity to reduce the probability of false negative predictions. With this 
restriction, the maximum value of pAUC obtained would be 20%. The values of 
pAUC, sensitivity and specificity expressed in percentage, with a 95% of 
confidence interval, are listed in Table 4, and ROC curves obtained for 
metabolites with the highest discrimination capability  are shown in Figure 2. As 
can be seen, the compounds that presented a higher value of pAUC were the 
trisaccharide phosphate (10.6%), maltotriose (10.0%), nonanedioic acid (7.9%) 
and maltotetraose (6.4%). These data show that the marker with the best 
discrimination capability of this dataset was the trisaccharide phosphate.  
 Regarding specificity and sensitivity, the compound with the highest 
specificity was muconic acid (100%), followed by maltotetraose, the sulfonic 
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lipid, GluVal dipeptide and histidine, all with 97.1% of specificity for 
discrimination of patients with lung cancer from control individuals. However, 
any of these compounds exhibits the highest sensitivity, which was attributed to 
the trisaccharide phosphate (72.7%). This fact supports the necessity for 
combining metabolites to develop a panel of markers in order to obtain statistical 
models with improved prediction capability. 
Table 4. Parameters of the ROC curves obtained for each identified metabolite by 
selecting a specificity range from 80 to 100%. pAUC, sensitivity and specificity are 
included with a 95% of confidence interval (CI). 
Marker 
% pAUC 
(95% CI) 
% Specificity 
(95% CI) 
% Sensitivity 
(95% CI) 
Trisaccharide phosphate 10.6 (6.5–15.3) 80.0 (65.7–91.5) 72.7 (54.5–90.9) 
Maltotriose 10.0 (5.2–14.9) 91.4 (80.0–100.0) 63.6 (45.5–81.8) 
Nonanedioic acid 7.9 (4.0–12.6) 88.6 (77.1–97.1) 50.0 (31.8–68.2) 
Urocanic acid 6.6 (2.6–11.8) 94.3 (85.7–100.0) 40.9 (22.7–63.6) 
Maltotetraose 6.4 (2.7–10.8) 97.1 (91.4–100.0) 31.8 (13.6–50.0) 
Sulfonic lipid 5.5 (2.1–9.7) 97.1 (91.4–100.0) 27.3 (9.1–45.5) 
MG (22:2) 4.8 (1.7–9.9) 94.3 (85.7–100.0) 31.8 (13.6–54.5) 
γ-GluLeu 4.0 (0.5–9.1) 82.9 (68.6–94.3) 45.5 (22.7–68.2) 
Muconic acid 3.0 (0.9–7.1) 100.0 (100.0–100.0) 13.6 (0.0–27.3) 
Citrulline 3.0 (0.4–6.8) 82.9 (68.6–94.3) 31.8 (13.6–54.5) 
Phenylalanine 2.7 (0.7–6.3) 82.9 (68.6–94.3) 27.3 (9.1–45.5) 
Suberic acid 2.5 (0.4–8.0) 80.0 (65.7–91.4) 31.8 (13.6–54.5) 
Tryptophan 2.3 (0.1–5.8) 94.3 (85.7–100.0) 13.6 (0.0–31.8) 
GluVal 1.6 (0.0–5.7) 97.1(91.4–100.0) 4.5 (0.0–13.6) 
Histidine 1.6 (0.0–4.8) 97.1 (91.4–100.0) 9.1 (0.0–22.7) 
Taurine 1.2 (0.0–4.4) 82.9 (68.6–94.3) 18.2 (4.5–36.4) 
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Fig. 2. ROC curves obtained for metabolites with the best prediction capability to 
discriminate lung cancer patients and control individuals. pAUC values calculated for 
specificity above 80% are included. 
 
3.5.  Development of panels with predction capability for lung cancer 
 The development of panels for discrimination between lung cancer 
patients and control individuals selected for this research was addressed by using 
PanelomiX as computational toolbox. This tool iteratively combines significant 
variables and thresholds to find panels of potential biomarkers with good 
prediction/discrimination parameters in terms of sensitivity and specificity. As 
mentioned above, the most important aspect in a prediction model for lung 
cancer is to reduce the probability of false negatives, while the probability of false 
positives is not critical as the disease could be confirmed by other tests. 
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Nevertheless, the development of discrimination models targeted at reducing 
false positives would also be useful as screening strategy to minimize the number 
of patients subjected to invasive confirmatory tests. In this research, the 
configuration of panels was supported on two statistical criteria: at least 80% 
sensitivity or specificity, which resulted in two panels of biomarkers. The panel 
with at least 80% specificity should allow decreasing considerably false negative 
rates. On the other hand, a biomarkers panel with at least 80% sensitivity should 
allow a significant decrease of false positive rates. PanelomiX was applied to the 
whole cohort to define panels of three biomarkers with the best classification 
parameters. The list of all identified metabolites (Table 1), in both positive and 
negative ionization modes, was considered as the set of variables. Cross-
validation was included in the development of both panels for internal validation, 
which reported information on the model stability. The classification capability of 
the panels was assessed by threshold sensitivity and specificity and the pAUC 
value. The best panel providing specificity above 80% was obtained with the 
combination of three metabolites including nonanedioic acid, γ-GluLeu and 
maltotriose (100.0% specificity and 63.6% sensitivity, while the pAUC was 13.3% 
(95% CI 9.6–16.9). Cross-validation for this model also reported good statistics 
parameters since specificity and sensitivity were 80.0% and 59.1%, respectively. 
This panel would allow diagnosing individuals with lung cancer with a low false 
negative rate. Figure 3.A shows the ROC curve obtained with this panel in 
comparison with that obtained independently for trisaccharide phosphate, which 
was the best independent marker of this configuration in terms of pAUC value. As 
can be seen, sensitivity was significantly improved by application of the panel.  
 On the other hand, the best panel providing sensitivity above 80% was 
obtained with two of the metabolites included in the previous panel (nonanedioic 
acid and maltotriose) and MG(22:2). Figure 3.B shows the ROC curve from this 
second panel together with that reported by the best independent marker of this 
configuration, which was MG(22:2). The parameters obtained for this panel were 
88.6% of specificity, 81.8% of sensitivity and a pAUC of 10.7% (95% CI 6.2–16.6). 
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Fig. 3. ROC curves obtained from the configured panels with: (A) at least 80% specificity 
to reduce false negatives and, (B) at least 80% sensitivity to reduce false positives. The 
ROC curves are compared with those provided by the marker with the best independent 
prediction capability, trisaccharide phosphate and MG(22:0), which are shown in grey. 
  As both panels were characterized by high sensitivity and specificity 
values, a proposed approach could be supported on the analysis of the four 
involved metabolites. The combined use of the two panels would allow reducing 
the number of cases subjected to confirmatory test with the minimum rate of 
false negative and positive rates. 
 
4. Conclusions 
 As previously exposed, one of the main limitations relative to the 
diagnostic of lung cancer is the stage at which this is detected as well as the 
characteristics of the existing available tests. These are invasive and require a 
high cost, which makes their application to all individuals defined by risk factors 
of lung cancer difficult. For this reason, more economical tests featured with high 
prediction capability are demanded for a preliminary screening, which should 
allow decreasing the number of individuals requiring confirmatory tests.  
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 Sweat has not been widely exploited in the clinical field despite the 
advantages associated to its sampling. The potential of sweat as biofluid for 
implementation in the diagnostic of lung cancer has been demonstrated. A 
prediction model based on a panel of metabolites including amino acids, sugars 
and some lipids has been built to discriminate patients with lung cancer from a 
control group. The high negative predictive value reflects the potential use of this 
biofluid to reduce the number of cases as possible positive cases to be subjected 
to confirmatory tests. 
 The discrimination capability of individual metabolites revealed that a 
trisaccharide phosphate presented the highest prediction capability. However, 
this compound is not present in the two panels of three metabolites generated for 
lung cancer prediction. The two panels included maltotriose and nonanedioic 
acid in combination with γ-GluLeu and MG(22:2). Both panels significantly 
improved the discrimination capability of independent metabolites. The first 
panel was characterized by 100% specificity and 63.6% sensitivity. Therefore, the 
false negative rate was 0%. The second panel reported specificity and sensitivity 
values above 81%.  
 These preliminary results emphasized the necessity of a large scale study 
to validate the proposed panels in order to reduce the proportion of individuals to 
be subjected to confirmatory tests, and to detect lung cancer in less advances 
stages. 
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Supplementary material 
 
 
Supplementary Fig. 1. Principal Component Analysis (PCA) built from the data set 
obtained after analysis (10 replicates) of sweat pools prepared from lung cancer patients 
and control individuals. 
 
 
Supplementary Table 1. Main characteristics of the cohort under study including the 
age, sex and body mass index (BMI). All data are expressed as percent or mean (range).  
1 Cigarettes consumption is included as pack-years. Pack-years = (average cigarettes smoked per day/20) x (years of 
smoking). 
2P-values were obtained by analysis of variance (ANOVA) —the non-parametric version (Kruskal-Wallis) in the case 
of age as it does not fit normal distribution. 
 
 
 
Individuals 
(n = 96) 
Lung cancer 
patients (n=41) 
Controls (n=55) 
P-value2 
Smokers (n=24) Non-smokers (n=31) 
Age, (year) 63 (42–87) 56 (38–85) 54 (40–83) 0.344 
Sex, (male %) 78 70 70 0.739 
Pack-years1 51 (15–102) 37 (10–80) 0  
BMI, (kg/m2) 26.8 (17–38) 27.8 (22.6–36.3) 27.6 (21.8–40.1) 0.440 
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 After development of approaches based on global profiling analysis in 
clinical metabolomics, the next step was to develop methods based on targeted or 
quantitative analysis of metabolites involved in relevant biological processes. All 
the protocols were developed by using human serum as biofluid. 
 Three of the targeted platforms have been applied to the analysis of 
different groups of metabolites in atherosclerotic patients. Thus, phospholipid 
profiles have been analyzed by LC–MS/MS in high resolution mode for 
evaluation of atherosclerotic patients with different diagnostics, thus leading to 
the proposal of a four-marker panel with prediction capability for stable angina 
and NSTEMI patients, as shows Chapter 8. 
 A hyphenated SPE–LC–MS/MS configuration for determination of eight 
essential amino acids allows discrimination between atherosclerotic patients with 
stable angina and acute myocardial infarction. The information, in Chapter 9, 
was supported on a cohort of 122 atherosclerosis patients, diagnosed with the aid 
of a catheterization test. 
 The content of Chapter 10 deals with metabolites involved in the 
tricarboxylic acids (TCA) cycle that had been previously proposed as 
cardiovascular biomarkers. A method for determination of the target metabolites 
based on GC–MS applied to serum from 223 patients —172 of them with 
significant coronary lesion— has demonstrated the influence of three 
cardiovascular risk factors such as obesity, hypercholesterolemia, and smoking 
habit on serum levels of TCA-cycle metabolites. Multifactor analysis of variance 
and statistical evaluation by ROC curves support interactions between the 
occurrence of a coronary lesion and the risk factors considered in this study, and 
the discrimination capability of these metabolites, respectively.  
  Assessment of cathelicidin as a biomarker of prone to infectious diseases 
status made mandatory a robust, automated, selective and sensitive platform for 
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determination of the peptide in serum samples. Chapter 11 shows such platform 
in which robustness was achieved by unattended operation of the approach, 
automation was allowed by online coupling of a commercial system for SPE with 
a triple quadrupole mass spectrometer, and selectivity and sensitivity were 
achieved by the joint effect of removal of interferents non-retained on the 
sorbent, and preconcentration in the solid-phase cartridge and the MS detector, 
respectively. In this way, short analysis time, and detection and quan-titation 
limits at the low μg/L levels were achieved.  
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Abstract 
 Atherosclerosis is one of the most frequent aetiology for myocardial 
infarction and death. It is also the main cause of angina pectoris, a perceived 
symptom that results  of a mismatch between myocardial supply and demand 
caused by the partial obstruction of the arteries. The correct diagnosis of 
atherosclerosis can led to a reduction of mortality. In this research, the 
phospholipids profile of serum samples from patients diagnosed with stable 
angina and non-ST elevation myocardial infarction (NSTEMI) or unstable angina 
have been compared to found potential markers to discriminate between stable 
angina and NSTEMI. Phospholipids profiles obtained by LC–QTOF MS/MS have 
led to the identification of four potential markers with significant difference 
between the two groups under consideration: lysoPC(20:5), PC(18:1/18:2), 
PC(18:0/20:4) and SM(d18:2/14:0). The panel generated with the four 
compounds have a disease prediction capability in the training set of 70.7 and 
66.0% for stable angina and NSTEMI patients, respectively. On the other hand, 
the validation set by application to an independent cohort improved the 
predictive power for angina stable patients (92.3%) while this was slightly 
decreased up to 50.0% for NSTEMI patients. The discrimination capability of the 
metabolite panel was assessed in terms of sensitivity and specificity by ROC 
analysis. In this way, LC–QTOF MS/MS has shown to be a useful strategy for 
phospholipid profiling in serum and development of tools to aid in clinical 
diagnostic. 
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1.  Introduction 
 Among of the most frequent causes of death worldwide are cardio-
vascular diseases and, in particular, atherosclerosis, with over 80% of deaths in 
low- and middle-income countries [1]. Atherosclerosis is the main cause of 
angina pectoris, a perceived symptom that results from a mismatch between 
myocardial supply and the demand caused by partial obstruction of the arteries. 
When the anaerobic threshold is crossed, the patient develops symptomatic 
angina pectoris (stable angina) that can appear after a physical effort or activity 
[2]. If this symptom is perceived with minimum activity and high frequency, the 
suited term is unstable angina. A rupture in the atherosclerotic plaque can 
generate a thrombus that can occlude partially or completely the normal blood 
flow. Complete thrombotic occlusion of a coronary artery causes myocardial 
necrosis and is termed acute ST-elevation myocardial infarction, also known as 
acute myocardial infarction (AMI), whereas incomplete occlusion does not cause 
myocardial necrosis and is termed non-ST elevation myocardial infarction 
(NSTEMI). Unstable angina and NSTEMI are often considered together because 
they can be indistinguishable upon first appearance [3]. 
 One of the main problems in clinical practice is the diagnosis of 
cardiovascular dysfunctions that are commonly detected in a relatively advanced 
stage of the disease course [4]. The initial diagnostic approach for coronary artery 
disease encompasses a detailed patient history, a complete physical examination, 
and an electrocardiogram, which is one of the test that supports the 
discrimination between stable angina and NSTEMI. The main limitation of the 
electrocardiogram is that its profile could be also altered by other cardiopathies 
such as acute pericarditis or left ventricular hypertrophy, resulting in false 
positive results [5]. After this preliminary evaluation, laboratory blood tests 
(troponin, creatine kinase,…), stress testing, and invasive cardiac catheterization 
may be necessary to obtain further insight of the diagnostic. 
 Blood lipoproteins contain a protein and a phospholipid component, 
which allow setting differences among them [6]. Extensive epidemiological 
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studies have revealed a major role of lipoproteins in the development of 
atherosclerosis, with special emphasis on LDL cholesterol, the concentration of 
which is directly related to the risk of coronary artery disease, while HDL 
cholesterol level is inversely related to this risk [7]. Despite LDL-lowering 
therapies are frequently recommended, cardiovascular events still occur. For this 
reason, the lipoprotein composition should play a relevant role in the occurrence 
and progression of atherosclerosis. In this sense, the plasma phospholipid 
transfer protein (PLTP) mediates the transfer of phospholipids from VLDL and 
LDL to HDL and it is able to modulate HDL size and composition [8]. 
Additionally, PLTP may also be involved in HDL cellular-mediated efflux of 
phospholipids and cholesterol [9]. The alteration of the content of negatively 
charged phospholipids in vascular cell membranes was also shown in patients 
with essential hypertension [10]. Other studies have suggested that the 
phospholipid composition of HDL could be a key factor in processes such as 
inhibition of adhesion molecules and also in its anti-inflammatory and anti-
oxidant properties [11]. On the other hand, the phospholipid content is one of the 
factors contributing to the closer lateral molecular packing in LDL [12]. 
 The objective of the present research was to compare the profile of 
phospholipids in serum from patients diagnosed with atherosclerosis after 
catheterization. Patients were classified in two different clinical groups: those 
with non-ST elevation myocardial infarction (NSTEMI) and those diagnosed with 
stable angina. Discrimination between both groups by multivariate methods are 
used to search for a predictive panel formed by marker phospholipids with 
capability to differentiate the two atherosclerotic diagnostics. Phospholipids 
analysis was accomplished by a selective solid-phase extraction (SPE) protocol 
with deproteinization and subsequent determination by liquid chromatography 
high resolution tandem mass spectrometry using a QTOF detector to take 
benefits from high accuracy for phospholipids identification. 
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2. Material and methods 
2.1. Reagents 
 MS-grade formic acid and acetonitrile (ACN) from Scharlab (Barcelona, 
Spain) were used for SPE sample preparation and to prepare the 
chromatographic mobile phases. LC-grade ammonia and methanol were also 
from Scharlab. Deionized water (18 mΩ·cm) from a Millipore Milli-Q water 
purification system was used. 
2.2. Instruments and apparatus 
 A vacuum manifold (Varian VacElut SPS 24, USA) was used for SPE–
deproteinization of phospholipids from human serum. A speed-vac 
ConcentratorPlus, from Eppendorf Ibérica (Madrid, Spain), was used to 
evaporate the methanol phase after SPE elution to concentrate the analytical 
sample. 
 An Agilent 1200 Series LC system (consisting of a binary pump, a vacuum 
degasser, an autosampler and a thermostated column compartment) coupled to 
an Agilent 6540 UHD Accurate-Mass Q–TOF hybrid mass spectrometer 
equipped with a dual electrospray (ESI) source (Santa Clara, CA, USA) was used. 
The chromatographic eluate was monitored in high-resolution mode. 
2.3. Cohort selected for the study 
 One hundred forty patients diagnosed with coronary atherosclerosis by 
catheterization were selected in the Cardiology Unit of Miguel Servet Hospital 
(Zaragoza, Spain). Two clinical diagnostics were distinguished in the selected 
cohort: unstable angina or non-ST elevation myocardial infarction (NSTEMI) 
diagnosed to 72 patients and stable angina to 68 patients. The main 
characteristics of the individuals forming the cohort under study are specified in 
Table 1. The independence of clinical factors and cardiovascular pathologies was 
proved according to the Pearson’s Chi squared test for categorical factors and by 
the Mann-Whitney test for numerical factors with a 95% of confidence level in 
both cases. The p-value obtained for each factor is also listed in Table 1. 
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Table 1. Main characteristics of the cohort as well as the p-value obtained after studying 
the independence of each factor from the disease under study. The test used for categorical 
factors was the Pearson’s Chi Squared test, while the Mann-Whitney test was used for 
numerical factors. 
Factor 
Population 
(n=140) 
Stable 
angina 
(n=68) 
NSTEMI 
(n=72) 
p-Value 
Age, yr 68 (33–96) 67 (42–82) 69 (33–96) 0.07 
Sex, % male 74.9 79.4 70.6 0.08 
Obesity, % obese (BMI≥30) 39.8 44.1 35.8 0.43 
Hypercholesterolemia, % 54.4 54.4 54.4 0.66 
Arterial hypertension, % 58.9 60.6 57.3 0.66 
Renal insufficiency, % 6.7 2.9 10.4 0.11 
Diabetes, % 24.2 26.5 22.1 0.58 
Smoking habit, % 49.8 54.4 45.6 0.45 
 
 Most atherosclerotic patients were taken medication as follows:  
β-blocking agents (78%), statins (92%), antiplatelet agents (88%) and aspirin 
(98%). However, distribution of patients under pharmaceutical treatment was 
equal for the two groups and, statistical analysis did not show significance for any 
treatment. 
2.4.      Blood extraction and serum isolation 
 Blood extraction immediately preceded coronary catheterization. All 
steps from blood extraction to analysis were performed in compliance with the 
guidelines dictated by the World Medical Association Declaration of Helsinki 
(2004), which were supervised by specialized personnel from Miguel Servet 
Hospital that approved the experiments. Individuals selected for this study were 
informed to obtain consent prior to sample collection. 
 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton, Dickinson, Franklin Lakes, NJ, USA) and 
incubated for 30 min at room temperature to allow coagulation. Then, the tubes 
were centrifuged at 2000 g for 15 min at 4 °C to isolate the serum fraction. Serum 
was placed in plastic ware tubes and stored at –80 °C until analysis. 
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2.5. Sample treatment 
 Phospolipids were extracted from serum samples using 30 mg 
HybridSPE® cartridges from Supelco (PA, USA) with the following protocol. A 
300 µL aliquot of serum of each patient was mixed with 700 µL of acetonitrile 
acidified with 1% formic acid (v/v) in the cartridge and left for 2 min. Then, the 
vacuum was applied to make the mixture to flow through the sorbent cartridge, 
which was then washed with 1 mL of acetonitrile acidified with 1% formic acid 
(v/v) and 1 mL of acetonitrile. Phospholipids were eluted by pH change using 1 
mL of methanol with 5% (v/v) ammonium hydroxide.  
 The extract was evaporated and the resulting residue was reconstituted 
with 300 µL of methanol with 5% (v/v) ammonium hydroxide and shaken for 30 
s before injection into the LC–QTOF MS/MS equipment. 
2.6. LC–QTOF MS/MS analysis 
 Chromatographic separation was performed using a C18 reverse-phase 
analytical column (Mediterranean, 50 mm x 0.46 mm i.d., 3 µm particle size) 
from Teknokroma (Barcelona, Spain), which was thermostated at 25 °C. The 
mobile phases were water (phase A) and acetonitrile (phase B) both with 0.1% 
formic acid as ionization agent. The LC pump was programmed with a flow rate 
of 0.7 mL/min with the following elution gradient: 25% phase B was kept as 
initial mobile phase constant from min 0 to 2; from 25 to 100% of phase B from 
min 2 to 12, and kept at 100% for 3 min. A post-time of 5 min was set to 
equilibrate the initial conditions for the next analysis. The injection volume was 5 
µL and the injector needle was washed between injections with 80% methanol for 
10 times. Furthermore, the needle seat back was flushed for 12 s at a flow rate of 
4 mL/min with 80% methanol to avoid cross contamination. 
 The parameters of the electrospray ionization source operating 
sequentially in negative and positive ionization modes were as follows: the 
capillary and fragmentor voltage were set at ±3.5 kV and 175 V, respectively; N2 
in the nebulizer was flowed at 60 psi; the flow rate and temperature of the N2 as 
drying gas were 10 L/min and 350 °C, respectively. The instrument was 
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calibrated and tuned according to procedures recommended by the 
manufacturer. MS and MS/MS data were collected in both polarities using the 
centroid mode at a rate of 2.6 spectrum/s in the extended dynamic range mode 
(2Ghz). Accurate mass spectra in auto MS/MS mode were acquired in MS m/z 
range 60–1100 and MS/MS m/z range 60–1100. The instrument gave typical 
resolution 15000 FWHM (Full Width at Half Maximum) at m/z 118.086255 and 
30000 FWHM at m/z 922.009798. To assure the desired mass accuracy of 
recorded ions, continuous internal calibration was performed during analyses by 
using the signals at m/z 121.0509 (protonated purine) and m/z 922.0098 
[protonated hexakis(1H,1H,3H-tetrafluoropropoxy)phosphazine or HP-921] in 
positive ion mode; while in negative ion mode ions with m/z 119.0362 (proton 
abstracted purine) and m/z 966.0007 (formateadduct of HP-921) were used.The 
auto MS/MS mode was configured with 2 maximum precursors per cycle and an 
exclusion window of 0.25 min after 2 consecutive selections of the same 
precursor ion. The collision energy selected was 25 V. 
2.7. Data processing and statistical analysis 
 MassHunter Workstation software (vesion 5.00 Qualitative Analysis, 
Agilent Technologies, Santa Clara, CA, USA) was used to process all analysis data 
obtained by LC–QTOF in MS/MS mode. Identification of the different phos-
pholipid families was carried out with a search algorithm including characteristic 
product ions and neutral losses of each phospholipid class and ions ascribed to 
the alkanoyl chains. Then, identification was validated with the aid of the 
METLIN MS and MS/MS databases (http://metlin.scripps.edu), the Human 
Metabolome Database (HMDB, version 3.5) and the Lipid Maps online tool for 
glycerophospholipids product ion calculation (http://www.lipidmaps.org). 
 The dataset obtained after identification included the list of all 
phospholipids detected in serum samples from atherosclerotic patients of the 
cohort. This dataset was exported as compound exchange format (.cef) files for 
each sample and imported into the Mass Profiler Professional (MPP) software 
package (version 2.2, Agilent Technologies, Santa Clara, CA, USA) for further 
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processing. Preprocessing of data was based on the alignment of compounds and 
logarithmic transformation to reduce relatively large differences among the 
respective abundances of phospholipids in serum. 
 MPP software allowed statistical analysis of data to detect variability 
sources as well as supervised analysis of the data by Partial Least Squares–Data 
Analysis (PLS–DA). The autoscaling was set as pretreatment in the case of PLS–
DA and an N-fold cross-validation model was selected for this study. With this 
model, the individuals of the input data are randomly divided into N equal parts; 
N-1 parts are used for model training, and the remaining part is used for 
validation. Thus, each object is used at least once in training and once in 
validation and a confusion matrix is generated. This whole process can then be 
repeated as many times as specified by the number of repetitions. Ten repetitions 
and a fold number of 3 were selected in all PLS–DA models. The search for 
marker phospholipids with discrimination capability was addressed with a web-
based tool called ROCCET (ROC Curve Explorer & Tester, http://www.roccet.ca). 
This is a training and testing resource to build and validate biomarker models 
based on metabolomics data [13]. 
 
3. Results and discussion 
3.1. Identification of phospholipids in serum samples 
 Phospholipids extracts obtained from human serum by SPE were 
analyzed by LC–QTOF in MS/MS acquisition mode. It is worth mentioning that 
the SPE cartridges used for sample preparation are packed with zirconia coated 
silica, which allows setting a selective interaction between the phosphate moiety 
(Lewis base) and Zr atoms, which act as a Lewis acid due to the acceptance of 
electrons by d-orbitals. The selectivity of this treatment enables to clean-up other 
lipids as well as proteins that could exert ionization suppression effects. 
Therefore, an oriented identification strategy was planned since only phos-
pholipid metabolites were present in the extract. 
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 Data-dependent methods based on product ion or neutral loss scanning 
modes in low-resolution mass spectrometry have been frequently tested for 
screening the different phospholipids classes and subclasses. For this purpose, 
characteristic ion products or neutral losses, which are representative of each 
phospholipid structure, have been monitored as identification and confirmatory 
strategy. However, mass accuracy has not been good enough to assure the 
identification of phospholipids, at least when using only one product ion or 
neutral loss scan modes or when working exclusively in one polarity mode. 
Despite of these evidences, few studies have described the utilization of high 
resolution mass spectrometry with QTOF or Orbitrap detectors to improve the 
identification capability of methods for analysis of phospholipids. However, the 
involvement of high-resolution mass spectrometry is crucial to success in 
metabolomics profiling of phospholipids as an attempt to find connection 
between their concentration in biofluids and certain pathologies. 
 Both positive and negative ionization modes were tested in this research 
to maximize the identification coverage. It is well-known that some phospholipid 
subclasses such as glycerophosphatidylcholines are optimally detected in positive 
ionization mode, while other subclasses such as glycerophosphatidylinositols and 
glycerophosphatidic acids are preferentially detected in the negative mode. This 
selection is supported on the sensitivity for ionization of precursor ions, but also 
on sensitivity and selectivity of product ions after suited fragmentation in the 
collision cell, which is crucial for identification. The preference of one or other 
ionization mode is strongly associated to the polar head group that defines the 
phospholipid subclass. 
 Fragmentation of phospholipids in mass spectrometry has been widely 
studied and the mechanisms involved in the fragmentation reactions of each 
phospholipid subclass have been described. Thus, representative product ions 
ascribed to the fragmentation of each phospholipid family are well-known [14]. 
This information was used in this research to develop an identification algorithm 
based on the most representative product ions pertaining to the different 
phospholipid families. For this purpose, human serum pools prepared with 
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aliquots of atherosclerotic patients affected by stable angina and NSTEMI were 
analyzed by the proposed approach combining SPE and LC–QTOF  
MS/MS. Glycerophosphatidylcholines and sphingomyelins, particularly 
ceramidephosphocholines, presented the same fragmentation pattern in positive 
ionization with the product ion m/z 184.0730 fitting the most characteristic 
fragment for both families, which corresponds to the phosphorylcholine moiety. 
In negative ionization mode, the fragmentation pattern for both families was also 
similar with the MS/MS spectra dominated by the presence of the [M–CH3]– 
product ion. The main difference between the MS/MS spectra of these two 
phosphorylcholine classes was found in the product ions ascribed to the alkanoyl 
chains, acyl and sphingosine units, which aid decisively to the identification of 
them. Sphingomyelins with ceramidephosphoethanolamine structure were not 
detected in serum from atherosclerotic patients; therefore, this subclass was not 
monitored. 
 Glycerophosphatidylethanolamines were properly identified in both 
ionization modes by detection of representative neutral loss (m/z 141.0205 and 
140.0096 in positive and negative ionization modes, respectively), which fits the 
phosphorylethanolamine moiety. In the case of glycerophosphatidylserines, the 
identification was supported on the detection of the neutral loss ascribed to the 
phosphorylserine polar group at 87.0350m/z in negative ionization mode, which 
fits the serine moiety. Fragmentation of phosphatidic acids was characterized by 
the product ion at 152.9975m/z in negative ionization mode, which is associated 
to the cyclic glycerophosphate derivative. The resting glycerophospholipid sub-
classes such as glycerophosphatidylinositols and glycerophosphatidylglycerols 
were not detected in serum samples of the selected cohort, despite their MS/MS 
behavior is also known. 
 Detection of the family-dependent product ions or neutral losses for each 
phospholipid subclass was combined with detection of the product ions 
associated to alkanoyl chains in negative ionization mode. This combination 
allowed elucidating the complete structure of the phospholipids by confirming 
the phospholipid subclass and the fatty acids present in the structure. Only in the 
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case of sphingomyelins the N-acyl chain did not provide a signal in the MS/MS 
spectra and, for this reason, identification of these phospholipids was based on 
the sphingophospholipid representative fragments and that corresponding to the 
unique alkanoyl chain. 
 The algorithm including the representative product ions, neutral losses of 
each phospholipid subclass, and the list of ions associated to the alkanoyl 
fragments for fatty acids from C12 to C30 was executed for all raw data sets 
generated after LC–QTOF MS/MS analysis of treated serum samples. 
Supplementary Table 1 shows the list of all phospholipids identified in human 
serum after analysis of the cohort studied in this research. Information about 
chromatographic retention time, precursor ion as well as the characteristic 
product ions supporting the identification are included. As can be seen, most of 
the phospholipids corresponded to phosphatidylcholines, which is the most 
common family of phospholipids detected in human serum. Thirty-four 
glycerophosphatidylcholines, including lyso forms, were identified in the 
analyzed cohort. Concerning fatty acids of phosphatidylcholine structure, 
saturated, monounsaturated and polyunsaturated fatty acids were detected. 
Additionally, fatty acids with odd number of carbons (C15:0 and C17:0) were 
detected, which could be explained by intake in the diet. It is also worth 
mentioning the detection of less conventional glycerophosphatidylcholines such 
as the plasmalogenlysoPC(P-16:0), lysoPC(OH-16:0) and PC(O-16:0/20:4), 
which contain palmityl alcohol in their structure.  
 Lysophosphatidylethanolamines with the most common fatty acids from 
16:0 to 22:6 were also detected in human serum, including lysoPE(O-18:1), which 
contains oleyl alcohol. A profile formed by seven sphingomyelins as 
ceramidephosphocholines was also identified. Conventional fatty acids such as 
palmitic acid, stearic acid and oleic acid were present in the sphingomyelin 
structure, while the sphingosine unit consisted of saturated, monounsaturated 
and polyunsaturated amino alcohols (18:0, 16:1, 18:1, 18:2 and 24:2). 
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 Two other phospholipid subclasses such as phosphatidylserines and 
phosphatidic classes were also identified in the cohort of atherosclerotic patients. 
The most concentrated LysoPA in serum, with oleic acid, was identified and 
detected in all samples. Finally, four phosphatidylserines including two 
plasmalogens such as PS(P-22:6/18:0) and PS(P-20:2/18:2),  PS(O-20:0/22:2) 
with an arachidyl alcohol and PS(18:4/22:4) with two polyunsaturated fatty acids 
conjugated with glycerol. 
3.2. Quality control and sample stability 
 A pool of serum samples from atherosclerotic patients was prepared for a 
quality control test and analysis of sample stability. Healthy control individuals 
were not included in this research since medication would be responsible of 
differences in the metabolite profiling. The extract obtained after application of 
the SPE protocol was sequentially analyzed 40 times by LC–TOF/MS in scan 
mode to obtain the profile of phospholipids present in serum. Ionization in 
positive mode was selected because glycerophosphocholines are the most 
concentrated phospholipid subclass in human serum, although the resting 
subclasses can also be detected in this polarity mode. The sample obtained after 
SPE treatment of the human serum pool was stored during the test in the 
autosampler of the LC system, which was refrigerated at 4 °C. Each analysis took 
17 min to be completed, which means that the complete study was finished within 
11.5 h. The initial data set was built after alignment of LC–TOF/MS 
chromatograms in scan mode according to retention time and mass accuracy.  
The tolerance window for both parameters was set at 0.4 min and 10 ppm for 
elution time and mass accuracy, respectively. Apart from this preprocessing step, 
a baselining treatment was also applied to the average of each variable across 
samples, which treats all molecular entities equally regardless of their abundance. 
After data pretreatment, the data set obtained was filtered using an algorithm 
based on detection frequency of entities in the replicates to minimize 
experimental variability. In particular, the algorithm eliminates the entities not 
detected in at least 100% of the replicates. A PCA was built for the data set 
obtained to evaluate the existence of variability sources that could be attributed 
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to instrumental precision in the detection step as well as to sample stability. The 
PCA scores plot is shown in Fig. 1 for PC1–PC2, which were only able to explain 
58.7% of the total variability. As can be seen, the only variability source is 
detected after 24 replicates, while analyses 25–40 are clearly separated. 
Discrimination was observed along PC2, which only explained 25.8% of the total 
variability included in the data set. This variability source could be associated to 
sample alteration since the group of samples 25–40 are clearly separated. The 
loadings plot, shown in Supplementary Fig. 1, revealed that sphingomyelins were 
relevant to explain the differences observed between the two groups of samples. 
In fact, the concentration of sphingomyelins in the extract clearly decreased after 
6 h. Taking into account that seven sphingomyelins were detected in the sample 
cohort, this aspect was considered in the processing of analysis sequences.  
 
Figure 1. PCA scores plot for samples injected in the stability study. 
 
 The subsequent step was to estimate the standard deviation in the 
intensity of the phospholipids detected in the replicates 1–24. This estimation 
allowed concluding that at least 95% of the molecular entities presented in all 
replicates reported a coefficient of variation below 25%. Therefore, instrumental 
precision is quite consistent and the stability of the sample in terms of 
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phospholipids concentration can be ensured for 6 h at 4 °C (equivalent to 24 
replicates). 
3.3.  Multivariate analysis for discrimination of atherosclerosis diagnostics  
 After identification, a database containing all compounds detected in the 
different serum samples was created. The database contained information about 
the molecular weight, formula, and retention time of each phospholipid. The 
algorithm “Find by database” was then executed to detect the presence of each 
phospholipid in the samples of the cohort and extract the quantitative area of 
each peak confirmed in the extracted ion chromatogram in MS mode. Confidence 
parameters were set at 10 ppm for mass accuracy and 0.3 min for retention time 
to minimize errors by quantitation of isomers. The resulting data set was then 
exported to the MPP software, which allowed filtering variables by frequency of 
occurrence in samples. Thus, the phospholipids no detected in at least 75% of 
samples in one condition (stable angina or NSTEMI) were excluded. The filtered 
data set was formed by 48 phospholipids distributed as follows: 13 
phosphatidylcholines, 18 lysophosphatidylcholines, 6 sphingomyelines, 7 phos-
phatidylethanolamines, 3 phosphatidylserines and 1 phosphatidic acid, which 
cover practically the different subclasses of phospholipids. The filtering step 
based on the occurrence of phospholipids in serum samples allowed ensuring the 
representativity of the data set associated to the serum phospholipid profile of 
atherosclerotic patients. The phospholipids, which were present in the processed 
data set, are listed in Fig. 2.  
 Once completed the data set containing quantitative information in 
relative terms of phospholipids levels in human serum, the next step of this 
research was to find a potential connection of this data matrix with 
atherosclerosis diagnostic. Previously, the data set was pretreated by log 
transformation to minimize the relevance of the phospholipids concentration in 
serum. Supplementary Fig. 1 shows the effect of this transformation on the 
variability observed for each phospholipid. 
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Figure 2. Phospholipids detected in all samples including their peak area variability 
before and after log2 transformation. The areas are plotted using box-and-whiskers. 
 Multivariate analysis was applied to develop a statistical model with 
capability to discriminate between the two groups diagnosed with 
atherosclerosis: stable angina versus NSTEMI. Thus, a PLS-DA model was 
created to find classification patterns related to the atherosclerosis diagnostic. 
The scores graph for the PLS–DA study is illustrated in Fig. 3. As can be seen, 
   
334 
Analysis of serum phospholipid profiles by LC–MS/MS in high 
resolution mode for evaluation of atherosclerotic patients  
discrimination was observed between the two groups using three-dimensional 
plots. Sensitivity and specificity values obtained in the training model were 76.1 
and 76.2%, respectively. On the other hand, the stability of the model was 
assessed by cross-validation, which reported sensitivity and specificity values of 
62.7 and 56.7%, respectively. These results suggest that phospholipid levels 
would be different in the two diagnostics of atherosclerosis under study, which 
means that the composition and concentration of phospholipids are altered by 
the occurrence or not of hypoxia [15-16]. For this reason, a prediction capability 
study is necessary to obtain further information. 
 
Figure 3. Scores plot of the PLS–DA model built to discriminate between patients 
diagnosed with stable angina and those diagnosed with non-ST elevation myocardial 
infarction (NSTEMI).  
 
3.4.  Prediction capability study, development and validation of a markers 
panel 
 Taking into account the discrimination level observed between the two 
atherosclerosis diagnostics in cardiovascular patients, it would be of interest to 
confirm the existence of phospholipid patterns responsible for the observed 
variability. For this purpose, the web-based tool ROCCET was used to find 
phospholipids with the highest contribution according to statistical analysis to 
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explain the occurrence of atherosclerotic diagnostics. In a first step of this 
protocol illustrated in Supplementary Fig. 2, identification of phospholipids 
statistically relevant between the two atherosclerosis diagnostics was carried out 
by the t-test with p-value<0.05 as significance level. Table 2 lists the four 
phospholipids that reported differences in serum concentration between stable 
angina and NSTEMI patients, which means discrimination attributed to the 
occurrence of hypoxia. The highest significance was observed for lysoPC(20:5), 
which contains the essential omega-3 eicosapentaenoic acid. Lysophos-
phatidylcholines have been previously related to atherosclerosis as they are the 
major phospholipid components of atherogenic lipoproteins, generated upon 
extensive LDL oxidation [17]. Two of the most concentrated phospholipids in 
human serum, PC(18:1/18:2) and PC(18:0/20:4), resulted significant (p-value 
0.0459 and 0.0115, respectively) to explain the severity of the atherosclerosis 
diagnostic, stable angina or NSTEMI. The fatty acids present in these two 
glycerophospatidylcholines were the three most concentrated C18 fatty acids 
(stearic acid, oleic acid and linoleic acid), and arachidonic acid, an omega-6 
essential fatty acid. The fourth phospholipid was the SM(d18:2/14:0), which gave 
a p-value of 0.0030. 
Table 2. Phospholipids with high significante (p<0.05) for discrimination of patients with 
stable angina and those diagnosed with non-ST elevation myocardial infarction 
(NSTEMI). 
Phospholipid AUC t-Test p-value Fold change 
PC(20:5) 0.6842 0.0008 0.9198 
SM(d18:1/16:0) 0.6142 0.0030 -0.8448 
PC(18:0/20:4) 0.6330 0.0115 -0.2646 
PC(18:1/18:2) 0.6090 0.0459 -0.2145 
 
 Supplementary Fig. 3 shows the box and whiskers diagrams obtained for 
the four metabolites in the two groups considered. As can be seen, only in the 
case of lysophosphatidylcholine levels are slightly increased in patients with 
NSTEMI in comparison with patients diagnosed with stable angina. This effect 
has been previously observed by Fernández et al. who concluded that 
lysoPC(16:0) and lysoPC(20:4) were positively correlated with HDL and, thus, 
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negatively correlated with cardiovascular disease risk factor [18]. Furthermore, 
polyunsaturated acyl lysophosphatidylcholine prevent inflammation [19]. The 
opposite behavior is shown by phosphatidylcholines and sphingomyelin, the 
levels of which are slightly higher in angina stable patients. This found is also in 
accordance with preceding research as plasma sphingomyelin levels have been 
found to be positively and independently related to the presence of coronary 
artery disease [20]. The same occurs with phophatidylcholines, which are related 
to inflammation and can be up synthetized in atherosclerotic lesions [21]. 
 The four statistically significant phospholipids detected in stable angina 
and NSTEMI patients were selected as features subset to evaluate the predictive 
power between the two conditions under study. The discrimination model was 
based on PLS–DA and the cohort was randomly divided into training and 
validation sets, which included 80% and 20% of the samples of each condition 
(113 and 27 samples for each set), respectively. Prediction model parameters 
obtained with the PLS–DA model generated for the two classes in the training 
and validation sets are shown in Table 3. Thus, the disease prediction capability 
in the training set was 70.7 and 66.0% for stable angina and NSTEMI patients, 
respectively. On the other hand, the validation set by application to an 
independent cohort improved the predictive power for angina stable patients to 
92.3%, while this was slightly decreased up to 50.0% for NSTEMI patients. 
Table 3. Prediction capability values and false positive rates (expressed as percent) 
obtained for the validation and training model created with the four phospholipids 
selected for patients with stable angina versus those diagnoses with non-ST elevation 
myocardial infarction (NSTEMI). 
 
Stable angina 
prediction 
capabiliy 
NSTEMI 
prediction 
capability 
False positive 
for NSTEMI 
False positive 
for stable 
angina 
Training model 70.7 66.0 30.5 32.7 
Validation model 92.3 50.0 36.9 12.5 
 
 This characterization was completed with the ROC analysis of the panel 
formed by the selected phospholipids. Fig. 4 illustrates the ROC curves obtained 
for this panel in the training and validation sets. As can be seen, the area under 
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the curve parameter (AUC) was 0.715 for the training set, while this was 0.747 for 
the external validation set. The performance of this panel of markers was 
assessed by estimation of sensitivity, selectivity and accuracy both in the training 
set and validation set by application of the model to this sub-cohort of samples 
not used to build the model. The optimum predictive model in the training set 
gave 66% and 70% of sensitivity and specificity, respectively. Nevertheless, the 
model could be improved in terms of sensitivity or specificity if a decrease of false 
positive or false negative rates is desired without reducing any parameter below 
60%. Thus, the best conditions to minimize false positives provided 77% 
sensitivity and 60% specificity, while the best model targeted at specificity 
reported 76% for this parameter and 60% sensitivity. It is worth mentioning the 
stability of the model, since this is well-balanced for sensitivity and specificity. 
The application of the statistical model to the validation set allowed improving 
both parameters, which were 79 and 78% for sensitivity and specificity, 
respectively. This means that only two of ten patients would be erroneously 
diagnosed with NSTEMI by metabolomics analysis (false positives), which could 
be confirmed by use of an electrocardiogram. 
 
 Figure 4. ROC curve obtained from the model created using the four phospholipids 
significantly different between patients with stable angina and those with NSTEMI. 
The ROC curve for both training and validation sets are represented by their area 
under the curve (AUC). 
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 Finally, the predictive capability of the panel of markers improved the 
independent prediction power of the four target phospholipids. Fig. 5 shows the 
ROC curves obtained for each phospholipid with information about the optimum 
values of sensitivity and specificity. The best behavior was found for lysoPC(20:5) 
that provided 62% of sensitivity and 70% of specificity, while a noticeable 
decrease was observed for the other three phospholipids. These results justify the 
selection of the panel to aid in the diagnosis of stable angina and NSTEMI in 
atherosclerotic patients and provide information which could be used for 
catheterization. Concerning phospholipids with the highest significance to 
explain the variability observed, it is worth mentioning the presence of essential 
omega-3 and omega-6 fatty acids such as linoleic acid, arachidonic acid and 
eicosapentaenoic acid. 
 
Figure 5. Individual ROC curve for lysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) and 
SM(d18:2/14:0) when discriminated from stable angina patients and those diagnosed with 
NSTEMI. 
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4. Conclusions 
 The analysis of phospholipids serum profiles by LC–QTOF MS/MS has 
shown to be a suitable strategy for biomarker discovery. A group of four 
phospholipids significantly different between patients with stable angina and 
those diagnoses with NSTEMI have been used to build a panel of markers which 
were composed by lysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) and 
SM(d18:2/14:0). 
 The panel of markers proposed for discrimination between stable angina 
and NSTEMI presented a disease prediction capability in the training set of 70.7 
and 66.0% for stable angina and NSTEMI patients, respectively. Furthermore, 
the ROC curve obtained for the model gives an area under the curve parameter 
(AUC) was 0.715 for the training set, while it was 0.747 for the external validation 
set. This ROC curve shows a 66% and 70% of sensitivity and specificity, 
respectively. These results warrant a larger scale study to validate the proposed 
model and support the usefulness of LC–QTOF/MSMS strategy to profile 
phospholipids for development of tools to aid in clinical diagnostics. 
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Supplementary Figure 2. Schematic overview of the procedure for generation and 
validation of the classification model. 
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Supplementary Figure 3. Box-and-whisker obtained from the log2 of the areas of 
lysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) and SM(d18:2/14:0) in the two groups under 
study: patients diagnosed with stable angina and those diagnosed with NSTEMI.  
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Determination of essential amino acids in human 
serum by a targeting method based on automated 
SPE–LC–MS/MS: Discrimination between 
atherosclerotic patients  
M. Calderón-Santiago, F. Priego-Capote, J.G. Galache-Osuna, M. D. Luque de 
Castro* 
 
Abstract 
 An automated method based on a hyphenated SPE–LC–MS/MS 
conﬁguration has been optimized for the determination of essential amino acids 
(threonine, valine, methionine, leucine, lysine, tryptophan, and phenylalanine) in 
human serum, with the aim of discriminating between different states of 
coronary artery disease. Validation in terms of sensitivity (detection limits below 
28.0 ng on column) and precision (repeatability expressed as relative standard 
deviation below 6.0%) supports the suitability of the method for application to a 
cohort of 122 atherosclerosis patients conﬁrmed catheterization test. The cohort 
was composed by 80 individuals diagnosed with stable angina and 42 patients 
who suffered from acute myocardial infarction (AMI). Both groups of individuals 
are differentiated by the occurrence of ischemia in AMI patients due to the 
formation of thrombi. The chemometric treatment of the data obtained by 
multivariate analysis of variance (MANOVA) allowed by isoleucine, a comparison 
both groups of diagnosed patients. Therefore, amino acids whose serum levels 
were affected by ischemia have been identiﬁed. The contribution of risk factors 
such as obesity and hypercholesterolemia as well as the individuals’ sex to the 
concentration of essential amino acids has also been studied. 
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1.  Introduction 
 Amino acids are molecules with a common structure that contains an 
amine group, a carboxylic acid group and a characteristic side-chain that varies 
among amino acids. They have critical functions to life with a direct involvement 
in metabolism by serving as the building blocks of proteins. Apart from their 
functions in proteins synthesis, amino acids are key regulators of gene expression 
and the protein phosphorylation cascade, and act as precursors for synthesis of 
hormones and low-molecular weight nitrogenous substances with enormous 
biological importance such as nitric oxide, polyamines, glutathione, taurine, etc 
[1]. The biochemical relevance of amino acids, their levels and those of their 
metabolites may be of interest in the study of metabolic and nutritional disorders 
as well as in other pathologies related with oxidative stress. 
 The heart is one of the organs more affected by reactive oxygen species 
(ROS) [2], so one of the pathologies related with oxidative stress is 
atherosclerosis, a disease that represents a state of heightened oxidative stress 
characterized by lipid and protein oxidation in the vascular walls [3–5]. 
Furthermore, atherosclerosis is clearly related with the inflammatory cascade 
where ROS are key mediators starting from the initiation of fatty streak 
development, through lesion progression, to ultimate in plaque rupture and 
thrombi formation (resulting in myocardial infarction) [6].  
 Atherosclerosis causes are not clear, but there are certain traits, 
conditions or habits known as risk factors that may raise the risk of suffering 
atherosclerosis [7]. Most common atherosclerosis risk factors are age, 
hypercholesterolemia, hypertension, diabetes, obesity and smoking. Among the 
different factors, obesity is a major public health crisis worldwide considered a 
leading risk factor for different pathologies such as diabetes, atherosclerosis, 
stroke, hypertension and some types of cancer [1,8,9]. Sex also influences 
atherosclerosis development, as men are more likely than women to develop this 
disease; however, sex difference narrows as men and women grow older. 
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 Due to their central role in biochemistry, amino acids are important in 
nutrition. Plasma amino acid concentrations represent the balance of protein 
turnover (protein synthesis and degradation), amino acids absorption from diet, 
and metabolism of individual amino acids [9]. In fact, there are essential amino 
acids (viz. leucine, isoleucine, lysine, methionine, phenylalanine, threonine, 
histidine, tryptophan and valine) that the human body cannot synthesize at the 
concentration demanded for normal development and may be obtained from 
diet. Some essential amino acids have been proposed as cardiovascular disease 
biomarkers. Thus, threonine and phenylalanine have been proposed as 
myocardial infarction biomarkers [10]. The explanations given to this behavior 
are either their metabolism pathways are obstructed by the ischemia and oxygen 
deficiency condition, or the catabolism of the injured myocardial proteins to 
amino acids is enhanced due to the ligation of the left anterior descending 
coronary artery. Also, leucine, isoleucine and threonine are compounds affected 
immediately (10 min) after the onset of myocardial infarction [11]. 
 Different analytical platforms have been proposed to determine amino 
acids in biofluids such as serum [12,13] and urine [14]. Most of them involve an 
electrophoretic or chromatographic step with subsequent determination by 
fluorimetry (usually with laser as excitation source), UV absorption spectro-
photometry or mass spectrometry. A derivatization step prior to separation to 
enhance detection of amino acids by increasing signal given by analytes or 
ionization properties can also be involved. In fact, different labelling reagents 
such as 9-fluorenylmethyl chloroformate have been proposed for derivatization 
of amino acids [15]. Methods without previous derivatization have also been 
reported for determination of amino acids in serum and urine [16,17]. 
Furthermore, a Hitachi analyzer based on ion exchange chromatography with a 
spectrophotometer detector specific for amino acids is available in the market 
[18]. This analyzer, which allows the determination of a wide range of amino 
acids in 70 min, has been used to study the levels of amino acids in both patients 
with heart failure and normal individuals. 
   
356 
Determination of essential amino acids in human serum by a targeting method based on 
automated SPE–LC–MS/MS: Discrimination between atherosclerotic patients  
 Because of the lack of automated methods for the simultaneous 
determination of essential amino acids of interest in the clinical field, the aims of 
this research were as follows: (i) to develop a method for determination of these 
amino acids in serum by on-line coupling of an automated solid-phase extraction 
system (Symbiosis-Pharma system) with an LC–MS/MS device; (ii) to apply the 
resulting method to the determination of the target compounds in a cohort 
formed by individuals affected by atherosclerosis; (iii) to correlate levels of 
essential amino acids in atherosclerotic patients and different risk factors such as 
obesity, sex, hypercholesterolemia and smoking habit. 
 
2. Material and methods 
2.1. Reagents 
 A multistandard solution of amino acids from Sigma–Aldrich (Madrid, 
Spain) with an individual concentration for each analyte of 0.5 mM ± 4% in a  
0.2 N litium citrate buffer (pH 2.2), 2% of thiodiglycol and 0.1% of phenol was 
used to optimize both chromatographic separation and detection. L-valine, L-
leucine, L-phenylalanine and L-lysine standards and phosphate buffer solution 
(PBS) were provided by Sigma–Aldrich. D-tryptophan was provided by Fluka 
(Spain) and L-methionine and L-threonin were from Merck (Madrid, Spain). An 
aqueous stock solution containing 100 µg/mL of each target amino acid was used 
to prepare diluted working solutions.  
 LC–MS grade acetonitrile and ammonium formate were purchased from 
Scharlab (Barcelona, Spain). Deionized water (18 mΩ cm) from a Millipore  
Milli-Q water purification system was used for preparation of all aqueous 
solutions. 
2.2. Blood extraction and serum isolation 
 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, USA) and 
incubated for 30 min at room temperature to allow coagulation. Then, the tubes 
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were centrifuged at 2000 g for 15 min at 4 °C to isolate the serum fraction 
(processing within 2 h after collection). Serum was placed in plastic ware tubes 
and stored at –80 °C until analysis. 
2.3. Cohort selected for the study 
 A total of 122 patients clinically diagnosed with an episode of either 
stable angina (80 individuals) or myocardial infarction (42 individuals) formed 
the cohort. All patients were affected by atherosclerosis after evaluation through 
a cardiac catheterization. The main characteristics of the patients are shown in 
Table 1. The cohort was composed by individuals with an average age of 66±14, 
81% of them male individuals, 53% smokers, 26% diabetic, 41% obese, 58% with 
hypertension and 50% with a high cholesterol level. 
Table 1. Features of the cohort under study. 
Characteristic  Patients (n=122) 
Age  65.5 ± 13.5 
Male sex, n (%)  99 (81.1) 
Obesity, n (%)  50 (41.0) 
High cholesterol level, n (%)  61 (50.0) 
 
 All steps from blood extraction to analysis were performed in compliance 
with the guidelines dictated by the World Medical Association Declaration of 
Helsinki of 2004, which were supervised by specialized personnel from Miguel 
Servet Hospital (Zaragoza, Spain). Individuals selected for this study were 
previously informed to obtain consent. 
2.4.      Instruments 
 Hyphenated SPE was performed with an automated robotized 
workstation Symbiosis-Pharma (Spark Holland, Emmen, The Netherlands) 
equipped with an autosampler Reliance (Spark Holland) furnished with a 250-μL 
sample loop and a refrigerated stacker sample compartment. The SPE 
workstation is endowed with a unit for SPE cartridge exchange —automatic 
cartridge exchanger (ACE)— and two high-pressure dispensers (HPD) for SPE 
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solvents delivery. Peek tubes of 0.25 mm i.d. (VICI, Houston, TX, USA) were 
used for all connections. The ACE unit included three switching valves, one of 
them equipped with a T-rotor, and two clamps. The Sparklink 3.10 SP#3 software 
was used to control the system. Hysphere MM anion cartridges (8 μm,  
10 mm x 2.0 mm, Spark Holland) were used as sorbent material in the SPE step. 
 Chromatography was performed with an Agilent (Palo Alto, CA, USA) 
1200 Series chromatograh composed by a binary pump and a Luna (3 μm,  
100 mm x 4.6 mm) hydrophilic interaction chromatography column (HILIC) 
from Phenomenex (Torrance, CA, USA). 
 Detection was carried out by an Agilent 6410 Triple quadrupole mass 
spectrometer, furnished with an electrospray ionization (ESI) source. 
2.5. Sample treatment 
 Serum samples (100 µL) immersed in an ice bath were treated for 
deproteinization with 600 µL methanol, the most common solvent used with this 
aim. The mixture was shaken for 1 min and the precipitate removed after 
centrifugation for 5 min at 6 °C and 13,800 × g. 400 µL of the upper phase was 
collected in a vial and diluted with 1 mL methanol, then placed in the Symbiosis 
autosampler, programmed to maintain the analytical sample at 15 °C until 
injection into the automatic SPE system coupled with the LC–MS/MS 
equipment. 
2.6. Analysis protocol for amino acids determination in serum 
 Basically, the sample preparation step starts by activation of the sorbent 
phase with acetonitrile and subsequent equilibration before sample loading with 
1 mL 50% acetonitrile containing 1% formic acid. After filling the 250-μL loop 
with analytical sample, this is loaded into the SPE cartridge with 0.5 mL  
90% acetonitrile containing 1% formic acid. Under these conditions, the amino 
acids were retained in the cartridge, which was rinsed with 1 mL 70% acetonitrile 
to remove potential interferents. All these steps are performed in the left clamp. 
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 Then, the cartridge is moved to the right clamp and 450 μL 90% 
acetonitrile containing 5% ammonium hydroxide passes through the cartridge for 
2 min and 15 s to elute the amino acids. The eluate from the cartridge is merged 
with the chromatographic mobile phase by a T-rotor and both mixed phases go to 
the column. The elution time was 2 min 16 s, after which, the valve with the T-
rotor is switched to allow the passage of mobile phase exclusively through the 
column. This initial mobile phase, with a flow of 0.6 mL/min, is composed by 
90% acetonitrile with 5 mM of ammonium formate as ionization agent. The SPE 
step finishes by rinsing the cartridge consecutively with 1% formic acid, 
acetonitrile and water (1 mL each). The cartridges can be reused for three times 
without loss of efficiency. 
 The gradient used for LC separation of the compounds goes from 90% 
acetonitrile (maintained for 5 min) to 70% of acetonitrile in 10 min (also 
maintained for 5 min). A post time of 5 min was necessary to equilibrate the 
column prior to the next injection. The column temperature was set at 15 °C. 
 MS detection was performed in positive ESI mode at unit resolution in 
both quadrupoles. The ESI parameters were set as follows: 4 kV capillary voltage, 
350 °C source temperature, and 50 psi pressure nebulizer. Nitrogen gas flowed at 
9 mL/min to dry the eluent at the ionization source. Precursor and product ions 
selected for selected reaction monitoring (SRM), and those respective collision 
energies, are shown in Table 2. 
 The dwell time was set at 50 ms for all transitions. The entire analytical 
process was completed in 27 min. Nevertheless, the automated system enabled 
the chromatographic analysis of one sample while a second sample can be 
simultaneously prepared. The voltage of the first quadrupole was set at 90 V, 
which allows an efficient filtering for all selected precursor ions. 
2.7. SRM-based quantitation 
 Calibration curves were run by diluting the stock solution with PBS. 
Calibration levels were expressed as ng on colum, ranging from 0.05 to 750. Five 
of them were injected in duplicate. This calibration model was selected because 
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no matrix effects were observed when recovery and ionization suppression were 
studied. 
Table 2. Parameters used for LC–MS/MS determination of essential amino acids. 
Compound 
Retention 
time (min) 
Precursor ion → Product ion 
(m/z) → (m/z) 
Collision 
energy (V) 
Phenylalanine 7.8 166.2 → 120.1 5 
Leucine/isoleucine 9.0 132.2 → 86.1 5 
Methionine 9.2 150.2 → 132.8 0 
Tryptophan 9.5 205.1 → 188.1 5 
Valine 10.7 118.2 → 72.3 10 
Threonine 13.9 120.1 → 74.2 0 
Lysine 14.3 147.2 → 84.1 10 
 
 
3. Results and discussion 
3.1. Development of the LC–MS method 
 A commercial standard solution containing the target amino acids 
(phenylalanine Phe, leucine Leu, isoleucine Ile, methionine Met, tryptophan Trp, 
valine Val, threonine Thr and lysine Lys) was used to optimize the LC–MS 
method. The process was initiated by optimization of the MS parameters, for 
which a generic chromatographic protocol starting with 90% acetonitrile and 
finishing with 40% acetonitrile was used. The recommendation of using a buffer 
solution when working with a HILIC column to obtain reproducible resolution 
results led to utilize 5 mM ammonium formate as ionizing agent, which gives a 
pH of 6. This value is in between the two pKa values of the majority of amino 
acids, at which the net charge of them is neutral. 
 Both positive and negative ionization modes were tested, but the highest 
sensitivity for most compounds was clearly achieved with the positive ESI mode. 
The electrospray variables were optimized by a univariate design. The ranges 
studied for temperature, pressure, and capillary voltage were 200–350 °C,  
30–50 psi, and 3000–4000 V, respectively. The effect of these three variables on 
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the signal intensity corresponding to the target ions was positive, but not 
significant; so all the variables were established at their maximum values tested. 
Superior values led to an increase of background noise. The most abundant ions 
of all amino acids under the optimum conditions were established as precursor 
ions, as shows Table 2, which corresponded in all cases with the ion [M+H]+. 
 The fragmentation of the different amino acids was studied using 
collision energies from 0 to 45 eV. Table 2 shows all product ions selected for 
each amino acid with the respective optimum collision energies. In most cases 
the product ion is produced after the loose of the carboxylic group, generating the 
ion [M–COOH]+. 
 Different gradients were tested seeking for appropriate separation 
between the target analytes in a time as short as possible. All the assayed 
gradients involved acetonitrile and water both contaning 5 mM ammonium 
formate as ionizing agent. The pH of the mobile phase strongly affected the 
chromatographic separation; thus, pHs between 3 and 9 were tested, being pH 6 
the optimum to attain a suited interaction with the chromatographic column. 
Values of pH out of the 5–7 range led to irreproducible results due to an 
inefficient retention of the analytes. Other variables that influenced the 
chromatographic separation —temperature and flow rate— were also studied. 
The best separation was obtained with the program under experimental. 
3.2. Development of the SPE protocol 
 Optimization of the SPE step was carried out under real conditions by 
using a serum pool spiked with the target amino acids. The optimization of the 
SPE protocol was divided into three main blocks: tests with sorbent materials, 
evaluation of the variables involved in each step of the SPE protocol and 
characterization of the process (detailed below under Section 3.3).  
3.2.1. Selection of the suited sorbent material 
 Attending to the variability in the chemical structure of the essential 
amino acids, seven types of SPE sorbent with different retention properties were 
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tested: Hysphere CN (silica-based cyanopropyl phase), Hysphere C2 (silica-based 
ethyl phase), Hysphere C8 (silica-based octyl phase), Hysphere C18 (silica-based 
octadecyl phase), Resin GP (polymeric polydivinylbenzene phase), MM anionic 
(mixed-mode phase containing a strong anion exchange functional group), and 
MM cationic (mixed-mode phase containing a strong cationic exchange 
functional group). Since the phase behavior is different for each type of cartridge, 
three protocols were developed to test sorbents under conditions dependant on 
their retention mechanisms: one for the anionic sorbent, other for the cationic 
sorbent and a third one, a generic protocol, for the rest of the phases. The 
differences were the solution used for equilibration of the cartridge and sample 
loading, and that one for elution of the target amino acids. Thus, the pH played a 
crucial role in this preliminary experiment. The three protocols were initiated 
with a step for solvation of the sorbents by using 1 ml acetonitrile. The sample 
was loaded in the ionic protocols with a 20% acetonitrile (v/v) solution with a 
difference in the pH to enhance the ionic interactions. Thus, the pH of the 
loading solution was alkaline for the anionic sorbent by using 2% ammonia, and 
acid for the cationic sorbent by using 1% formic acid. On the other hand, the 
generic protocol was based on sample loading with water. The elution, 
programmed with the chromatographic mobile phase (90%, v/v, acetonitrile), 
was also distinctive of the three protocols in terms of pH. Thus, the elution from 
the anionic sorbent was performed with 5 mM ammonium formate at pH 4, while 
the same composition but at pH 6 was applied to the elution in the generic 
protocol. These protocols were compatible with the chromatographic process 
since the elution solution does not alter the separation. In fact, in the generic 
protocol the elution and mobile phases were identical, while minimal changes 
were used in the elution solution tested in the anionic protocol. On the other 
hand, the alkaline elution from the cationic sorbent was carried out by using 5% 
ammonia in the mobile phase. This pH change was not compatible with the 
chromatographic process. For this reason, an especial mode designed for elution 
with the minimum volume at a reduced flow-rate was employed to minimize the 
influence on the chromatographic separation. This mode, called focusing elution, 
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has been previously employed in clinical analysis for determination of 
thyronamines in human plasma and tissue [19] and cocaine and its metabolites in 
blood or urine [20,21]. This strategy would allow elution under alkaline condi-
tions to be compatible with a chromatographic process in acid media. The 
instrumental configuration for this approach is shown in Fig. 1, which illustrates 
the main steps involved in the SPE process.  
 
Figure 1. Instrumental configuration including the main steps involved in the SPE step. 
 This preliminary experiment revealed that the cationic sorbent offered an 
optimum response for retention/elution of essential amino acids in serum. The 
acid media favored the retention of the target amino acids, which was 
complemented with an optimum elution under alkaline conditions to displace the 
retained analytes from the cationic sorbent. 
3.2.2.  Optimization of the main variables involved in the SPE process 
 Once the suitability of the MM cationic sorbent for analysis of essential 
amino acids in serum was checked, the variables involved in the SPE protocol 
(viz. composition of the solutions and flow-rate) were studied independently for 
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each SPE step: loading, rinsing and elution. A univariate strategy was used 
because the discontinuous character of the variables studied. The response 
factors, aimed at maximizing sensitivity and minimizing dispersion, were the 
area and height of the chromatographic peaks for the target amino acids.  
 Methanol and acetonitrile were tested as organic solvents in the loading 
solution using a dual strategy depending on the solvent concentration. For 
concentrations of organic solvent below 20% the samples were used as such, 
whereas superior concentrations (tested up to 100% acetonitrile) required a 
deproteinization step to avoid tubes clogging by massive precipitation of proteins. 
Deproteinization was also studied with both organic solvents using different 
dilution ratios (from 1:1 to 1:10, v/v). The best results were obtained after 
deproteinization with methanol using a 6:1 (methanol:serum v/v) ratio  
—600 µL methanol and 100 µL serum sample. By contrast, 90% acetonitrile 1% 
formic acid was the preferred option to load the sample by enhancing the ionic 
interaction. The deproteinization and subsequent loading with a high 
concentration of organic solvent improved the retention of the target analytes, 
favored the elimination of interferences and matrix effects and enabled to 
improve the reusability of the SPE cartridge. The pH of the loading solution, 2.1, 
was slightly below the pKa of the target amino acids except for phenylalanine 
(pKa=1.8). Therefore, retention of analytes was a mixed contribution of cationic 
exchange, preferred for all analytes, but also contribution of non-polar/polar 
interactions ascribed to the polymeric phase. 
 The rinsing step was also developed with acetonitrile by testing different 
concentrations. The deproteinization step simplified rinsing of the cartridge by 
pumping 1 ml  70% acetonitrile prior to elution of the target analytes.  
 Finally, the elution step was done in the focusing mode with a reduced 
volume of 90% acetonitrile/5% ammonia and a low flow rate to avoid effect on 
the chromatographic process developed at acid conditions. The volume of the 
elution phase, tested from 0.2 to 0.6 ml, provided 0.45 ml as the optimum.  
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 As Table 3 shows, a cleaning sequence formed by four steps was required 
to prepare the SPE cartridge for the following analysis. A reusability study 
enabled to report that each cartridge could be reused for three times by setting a 
cut-off value of 5% in terms of efficiency. The SPE process was completed in 7.4 
min, which enables to prepare the following sample while the chromatographic 
analysis is running. Supplementary Fig. 1 illustrates the TIC and SRM 
chromatograms obtained after analysis of serum from an atherosclerosis patient. 
Table 3. Sequence of operations for the overall SPE process. 
Step Solvent Volume (ml) 
Flow rate 
(ml/min) 
Time (s) 
Put the selected cartridge into the left clamp 10 
Solvation Acetonitrile 1.00 2.0 36 
Equilibration 50% acetonitrile 
1% formic acid 
1.00 2.0 36 
Sample loading 90% acetonitrile  
1% formic acid 
0.50 2.0 18 
Rinsing 70% acetonitrile 1.00 1.0 66 
Move cartridge from left to right clamp 5 
Elution 90% acetonitrile 
5% ammonia 
0.45 0.2 135 
Move cartridge from right to left clamp 5 
Rinsing Water 1.00 2.0 36 
Rinsing 2% formic acid 1.00 2.0 36 
Rinsing Acetonitrile 1.00 2.0 36 
Rinsing Water 1.00 2.0 36 
Total time 7 min 35 s 
 
3.3.  Validation of the method  
 The method resulting from optimization of variables was supported on a 
validation study for characterization in analytical terms. For this purpose, 
calibration curves were established by dilutions of the stock solution. The 
correlation coefficients and linear dynamic ranges are shown in Table 4. The 
sensitivity of the method was evaluated by estimation of the lowest limit of 
detection (LLOD) and that of quantitation (LLOQ), both determined by injecting 
in-series dilutions of the multistandard of amino acids to obtain signals 3 and 10 
times, respectively, the background noise (average noise value obtained for blank 
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injections in SRM chromatograms). The absolute concentrations that provided 
these signals are also listed in Table 4. 
Table 4. Analytical figures of merit of the method for analysis of essential amino acids in 
human serum. 
Analyte 
LOD 
(ng on column) 
Linear dynamic range 
(ng on column) Correlation 
coefficient 
LOQ Maximum 
Tryptophan 0.6 1.9 760.0 0.996 
Valine 28.0 95.0 760.0 0.969 
Leucine/isoleucine 0.6 1.9 760.0 0.996 
Methionine 0.6 1.9 760.0 0.993 
Threonine 0.6 1.9 760.0 0.996 
Phenylalanine 0.6 1.9 760.0 0.996 
Lysine 0.6 1.9 100.0 0.995 
 
 The accuracy of the method and potential matrix effects were assessed by 
analysis of non-spiked and spiked serum samples at two concentration levels 
(100 and 300 ng/mL) and by comparison to the analysis of aqueous solutions of 
the standard mixture at the two concentrations. The recovery factor for each 
analyte was studied with the two-cartridge configuration shown in Fig. 2 by the 
analysis of five replicates of a non-spiked serum pool. Two MM cationic 
cartridges were in-series located, so after sample injection, the amount of amino 
acids non retained in the first cartridge was retained in the second. The eluates 
from both cartridges were sequentially injected into de QqQ analyzer, estimating 
the concentration retained in each cartridge. The recovery factor in this system 
was calculated as amount retained in cartridge 1/(amount retained in cartridge 1 
+ amount retained in cartridge 2). The recoveries ranged between 99.4–99.9% 
for the target analytes, which ensured quantitative retention/elution of them.  
 Matrix effects were estimated by analysis of spiked serum and 
multistandard solutions at the two levels. The peak areas for chromatographic 
signals obtained from the analysis of the blank (non-spiked serum) were 
substracted from those reported by the analysis of spiked serum. The recovery 
factor in this case ranged from 96.9–99.9%, which ensures the absence of matrix 
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effects. This is justified taking into account that a deproteinization step was 
previously carried out.  
 
Figure 2. Two-cartridge configuration employed to calculate the recovery factor. 
 Within-laboratory reproducibility and repeatability were evaluated in a 
single experimental setup with duplicates by daily experiments carried out for a 
week with a serum pool . The repeatability, expressed as relative standard 
deviation (RSD), ranged from 2.3 to 6.0 %, and the within-laboratory 
reproducibility, also expressed as RSD, ranged from 3.9 to 10.4 %. 
3.4.  Application of the method to human serum from atherosclerosis 
patients 
 Different studies have evidenced that amino acid levels can be related 
with cardiovascular diseases. The method optimized in this research was applied 
to human serum sampled from individuals affected by atherosclerosis (n=122), 
which is one of the most frequent causes of cardiovascular diseases. Eighty of 
these patients were diagnosed with stable angina while the rest of the individuals 
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(42) had suffered an acute myocardial infarct. Therefore, the main difference 
between both groups is that the latter had presented the formation of thrombi 
with subsequent lesions derived from ischemia.  
Table 5. Comparison between normal levels of essential amino acids in plasma and levels 
obtained in serum of cardiovascular patients. 
Analyte 
Normal levels 
(μg/ml) 
Levels in cardiovascular patients 
(μg/ml) 
Threonine 16.7±3.9 7.8±3.8 
Valine 27.3±5.0 8.0±5.4 
Leucine + isoleucine 24.3±5.1 30.9±16.8 
Tryptophan 9.0±1.5 7.4±5.0 
Lysine 27.5±4.7 5.5±2.0 
Methionine 3.7±0.6 24.5±13.1 
Phenylalanine 9.4±1.5 45.4±25.6 
 
 The concentrations found for each target amino acid in samples from 
atherosclerosis patients are listed in Table 5. The samples were injected in 
triplicate resulting in RSD values lower than those estimated in the repeatability 
test. Averaged levels in healthy individuals for these analytes according to the 
Human Metabolome Database are also included to compare between them. These 
results were provided by Cynober after analysis of plasma with the Hitachi 
analyzer . Anyway, different studies have reported that serum and plasma levels 
of amino acids are comparable except for dicarboxilic amino acids that are high 
concentrated in red blood cells . As can be seen, levels of threonine, valine and 
lysine were below normal levels detected in plasma. On the other hand, 
leucine/isoleucine, methionine and phenylalanine were found above normal 
levels in plasma. These results are in partial agreement with other studies found 
in the literature. Thus, Yao et al. have reported elevated levels of threonine and 
phenylalanine in individuals affected by a myocardial infarction . On the other 
hand, increased levels of leucine/isoleucine and decreased concentrations of 
lysine, threonine and phenylalanine were found in plasma from patients who 
suffered a heart failure as compared to healthy individuals. In the study proposed 
here, phenylalanine levels were above normal levels in patients with stable angina 
and with myocardial infarction. On the other hand, threonine levels were below 
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the normal levels; while a significant increase of threonine level in patients with 
myocardial infarction as compared to patients with stable angina was found. 
 Associations between the concentrations of the target amino acids in 
serum were detected by correlation analysis with a statistical significance at 95% 
confidence level (P<0.05). High correlations were found between all pairs of 
essential amino acids, except for the tryptophan-phenylalanine and tryptophan-
threonine pairs. 
 The influence of age on amino acids levels was also studied in four groups 
of patients defined to obtain a normal or Gaussian distribution: 36–50, 51–65, 
66–80, and 81–96 years old. With these groups, the skewness and kurtosis 
coefficients were in the range 0±2 for the studied cohort, which is required for a 
normal distribution. An ANOVA test revealed no significant differences were 
detected between groups, so the age does not exert any influence on the 
concentrations of essential amino acid. 
 After this characterization, the influence of factors such as obesity, 
hypercholesterolemia, sex and atherosclerosis on the concentration of essential 
amino acids was studied. A Multifactor Analysis of Variance (MANOVA) test was 
applied to detect the influence of these factors and their interactions. This 
chemometric approach enables to estimate the significance of different sources of 
variation by analysis of metabolomics data. The variability observed in the data 
set for each compound is decomposed into contributions to different factors. The 
contribution of each factor (or interaction between factors) is measured by 
removing the effects of all other factors and expressing it as a sum of squares. The 
values and the percent that they represent in the total variability of the 
compound are shown in Table 6. The concentrations of lysine (p=0.0335) and 
threonine (0.0058) were significant in atherosclerosis patients as a function of 
either occurrence of ischemia or not. This can be confirmed by visualization of 
the box-and-whisker plots representing the concentrations of both essential 
amino acids for patients with stable angina and acute myorcardial infarction (Fig. 
3). 
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Figure 3. Box-and-whiskers plots for lysine and threonine including mean and 95% least 
standard deviation for patients with stable angina and myocardial infarction. 
 
 As can be seen, serum concentrations of lysine and threonine were higher 
in patients who had suffered a myocardial infarct. Apart from this statistical 
significance, the concentration of both analytes was also influenced by the 
interaction of ischemia–sex factors. Discrimination between male and female 
individuals is exposed in Fig. 4 that shows a high relevance of sex to explain the 
variability of the results. Threonine (p=0.0453) and lysine (p=0.0214) levels are 
considerably increased in those female atherosclerotic patients who had suffered 
a myocardial infarct. In the case of male individuals, only threonine increased its 
serum concentration as a result of ischemia. However, lysine level did not report 
the same behavior since it was slightly decreased due to ischemia.   
 
 
Figure 4. Interaction plot showing the influence of the sex in threonine levels for patients 
diagnosed with stable angina or myocardial infarction. 
   
372 
Determination of essential amino acids in human serum by a targeting method based on 
automated SPE–LC–MS/MS: Discrimination between atherosclerotic patients  
 
  
Figure 5. Box-and-whiskers plots for valine and methionine including mean and 95% of 
least standard deviation for obese and non-obese patients. 
 Concerning the two risk factors, only obesity contributed to explain the 
variability in the concentrations of essential amino acids. As can be seen, valine 
levels (p=0.0167) and, particularly, methionine levels (p=0.0001) were highly 
influenced by obesity. The box-and-whisker plots, including the 95% least 
significance difference for the levels of valine and methionine in obese and non-
obese atherosclerotic patients is shown in Fig 5. The two plots show significantly 
increased levels of both amino acids in obese atherosclerotic patients, which 
could be ascribed to diet. 
 The interaction between sex and obesity expressed the variation of 
methionine with statistical significance (p=0.0479). Thus, levels of methionine 
were higher in serum from non-obese male patients than in non-obese female 
patiens. The opposite situation was found with obese patients that reported 
higher methionine concentrations in female atherosclerotic patients (Fig. 6).  
 
Figure 6. Interaction plot showing the influence of the sex in methionine levels for obese 
and non-obese patients. 
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 Finally, interaction between obesity and cholesterol explained with 
statistical significance (p=0.0214) variation on valine levels. In this case (Fig. 7), 
valine levels were higher in non-obese individuals with hypercholesterolemia and 
also in obese individuals with normal cholesterol levels. 
 
Figure 7. Interaction plot showing the influence of the hypercholesterolemia in valine 
levels for obese and non-obese patients. 
 
4. Conclusions 
 An automated method based on an SPE–LC–MS/MS configuration has 
been developed for analysis of essential amino acids in human serum. The 
method was optimized for high-throughput analysis of samples with 
synchronization of the sample preparation and determination steps. The 
applicability of the method has been supported on analysis of a cohort of 
atherosclerotic patients diagnosed with stable angina and acute myocardial 
infarction. The ischemia phenomena, present in patiens who had suffered an 
infarct, has revealed a significant contribution in the concentration of two 
essential amino acids such as threonine and lysine. This effect was more 
pronounced in female than in male individuals. The influence of obesity, as an 
important risk factor in cardiovascular diseases, has also been elucidated 
indicating higher levels of valine and methionine in serum from obese 
individuals. 
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Abstract 
 Metabolites involved in the tricarboxylic acid (TCA) cycle have previously 
been proposed as cardiovascular biomarkers. This cycle plays a key role in cell 
metabolism and the levels of the involved metabolites can also be affected by 
other physiological factors. The influence of three cardiovascular risk factors such 
as obesity, hypercholesterolemia, and smoking habit on serum levels of  
TCA-cycle metabolites has been studied in patients diagnosed with significant 
coronary lesion. For this purpose, a method based on GC–MS for determination 
of the target metabolites (viz. citric/isocitric, pyruvic, aconitic, oxaloacetic, malic, 
fumaric and succinic acids) in serum has been developed. The high accuracy and 
throughput analysis featuring the method have allowed application to a cohort of 
223 patients, 172 of them with significant coronary lesion. Multifactor analysis of 
variance has revealed interactions between the occurrence or not of a coronary 
lesion and the risk factors considered in this study. These interactions were 
crucial to explain the levels of target TCA metabolites. Statistical evaluation by 
ROC curves allowed evaluating the discrimination capability of those significant 
metabolites with the occurrence of coronary lesions.  
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1.  Introduction 
 The citric acid cycle, also known as the tricarboxylic acids cycle (TCA 
cycle) or the Krebs’ cycle, consists of a series of chemical reactions aimed at 
generating energy (ATP) through oxidization of acetate from carbohydrates, fats 
and proteins into carbon dioxide and water. In addition, the cycle provides 
precursors for the biosynthesis of compounds including certain amino acids as 
well as the reducing agent NADH, involved in a number of biochemical reactions 
(Suppl. Fig. 1). Oxygen is needed along the TCA pathway since the different 
coenzymes involved in the process need subsequent re-oxidation [1]. Drop of 
oxygen levels in cells interrupts activity in the Krebs cycle; therefore, the products 
from glycolysis would not be processed as required. 
 Alterations in the TCA cycle have been correlated with numerous 
pathologies such as cancer [2], cardiovascular diseases [3], metabolic syndrome 
[4] and neurodegenerative disorders [5], where oxidative stress plays a key role 
[6–9]. The importance of the TCA cycle in the metabolic defensive mechanism 
against oxidative stress is clear as this cycle is the main producer of pro-oxidant 
NADH. Thus, alterations in the TCA cycle could modulate the production of 
reactive oxygen species (ROS) by increasing the concentration of ROS and 
shortening cellular longevity as a result. The link between TCA cycle and ROS 
homeostasis may explain the fact that an inefficient functioning of the former 
characterizes various pathological conditions and ageing [10].  
 Atherosclerosis, one of the most common cardiovascular diseases, is 
attributed to the accumulation of lipids, macrophages, smooth muscle cells, etc. 
in the walls of arteries, thus reducing the lumen of arteries. The result is the ap-
pearance of coronary lesions, which make difficult the blood supply of nutrients 
and oxygen to the heart muscle. The relationship between cardiovascular diseases 
and the TCA cycle has been supported on the appearance of ROS and oxygen sup-
ply deficiency (ischemia) [11]. In fact, metabolites involved in the TCA cycle have 
been widely suggested as cardiovascular biomarkers [12–15]. Thus, citric acid was 
found at lower concentration in patients with non-ST elevation acute coronary 
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syndrome (NSTEACS) as compared to both patients with stable coronary artery 
disease and controls [12]. Also, succinate and malate were detected at high con-
centrations in the circulation system of groups affected by myocardial infarction 
[13], although inhibition of the TCA cycle is supposed on myocardial ischemia. In 
fact, citric acid level was decreased in groups with clear-cut inducible ischemia 
[14]. Additionally, α-ketoglutaric acid is within the plasma metabolites that 
allowed discrimination between individuals with high and low risk of suffering 
cardiovascular diseases in general terms, according to well-known risk factors 
such as age, hypertension, hypercholesterolemia, obesity or smoking habits [15]. 
It can be of interest to know how these factors, together with cardiovascular 
disorders, can affect the levels of metabolites involved in the TCA cycle.  
 Different analytical platforms have been developed to determine com-
pounds of the TCA cycle, the most common being GC–MS after derivatization 
[16–18]. Other strategies such as LC with either fluorescence (after 
derivatization) or photometry detection [19,20] have also been used. In this 
research, a method based on GC–MS has been proposed for determination of 
TCA cycle metabolites in human serum from individuals diagnosed with 
significant coronary lesions. The objective was to study the potential effects of 
risk factors for the occurrence of coronary lesions such as obesity, 
hypercholesterolemia or smoking habit on serum levels of metabolites of the TCA 
cycle. The data thus obtained have been treated searching for factors that could 
explain variations in the level of metabolites of the TCA cycle. 
 
2. Material and methods 
2.1. Materials, reagents and chemicals 
 The target metabolites were citric acid, oxaloacetic acid, aconitic acid, 
isocitric acid, pyruvic acid, α-ketoglutaric acid, malic acid, fumaric acid and 
succinic acid, supplied by Sigma–Aldrich, Co. (St. Louis, MO, USA). Isotopic 
(15N) glutamic acid from Sigma–Aldrich was used as internal standard for 
quantitation of TCA metabolites. Methanol, formic acid and chloroform were 
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from Panreac (Barcelona, Spain). Bis-(trimethylsilyl)-fluoroacetamide (BSTFA) 
and trimethylchlorosilane (TMCS) from Sigma–Aldrich were used as silylation 
agents in the derivatization step. Pyridine from Merck (Darmstadt, Germany) 
was used as derivatization solvent. Deionized water (18 MΩ • cm) from a 
Millipore Milli-Q water purification system was used to prepare the solutions.  
2.2. Cohort selected for the study 
 A total of 223 patients diagnosed with different cardiovascular problems 
were recruited at the Cardiology Unit of Miguel Servet Hospital (Zaragoza, 
Spain). Among them, 172 patients were affected by a significant coronary artery 
lesion as atherosclerosis after evaluation through cardiac catheterization 
(angiographic stenosis revealed a reduction of the arterial lumen ≥ 70%). Blood 
samples from these patients were collected within 7 days after catheterism 
intervention. The rest of the patients (n=51) were affected by other clinical 
manifestations without significant coronary lesion such as chest pain, angina, 
and heart failure, or were heart transplanted individuals. The main 
characteristics of the patients are shown in Table 1 with discrimination between 
individuals diagnosed with a coronary lesion or not. The average age of the cohort 
was 66±14, with a similar range for patients with and without coronary lesion. A 
70.4% of the total individuals were male, most of them affected by a coronary 
lesion. Concerning risk factors, 46.2% of total individuals were smokers, 31.4% 
obese and 45.7% with hypercholesterolemia.  
Table 1. Features of the cohort under study. 
Characteristic 
Patients 
(n=223) 
Patients with 
coronary lesion 
(n=172) 
Patients without 
coronary lesion 
(n=51) 
Fisher’s 
exact test 
p-value 
Age 66 ± 14 67.7 ± 13.4 61.5 ± 12.8 – 
Male gender, n (%) 157 (70.4) 136 (79.1) 21 (41.2) 0.000*** 
Smoking habit, n (%) 103 (46.2) 86 (50.0) 17 (33.3) 0.026* 
Obesity, n (%) 70 (31.4) 57 (33.1) 13 (25.5) 0.195 
High-cholesterol level, n (%) 102 (45.7) 88 (51.2) 14 (27.5) 0.002** 
 * P-value between 0.05 and 0.01. 
** P-value between 0.01 and 0.001. 
*** P-value lower than 0.001. 
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2.3. Blood extraction and serum isolation 
 Venous blood was collected in evacuated sterile serum tubes without 
additives (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, USA) and incu-
bated for 10 min at room temperature to allow coagulation. Then, the tubes were 
centrifuged at 2000 × g for 15 min at 4 °C to isolate the serum fraction 
(processing within 1 h after collection). Serum was placed in plastic ware tubes 
and stored at –80 °C until analysis.  
 All steps from blood extraction to analysis were performed in compliance 
with the guidelines dictated by the World Medical Association Declaration of 
Helsinki (2004), and supervised by specialized personnel from Miguel Servet 
Hospital (Zaragoza, Spain). Individuals selected for this study were previously 
informed to obtain consent. 
2.4.      Instruments and apparatus 
 A micro-centrifuge Sorvall Legend Micro 21R from Thermo Scientific 
(Waltham, MA, US) was used to separate the phases after extraction and protein 
precipitation. A speed-vac Concentrator Plus, from Eppendorf Ibérica (Madrid, 
Spain), was used to evaporate the methanol phase before derivatization. A block 
heater from Stuart (Afora, Barcelona, Spain) was used to maintain constant the 
temperature during the derivatization step. 
 A Varian CP-3800 Gas-Chromatograph coupled to a Saturn 2200 ion-
trap mass spectrometer (Sugar Land, TX, USA) equipped with a VF-5ms Factor 
Four capillary column (30 m x 0.25 mm, 0.25 μm), also provided by Varian, was 
used for the specific analysis of organic acids in the extracts. The overall system 
was controlled and the data acquired and processed by using Star Chroma-
tography Workstation 6.0 software (Varian, Walnut Creek, California, USA). All 
injections were carried out using a Varian 8400 autosampler equipped with a 10 
μl syringe from SGE (Scharlab, Barcelona). 
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2.5. Sample preparation for analysis of tricarboxylic acids 
 First, 5 μL of the internal standard stock solution at 80 µg/mL was added 
to the serum sample (150 μL) prior to deproteinization with 300 μL of methanol. 
The mixture was vortexed for 1 min and subsequently cooled at –20 ºC for 3 min. 
The resulting precipitate was separated by centrifugation at 14000 × g for 15 min 
at 4 ºC and the methanol aqueous phase was isolated and cleaned by extraction 
of non-polar compounds with 300 μL of chloroform. The clean phase was 
concentrated by evaporation and the resulting residue was reconstituted with 10 
μL of pyridine and 1 μL of formic acid. For derivatization, 90 μL of a 98:2 
BSTFA–TMCS mixture was mixed with the analytical sample, shaken for 30 s 
and maintained at 30 °C for 30 min before injection into the chromatograph. 
2.6. GC–MS analysis  
 Eight µL of the derivatized solution was injected into the GC instrument 
with the following split ratio program: 1:50 (0 min), 1:1 (0.5 min), 1:100 (3.5 min) 
and 1:20 (4.5 min). The injector temperature was programmed as follows: from 
70 °C (held 0.5 min) to 270 °C (maintained for 25.5 min) at a rate of 150 °C/min. 
Carbon dioxide was used as coolant gas for the injector in order to reduce 
analysis time. The column temperature was programmed from 60 °C (held 1 min) 
to 300 °C (maintained for 5 min) at a rate of 10 °C/min. Helium was used as 
carrier gas at a constant flow rate of 1 mL/min.  
 Electron impact ionization (EI) positive mode was selected prior to single 
ion monitoring of each analyte by ion trap in microselected ion storage (μSIS) 
mode. The instrumental parameters were set at the following values: filament 
emission current 70 µA; transfer line, ion trap and manifold temperatures 280, 
200 and 50 °C, respectively. The scan time for data acquisition was set at 1.0 s, 
and the number of microscans per second for each segment was a function of the 
mass range under study (always from 50 m/z to ten units above the highest mass 
monitored in the segment). 
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2.7. Statistical analysis 
 Statgraphics Centurion (XV.I version, Statpoint Technologies Inc.), R 
(URL http://www.R-project.org) and pROC (1.5.1 version, URL 
http://web.expasy.org/pROC/) were used for data analysis.  
 The Kolmogorov-Smirnov test was used to check if TCA serum levels 
showed normal distributions in the cohort selected for the study. Statistical 
significance analysis (set at 0.05) was carried out by the non-parametric Mann-
Whitney test for continuous variables, while the Fisher exact test was used for 
categorical variables. Multifactor analysis of variance was tested to evaluate the 
significance of each factor as well as two-factor interactions after normalization 
of TCA serum levels by box-cox transformation. 
 A receiver–operating characteristic (ROC) curve was determined in each 
cohort for each individual predictor, and a cutoff value was selected as the 
threshold predicting the occurrence of a coronary lession with specificity >90%. 
Partial ROC AUCs (pAUC) [21,22] were calculated using an adaptation of 
algorithms previously reported [23]. pAUCs were restricted between 90–100% 
specificity, considering an efficient predictor in clinical practice should be able to 
identify clearly at least nine out of ten patients as having a favorable prognosis for 
negative tests. 
 
3. Results and discussion 
3.1. Optimization of sample preparation 
 Sample preparation was optimized by a serum pool to which the suited 
volume of internal standard was added to eliminate signal fluctuations due to 
variations in the injection volume. The protein content in serum justified the 
inclusion of a deproteinization step, efficiently carried out with methanol in a 2:1 
methanol–serum ratio. Methanol has been widely used for protein precipitation 
by virtue of its high reproducibility and efficiency [24]. After centrifugation, 
different organic solvents were tested for the removal of organic interferences by 
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liquid–liquid extraction. An 1:1 methanol–chloroform ratio provided no 
significant losses of metabolites but a significant decrease of the background 
signal.  
 The reaction temperature and time of the derivatization step were also 
optimized, and the necessity for including an oximation step was tested as some 
methods for analysis of organic carboxylic acids include this step [18,25,26] while 
some others do not [16,17,19]. Oximation was found to be unnecessary; therefore, 
the residue from evaporation was directly reconstituted with 10 μL of pyridine 
(the optimum medium for derivatization with BSTFA–TMCS). The difficulty for 
complete dissolution of the residue made necessary the addition of 1 μL of formic 
acid. After shaking, 90 μL of the derivatization mixture (98:2 BSTFA–TMCS) was 
added to form trimethylsilyl (TMS) derivatives [27]. Several aliquots of the serum 
pool were prepared in this way, each maintained at different temperature (from 
25 to 60 °C) for different times (from 15 to 60 min) to establish the optimum 
operational conditions for derivatization of the target metabolites. The best 
results were obtained at 30 °C for 30 min. Supplementary Fig. 2 shows the effect 
of temperature and derivatization time on the efficiency of the reaction for three 
representative metabolites. 
3.2. Characterization of the GC–MS method 
 Isotopic glutamic acid was selected as internal standard to control 
potential errors in the protocol. The mass spectra of the TMS-derivatized 
compounds formed in the EI source led to fragment ions predicted from their 
chemical structure. The monitored ions were in accordance with research in 
which the analytes were determined using the same derivatizing reagent [16,18]. 
The quantitation ions for all target compounds, including the internal standard, 
are shown in Table 2, which also includes the chromatographic retention times. 
The chromatogram obtained from a serum sample spiked with 100 µg/L of each 
analyte is shown in Fig. 1. 
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Fig. 1. Single ion monitoring chromatograms from a serum sample spiked with 100 μg/L 
of the target metabolites and the internal standard (IS). 
 
Table 2. Quantitation ion and retention time for each target compound. 
 
Compound Quantitation ion (m/z) Retention time (min) 
Glutamic acid (isotopic  marker) 291.2 5.8 
Oxaloacetic acid 290.0 6.1 
Pyruvic acid 174.0 6.5 
Succinic acid 335.5 9.9 
Fumaric acid 278.3 10.4 
Malic acid 335.3 12.1 
α-Ketoglutaric acid 304.3 13.1 
Aconitic acid 229.4 15.1 
Citric acid/Isocitric acid 465.4 15.6 
 
 The calibration equations were established by using the analyte/internal 
standard peak-area ratio as a function of the concentration of each analyte in 
order to circumvent matrix effects. The linear dynamic range for each analyte is 
shown in Table 3. Characterization of the method also involved calculation of 
limits of detection (LODs) and quantification (LOQs), which were estimated by 
diluting a water solution of the target compounds. The LOD for each analyte was 
expressed as the mass of analyte which gives a signal 3σ above the mean blank 
P
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signal (where σ is the standard deviation of the blank signal), and the LOQ as the 
mass of analyte which gives a signal 10σ above the mean blank signal. Values of 
LOD and LOQ for each analyte, expressed as concentration in serum, are shown 
in Table 3. Sensitivity values reported with this method were better than those 
described in recently published methods, which presented minimum LOD values 
of 10 and 20 µg/L for α-ketoglutaric acid and citric acid, respectively [29], while 
in other cases LODs from 56 to 140 µg/L [24,28] have been reported. 
 
Table 3. Limits of detection (LOD) and quantitation (LOQ) for each target compound and 
linear dynamic range of the calibration curve. 
 
Compound 
LOD 
(µg/L) 
Linear dynamic range (µg/L) 
LOQ 
Maximum 
limit 
Oxaloacetic acid 2.00 6.67 388 
Pyruvic acid 10.00 33.33 317 
Succinic acid 2.00 6.67 1107 
Fumaric acid 2.00 6.67 626 
Malic acid 2.00 6.67 526 
α-Ketoglutaric acid 10.00 33.33 425 
Aconitic acid 2.00 6.67 321 
Citric/Isocitric acid 20.00 66.70 402 
 
 The precision of the method was calculated by injecting different aliquots 
of the same sample twice a day for seven days. The results obtained for each 
compound in terms of intra-day and inter-days precisions, expressed as percent 
of relative standard deviation (RSD), are shown in Table 4. Those values were 
quite acceptable for analysis of biological samples. As an example, Lu et al. [29] 
obtained intraday variability values twice or six times higher than those obtained 
with our method. The accuracy of the method was calculated by comparing a 
serum sample spiked with a known quantity of analyte with the same serum 
sample without spiking. Results obtained are shown in Table 4. 
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Table 4. Precision study expressed as percent of relative standard deviation (% RSD) and 
accuracy obtained expressed as recovery percentage. 
Compound 
Intra-day 
precision 
Inter-day 
precision 
Accuracy 
Oxaloacetic acid 11.4 17.4 102.7 
Pyruvic acid 7.7 17.2 100.8 
Succinic acid 5.3 15.8 99.8 
Fumaric acid 5.2 5.8 100.1 
Malic acid 4.6 6.4 100.0 
α-Ketoglutaric acid 7.7 14.8 101.9 
Aconitic acid 3.2 7.9 109.5 
Citric/Isocitric acid 9.4 15.4 95.4 
 
3.3. Application of the method to human serum samples from the cohort 
under study 
 As commented under “Introduction”, different studies have evidenced 
that the levels of compounds involved in the TCA cycle could be related to 
cardiovascular diseases. In this study, the relationship between TCA serum levels 
and the diagnosis of coronary lesions has been studied by considering different 
risk factors influencing the occurrence of cardiovascular disorders. The risk 
factors studied were obesity, hypercholesterolemia and smoking habit. Apart 
from them, an anthropometric factor such as individual gender was considered in 
the statistical analysis. The study of categorical variables revealed statistical 
significance of three factors by application of the Fisher's exact test (see Table 1): 
smoking habit (p = 0.026) and, specially, hypercholesterolemia (p = 0.002) and 
gender (p = 0.000). The obesity did not report a statistical contribution to the 
presence of coronary lesion in the target cohort.  
 For analysis of TCA in serum, the samples were injected in triplicate, and 
the RSD values were of the same order as those estimated in the precision study. 
Average concentration for each target compound, with the corresponding 
standard deviation, differentiated patients with significant coronary lesion from 
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those without coronary lesion, as shows Table 5. Since TCA concentrations did 
not show normal distributions (Kolmogorov–Smirnov test) between-group 
differences were tested with the non-parametric Mann–Whitney U test. This 
non-parametric test did not detect significance of any metabolite between 
individuals with or without coronary lesion. Prior to application of this test, the 
influence of individuals age on the levels of target metabolites was studied by 
grouping the patients to obtain a normal or Gaussian distribution: 36–50, 51–65, 
66–80, and 81–96 year old. With these ranges, the skewness and kurtosis 
standard were between 0±2, fulfilling the condition required for normal 
distributions. No significant differences were detected between groups, so the age 
did not influence levels of the target compounds. 
Table 5. Levels of TCA cycle metabolites in the cohort under study expressed as 
mean±standard deviation (µg/L). 
Compound 
With significant 
coronary lesion 
Mean ± SD (n=3) 
Without coronary 
lesion 
Mean ± SD (n=3) 
Mann-Whitney 
U test 
P-value 
Oxaloacetic acid 50.9 ± 28.9 49.0 ± 20.6 0.3903 
Pyruvic acid 152.8 ± 74.2 134.3 ± 88.1 0.1227 
Succinic acid 151.2 ± 76.7 219.3 ± 126.9 0.5411 
Fumaric acid 164.9 ± 27.0 164.9 ± 23.7 0.6070 
Malic acid 43.3 ± 27.5 52.1 ± 33.9 0.2028 
α-Ketoglutaric acid 64.3 ± 57.4 80.9 ± 57.9 0.2565 
Aconitic acid 150.4 ± 77.3 175.7 ± 108.9 0.9169 
Citric/Isocitric acid 228.0 ± 147.5 238.6 ± 160.1 0.6297 
 
 Interactions between categorical and quantitative variables were 
analyzed by a multifactor analysis of variance. The variability of each compound 
was decomposed into contributions from different factors. The contribution of 
each factor (or interaction between factors) was measured by removing the 
effects of all other factors and expressing the contribution as a sum of squares. 
The values and the percent they represented in the total variability of the 
compounds are shown in Suppl. Table 1. As can be seen, risk factors were very 
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influential on the levels of pyruvic acid, oxaloacetic acid, aconitic acid and 
fumaric acid. In particular, the smoking habit contributed to explain the levels of 
pyruvic acid (p = 0.0456), oxaloacetic acid (p = 0.0141) and fumaric acid (p = 
0.0254); therefore, smoking is the most influential of the risk factors under study 
on the level of these TCA. Concerning aconitic acid, its serum level was 
significantly explained by the occurrence of coronary lesions. In the case of 
pyruvic acid, Fig. 2A shows that its serum level was higher in smoking patients, 
which is justified by the level of oxygen in blood from smokers, which is lower 
than in non-smokers and explains the decreased efficiency of the Krebs cycle in 
the latter. 
  Oxalacetic and fumaric acids, integrated in the last pathways of the Krebs 
cycle (see Fig. 2A), showed a behavior similar to that of pyruvic acid. Concerning 
interaction coronary lesion–aconitic acid, Fig. 2B shows that the concentration of 
this TCA was lower in individuals diagnosed with coronary lesion than in the rest 
of individuals in the cohort. 
No significant contribution was found for the resting factors under study, namely, 
the individuals gender, obesity or hypercholesterolemia, although the interaction 
effect between factors was critical. Thus, the analysis of two-factor interactions 
revealed the importance of certain risk factors to explain serum levels of the 
target TCA metabolites. Two of the main interactions were coronary lesion × 
smoking habit and coronary lesion × obesity, with highly-significant influence on 
pyruvic acid (p = 0.0029) as well as malic acid (p = 0.0214) and  
α-ketoglutaric acid (p = 0.0021). As Fig. 3 shows, the influence of obesity and 
smoking habit was critical to understand these results since an opposite effect 
was observed depending on obese/non-obese and smoker/non-smoker 
conditions of the individuals. Concerning α-ketoglutaric and malic acids, serum 
levels were considerably higher in obese individuals diagnosed with a coronary 
lesion, but not in non-obese individuals. Pyruvic acid also revealed a 
contradictory behavior since smoker individuals diagnosed with coronary lesion 
reported higher concentrations than smoking individuals without coronary 
lesions and also than non-smoking individuals (Fig. 3B). One other interaction 
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contributing to explain levels of TCA metabolites was the gender × smoking 
habit, which influenced serum concentrations of pyruvic and succinic acids. The 
behavior observed for both TCA metabolites is shown in Suppl. Fig. 3. Previous 
studies have reported that gender can also affect metabolites involved in the TCA 
cycle since men generally burn calories more quickly than women as the former 
posses more muscle tissue [30]. This fact could explain the levels found in non-
smoking individuals, but not the change observed for smokers, which 
preferentially affects women. This may be due to the fact that women are more 
vulnerable than men to tobacco smoking effects, shown by more breathlessness, 
coughing and bronquitis [31].  
 
Fig. 2. Mean normalized concentrations in serum (95% of standard deviation) for  
(A) pyruvic, fumaric and oxaloacetic acids in patients with/without smoking habit;  
(B) aconitic acid in patients with/without coronary lesion. The concentration values were 
normalized by dividing each value by the highest concentration value. 
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Fig. 3. Interaction plot of: (A) obesity × significant coronary lesion on α-ketoglutaric and 
malic acid levels; (B) smoking habit × significant coronary lesion on pyruvic acid levels. 
 
3.4.  Evaluation of the TCA predictors by ROC curves 
 The multifactor analysis of variance revealed the influence of coronary 
lesions on the variability of concentrations of TCA metabolites in serum, directly 
(aconitic acid) or by interaction with risk factors such as smoking habit (pyruvic 
acid) or obesity (malic and α-ketoglutaric acids). These results were validated by 
ROC curves and by estimation of the pAUC. Evaluation of a predictor by the total 
AUC is not recommended when the performance test only takes place in high 
specificity or high sensitivity regions [32]. For this reason, the pAUC parameter is 
more suited since it is restricted to specific regions of the curve. In this study, 
aconitic acid was evaluated by one-factor ROC curves (ocurrence or not of 
coronary lesion), while malic-, α-ketoglutaric- and pyruvic acids were evaluated 
by a two-factor ROC curves to take into account the interaction effects detected in 
the multifactor analysis of variance. Thus, malic and α-ketoglutaric acids were 
evaluated by the occurrence of coronary lesion and obesity as factors, while 
pyruvic acid was evaluated by the occurrence of coronary lesion and smoking 
habit as factors. Figure 4 shows the ROC curves for the four TCA metabolites 
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highlighting the specificity threshold (above 90%) for each TCA metabolite to 
reduce the probability of false negative predictions. According to the ROC curves, 
aconitic and pyruvic acids were able to discriminate patients with or without 
coronary lesions (with smoking habit or not for pyruvic acid) with high specificity 
(92 and 91%, respectively), but with low sensitivity (21 and 17%, respectively). 
The situation was different for the other two TCA metabolites the concentration 
profiles of which were significantly explained by the interaction between 
coronary lesion and obesity. Thus, malic acid was able to discriminate individuals 
with coronary lesions with specificity of 92% and sensitivity of 49%, while α-
ketoglutaric acid reported values of 93% specificity and 56% sensitivity. The α-
ketoglutaric acid seems to have a higher discrimination capability than malic 
acid. However, these results need to be supported on the pAUC parameter of the 
two ROC curves, which was 2.3% for α-ketoglutaric acid and 4.2% for malic acid. 
These values enable to conclude that α-ketoglutaric acid discrimination capability 
is less robust than that observed for malic acid. 
 
Fig. 4. ROC curves of malic, aconitic, α-ketoglutaric and pyruvic acids for the one- factor 
or two- factors combination for which each acid was significant. The vertical light grey 
shape corresponds to the pAUC region (between 90 and 100% specificity). 
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4. Conclusions 
 The relevance of three risk factors such as hypercholesterolemia, obesity 
and smoking habit on cardiovascular diseases has been studied through their 
influence on serum levels of TCA metabolites for patients diagnosed with 
coronary lesions. The consideration of these risk factors was crucial to explain the 
variability of the target TCA for patients with coronary lesion versus control 
individuals. TCA metabolites are primary metabolites that could be affected by 
numerous internal and external aspects. For this reason, these factors should be 
considered when TCA cycle metabolites are proposed as potential biomarkers in 
clinical diagnosis. In this study, the statistical analyses were supported on ROC 
curves and their related parameters to validate the discrimination capability of 
TCA metabolites. Statistical analysis revealed that malic acid and α-ketoglutaric 
acid led to models with high specificity and acceptable sensitivity for 
discrimination between patients with and without coronary lesions. The 
discrimination model of α-ketoglutaric acid was less robust than that of malic 
acid. 
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Supplementary material 
 
 
 
Supplementary Fig. 1. Krebs’ cycle scheme including interactions with cholesterol, fatty 
acids and carbohydrates. 
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Supplementary Fig. 2. GC–MS peaks of aconitic, fumaric and succinic acids obtained at 
different derivatization times and temperatures in the optimization step. 
 
 
 
 
Supplementary Fig. 3. Interaction plot of smoking habit × gender on pyruvic and 
succinic acid levels. 
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Analytical platform for veriﬁcation and 
quantitation of target peptides in human serum: 
Application to cathelicidin  
M. Calderón-Santiago, J.M. Mata-Granados, F. Priego-Capote*, J.M. Quesada-
Gómez, M. D. Luque de Castro 
 
Abstract 
 A selective and sensitive, fully automated platform for veriﬁcation and 
quantitative determination of target peptides in bioﬂuids is proposed and then 
validated by development of a method for analysis of cathelicidin in human 
serum. The method is based on the on-line coupling of solid-phase extraction 
(SPE) and tandem mass spectrometry with direct infusion. Mass spectrometry 
analysis was carried out by multiple reaction monitoring using three transitions 
(one for quantitative analysis and two for qualitative analysis), all them 
conﬁrmed by in silico fragmentation of the target peptide. Samples were 
prepared in the SPE workstation on a polymeric divinylbenzene resin by 
preconcentration, deproteinization, and cleanup, removing salts and 
interferences after direct injection of human serum. The analytical process 
required 12 min. The limits of detection and quantitation were 2.5 and 8.25 µg/L, 
respectively (0.20 and 0.66 pg on column). Repeatability and within-laboratory 
reproducibility were 2.4% and 2.7%, respectively. A dual-cartridge conﬁguration 
was used to test recovery of cathelicidin in serum, resulting in 80%. Because 
quantitative retention in the cartridge was assessed, determination of cathelicidin 
was validated without using synthetic peptides labeled with stable isotopes. The 
hyphenated system allows full automation, thereby improving reproducibility 
and accuracy, as demanded by clinical analysis.  
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1.  Introduction 
  Targeted mass spectrometry (MS)1 is emerging as an analytical 
technique capable of selective and sensitive detection and quantitation of any 
protein/peptide of interest (or modiﬁcation thereof) [1–4]. In selected reaction 
monitoring (SRM) mode, peptides (precursors) from target proteins are 
selectively detected and caused to fragment (products) in the mass spectrometer. 
The resulting product ions are used for selective quantitation of the peptide and, 
therefore, the protein from which it was derived. This two-stage ﬁltering process 
allows chemical background to be overcome by improving the signal-to-noise 
ratio and permits selective determination of target peptides. 
 The ﬁrst step in developing an SRM-based assay involves the selection of 
a subset of peptides as quantitative candidates for each protein. Signature 
peptides correspond to the subset of proteotypic peptides that are also the 
highest responding peptides for each protein in terms of sensitivity [5]. The 
major challenge for SRM is to decide the target peptides to be monitored taking 
into account that each protein has multiple enzymatic cleavage sites. The 
selection of signature peptides is currently based on detection in the preliminary 
MS data [1,3], identiﬁcation in databases containing MS experimental data [6,7] 
or the use of computational approaches designed to predict proteotypic peptides 
[8,9]. This can be done manually, for example, by theoretic digestion of the 
sequences of interest and blasting of all resulting peptides 
(http://www.ncbi.nlm.nih.gov/blast/Blast.cgi) [10]. After selecting signature 
peptides, the targeted SRM–MS assay should be independently optimized for 
each peptide to select the appropriate precursor-to-product ion transitions [11]. 
 SRM has proven to be a successful method for discovery and validation of 
novel biomarkers [1,12,13], and in comparison with other alternatives such as 
enzyme-linked immunosorbent assays (ELISAs), it is cost-effective, quicker to 
design, and suitable for multiplexed analysis [4]. Mass spectrometry in SRM 
mode requires a high level of ion separation but not necessarily high resolution. 
Therefore, the instrumentation used to measure peptide SRMs is similar to that 
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existing in robust platforms present in analytical laboratories. Increased 
throughput is also possible by direct coupling of separation (via liquid 
chromatography [LC]) to MS [3,14]. However, automation of sample preparation 
is a challenge in the analysis of target peptides. 
 Quantitation in SRM-based approaches is mostly carried out with stable 
isotopes by calculating the ratio of the signal response of the endogenous peptide 
to a stable isotope-labeled version of the peptide spiked as an internal standard at 
a known concentration (AQUA [absolute quantitation] methodology) [2]. The 
main limitation is the cost of isotopic-labeled peptides that need to be 
synthesized after optimization of the protocol. Another possibility is to evaluate 
potential errors of the method with an internal validation step, avoiding internal 
standard-based quantitation. An internal standard can be highly useful, but its 
selection also creates a problem unless a labeled isotopic standard is used. 
However, the synthesis of a isotopically labeled version of peptides is expensive, 
particularly if long peptides are the target of the analysis. Internal validation can 
be achieved by implementation of a solid-phase extraction (SPE) step that 
validates the analytical method by estimation of the recovery factor. For this 
purpose, spiked and nonspiked serum samples are used to support that the 
method is independent of matrix interferences after optimization of each step of 
the SPE protocol. This matrix independence is the key aspect for this assumption. 
The development of robust and automatic platforms for analysis of peptide 
panels or with high capability for fast individual determination of them is highly 
desirable. 
 Cathelicidin or LL-37 is a peptide formed by 37 amino acids with an  
α-helix secondary structure. It is one of the human antimicrobial peptides that 
take part in the immune response. LL-37 is synthesized as an inactive peptide 
called hCAP-18, which is cleaved by serine proteases in the target tissue to 
activate the C-terminal antimicrobial peptide (LL-37) operating in the ﬁrst line of 
defense [15]. Cathelicidin stimulates endothelial proliferation, promoting the 
accumulation of leukocytes in the inﬂammation focus or in a wound [16]. 
Furthermore, this peptide protects against necrotic skin and possesses a synergic 
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effect with β-defensins (other type of human antimicrobial peptides) [17,18]. The 
levels of this peptide, estimated as messenger RNA (mRNA), can be related to 
different diseases such as eczema herpeticum, infective cellulites, and pulmonary 
tuberculosis [19–21]. This relationship confers cathelicidin a promising capability 
as biomarker that still needs to be deﬁned. Preliminary results have revealed that 
low plasma levels of cathelicidin predict increased infectious disease mortality in 
patients undergoing hemodialysis [22]. 
 Despite this relationship, few methods have been reported for deter-
mination of LL-37 in human serum or plasma. Recently, LL-37 plasma levels 
have been estimated using a commercial ELISA kit, an expensive approach with a 
protocol time of 3.5 h [23]. Cathelicidin levels have also been estimated using 
transcriptomic approaches by determination of cathelicidin mRNA expression 
[20,21]. However, it has been supposed that cathelicidin levels are exclusively 
linked to its mRNA expression. The aim of this research was to develop an 
automatic analytical platform for robust targeted analysis of peptides —a 
platform that has been validated by analysis of cathelicidin. 
 
2. Material and methods 
2.1. Chemicals 
 LC–MS-grade methanol, acetonitrile, formic acid, and acetic acid were 
purchased from Scharlab (Barcelona, Spain). Deionized water (18 mΩ cm) from a 
Millipore Milli-Q water puriﬁcation system was used for preparation of all 
aqueous solutions. LL-37 (cathelicidin) standard (97.4% purity tested by high-
performance liquid chromatography [HPLC] analysis) was provided by Bachem 
(Weil am Rhein, Germany). 
 Commercial standard cathelicidin was weighed and dissolved in water 
according to the manufacturer’s instructions to obtain a 500 mg/L stock solution. 
Working solutions were prepared by dilution of the appropriate volume of stock 
solution in water. 
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2.2. Blood extraction and serum isolation 
 Venous blood was collected in evacuated sterile tubes for whole blood 
hematology determination (Vacutainer, Becton Dickinson, Franklin Lakes, NJ, 
USA) and centrifuged at 4000 rpm for 10 min to isolate the serum fraction 
(processing within 2 h after collection). Serum was placed in a plasticware tube 
and stored at or below –80 °C until analysis. All steps from blood extraction to 
analysis were performed in compliance with the guidelines dictated by the World 
Medical Association Declaration of Helsinki of 2004, which were supervised by 
the ethical review board of Reina Soﬁa Hospital (Cordoba, Spain) that approved 
the experiments. Individuals selected for this study were told to obtain consent 
prior to this research. 
2.3. SPE–tandem mass spectrometry configuration 
 Fig. 1 illustrates a scheme of the conﬁguration device. A Midas auto-
sampler furnished with a 200 µl sample loop connected to an SPE workstation 
Prospekt-2 system (Spark Holland, Emmen, Netherlands) was used to automate 
SPE. The Prospekt-2 system consisted of an automatic cartridge exchanger and a 
high-pressure dispenser, which enabled fully automated performance of sample 
preparation, controlled by SparkLink version 2.10 software. Hysphere Resin GP 
cartridges (8 µm, 10 x 2.0 mm, Spark Holland) were used for the SPE step. The 
Prospekt-2 system was on-line connected to an Agilent 1200 Series LC system 
(Palo Alto, CA, USA), which consists of a binary pump and a vacuum degasser. 
The eluate was introduced directly into an Agilent 6410 triple quadrupole (QqQ) 
detector furnished with an electrospray ionization (ESI) source. Agilent 
MassHunter Workstation was the software for data acquisition, qualitative 
analysis, and quantitative analysis. 
2.4.      Analytical protocol for determination of cathelicidin 
 Human serum (0.5 ml) was vortexed with 0.5 ml of 15% formic acid for 
30 s into an amber injection vial, which was placed in the autosampler. The 
resulting solution (200 µl) was injected into the SPE–tandem mass spectrometry 
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(MS/MS) system following a sequence of automatic operations. Basically, the 
sample preparation step starts with methanol activation of the stationary phase 
with subsequent equilibration before sample loading with 2 ml of aqueous formic 
acid. Under these conditions, LL-37 cathelicidin is retained in the cartridge, 
which is washed with 10% methanol/0.1% formic acid aqueous solution to 
remove potential interferences. Elution starts by switching the left clamp valve 
and pumping 40% acetonitrile/1% formic acid/2% acetic acid solution with the 
LC pump at 1.0 ml/min. The SPE step ﬁnishes by purging the tubes of the 
Prospekt-2 system. Cartridges were reused for three replicates of each sample. 
 MS detection was performed in positive ESI mode at unit resolution in 
both quadrupoles. The ESI parameters were set as follows: 5.3 kV capillary 
voltage, 315 °C source temperature, and 60 psi pressure nebulizer. Nitrogen gas 
was ﬂowed at 10 ml/min to dry the eluent. The precursor ion for cathelicidin was 
749.6 m/z with a charge state of z = 6, which was efﬁciently ﬁltered by setting the 
voltage of the ﬁrst quadrupole at 220 V. Optimal collision energy of 30 eV 
activated the precursor ion to generate product ions 854.0, 876.6, and 819.5 m/z 
selected as quantitation and qualiﬁer ions by multiple reaction monitoring 
(MRM). The dwell time was ﬁxed at 200 ms for all SRM transitions. The entire 
analytical process was completed in 12 min. 
2.5. In silico elucidation of SRM transitions 
 The m/z value of the ﬁrst quadrupole was determined by the mass 
(4492.58 Da) and the predominant charge state of a peptide. The mass of the 
fragment ions was theoretically estimated by in silico fragmentation of the 
precursor ion using the Protein Prospector MS product website developed by the 
University of California, San Francisco (http://prospector2.ucsf.edu/prospector/ 
cgi-bin/msform.cgi?form=msproduct). The parameters considered for this frag-
mentation were quadrupole-based fragmentation, predominant generation of b 
and y ions [24,25] with –H2O and –NH3 neutral losses, and +H2O peeling 
sequence, maximum charge state z = 9, and ±0.6 Da mass fragment tolerance. 
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2.6. Validation of the transitions selected for analysis  
 The three most intense transitions were selected for qualitative and 
quantitative analysis of cathelicidin peptide. These transitions were subsequently 
detected by search in the proﬁle of theoretic fragment ions generated by in silico 
digestion of the precursor peptide. 
2.7. SRM-based quantitation 
 The standard addition method was used to obtain the calibration model 
for cathelicidin and validate the analytical method. Calibration curves (see Fig. S1 
in Supplementary material) were constructed by spiking human serum with 
known amounts of cathelicidin solutions. This calibration model was selected to 
correct matrix effects occurring during sample preparation (recovery, saturation 
effects) and analysis (suppression). Calibration solutions were prepared from 
cathelicidin stock solutions (25 and 500 mg/L) at 25, 50, 75, 100, 200, and  
500 µg/L. Three of them were injected in triplicate. In all cases, the samples were 
human serum spiked with the target analyte; therefore, another calibration level 
corresponded to 0 µg/L standard addition. 
 
3. Results and discussion 
3.1. Development of the MS protocol 
 Preliminary experiments can be exploited to derive information about the 
predominant precursor charge state and the MS/MS fragmentation pattern of a 
target peptide. However, it is important to be aware that the ionization conditions 
can affect distribution of the charge state. Ionization optimization was initially 
focused on the selection of the preferred ESI mode for MS analysis of 
cathelicidin. This was performed by direct injection of standard solutions using 
both positive and negative ESI modes. The highest sensitivity was achieved with 
positive ESI mode that generated different charge states and, therefore, different 
m/z signals. The inﬂuence of the ionization agent was studied by the addition of 
different concentrations of triﬂuoroacetic acid, acetic acid, and formic acid. The 
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best results were obtained by a combination of 1–2% formic acid/acetic acid in a 
30% methanol aqueous solution. The electrospray variables were set by a 
multivariate response surface design consisting of 16 experiments and two 
central points (experimental runs in which the value of each factor is the median 
of the values used in the factorial portion) by monitoring the ion indicated 
previously. The ranges studied for the temperature, pressure, and capillary 
voltage were 185–315 °C, 10–60 psi, and 2700–5300 V, respectively. The effect of 
these three variables in the signal intensity corresponding to the target ion was 
positive, so all of the variables were established at their maximum values. 
 The m/z value of the ﬁrst quadrupole was determined by the mass 
(4492.58 Da) and the predominant charge state of a peptide, which was z = 6, as 
shown in the mass spectrum illustrated in Fig. 2, obtained in full scan mode by 
direct injection of an LL-37 standard. In the mass range under study (0–2000 
Da), the charge distribution ranged from z = 3 to 6. Therefore, the ion 749.6 m/z 
with charge state z = 6 was selected for quantitative purposes. 
 
Fig.2. Mass scan in the range of 0–2000 Da by direct infusion of a cathelicidin standard 
showing the signals corresponding to the most stable charge states. 
 The mass of the product ions was theoretically estimated by in silico 
fragmentation of the precursor ion using the Protein Prospector MS product 
website. Table S1 (see Supplementary material) shows the sequence of b and y 
ions generated with fragmentation in the hexapole collision cell, including –H2O 
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and –NH3 neutral losses and +H2O peeling sequence. A maximum charge state 
z = 9 was set with ±0.6 Da mass fragment tolerance. It is worth emphasizing that 
the transitions selected for qualitative and quantitative analysis of LL-37 should 
be selective enough to develop a highly selective and sensitive assay. The 
distribution of relative fragment ion intensities is dependent on the type of 
instrument used and the operating parameters. This is particularly relevant when 
ion-trap-derived data are used to select transitions for a QqQ instrument. Owing 
to the different mode of collision-induced activation in ion traps compared with 
quadrupole collision cells, higher b-type ions and doubly charged fragments are 
usually less prominent or absent in the QqQ instrument mass spectra. Product 
ions with greater m/z than that of the precursor ion are preferred because they ﬁt 
in with a greater proportion of the original peptide in the spectrum; therefore, the 
selectivity is signiﬁcantly increased by these transitions [26,27]. 
 
Fig. 3. MS/MS spectra generated by fragmentation of cathelicidin precursor ion  
749.6 m/z with collision energies from 15 to 45 eV. 
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 MS/MS behavior of cathelicidin was studied using different collision 
energy values from 15 to 45 eV. Fig. 3 shows the MS/MS spectra where the 
fragmentation dependence on the collision energy applied in the cell can be 
observed. Fragmentation of the precursor ion is not signiﬁcant up to 25 eV by 
generation of different product ions at 819.5, 854.0, and 876.6 m/z that 
theoretically ﬁt for ions y335+, y355+, and y365+, respectively, according to 
Supplementary Table S1. Collision energy of 30 eV was the optimal value, as 
deduced from Fig. 3 by virtue of the efﬁcient fragmentation conﬁrmed by the 
intensity ratio of the signals corresponding to precursor and product ions. Higher 
values of collision energy led to an exhaustive fragmentation of the precursor ion 
without a significant increase of the product ion signal. The product ion at  
854.0 m/z was selected for quantitation, and the transitions to 819.5 and  
876.6 m/z were selected as qualiﬁers for veriﬁcation. Fig. 4A shows the result of 
the analysis of a 50 ng/ml cathelicidin standard by direct infusion with MS/MS 
detection in SRM mode. In simple protein mixtures, a single transition may be 
sufﬁcient to monitor a particular protein of interest, but in complex samples such 
as serum and other bioﬂuids, multiple transitions per peptide are generally 
required because of the interferences caused by background and peptides coming 
from high-abundant proteins. 
 
Fig. 4. SRM analysis provided by a 50-ng/L cathelicidin standard (A) and a serum sample 
from a healthy donor (B). 
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3.2. Development of the SPE protocol 
 After optimization of the detection step, automatic SPE was optimized. 
All variables were studied by a univariate mode due to the inclusion of 
noncontinuous variables such as composition of loading, washing, or elution 
solutions. The response variables for optimization of the SPE step were both the 
area and height of the peak signal to maximize sensitivity and minimize 
dispersion. The SPE step was validated by using a dual conﬁguration with two 
cartridges to estimate the recovery factor (calculated as the analyte fraction 
retained in the ﬁrst cartridge), which was the response variable of this 
optimization study. Serum spiked with LL-37 was used to select the most efﬁcient 
SPE sorbent, and the rest of variables, the range within which they were studied, 
and the optimal values are shown in Table 1. Concerning the SPE cartridge, eight 
types of SPE sorbent with different retention properties were tested: Hysphere 
CN (silica-based cyanopropyl phase), Hysphere C2 (silica-based ethyl phase), 
Hysphere C8 (silica-based octyl phase), Hysphere C8 (EC) (end-capped silica-
based octyl phase), Hysphere C18 (silica-based octadecyl phase), Hysphere C18 
HD (high-density silica-based octadecyl phase), Hysphere Resin GP (polymeric 
polydivinylbenzene phase), and Hysphere Resin SH (strong hydrophobic-
modiﬁed polystyrene-divinylbenzene). The best results, in terms of pre-
concentration and cleanup, were obtained with the Hysphere Resin GP cartridge, 
which showed higher cathelicidin retention, the highest recovery, and a 
homogeneous elution. Another aspect of the optimization study was focused on 
the composition and pH of the different solutions used in the SPE protocol for 
loading the sample and washing the cartridge for efﬁcient removal of interferents 
and salts and LL-37 elution. The composition of the solutions was studied by the 
addition of organic solvents in a wide concentration range to favor cathelicidin 
retention, cleanup, and elution. The three operations were also favored by acid 
pHs, as Table 1 shows. In addition, other variables studied were volume and ﬂow 
rate of the different solutions as well as the elution time, which was controlled by 
switching the valve clamp. 
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Table 1. Optimization of main variables involved in SPE step. 
Variable Tested range 
Optimal 
conditions 
Conditions 
employed 
SPE sorbent 
Hysphere CN, C2, C8, C8-EC, C18, C18-
HD, Resin GP and Resin SH 
Hysphere 
Resin GP, 
Resin SH and 
C8 
Hysphere 
Resin GP 
Loading 
solvent 
Composition 
Organic 
proportion in 
the aqueous 
phase 
0–50% methanol and 
acetonitrile 
0% organic 
phase 15% formic 
acid 
Acidification 
0–15% formic acid and 
acetic acid 
15% formic 
acid 
Volume 0.5–4 ml  2 ml 2 ml 
Flow Rate 0.5–3 ml/min  0.5 ml 0.5 ml 
Washing 
 solvent 
Composition 
Organic 
proportion in 
the aqueous 
phase 
0–50% methanol and 
acetonitrile 
10% methanol 10% methanol 
with 0.1% 
formic acid 
Acidification 0.1–10% of formic acid 
0.1% formic 
acid 
Volume 0.5–4 ml  2 ml 2 ml 
Flow rate 1–3 ml/min  1 ml/min 1 ml/min 
Elution  
solvent 
Composition 
Organic 
proportion in 
the aqueous 
phase 
Acetonitrile, methanol, 
tetrahydrofurane, and 
isopropanol in different 
proportions 
40% 
acetonitrile 
40% 
acetonitrile 
pH for optimal 
cathelicidin 
ionization 
0.5–2% formic acid and 
acetic acid 
1% formic acid 
and 2% acetic 
acid 
1% formic acid 
and 2% acetic 
acid 
Elution time 0.5–2 min  1 min 1 min 
Flow rate 0.4–1 ml/min  1 ml/min 1 ml/min 
 
 A key factor was the dilution of the serum samples to improve the loading 
step, minimize proteins interactions, and maximize cathelicidin retention in the 
cartridge, thereby increasing cathelicidin recovery. Water, different 
concentrations of formic acid, and 50 mM phosphate buffer in the pH range 3.0 
to 7.5 were used as solutions for dilution from 50% to 90%. The best results were 
obtained with 15% aqueous formic acid diluting up to 50% (7.5% ﬁnal formic acid 
concentration in the sample). Fig. 4B illustrates the result of the analysis of a 
human serum sample with SPE as sample preparation; it was highly efﬁcient, as 
demonstrated by comparison with the analysis of an LL-37 standard. The 
automated protocol developed with the SPE workstation is schemed in Table 2, 
which also includes the time required for the different steps. 
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Table 2. Scheme of automated SPE protocol for preconcentration and cleanup of 
cathelicidin in human serum prior to on-line elution to mass spectrometer. 
Step Solvent 
Volume 
(ml) 
Flow 
(ml/min) 
Duration 
1 New cartridge and Star autosampler 
2 Solvation Methanol 1 3 0 min 26 s 
3 Equilibration 15% formic acid 2 3 0 min 52 s 
4 Equilibration 15% formic acid 1 1 1 min 06 s 
5 
Sample 
application 
15% formic acid 2 0.5 4 min 12 s 
6 Wash cartridge 10% methanol and 0.1% formic acid 2 1 2 min 12 s 
7 Elution 
40% acetonitrile, 1% formic acid, and 
2% acetic acid 
1 1 1 min 00 s 
8 Wash cartridge Methanol 2 3 0 min 52 s 
9 Wash cartridge Water 4 3 1 min 44 s 
Total time 12 min 36 s 
 
3.3. Validation of the method 
 Analytical characterization of the method was carried out with a serum 
pool from healthy individuals. The lowest limit of detection (LLOD) and lowest 
limit of quantitation (LLOQ) were determined by injecting dilution series of 
cathelicidin to obtain the concentration with a signal 3 and 10 times the noise 
(average noise value obtained for blank injections in the region of the spectrum of 
interest), respectively, resulting in LLOD and LLOQ values of 2.5 and 8.25 µg/L, 
respectively (0.20 and 0.66 pg/injection). Calibration curves were established by 
applying the method of standard additions using cathelicidin stock solutions. 
Different levels of the target peptide (25–500 µg/L) were added to pool aliquots 
to plot signal responses versus the spiked concentration. The correlation 
coefﬁcient was 0.998, and the linear dynamic range was from 8.25 to 500 µg/L. 
 The accuracy of the method and potential matrix effects were assessed by 
analysis of nonspiked and spiked serum samples at a high concentration level 
(100 µg/L) to evaluate the retention capability of the cartridge. The recovery of 
cathelicidin was calculated with the two-cartridge conﬁguration of the Prospekt-2 
system by analysis of ﬁve replicates [28]. Two Hysphere Resin GP cartridges were 
located in serial, so after sample injection the amount of cathelicidin not retained 
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in the ﬁrst cartridge was retained in the second. The eluates from both cartridges 
were sequentially injected into the QqQ analyzer, estimating the concentration 
retained in each cartridge. The recovery factor in this system was calculated as 
amount retained in cartridge 1/(amount retained in cartridge 1 + amount 
retained in cartridge 2), resulting in 80% recovery. This study was carried out at a 
high concentration of cathelicidin as compared with the normal range. 
Nevertheless, this recovery was conﬁrmed by repetition of the test with samples 
from the individual cohort selected for validation of the method. 
 Within-laboratory reproducibility and repeatability were evaluated in a 
single experimental setup with duplicates by experiments carried out with a 
serum pool for 1 week [29]. The repeatability, expressed as relative standard 
deviation (RSD), was 2.4%, and the within-laboratory reproducibility, also 
expressed as RSD, was 2.7%. 
3.4.  Application of the method to human serum samples 
 Serum samples isolated from intensive care patients (n = 17) and healthy 
blood donors as a control group (n = 23) were collected (Regional Blood Donors 
Center, Córdoba, Spain) to compare LL-37 levels and establish normal con-
centrations in human serum. The mean age of the population was 41 ± 16 years 
formed by 26 males and 14 females individuals. The samples were injected in 
triplicate, being an RSD lower than that estimated in the repeatability test. As can 
be seen in Fig. 5, the group formed by intensive care patients possessed a higher 
variability in LL-37 proﬁle as compared with the group of control individuals, 
which can be represented by a normal distribution. In addition, the average LL-
37 level was higher in intensive care patients (48.4 ± 29.8 ng/ml) than in the 
control group (34.9 ± 18.7 ng/ml). However, no statistical differences were found 
with a running t test (P = 0.22) taking into account standard deviation values 
illustrated in Fig. 5. These preliminary results enable us to conclude only that 
cathelicidin levels were within a controlled range in healthy individuals, whereas 
signiﬁcant variability was found in intensive care patients. In this research, a 
reduced variable cohort was analyzed to study cathelicidin levels. A subsequent 
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step would be to study a more representative cohort classiﬁed according to 
pathological states to discriminate between them. This could be the initial step to 
evaluate the potential of cathelicidin as a clinical biomarker for different 
pathologies. 
 
Fig. 5. Cathelicidin levels found in intensive care patients versus a control group of 
healthy individuals. 
 
4. Conclusions 
 An automated platform has been proposed for veriﬁcation and 
quantitative analysis of target peptides in bioﬂuids. The method is based on 
direct injection of the bioﬂuid into an automated SPE device where sample 
preparation is efﬁciently carried out by desalting and deproteinization. This is 
one of the main differences compared with other devices existing in the literature 
[30], especially those designed for biochemical assays developed with standard 
solutions and, therefore, not useful for clinical analysis of bioﬂuids. In this way, 
the resulting eluate is eluted directly into the mass spectrometer with highly 
efﬁcient ionization without affecting electrospray performance. The method was 
applied to the analysis of cathelicidin peptide in human serum. The analyte was 
detected by MS/MS in SRM mode using three different transitions for 
veriﬁcation and quantitative determination. The use of an internal standard was 
avoided by SPE validation using tests with dual cartridge conﬁgurations to check 
quantitative retention of cathelicidin. In this way, sample spiking with synthetic 
peptides labeled with stable isotopes, which notably increases the cost of the 
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analysis, is not required. The overall method was properly validated by 
application to human serum samples in order to set the average concentration of 
cathelicidin peptide in healthy individuals. This is another beneﬁt versus single-
cartridge conﬁgurations that omit internal validation tests [31].  
 The approach presented here could be used as a template for quantitative 
analysis of other peptides such as clinical biomarkers and target proteins after 
enzymatic hydrolysis to generate representative peptides. Thus, with minor or no 
changes, it can be applied to any other peptide with a considerably reduced cost 
per analysis, complete automation without implementation of robotized work-
stations, and an extra level of selectivity to suppress cross-reactivity. 
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Supplementary Fig. 1. Calibration curve obtained for cathelicidin using standard 
addition method. 
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Supplementary Table  1. In silico fragmentation of cathelicidin (LL-37). 
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 La normativa actual de la Universidad de Córdoba referente a la presen-
tación de la Memoria de la Tesis Doctoral, en la modalidad en la que se incluyen 
los artículos (publicados o próximos a su publicación) como tales, establece que 
ha de incluirse una sección de discusión conjunta de los resultados. 
 La investigación que constituye la parte principal de la Tesis tiene como 
denominador común la metabolómica en el área en dos de las vertientes de esta 
disciplina ómica: El diagnóstico, pronóstico y tratamiento de enfermedades, y la 
nutrición. Ambas constituyen dos de los pilares básicos que soportan el concepto 
de medicina personalizada. La investigación que se presenta en esta Memoria se 
ha dividido en tres secciones en función, tanto del objetivo perseguido, como de 
la estrategia metabolómica utilizada en cada caso. Con este criterio, la Sección I 
recoge el desarrollo de diferentes innovaciones metodológicas orientadas a 
mejorar dos parámetros analíticos básicos, tales como sensibilidad y selectividad, 
pero también a ampliar el número de metabolitos detectados y facilitar la 
posibilidad de su identificación. Por su parte, las Secciones II y III se dedican a 
las dos estrategias básicas en metabolomica: Análisis global (“untargeted 
analysis”) y análisis orientado (“targeted analysis”), respectivamente. En 
concreto, la Sección II recoge la investigación realizada sobre perfiles metabólicos 
(“profiling analysis”), que es el análisis global más utilizado en metabolómica 
clínica y cuyo objetivo es abarcar la mayor parte posible del metaboloma de un 
biofluido o un tejido dado. Por el contrario, la Sección III engloba la investigación 
sobre determinación de grupos específicos o familias de compuestos de interés 
clínico por su implicación en rutas biológicas cruciales que pueden alterarse o 
desregularse como consecuencia de ciertos estados patológicos. Los metabolitos 
estudiados y que constituyen esta sección fueron aminoácidos esenciales, 
compuestos implicados en el ciclo de los ácidos tricarboxílicos, fosfolípidos y un 
péptido antimicrobiano: La catelicidina. Los resultados obtenidos en cada una de 
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las tres secciones se discuten a continuación, no sin antes comentar algunos 
aspectos instrumentales.  
El uso de la espectrometría de masas como técnica para la detección es 
común a las tres secciones. Las propiedades analíticas de esta técnica, en 
términos de sensibilidad, selectividad, exactitud, precisión y resolución, la 
convierten en la herramienta más útil para análisis metabolómico, tanto 
orientado como global, en muestras clínicas. Las dos estrategias típicas en 
metabolómica se benefician de esta técnica en sus diferentes modos, que son 
función del objetivo que se persiga: Análisis cualitativo o cuantitativo. Entre los 
diferentes tipos de espectrómetros de masas el más utilizado para análisis global 
es el QTOF gracias a su alta resolución (exactitud en la relación m/z), velocidad 
de barrido y sensibilidad a un precio competitivo. Por estas razones constituye el 
detector más adecuado para análisis cualitativo y también para cuantificación 
relativa. Por otra parte, el QqQ es tremendamente operativo en análisis 
orientado, por su sensibilidad y selectividad para análisis confirmatorio. Por 
tanto, es éste el detector de masas óptimo con fines cuantitativos. Teniendo en 
cuenta la complejidad de las muestras clínicas, los espectrómetros de masas son 
muy adecuados en metabolómica clínica, especialmente cuando se acoplan a 
sistemas de separación cromatográficos. La naturaleza de la técnica de 
separación (principalmente un cromatógrafo de gases o de líquidos) depende de 
las propiedades químicas de los metabolitos en estudio. 
 
Sección I. Desarrollo metodológico e innovación en análisis 
metabolómico 
 A pesar de que los avances tecnológicos —que incluyen muy espe-
cialmente la espectrometría de masas de alta resolución— permiten la detección 
de metabolitos de forma fiable, existen aún algunas debilidades de la técnica en 
análisis metabolómico que tienen que superarse, especialmente las relacionadas 
con la obtención de perfiles metabólicos o análisis global. 
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 Uno de los problemas en la obtención de perfiles metabólicos es la 
dificultad de abarcar la detección de todos los metabolitos mediante una única 
plataforma analítica, ya que el metaboloma está compuesto por una amplia 
variedad de metabolitos con muy diferentes estructuras químicas y presentes en 
un rango muy amplio de concentraciones. Otro aspecto clave es la complejidad de 
la mayor parte de los biofluidos generalmente utilizados en análisis clínico, tales 
como suero/plasma, orina o saliva; lo que dificulta aún más las aplicaciones 
clínicas de la metabolómica. En el desarrollo de la investigación que constituye 
esta Tesis Doctoral se plantearon tres retos para contribuir a la resolución de 
estos problemas, cuyos resultados se recogen en esta sección. Uno de ellos se 
refiere a la preparación de la muestra de un biofluido poco estudiado como es el 
sudor, y que presenta como principales ventajas su muestreo no invasivo y una 
composición simple si se compara con otros biofluidos tales como sangre u orina. 
La proposición de biofluidos alternativos en análisis clínico es de gran interés si 
se tiene en cuenta que los convencionales son con frecuencia poco o nada 
selectivos para reflejar cambios asociados a alteraciones fisiológicas. El segundo 
reto se orientó al desarrollo de una estrategia de preparación de la muestra con la 
que aumentar la detección de metabolitos en el análisis de muestras clínicas 
mediante LC–MS/MS. La plataforma instrumental para el desarrollo de la estra-
tegia fue un sistema automático para SPE acoplado en línea al LC–QTOF. El 
dispositivo para SPE incluyó dos sorbentes con propiedades complementarias 
para la retención. El tercer reto fue también una innovación metodológica basada 
en la aplicación en metabolómica del fraccionamiento en fase gaseosa (GPF) con 
el que se pretendió mejorar la detección en análisis mediante MS/MS de 
metabolitos en suero humano. Los resultados en cada caso fueron los siguientes: 
 
Capítulo 1 
  La investigación que se recoge en este capítulo se dedicó a la 
optimización de un protocolo de tratamiento de muestra previo al análisis de 
sudor mediante LC–MS/MS. Esta muestra, por la que empieza a aumentar el 
   
442 
Espectrometría de masas para la identificación y  
cuantificación de biomarcadores metabolómicos en análisis clínico 
 
interés para estudios clínicos, presenta, como principales ventajas frente a otros 
biofluidos su muestreo no invasivo (que puede realizarse por personal no 
especializado), su composición simple y el no requerir estandarización (que sí es 
necesaria en orina). La utilización de otros biofluidos de mayor complejidad 
puede llevar a modelos de predicción basados en metabolitos que no son 
selectivos del proceso biológico en estudio. Esto puede ser debido a inter-
ferencias causadas por otros procesos biológicos.  
 El planteamiento de la optimización implicó el uso de dos modos 
cromatográficos para el análisis en sudor: El modo en fase reversa utilizando una 
columna de C18 y el basado en interacción hidrofílica (HILIC) con la columna 
correspondiente. Respecto a la preparación de la muestra, el análisis directo del 
sudor permitió detectar 67 y 57 entidades moleculares en el modo de ionización 
positivo para los métodos analíticos basados en C18 y en HILIC, respectivamente; 
mientras que en el modo de ionización negativo el número de entidades 
moleculares fue de 29 y 37, respectivamente, para las columnas citadas. La 
variabilidad entre individuos fue evaluada mediante análisis de 7 muestras del 
mismo individuo tomadas en diferentes días y analizadas en duplicado cada día 
durante un intervalo de 5 días. Este estudio también permitió evaluar la 
reproducibilidad metodológica de esta etapa, ya que la variabilidad estimada 
como desviación estándar relativa  (RSD) estuvo en el rango del 2 al 21%. Estos 
valores indican que el sistema de muestreo es suficientemente reproducible para 
investigación en metabolómica. A pesar del alto número de entidades 
moleculares detectadas en el modo de ionización positivo, todavía la etapa de 
preparación de la muestra mejoró la detección de metabolitos. Para ello se 
compararon diferentes protocolos de preparación de la muestra previos a los dos 
modos cromatográficos para la obtención del perfil metabolómico global del 
sudor. Entre los protocolos ensayados, la hidrólisis ácida o básica no resultó 
recomendable, ya que la muestra se afectaba, tal como puso de manifiesto la 
aparición de gran cantidad de artefactos. Por el contrario, el análisis directo del 
sudor después de la dilución apropiada resultó ser una buena opción para 
obtener una instantánea representativa del metaboloma del sudor. Algunos de los 
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compuestos exógenos encontrados en el análisis de este biofluido eran 
componentes del sistema de muestreo. Entre ellos, los más significativos fueron 
el metil- y el propilparabeno, y especialmente la pilocarpina, que se utiliza para 
estimular la sudoración antes del muestreo.  
 Finalmente, la identificación de un alto número de componentes del 
sudor, en total 43 metabolitos, pertenecientes a una amplia variedad de familias 
corroboró que el protocolo de análisis basado en LC–QTOF MS/MS es una buena 
estrategia para analizar sudor. De hecho, se identificaron 19 aminoácidos, 
incluyendo todos los aminoácidos esenciales, excepto la lisina. También se 
identificaron compuestos exógenos, como la cafeína y la teofilina, así como ácidos 
dicarboxílicos, tales como el sebácico, el subérico, el azealico o el butanodioico. 
Este estudio de identificación contribuye a conocer este biofluido tan poco 
estudiado y sugiere que, puesto que algunos de los metabolitos identificados 
habían sido anteriormente evaluados en otros biofluidos como potenciales 
biomarcadores, el sudor puede también proponerse como biofluido para la 
búsqueda de biomarcadores. 
 
Capítulo 2  
 La investigación que conforma este capítulo se dedicó al desarrollo de 
una estrategia para aumentar la detección de metabolitos. La diversidad química 
del metaboloma exige nuevas plataformas analíticas para aumentar la capacidad 
de detección. En este caso, la plataforma estuvo basada en la combinación de un 
sistema automático de SPE y un equipo LC–QTOF para aprovechar los beneficios 
de la excelente selectividad de los sorbentes utilizados en SPE y la alta resolución 
del detector QTOF. El dispositivo de SPE se acopló en línea con el equipo LC–
QTOF para la automatización total del método. De esta forma, la intervención del 
analista se limita a colocar los viales en el automuestreador. La plataforma se 
aplicó al análisis de suero humano como biofluido modelo. Se comparó la 
detección de los posibles metabolitos en suero tras el uso de varios sorbentes 
actuando con mecanismos simples o duales (materiales poliméricos y resinas). 
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Mediante solapamiento de la capacidad de análisis del equipo SPE–LC–MS/MS 
con los diferentes sorbentes, se detectaron 3445 entidades moleculares con 
parámetros predefinidos en términos de carga, distribución isotópica, intensidad 
de señal y frecuencia de detección en las réplicas analíticas. Una combinación de 
cuatro sorbentes (resina de polidivinilbenceno, C18 y sorbentes poliméricos con 
interacciones aniónicas/catiónicas) hicieron posible la detección de más del 81% 
del total de la detección conseguida con la serie completa de sorbentes ensayados. 
Por tanto, esta innovación abre una nueva puerta a la mejora de la capacidad de 
detección en metabolómica utilizando métodos basados en una única plataforma, 
en este caso LC–MS/MS. 
 Un desarrollo extra incluido en esta investigación fue el de métodos 
basados en la combinación de pares de protocolos SPE llevados a cabo en una 
configuración SPE–SPE–LC–MS. Con este propósito, se hizo circular una única 
alícuota a través de dos sorbentes SPE complementarios situados en línea. La 
elución de ambos cartuchos se realizó de forma independiente y secuencial para 
su análisis mediante LC–MS. Se potenció así la selectividad de este modo de 
fraccionamiento de la muestra y se maximizó la rapidez del análisis. Las 
configuraciones en serie diseñadas permitieron conseguir capacidad de detección 
en el rango del 79.5 al 99.7% del número total de entidades moleculares 
detectadas mediante análisis separados utilizando la serie completa de sorbentes. 
Esta alternativa tiene un interés especial en estudios clínicos en los que las 
muestras son escasas o muy valiosas.  
 
Capítulo 3 
 Una de las principales debilidades del análisis metabolómico global 
mediante espectrometría de masas es la necesidad de una información amplia 
para una identificación correcta de los metabolitos encontrados en un deter-
minado biofluido. Este hecho hace necesaria la inyección del compuesto puro en 
cuestión, o la obtención de información de alta calidad, tanto de MS como de 
MS/MS para identificar el compuesto mediante búsqueda en bibliotecas al efecto. 
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Los métodos de análisis por MS/MS propuestos hasta ahora para 
identificar las entidades moleculares de interés en un estudio global implican dos 
o más análisis diferentes. Se requiere una primera inyección de las muestras en el 
modo MS, seguida de una selección de los iones precursores potenciales de los 
que se requiere información mediante MS/MS, y un segundo análisis en modo 
MS/MS orientado. Por otra parte, el modo “auto MS/MS” es una estrategia más 
corta que consiste en ciclos a lo largo de todo el conjunto de barrido de MS de 
fragmentación de dos o tres de los iones detectados en el barrido previo. La 
selección de los potenciales precursores puede restringirse usando rangos de 
masas o tipo de carga, así como un límite de intensidad de respuesta.   
La estrategia GPF consiste en la combinación de diferentes métodos 
basados en barridos de MS utilizando el mismo rango de masas, pero diferentes 
intervalos para la selección de iones precursores de manera que se cubra todo el 
rango del ion precursor deseado. Esta estrategia, aplicada con éxito en proteó-
mica para incrementar el número de proteínas identificadas en una serie de 
muestras, no había sido utilizada en metabolómica; por tanto, éste fue el objetivo 
de la investigación recogida en este capítulo.   
En metabolómica, la inyección de varias réplicas de la misma muestra es 
una práctica habitual, ya que la obtención de un perfil metabólico seguro requiere 
al menos tres réplicas por muestra. Por tanto, el uso de GPF combinado con el 
número apropiado de réplicas es una herramienta efectiva para aumentar las 
posibilidades de identificación sin necesidad de realizar posteriores inyecciones 
de muestra. En esta investigación se ensayaron combinaciones de 2, 3, 4 y 6 
intervalos de selección del ión precursor, cubriendo en todos los casos desde 100 
a 1000 m/z, y se compararon con el método convencional o modo “auto MS/MS”. 
El biofluido seleccionado para este estudio fue suero, el más comúnmente 
empleado en análisis metabolómico clínico y nutricional por su papel de principal 
portador de metabolitos en el organismo humano. El uso de la metodología GPF 
en metabolómica para el análisis de suero mediante LC–MS/MS ha demostrado 
ser una estrategia efectiva para incrementar la cantidad de información sobre 
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algunos compuestos La mejor elección entre todas las combinaciones estudiadas 
resultó ser un método para dividir el rango de masas de ión precursor en cuatro 
intervalos. De esta forma se obtuvo información para al menos el 80% de todas 
las entidades detectadas. Por el contrario, el modo convencional de adquisición 
de datos (“auto MS/MS”) proporcionó información sólo para 48–57% de las 
entidades moleculares detectadas y, por tanto, fue menos efectivo para la 
identificación inequívoca de los metabolitos.  
 Esta investigación ha mostrado que la combinación de diferentes méto-
dos que incluyen distintos intervalos de iones precursores puede incrementar el 
número de entidades potenciales que proporcionen información MS/MS. Los 
resultados de esta estrategia se han corroborado mediante identificación de 
diferentes familias de metabolitos y la evaluación de la información de MS/MS 
registrada para cada compuesto en cada una de las combinaciones ensayadas. 
 
Sección II. Metabolómica global: Estudios de intervención 
basados en nutrimetabolómica y búsqueda de biomarcadores 
de enfermedades 
 Esta sección se centra en la aplicación del análisis metabolómico global 
en estudios clínicos para poner de manifiesto la efectividad de esta estrategia. El 
análisis global en metabolómica puede dividirse en dos categorías genéricas en 
función del objetivo de la investigación: La primera se refiere a la búsqueda de 
biomarcadores y la segunda a la comprensión y explicación del efecto de un 
cambio en una determinada ruta metabólica o un sistema biológico en general. 
Las dos categorías han sido objeto de la investigación que se recoge en esta 
sección, que abarca dos diferentes áreas de aplicación ambas orientadas a la 
medicina personalizada: Diagnóstico, pronóstico y tratamiento de enfermedades, 
y metabolómica nutricional. En lo que se refiere al área puramente clínica se han 
considerado dos enfermedades claves: La aterosclerosis, una de las causas 
principales de muerte en todo el mundo, y el cáncer de pulmón como uno de los 
tipos de cáncer que causa más muertes al ser el segundo más comúnmente 
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diagnosticado. En lo que se refiere al área nutricional, la investigación realizada 
forma parte del proyecto denominado Lipgene, un proyecto europeo para la 
investigación de la interacción de los nutrientes y el genotipo en el síndrome 
metabólico, término usado para relacionar varios factores de riesgo en las 
enfermedades cardiovasculares. 
Es conveniente poner de manifiesto que se utilizaron dos tipos de 
muestras para el desarrollo de la investigación: Suero y sudor, dos biofluidos con 
muy diferentes características químicas. Se utilizaron también diferentes herra-
mientas estadísticas para la evaluación de los biomarcadores: Generación de 
paneles formados por combinación de marcadores y estudio de matrices de datos 
generados en análisis univariante y multivariante. 
Se requieren sistemas de masas de alta resolución para el análisis 
metabolómico global con el fin de conseguir una buena exactitud en la medida de 
la relación m/z que haga posible la identificación del máximo número de meta-
bolitos detectados en el biofluido en estudio. Un equipo QTOF es el preferido en 
estos casos porque satisface las necesidades del análisis global, ya que permite 
obtener espectros MS/MS de los iones precursores detectados y proporciona 
suficiente información para la identificación inequívoca de los metabolitos. 
Existen bases de datos con información de MS y de MS/MS de una amplia 
variedad de compuestos. Entre las más importantes de estas bases se encuentra 
la base de datos de metabolitos basada en MS/MS (Metabolite and Tandem MS 
Database –METLIN), seguida del banco de masas (MassBank). Otra base de 
datos como es la del metaboloma humano (Human Metabolome Database –
HMDB), no proporciona espectros de MS/MS de alta resolución para todos los 
metabolitos, ya que la mayoría de los espectros se han adquirido con un equipo 
de triple cuadrupolo. Otras bases de datos son útiles para obtener información 
sobre las rutas metabólicas en las que están implicados deter-minados grupos de 
metabolitos. Éste es el caso de la Enciclopedia Kyoto de Genes y Genomas (Kyoto 
Encyclopedia of Genes and Genomes —KEGG). 
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Los resultados obtenidos en la investigación que se recoge en los 4 
capítulos que conforman la Sección II de esta Memoria se discuten a 
continuación. 
 
Capítulo 4 
 La investigación sobre nutrición es uno de los pilares fundamentales en 
los que se soportan las vías hacia la Medicina Personalizada. La dieta es uno de 
los factores externos más importantes que contribuyen a alterar los bloques 
básicos de la biología de sistemas: El genoma, el transcriptoma, el proteoma y el 
metaboloma. La relación directa entre el metaboloma y el fenotipo convierte la 
nutrimetabolómica en un área de gran actividad. En este contexto, el análisis 
metabolómico global puede ayudar a dilucidar la respuesta biológica en 
individuos sometidos a dietas de intervención. Éste ha sido el principal objetivo 
de la investigación que se discute en este capítulo: Comparar las diferencias 
metabólicas encontradas en los perfiles de suero obtenido de individuos 
sometidos a 4 dietas de intervención a lo largo de 12 semanas. Las dietas se 
planificaron como parte del proyecto Lipgene y se diferenciaban en la calidad y 
cantidad de grasa. Las muestras de suero se dividieron en dos fases mediante 
extracción líquido–líquido (por tanto, en metabolitos polares y no polares), y 
cada una de las fases se analizó independientemente mediante LC–QTOF en 
modo MS/MS. 
 El análisis estadístico supervisado PLS-DA permitió distinguir 
diferencias metabólicas asociadas a la dieta de intervención, así como detectar 
diferencias en los perfiles de metabolitos (polares y no polares) causadas por las 
dietas ingeridas. Los modelos de discriminación basados en PLS-DA y en análisis 
de cambio permitieron la identificación de los metabolitos que alteraron su 
concentración por la dieta de intervención. En relación con la fracción no polar, 
el papel de los fosfolípidos fue determinante para explicar las diferencias 
metabólicas entre individuos. Se encontraron diferencias críticas en las concen-
traciones de las glicerofosfatidilcolinas que incluían PUFAs como sustituyentes. 
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De hecho, la principal diferencia entre dietas correspondió a tres de los glicero-
fosfolípidos más comunes en sangre humana —PC(16:0/18:2), PC(18:0/16:2) y 
PC(18:0/18:2)—, cuyos niveles dependieron estrechamente de la dieta. También 
los ácidos grasos y las esfingomielinas formaron parte de la lista de metabolitos 
no polares alterados por las dietas de intervención. Por tanto, la influencia de las 
dietas en la fracción lipídica fue muy significativa. 
Por otra parte, el análisis de la fracción polar también reveló diferencias 
metabólicas entre individuos en función de las dietas. Las carnitinas, los ami-
noácidos, los ácidos biliares y los derivados de purina fueron los metabolitos de 
esta fracción más afectados por la dieta. También se encontró una estrecha 
conexión entre las principales rutas metabólicas alteradas en los individuos 
sometidos a los periodos de intervención y el metabolismo de los lípidos. El 
análisis global permitió establecer diferencias metabólicas asociadas a la dieta, a 
pesar de la enorme variabilidad biológica observada en la cohorte seleccionada 
para el estudio.  
 
Capítulos 5 y 6 
 En estos dos capítulos se recoge el estudio sobre potenciales bio-
marcadores de aterosclerosis mediante análisis de muestras de suero de 
pacientes afectados por diferentes enfermedades cardíacas. El estudio que se 
discute en el Capítulo 5 se orientó a la búsqueda de diferencias metabólicas entre 
pacientes con angina estable, con infarto de miocardio sin elevación del segmento 
ST (NSTEMI) o angina inestable, y con infarto agudo de miocardio (AMI). Por su 
parte, el estudio que recoge el Capítulo 6 se dedicó a la búsqueda de marcadores 
para el seguimiento de la aterosclerosis mediante comparación de pacientes con 
angina estable con los que padecían infarto agudo de miocardio. En el primer 
estudio se ensayaron diferentes modos cromatográficos que permitieron elegir la 
mejor opción para cubrir el máximo número de entidades moleculares, 
equivalentes a potenciales metabolitos. De forma adicional, se seleccionó una 
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etapa simple de precipitación de proteínas como única etapa de preparación de la 
muestra con el fin de minimizar la pérdida de metabolitos usual de esta etapa. 
 Una vez establecida la metodología analítica, se analizaron las muestras 
de suero y los datos generados se trataron de acuerdo con las necesidades de los 
resultados globales: Alineamiento y extracción de las entidades moleculares y el 
análisis estadístico correspondiente para encontrar diferencias estadísticas entre 
los grupos en estudio. Se identificó un grupo de 13 metabolitos que presentó 
diferencias de concentración significativas entre los tres grupos de pacientes 
ateroscleróticos. La mayoría de los metabolitos eran lípidos y algunos ácidos 
biliares, como el cólico y el desoxicólico. La bilirrubina fue el metabolito más 
diferenciador, con un valor de p de 0.0012. Algunos de los compuestos 
identificados habían sido relacionados previamente con enfermedades cardio-
vasculares o con estrés oxidativo, ambos con enorme influencia en la 
aterosclerosis. Tras la comparación de las medias de los metabolitos identificados 
como significativos en los tres grupos, se encontró similaridad entre AMI y 
angina instable o NSTEMI, mientras que la diferencia entre los valores en 
pacientes con infarto de miocardio y angina estable fue significativa. Se 
encontraron también otros metabolitos que, si bien no presentaban una 
diferencia significativa entre grupos, sí mostraron una tendencia, creciente o 
decreciente, de angina estable a angina inestable/NSTEMI y a AMI. 
La misma plataforma analítica, LC–QTOF MS/MS, se utilizó en el Capí-
tulo 6, ya que había mostrado ser también una estrategia adecuada para la 
búsqueda de biomarcadores. Este estudio se aplicó a la discriminación de 
pacientes ateroscleróticos afectados por angina estable y AMI. En este caso se 
estudió también la influencia de los factores de riesgo (tales como hábito de 
fumar, obesidad e hipercolesterolemia) mediante análisis de la capacidad de 
predicción de los potenciales marcadores en pacientes con factor de riesgo 
específico. Como este segundo estudio se orientó al desarrollo de un panel de 
marcadores, su evaluación y la de los potenciales marcadores individuales se 
realizó mediante análisis de curvas ROC y se validó su funcionamiento mediante 
los tests de diagnóstico médico con clasificación bi-naria. De esta forma, la mejor 
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capacidad de predicción se obtuvo para los pacientes ateroscleróticos con 
hipercolesterolemia, para los que la bilirrubina, el 13-HpODE, el 5-HETE y el 
índice de masa corporal dieron valores de especificidad del 91%, y de sensibilidad 
entre el 48 y el 62%. 
Basado en estos resultados, se ha propuesto un panel de marcadores para 
la predicción del infarto agudo de miocardio, frente a individuos con angina 
estable, con una especificidad del 85.1% y una sensibilidad del 80.8%, lo que da 
lugar a pocas posibilidades de falsos positivos y negativos. Los metabolitos que 
componen el panel son dos lípidos, el 13-HpODE y el lysoPC(22:6), junto con el 
índice de masa corporal como variable antro-pométrica relacionada con la 
obesidad. La confirmación de los resultados del modelo propuesto requiere su 
aplicación en un estudio a gran escala. 
 
Capítulo 7 
 El objetivo de la investigación que se discute en este capítulo fue evaluar 
el potencial de un biofluido menos común como es el sudor para discriminar 
entre individuos afectados por cáncer de pulmón y donantes sanos. El sudor no 
ha recibido hasta ahora atención como muestra para la búsqueda de bio-
marcadores de cáncer —a pesar de sus comentadas cualidades como el no 
requerir un muestreo invasivo y tener una matriz menos compleja que la sangre o 
la orina. Posiblemente esta laguna era debida a la ausencia de un protocolo de 
muestreo homogéneo y que proporcionara un volumen de muestra suficiente 
para el análisis. No obstante, los avances en instrumentación analítica han 
logrado que en la actualidad se disponga de equipos con la sensibilidad adecuada 
para el análisis de pequeños volúmenes de muestra. Este hecho, junto con la 
mejora de los protocolos de muestreo del sudor, suficientemente reproducibles 
para estudios de cáncer de pulmón, han hecho posible el uso de este biofluido 
para un potencial diagnóstico de esta enfermedad. Esta búsqueda responde a la 
necesidad de nuevas herramientas para el diagnóstico de este cáncer, ya que los 
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tests que existen en la actualidad son invasivos y tienen un coste alto, lo que hace 
impracticable su aplicación a todos los individuos con riesgo de padecerlo. 
Como en capítulos anteriores, se utilizó la plataforma LC–QTOF MS/MS 
junto con el modo más simple de preparación de la muestra, que consistió en 
dilución con la fase móvil cromatográfica inicial. Con estas premisas, el potencial 
del sudor como biofluido para su implantación en diagnóstico de cáncer se 
demostró de la siguiente forma: Se construyó un modelo de predicción basado  en  
un panel de metabolitos que incluyó aminoácidos, azúcares y algunos lípidos y 
que permitió discriminar entre pacientes con cáncer y un grupo control. Su alto 
valor predictivo permite prever su potencial uso para reducir el número de 
posibles casos que tienen que someterse a tests confirmatorios. 
La capacidad de discriminación de metabolitos individuales reveló que 
un trisacárido fosfato presentaba el valor más alto de sensibilidad para una 
especificidad mínima del 80%. Sin embargo, este compuesto no estaba presente 
en los dos paneles de tres metabolitos generados para la predicción de cáncer de 
pulmón. Los dos paneles incluían maltotriosa y ácido nonanedioico, en 
combinación con γ-GluLeu y MG(22:2). Ambos paneles mejoraban de forma 
significativa la capacidad de discriminación de los metabolites independientes. El 
panel se caracterizó por el 100% de especificidad y el 63.6% de sensibilidad; por 
tanto, la presencia de falsos negativos fue 0%. El segundo panel proporcionó 
valores de especificidad y sensibilidad del 82%. 
 Estos resultados preliminares hacen muy conveniente un estudio a gran 
escala para validar los paneles propuestos con un doble objetivo: Reducir el 
número de individuos que tengan que someterse a un test confirmatorio y 
detectar el cáncer de pulmón en una etapa lo más temprana posible. 
    
Sección III. Análisis orientado de potenciales biomarcadores 
El análisis orientado en metabolómica se define como aquél que se aplica 
a una muestra para la cuantificación de un grupo o familia de compuestos, o 
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incluso un único metabolito. A pesar de que sólo se pueden detectar compuestos 
predefinidos utilizando esta estrategia metabolómica, posee una serie de ventajas 
respecto al análisis global. La principal de ellas es que tanto la preparación de la 
muestra como la detección se optimizan para reducir el número de interferentes y 
que la selectividad, y también la sensibilidad, sean máximas con la plataforma 
seleccionada para el análisis. Con este criterio, en el caso de determinar 
compuestos no polares, se prefiere una columna de C18 o similar, mientras que 
para compuestos polares la mejor selección es una HILIC o de intercambio 
iónico. La preparación de la muestra depende, lógicamente, de la naturaleza de 
los analitos y en algunos casos se requiere una etapa de derivatización, como 
ocurre en el análisis mediante GC–MS. En otros casos la extracción en fase sólida 
es la major alternativa para eliminar los interferentes y preconcentrar los 
metabolitos problema. 
El número de compuestos considerados en cada estudio puede variar 
desde un único metabolito a una familia que comprenda un número grande de 
compuestos, como es el caso de los fosfolípidos. Cuando el número de com-
puestos es suficientemente pequeño para optimizar la preparación de la muestra 
y la detección para cada uno de ellos, y se puede obtener su recta de calibrado 
individual  —porque la existencia de patrones lo permite— se puede conseguir la 
cuantificación de todos los compuestos problema. Por el contrario, si el número 
de compuestos es grande y no existen patrones para todos ellos —y, por tanto, la 
obtención de las curvas de calibrado no es completa— la cuantificación de los 
metabolitos que carecen de patrones se hace generalmente de forma relativa con 
respecto al metabolito para el que existe patrón y que tiene la estructura más 
similar a él. 
 Los paneles de compuestos seleccionados en esta investigación para 
análisis orientado estuvieron compuestos por metabolitos implicados en rutas 
metabólicas conocidas y que juegan un papel relevante en ciertas patologías. 
Además, estos metabolitos habían sido descritos previamente como potenciales 
biomarcadores. Tres de las cuatro plataformas analíticas optimizadas en esta 
sección se orientaron al estudio de diferentes familias de metabolitos, como 
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aminoácidos esenciales, compuestos implicados en el ciclo de los ácidos 
tricarboxílicos y fosfolípidos. La cohorte seleccionada para el estudio estaba 
formada por pacientes diagnosticados con diversas afecciones cardíacas. Con la 
cuarta de las plataformas optimizadas se analizó un péptido antimicrobiano del 
que se determinó comparativamente su concentración en suero de individuos 
sanos y de pacientes de la unidad de cuidados intensivos. 
 En relación a la naturaleza química de los compuestos analizados, dos de 
los métodos se basaron en LC–MS, uno en GC–MS y otro en infusión directa en 
MS/MS. Tanto en este último método como en los basados en LC–MS, se 
aprovecharon las ventajas que aporta la SPE como preparación de muestra de 
forma automatizada y con acoplamiento en línea a etapas posteriores del proceso 
analítico. 
 En lo que se refiere a las estrategias de tratamiento de datos, se utilizó un 
esquema general similar al de la sección previa —análisis univariante y 
multivariante— junto con nuevas herramientas con diferente capacidad. Como en 
la sección anterior, se utilizaron las dos formas de análisis univariante, 
paramétrico y no paramétrico, pero también estrategias de análisis multivariante 
supervisado y no supervisado. También se utilizaron diseños multivariantes y 
univariantes para obtener el valor óptimo de cada parámetro que afectaba al 
método en cuestión, siempre en función de la metodología a desarrollar.  
 
Capítulo 8 
 Este capítulo está dedicado a una plataforma para el análisis de 
fosfolípidos en suero con el propósito de determinar el perfil de estos compuestos 
en pacientes ateroscleróticos. Los fosfolípidos son una familia de lípidos que, 
además de ser componentes mayoritarios de las membranas celulares, cons-
tituyen una parte importante de la composición lipídica de las lipoproteínas 
presentes en la sangre. La mayoría de los fosfolípidos contiene un diglicérido o 
monoglicérido, un grupo fosfato y una molécula orgánica simple, tal como colina, 
etanolamina o serina, que dan nombre a las diferentes clases de fosfolípidos. Una 
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excepción a esta regla es la esfingomielina, que deriva de la esfingosina en lugar 
de derivar del glicerol. Como esta familia de lípidos abarca un gran número de 
metabolitos que incluye glicerofosfatidilcolinas (PC), glicerofosfatidiletanola-
minas (PE), glicerofosfatidilserinas (PS) y esfingomielinas (SM), entre otras, es 
parti-cularmente difícil construir las curvas de calibración para todos ellos. Por 
esta razón, los perfiles de fosfolípidos del suero se obtuvieron mediante LC–
QTOF MS/MS, una plataforma que permite la identificación de fosfolípidos 
gracias a su alta resolución. La identificación de fosfolípidos en suero puede 
llevarse a cabo por la información que proporcionan en MS/MS, ya que su 
modelo de fragmentación es conocido. Se combinaron, además, los modos de 
ionización positivo y negativo para obtener resultados complementarios.  
 En cuanto a la preparación de la muestra, se centró en el aislamiento de 
los fosfolípidos de la matriz del suero y a su preconcentración. Con estos fines, 
una etapa de extracción en fase sólida utilizando cartuchos de un sorbente que 
interacciona selectivamente con el grupo fosfato (sílice recubierta de circonio) 
permitió una retención selectiva de los metabolitos con este grupo funcional. 
Ochenta y un fosfolípidos se detectaron e identificaron utilizando esta plataforma 
de los que 48 estaban presentes al menos en el 75% de las muestras estudiadas 
(140 de pacientes diagnosticados con aterosclerosis coronaria, 72 con angina 
inestable o NSTEMI y 68 con angina estable).  
 El análisis estadístico de los datos obtenidos permitió identificar cuatro 
fosfolípidos a concentraciones significativamente diferentes en pacientes con 
angina estable con respecto a los que padecían angina inestable o NSTEMI: 
LysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) y SM(d18:2/14:0). 
 Se utilizó una herramienta analítica conocida como ROCCET para 
construir un panel de marcadores con los anteriores metabolitos con el que 
discriminar entre pacientes ateroscleróticos que padecían angina estable o 
inestable/NSTEMI. El panel presentó una capacidad de predicción de la 
enfermedad en el set de entrenamiento del 70.7 y 66.0% para angina estable e 
inestable/NSTEMI, respectivamente. Además, la curva ROC del modelo presentó 
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un área bajo la curva de 0.715 para el set de entrenamiento y de 0.747 para el set 
de validación externa, mostrando un 66 y 70% de sensibilidad y especificidad, 
respectivamente. Estos resultados merecen un estudio a gran escala para validar 
el modelo propuesto y asegurar la utilidad de la estrategia basada en LC–QTOF 
MS/MS para establecer el perfil de fosfolípidos que permita el desarrollo de 
herramientas para asistir en  diagnóstico clínico. 
 
Capítulo 9 
 Considerando el perfil de aminoácidos esenciales y su relevancia bioló-
gica, el objetivo del presente capítulo fue desarrollar una plataforma automa-
tizada para la determinación de aminoácidos esenciales en suero con vistas a 
conocer si existen diferencias significativas entre sus niveles dependiendo del 
tipo de pacientes ateroscleróticos. Con este propósito, se adoptó el sistema SPE–
LC–MS/MS como configuración instrumental. 
 El número de metabolitos en este caso permitió la optimización completa 
del proceso analítico, así como la caracterización del método desarrollado: Curvas 
de calibración, rango dinámico, límites de detección y de cuantificación, 
reproducibilidad y repetitividad. Se tuvieron en cuenta las características físico-
químicas de los analitos —aminoácidos— para el diseño del método. Con este 
criterio, en la optimización de la preparación de la muestra mediante SPE se 
utilizaron cartuchos catiónicos, dado que los aminoácidos adquieren carga 
positiva en medio ácido. Teniendo en cuenta el carácter polar de los metabolitos, 
en la etapa de separación cromatográfica, se seleccionó una columna HILIC (fase 
móvil acuosa, inicial con 90% de acetonitrilo y final con 40%, en todo momento 5 
mM en formiato amónico y con pH 6). Puesto que las fases cromatográficas no 
coincidían con el disolvente requerido para eluir los aminoácidos del cartucho 
(90% acetonitrilo, 5% amoníaco, 5% agua), se eligió el modo de elución 
“focusing”. Este modo está especialmente indicado para la elución con un 
mínimo volumen de eluyente diferente de la fase móvil. El caudal de la etapa de 
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elución debe ser pequeño para minimizar su influencia en la separación 
cromatográfica. 
 Una vez optimizado, el método se aplicó al análisis de muestras de suero 
de 122 pacientes ateroscleróticos (80 con angina estable y 42 que habían sufrido 
previamente un infarto agudo de miocardio). El análisis de esta serie de muestras 
reveló que la isquemia, presente en los pacientes que habían sufrido un infarto, 
tenía un efecto significativo en la concentración de dos aminoácidos esenciales: 
Treonina y lisina. Este efecto era más pronunciado en mujeres que en hombres. 
La influencia de la obesidad, un factor de riesgo clave en enfermedades 
cardiovasculares, también se elucidó poniéndose de manifiesto niveles de valina y 
metionina más altos en suero de individuos obesos. Esta investigación permitió 
establecer diferencias significativas en el perfil de aminoácidos esenciales presen-
tes en suero de individuos diagnosticados con aterosclerosis, con especial énfasis 
en la importancia de factores de riesgo para mejorar la discriminación. 
 
Capítulo 10 
 En este capítulo se discuten la puesta a punto y la aplicación de un 
método para la determinación en suero de compuestos implicados en el ciclo de 
los ácidos tricarboxílicos (TCA) mediante el uso de GC–MS tras una etapa de 
derivatización, una estrategia muy común para la determinación de esta familia 
de compuestos. El ciclo de los TCAs también se conoce como ciclo del ácido 
cítrico o ciclo de Krebs’, y participa en la generación de energía a partir de 
carbohidratos, grasas y proteínas. Está también relacionado con la generación de 
ciertos aminoácidos y ácidos grasos, y es la ruta metabólica central de los 
organismos aeróbicos. 
Se optimizaron tanto la preparación de la muestra como la determinación 
para conseguir la máxima sensibilidad y selectividad posibles. El método se basó 
en, (i) precipitación de proteínas con metanol, (ii) limpieza de la fase líquida 
mediante extracción líquido–líquido con cloroformo para eliminar los inter-
ferentes no polares, (iii) derivatización por sililación; (iv) análisis mediante GC–
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MS. El método se aplicó a muestras de suero de 223 pacientes diagnosticados con 
diferentes enfermedades cardiovasculares (172 con lesiones coronarias 
significativas y 51 afectados por otros problemas cardiovasculares, pero sin 
lesiones coronarias). Los compuestos del TCA son primariamente metabolitos 
que pueden verse afectados por un número amplio de factores internos y 
externos. Por esta razón es importante considerar la influencia de los factores de 
riesgo cuando se proponen los metabolitos del ciclo TCA como potenciales 
biomarcadores en diagnosis clínica. Por tanto, se estudió la influencia de tres 
factores de riesgo como la hipercolesterolemia, la obesidad y el hábito de fumar 
en los niveles en suero de los metabolitos del TCA en paciente diagnosticados con 
lesiones coronarias. La consideración de estos factores de riesgo resultó crucial 
para explicar la variabilidad de esos metabolitos en pacientes con lesión 
coronaria frente a los individuos control. En este estudio, el análisis estadístico 
estuvo soportado en curvas ROC y sus parámetros característicos para validar la 
capacidad de discriminación de los metabolitos del TCA. 
 Los resultados obtenidos revelaron que los ácidos málico y α-
cetoglutárico conducen a modelos con alta especificidad y aceptable sensibilidad 
para la discriminación entre pacientes con o sin lesiones coronarias considerando 
también la obesidad (un factor de riesgo que influyó en los niveles de estos dos 
metabolitos). No obstante, el modelo de discriminación del ácido α-cetoglutárico 
fue menos robusto que el del ácido málico. 
 
Capítulo 11 
 La plataforma analítica orientada a la que se dedica este capítulo se 
centró en la cuantificación de péptidos de interés clínico. La plataforma se 
fundamenta en el acoplamiento en línea de la SPE y la espectrometría de masas 
en tándem con infusión directa, con el fin de hacer posible el desarrollo de 
métodos rápidos, con alta sensibilidad y selectividad. La aplicabilidad de la 
plataforma se comprobó mediante su aplicación a la determinación de un péptido 
antimicrobiano en suero humano: La catelicidina. El modo de seguimiento 
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selectivo de reacciones (SRM) se configuró con  tres transiciones confirmadas 
por fragmentación in silico del péptido en cuestión. Se evitó el uso de un estándar 
interno mediante validación de la  SPE realizando ensayos con configuraciones 
de doble cartucho para asegurar la retención cuantitativa de la catelicidina.  
 Mediante el sistema automatizado de SPE se llevó a cabo la desa-
linización y desproteinización de la muestra de forma eficaz utilizando como 
sorbente una resina polimérica de divinilbenceno. La eficacia de esta etapa es de 
crucial importancia en análisis de biofluidos, en los que frecuentemente la etapa 
de preparación de la muestra incluye una etapa de desproteinización con disol-
ventes orgánicos. El proceso analítico requirió sólo 12 min por muestra. Los 
límites de detección y de cuantificación fueron 2.5 y 8.25 µg/L, respectivamente 
(0.20 and 0.66 pg en columna), que ponen de manifiesto la alta eficiencia de la 
combinación SPE–MS/MS. La repetibilidad y la reproducibilidad en el labo-
ratorio fueron 2.4% y 2.7%, respectivamente; lo que demuestra la precisión del 
método desarrollado.  
 Como la catelicidina participa en la respuesta inmunitaria, operando en 
primera línea de los mecanismos de defensa, el método se validó por aplicación a 
muestras de suero de pacientes de la unidad de cuidados intensivos (n=17) y de 
donadores sanos (n=23). Aunque los niveles de catelicidina en los pacientes en 
cuidados intensivos fueron mayores que en los inviduos sanos, no se encontraron 
diferencias significativas entre ambos grupos. 
 La plataforma analítica propuesta en este capítulo puede ser de interés 
para el análisis de otros péptidos, tales como biomarcadores clínicos y de 
proteínas problema después de hidrólisis enzimática para generar péptidos 
representativos. Por tanto, con cambios adecuados o sin ellos, podría utilizarse 
para cualquier otro péptido con una disminución considerable del coste por 
análisis, si se compara con el de los tests basados en inmunoensayo. También se 
consigue una completa automatización sin necesidad de usar estaciones de 
trabajo robotizadas, así como un grado extra de selectividad al suprimirse las 
reacciones cruzadas. 
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 The current regulation of the University of Córdoba on the writing of 
doctoral dissertations dictates that any articles deriving from the doctoral work, 
whether published or awaiting publication, are to be included in the Thesis report 
as such and that the report should include a section presenting a joint discussion 
of the results.  
 The research leading to the main part of this doctoral work revolved 
largely around clinical metabolomics. This choice of research topic was prompted 
by the strong impact of this omics discipline on two especially attractive fields, 
namely: (a) diagnosis, prognosis and treatment of diseases; and (b) nutrition. 
These two fields are the cornerstones of PM. The research presented here is 
described in three different sections according to the aim and the specific 
metabolomic strategy used for each purpose. 
Thus, Section I focuses on the development of new methodologies to 
improve the basic analytical properties sensitivity and selectivity, and also to 
increase metabolite coverage and facilitate identification of potential biomarkers. 
The second and third sections are devoted to two basic metabolomics 
strategies: untargeted and targeted analysis. Specifically, Section II deals with 
profiling analysis, which is the most widely used mode of untargeted analysis in 
clinical metabolomics and aims to cover the metabolomes of specific biofluids or 
tissues as comprehensively as possible. 
By contrast, Section III is concerned with the determination of specific 
groups or families of compounds which are of clinical interest because of their 
involvement in crucial biological pathways that can be altered or deregulated by 
certain pathological conditions. The target metabolites addressed in this section 
include essential amino acids, metabolites involved in the tricarboxylic acids 
cycle, phospholipids and the antimicrobial peptide cathelicidin. 
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The results pertaining to each section are summarized below. One com-
mon link between the three is the use of mass spectrometry for detection. The 
analytical sensitivity, selectivity, accuracy, precision and resolution of mass 
spectrometry make this technique the most suitable tool for targeted and 
untargeted metabolomic analysis of clinical samples. Both metabolomics strate-
gies have taken advantage of this technique for qualitative and quantitative 
analyses. Thus, untargeted analysis has benefited greatly from the high resolution 
(i.e., high m/z accuracy), scan velocity and sensitivity, and competitive pur-
chasing cost, of QTOF mass spectrometers, which have turned it into the 
preferred choice for qualitative analysis and relative quantitation. On the other 
hand, QqQ mass spectrometers are better suited to targeted analysis by virtue of 
their high sensitivity and selectivity for confirmatory analysis —and hence for 
quantitation. Given the complexity of clinical samples, mass spectrometers are 
better suited to clinical metabolomics, especially when used in combination with 
chromatographs. The choice of a specific technique (gas chromatography or 
liquid chromatography, mainly) for separation, when needed, depends on the 
chemical properties of the target metabolites.  
 
Section I. Methodological development and innovation in 
metabolomic analysis 
 Metabolomics analysis continues to be subject to some shortcomings for 
untargeted and profiling analysis despite recent cutting-edge technological ad-
vances including accurate, high resolution mass spectrometry measurements for 
expeditious detection of metabolites.  
 One of the problems with profiling metabolomics is the difficulty of 
covering all possible metabolites with a single analytical platform; this is a result 
of metabolomes encompassing a wide variety of metabolites differing widely in 
chemical structure and concentration. One other crucial problem arises from the 
complexity of some biofluids typically used in clinical analysis (viz., serum, 
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plasma, urine, saliva), which further hinders development of clinical meta-
bolomics applications. 
The previous problems were addressed in three different ways here. One 
involved preparing samples of such a scarcely studied biofluid as sweat, which 
has substantial advantages including non-invasive sampling and a simple com-
position relative to conventional biofluids such as blood or urine. Using new, 
alternative types of samples in clinical analysis can be useful to overcome the low 
selectivity of conventional biofluids to metabolic changes associated to physio-
logical changes. One other challenge was developing an effective sample prepara-
tion strategy to increase metabolite coverage in the LC–MS/MS analysis of 
clinical samples. The strategy used for this purpose was an automated SPE 
system coupled on-line to LC–QTOF. The SPE system was used with two dif-
ferent sorbents possessing complementary retention properties for sequential 
elution to the chromatograph. The third challenge was another methodological 
innovation, namely: using gas phase fractionation in metabolomics to improve 
metabolite detection in the MS/MS analysis of human serum. The results provid-
ed by each approach are summarized below. 
 
Chapter 1 
 The research work described in this chapter was aimed at developing an 
optimized sample treatment protocol for the LC–MS/MS analysis of sweat, an 
uncommon biofluid which is arising increasing interest for clinical studies by 
virtue of its easy, non-invasive sampling —even by unskilled personnel—, simple 
composition and, unlike urine, the need for no standardization. More complex 
biofluids have led to prediction models based on unselective metabolites by effect 
of interferences from other biological processes.  
 The experimental optimization plan involved using two different chroma-
tographic modes for sweat analysis, namely: a reversed phase mode using a C18 
column and a HILIC mode using an appropriate column. Direct analysis of sweat 
enabled detection of 67 and 57 molecular features with the C18 and HILIC 
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analytical method, respectively, in the positive ionization mode, and 29 and 37 
features, respectively, in the negative ionization mode. Intra-individual 
variability was assessed by duplicate analysis of 7 samples from the same 
individual on different days over a period of five. This study also allowed 
evaluation of the methodological reproducibility of this step, the estimated 
variability as RSD of which ranged from 2 to 21%. Therefore, the sampling system 
was reproducible enough for metabolomic research. 
 Despite the large number of potential molecular features detected in the 
positive ionization mode, metabolite coverage was further improved by the 
sample preparation step. To this end, various preparation protocols were used in 
the two chromatographic modes for the overall metabolomics profiling analysis 
of sweat. Sweat hydrolysis, whether acid or basic, proved unsuitable for 
metabolite profiling because it altered the integrity of the samples judging by the 
presence of many artifacts. By contrast, direct analysis after dilution proved 
effective to obtain a representative snapshot of sweat metabolome. Also, C18 
SpinColumn SPE cartridges resulted in improved sensitivity and reduced the 
presence of exogenous compounds. Some exogenous compounds detected in this 
biofluid were components of the sweat extraction system (particularly 
methylparaben, propylparaben and pilocarpine, the last of which was used to 
stimulate sweating prior to sampling). A clean-up step with HILIC SPE cartridges 
was found to be preferable for the analysis of lipid metabolites such as 
monoacylglycerols. 
The optimized LC–QTOF MS/MS protocol afforded the identification of a 
large number of sweat components (a total 43 metabolites from a wide variety of 
families), which testifies to its effectiveness for analysing sweat. The metabolites 
identified included all essential amino acids except lysine —a total of 19 
compounds. Exogenous compounds such as caffeine and theophylline were also 
identified, and so were various dicarboxylic acids (sebacic, suberic, azelaic and 
butanedioic). The results of this identification study can help us better under-
stand this poorly known biofluid and suggest that, since some of the metabolites 
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identified had previously been assessed as potential biomarkers for other bio-
fluids, sweat may be a candidate biofluid for finding new biomarkers. 
 
Chapter 2 
 The work described in this chapter focused on the development of an 
innovative approach to increase metabolite coverage. The high chemical diversity 
of the metabolome requires new analytical platforms to improve existing detec-
tion capabilities. The platform used for this purpose here was a combination of an 
automated SPE device and an LC–QTOF system intended to take advantage of 
the high selectivity of SPE sorbents and the high resolution of QTOF detectors. 
The SPE device was coupled on-line to the LC–MS/MS instrument for fully 
automated operation —in fact, all the analyst needs to do is placing sample vials 
on the autosampler. 
The proposed approach was used for the analysis of human serum as a 
model biofluid. Detection of tentative metabolites in serum with various sorbents 
acting via single or dual retention mechanisms was compared, using polymers 
and resins for dual retention. Using different sorbents allowed the detection 
capabilities of SPE–LC–MS/MS to be maximized and up to 3445 molecular 
entities detected under specific conditions of charge state, isotopic distribution, 
signal intensity and detection frequency. A combination of four sorbents (viz., 
polydivinylbenzene resin, C18, and anionic and cationic mixed mode materials) 
afforded more than 81% of the total coverage obtained with the whole set. 
Therefore, the proposed approach opens a new door to enhancing the detection 
capabilities of metabolomic methods using a single platform (LC–MS/MS here). 
 An additional study was conducted to develop other methods using 
combinations of two SPE protocols conducted on automated SPE–SPE–LC–MS 
configurations. For this purpose, a single aliquot was serially circulated through 
two complementary SPE sorbents, the two cartridges being independently eluted 
and the eluted metabolites sequentially analysed by LC–MS. This increased the 
selectivity of this hyphenated sample fractionation scheme and maximized 
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throughput. Thus, the serial configurations used afforded detection coverages 
ranging from 79.5 to 99.7% of all molecular features detected by separate analysis 
with the whole set of sorbents. This approach can be very interesting for clinical 
studies on scant or highly valuable samples.  
 
Chapter 3 
 One of the weaknesses of untargeted metabolomic analysis by mass 
spectrometry is the need to obtain a large amount information for correct identi-
fication of metabolites in the particular biofluid under study. This requires either 
separate injection of the target compounds in pure form or acquisition of high-
quality MS and MS/MS information to identify them through a library search. 
 Existing MS/MS methodologies for identifying molecular features in 
untargeted analysis involve two or more steps including injection of samples in 
the MS mode, selection of potential precursors for obtainment of MS/MS 
information and targeted MS/MS analysis. The “auto MS/MS” mode is 
comparatively less time-consuming as it involves cycling through the chroma-
tographic run of MS scans and subsequent fragmentation of two or three of the 
ions detected in the previous scan. Selection of potential precursors can be 
restricted to specific mass ranges or charge states, and an abundance threshold 
be established.  
 The strategy based on GPF uses a combination of MS scans over the same 
mass range but different intervals to select precursor ions spanning the whole 
desired precursor range. This strategy, which had been successfully applied to 
increase the number of proteins identified in proteomics sample batches, had 
never before been used in metabolomics. This was thus the primary goal of the 
research work described in this chapter. 
 Because accurate metabolomics profiling requires using at least three 
replicates per sample, replication is a usual practice in metabolomics studies. 
Using GPF in combination with an adequate number of replicates is an effective 
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approach to enhancing identification capabilities without the need for further 
sample injections. In this doctoral work, we used combinations of 2, 3, 4 and 6 
intervals to select precursors spanning the m/z range from 100 to 1000 for 
comparison with the results of the conventional “auto MS/MS” mode. 
 This study was conducted on serum, which is the most widely used 
biofluid for clinical and nutritional metabolomic analyses by virtue of its role as a 
primary carrier of metabolites in the human body. Using GPF methodology for 
serum analysis by LC–MS/MS in metabolomics has proved an effective strategy 
for increasing the amount of MS/MS information available on some compounds. 
A combined method splitting the range of precursor ion masses into four 
intervals was found to be the best choice; thus, it provided MS/MS information 
for at least 80% of all detected entities. By contrast, the conventional “auto 
MS/MS” data acquisition mode afforded identification of only 48–57% of all 
detected molecular entities and was therefore less effective for unequivocal 
identification of metabolites.  
 Based on the results, a combination of methods using different intervals 
of precursor ion masses can increase the number of entities potentially detected 
from MS/MS information, as confirmed by identifying various families of 
metabolites and assessing recorded MS/MS information for each target com-
pound in each combination. 
 
Section II. Untargeted metabolomics: intervention study 
based on nutrimetabolomics, and search for disease bio-
markers  
 This section focuses on the use of different untargeted metabolomic 
approaches to confirm the effectiveness of this strategy for clinical studies. 
Untargeted metabolomics studies can be classified into two general categories 
depending on the particular purpose, namely: (a) discovery of biomarkers, and 
(b) understanding a specific metabolic pathway or an overall biological system. 
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Both categories were addressed here in relation to two aspects of Personalized 
Medicine, namely: (a) diagnosis, prognosis and treatment of diseases, and (b) 
nutritional metabolomics. 
The purely clinical area was examined in connection with atherosclerosis, 
which is one of the leading cause of death worldwide, and lung cancer, which is 
the leading and second most frequently diagnosed cause of cancer death. The 
nutritional area was explored in research conducted within the framework of the 
Lipgene study. Lipgene is a European project focusing on the interaction of 
nutrients and genotype in the metabolic syndrome —a term that encompasses 
several risk factors for cardiovascular disease. Experiments were conducted on 
two different types of matrix: serum and sweat, which are two biofluids of 
different chemical diversity. Various statistical tools for evaluation of biomarkers, 
panels consisting of several markers, and univariate and multivariate analysis of 
the data set, were used for this purpose. 
 Untargeted metabolomics analyses require using high mass resolution 
systems in order to ensure a high enough m/z accuracy to identify as many 
metabolites in the target biofluid as possible. QTOF is a preferential tool here as 
it fulfils the requirements of untargeted analysis while facilitating acquisition of 
MS/MS spectra for precursor ions that contain enough information for the 
unequivocal identification of metabolites. A number of MS and MS/MS databases 
containing useful information for a wide variety of compounds exist, especially 
prominent among which are the Metabolite and Tandem MS Database (METLIN) 
and the MassBank. By contrast, the Human Metabolome Database (HMDB) 
contains MS/MS spectra with inadequate resolution for some metabolites 
because most of the spectra were acquired with a triple quadrupole system. Some 
databases are useful to obtain information about metabolic pathways involving a 
specific group of metabolites; such is the case with the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) database. 
 The results obtained in the work described in the four chapters of Section 
II are discussed in detail below. 
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Chapter 4 
 Nutritional research provides another crucial pillar for Personalized 
Medicine. Diet is one of the most important external factors contributing to 
changes in the main blocks of the Systems Biology concept, namely: genome, 
transcriptome, proteome and metabolome. The direct relationship between meta-
bolome and phenotype has turned nutrimetabolomics into a very active research 
area. For example, untargeted metabolomic analysis can be useful to elucidate 
the biological response of individuals under intervention diets. This was the main 
purpose of the research work conducted here: to compare the metabolic dif-
ferences between serum profiles from individuals following four different 
intervention diets for 12 weeks. The diets were planned as part of the Lipgene 
project and differed in fat quality and quantity. Liquid–liquid extraction was used 
to split serum samples into two fractions (polar and non-polar metabolites) that 
were analysed separately by LC–QTOF in the MS/MS mode.  
 Supervised statistical analysis (PLS-DA) allowed metabolic differences 
associated to the intervention diet, and differences in metabolite profiles (polar 
and non-polar compounds) due to each diet, to be detected. Discrimination 
models based on PLS-DA and fold change analysis led to identification of 
metabolites whose concentration in serum was altered by the intervention diet. 
Phospholipids in the non-polar fraction were found to play a central role in 
metabolic differences between individuals. Thus, critical differences in the 
concentrations of glycerophosphatidylcholines including PUFAs as substituents 
were observed. The greatest differences between diets were those in three of the 
most common glycerophospholipids in human blood [PC(16:0/18:2), 
PC(18:0/16:2) and PC(18:0/18:2)], the levels of which differed between diets. 
Non-polar metabolites altered by the intervention diets included some essential 
fatty acids and sphingomyelins. Therefore, the diets had a considerable influence 
on the lipid fraction. 
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 Analysis of the polar fraction also revealed metabolic differences between 
individuals under different diets. Carnitines, amino acids, bile acids and purine 
base derivatives were among the most representative metabolites in this altered 
fraction. A strong connection between the major pathways altered —most relating 
to lipid metabolism— in individuals under the intervention diets was observed. 
Untargeted analysis allowed diet-related metabolic differences to be identified 
despite the high biological variability in the studied cohort.  
 
Chapters 5 and 6 
 These two chapters describe the metabolomic study of potential 
biomarkers for atherosclerosis identified by analyzing serum samples from 
patients suffering from various heart diseases. The study described in Chapter 5 
involved a search for metabolomic differences between patients with stable 
angina, non-ST elevation myocardial infarction (NSTEMI) or unstable angina 
and acute myocardial infarction (AMI), whereas that described in Chapter 6 was 
aimed at finding effective markers for monitoring atherosclerosis by comparing 
patients with stable angina and acute myocardial infarction. In the former study, 
various chromatographic modes were used to identify that leading to the greatest 
possible coverage of potential molecular features —which are equivalent to 
tentative metabolites. The only sample pretreatment needed was protein preci-
pitation, which minimized metabolite losses during the sample preparation step.  
 The ensuing methodology was used to analyze serum samples and the 
data thus obtained were processed according to the particular needs for 
untargeted results, namely: alignment and extraction of potential molecular fea-
tures, and statistical analysis for differences between groups. A group of 13 meta-
bolites with significant differences in concentration between the three different 
groups of atherosclerotic patients was identified. The metabolites were mostly 
lipids, but also included some bile acids (e.g., cholic and deoxycholic acids). 
Bilirubin was the most discriminating metabolite, with p = 0.0012. Some of the 
com-pounds identified had previously been associated to cardiovascular disease 
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or oxidative stress, both of which are highly influential on atherosclerosis. A com-
parison of means for significantly identified metabolites between the three 
groups revealed some similarity between AMI and unstable angina/NSTEMI, and 
the greatest differences in metabolites levels to be those between myocardial 
infarction and stable angina patients. Some other metabolites were not 
significantly different between groups, but tended to increase or decrease from 
stable angina to unstable angina/NSTEMI to AMI. 
 The LC–QTOF MS/MS analytical platform was also used in the research 
work described in Chapter 6 and found to be a suitable choice for biomarker 
discovery. This study was applied to the discrimination of atherosclerotic patients 
affected by stable angina and by a previous AMI episode. The influence of risk 
factors such as smoking habit, obesity and hypercholesterolemia was examined 
by assessing the predictive ability of potential markers in patients with a specific 
risk factor. Because the aim was to develop a panel of markers, assessment was 
based on ROC curve analysis, which is the golden standard for assessing 
performance of medical diagnostic tests with binary classification. The best 
predictions were those for atherosclerotic patients with hypercholesterolemia as 
obtained with bilirubin, 13-HpODE, body mass index (BMI) and 5-HETE, which 
had 91% specificity and 48–62% sensitivity.  
 A panel of markers for predicting acute myocardial infarction versus 
stable angina was compiled that featured 85.1% specificity and 80.8% sensitivity, 
and hence few false negatives or positives. The metabolite panel comprised the 
lipids 13-HpODE and lysoPC(22:6) in addition to BMI, which is an obesity-
related anthropometric variable. In any case, these results and the proposed 
model require validation in a large-scale study. 
 
Chapter 7 
 The aim of the work described in this chapter was to evaluate the 
potential of such a scarcely studied biofluid as sweat for discriminating indi-
viduals with lung cancer from healthy donors. Sweat has in fact been scarcely 
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used as a sample to search for cancer biomarkers despite its above-described 
advantages including non-invasive collection and lesser complexity than blood or 
urine. This has largely been the result of the lack of uniform sweat sampling 
protocols providing large enough volumes for analysis. However, advances in 
analytical instrumentation have raised sensitivity to a level facilitating the 
analysis of small sample volumes. This fact, together with improvements in sweat 
collection protocols which have made them reproducible enough for biomarker 
searching, has turned sweat into a useful sample for diagnosis of lung cancer. 
New tools for diagnosing lung cancer are needed, however, because currently 
available tests are invasive and expensive —and hence impossible to apply to all 
individuals at risk. 
 As in previous chapters, LC–QTOF MS/MS was used in combination with 
the most simple possible sample treatment:  dilution with the initial chroma-
tographic phase. This analytical platform was used to assess the potential of 
sweat as a biofluid for diagnosing lung cancer by developing a prediction model 
based on a panel of metabolites including amino acids, sugars and some lipids to 
discriminate patients with lung cancer from a control group. The high negative 
predictive value of this approach testifies to the potential usefulness of this 
biofluid for reducing the number of positives requiring confirmatory analysis. 
 A trisaccharide phosphate was found to be the best discriminator among 
individual metabolites. However, this compound was not present in both three-
metabolite panels used to predict lung cancer. The two panels included 
maltotriose and nonanedioic acid, in combination with γ-GluLeu and MG(22:2). 
Both significantly improved the discrimination capabilities of individual meta-
bolites. Thus, the former panel featured 100% specificity and 63.6% sensitivity —
and hence a false negative rate of 0%—, and the latter 81.0% specificity and 
sensitivity. 
 These preliminary results exposed the need for a large-scale study to vali-
date the proposed panels in order to reduce the proportion of individuals re-
quiring confirmatory testing, and to be able to detect lung cancer at earlier stages. 
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Section III. Targeted analysis of potential biomarkers 
 Targeted analysis in metabolomics is defined as the analysis of a sample 
to quantify a specific group or family of metabolites, or even a single metabolite. 
Although it only allows certain compounds to be detected, this metabolomic 
strategy has some clear-cut advantages over untargeted analysis. The main 
advantage is that sample preparation and detection can be optimized to reduce 
the number of interferents and maximize the selectivity and sensitivity by using 
an appropriate analytical platform. Thus, a C18 column is to be preferred for non-
polar compounds and a HILIC column for polar compounds. Sample treatment is 
also analyte-dependent and occasionally includes a derivatization step (e.g., with 
GC–MS analysis) or requires SPE for removal of interferents and precon-
centration of target metabolites. 
 The number of compounds included in each targeted study can range 
from a single metabolite to a large family (e.g., phospholipids). When the number 
of target compounds is small enough to allow both sample preparation and 
detection to be optimized, and a calibration curve for each individual metabolite 
obtained, absolute quantitation of the target compounds is feasible. On the other 
hand, if the number of target compounds is too large or some lacks a standard 
from which a calibration curve can be constructed, then absolute quantitation of 
all metabolites is impossible and those lacking a standard must be quantified in 
relation to the most similar metabolite having one. 
 The panel of compounds used here for targeted analysis consisted of 
metabolites involved in some well-known metabolic pathways that play a central 
role in certain medical conditions. The metabolites concerned had been pre-
viously studied as potential biomarkers. Three of the four platforms used were 
applied to different metabolite families including essential amino acids, com-
pounds involved in the tricarboxylic acids cycle and phospholipids. The target 
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cohort consisted of patients diagnosed with diverse cardiovascular diseases. The 
fourth platform used an antimicrobial peptide as target to compare serum levels 
in healthy individuals and intensive care patients. 
 Based on their chemical nature, the target metabolites were determined 
with two LC–MS methods, a GC–MS method and a direct-infusion MS/MS 
method. The last one, and those using LC–MS, benefited from the advantage of 
SPE for automated sample preparation coupled on-line with other steps of the 
analytical process. 
 Data processing was based on the general scheme used in the previous 
section (univariate and multivariate analysis) in addition to new tools differing in 
scope. Both parametric and non-parametric univariate analysis, and supervised 
and unsupervised multivariate strategies were also used here. Multivariate and 
univariate designs were additionally used to optimize each variable affecting 
performance of the different methodologies.  
 
Chapter 8 
 The work described in this chapter involved using a platform to analyse 
phospholipids in serum with a view to elucidating their profile in atherosclerotic 
patients. Phospholipids are a family of lipids constituting the major components 
of cell membranes and a sizeable portion of the lipid fraction of blood 
lipoproteins. Most phospholipids contain a diglyceride or monoglyceride unit, a 
phosphate group and a simple organic molecule such as choline, ethanolamine or 
serine after which phospholipids classes are named. One exception to this rule is 
sphingomyelin, which is derived from sphingosine instead of glycerol. The fact 
that this family of lipids encompasses a large number of metabolites including 
glycerophosphatidyl-cholines (PC), glycerophosphatidylethanolamines (PE), 
glycerophosphatidyl-serines (PS) and sphingomyelins (SM), among others, 
precludes constructing calibration curves for all. For this reason, serum 
phospholipid profiles were obtained by LC–QTOF MS/MS, a platform that allows 
identification of phospho-lipids thanks to its high resolution. Phospholipids in 
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serum can be easily identified from MS/MS information —their fragmentation 
pattern is quite accurately known. Analyses in the positive and negative 
ionization modes were used in combination to obtain complementary results.  
 Sample preparation was intended to isolate phospholipids from serum 
for preconcentration and removal of potential interferents. This was accompli-
shed by using SPE with cartridges interacting selectively with the phosphate 
group (zirconia coated silica) in order to selectively retain metabolites containing 
this functional group. A total of 81 phospholipids were thus detected and 
identified with this platform; 48 were present in at least 75% of samples (from 
140 patients diagnosed with coronary atherosclerosis: 72 with unstable 
angina/NSTEMI and 68 with stable angina). Statistical analysis of the results 
allowed four phospholipids present at concentrations significantly differing 
between patients with stable angina and unstable angina/NSTEMI to be 
identified, namely: LysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) and 
SM(d18:2/14:0). 
 An on-line computer tool called ROCCET was used to build a panel of 
markers with these four metabolites in order to discriminate between 
atherosclerotic patients with stable angina and unstable angina/NSTEMI. The 
panel exhibited a disease prediction ability for the training set of 70.7 and 66.0% 
for stable angina and unstable angina/NSTEMI, respectively. Also, the area 
under the ROC curve of the model was 0.715 for the training set and 0.747 for the 
external validation set, with 66.0% sensitivity and 70.0% specificity. These 
results warrant a large-scale study to validate the proposed model and testify to 
the usefulness of the LC–QTOF MS/MS strategy for profiling phospholipids with 
a view to developing effective aids for clinical diagnosis. 
 
Chapter 9 
 Taking into account the profile of essential amino acids and their 
biological relevance, the objective in the study of Chapter 9 was to develop an 
automated platform for determining essential amino acids in serum and to 
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identify quantitative differences in amino acids levels between atherosclerotic 
patients by using the SPE–LC–MS/MS system as instrumental set-up. 
 The number of metabolites thus identified was large enough to optimize 
the whole analytical process and to characterize the ensuing method in terms of 
calibration curve, dynamic range, limit of detection and quantitation, repro-
ducibility and repeatability. The method for determining amino acids was de-
signed with provision for their physico–chemical properties. Thus, because 
amino acids acquire positive charge in an acid medium, the sample treatment 
was based on cationic SPE cartridges. Also, their polar nature dictated the use of 
a HILIC column for chromatographic separation —with an aqueous mobile phase 
containing a variable proportion of acetonitrile from 90% at the beginning to 
40% at the end in addition to 5 mM ammonium formate at pH 6 throughout—, 
and the fact that the chromatographic phases were incompatible with the solvent 
needed to elute amino acids from the cartridge (90% acetonitrile, 5% ammonia 
and 5% water) required elution in the focusing mode. This mode was specially 
designed for elution with the minimum volume of an eluent other than the 
mobile phase. The elution step was conducted at a low flow rate in order to 
minimize its effect on chromatographic separation. 
 The ensuing optimized automated method was used to analyse samples 
from 122 atherosclerotic patients (80 with stable angina and 42 who had 
previously had acute myocardial infarction). Analysis of this batch of samples 
revealed that ischemia, present in patients with a history of infarction, had a 
substantial effect on the concentration of two essential amino acids (threonine 
and lysine), particularly in females. The influence of obesity, an important risk 
factor for cardiovascular disease, was also examined and obese individuals were 
found to have increased levels of valine and methionine in serum. This research 
allowed establishing significant differences in the profile of essential amino acids 
in serum from individuals diagnosed with atherosclerosis, with special emphasis 
on the importance of risk factors to improve the discrimination capability. 
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Chapter 10 
 This chapter is devoted to the determination of the compounds involved 
in the tricarboxylic acids (TCAs) cycle in serum by GC–MS after derivatization —
a common choice for this family of compounds. The TCA cycle is also known as 
the “citric acid cycle” or “Krebs’ cycle”, and takes part in the production of energy 
from carbohydrates, fats and proteins. Also, it is associated with the production 
of some amino acids and fatty acids, and is the central metabolic pathway for 
aerobic organisms.  
 Sample preparation and determination were optimized for maximal 
analytical sensitivity and specificity by precipitating proteins with methanol and 
cleaning up the resulting liquid phase by liquid–liquid extraction with chloro-
form to remove non-polar interferents, the clean phase then being derivatized by 
silylation prior to GC–MS analysis. The ensuing method was applied to samples 
from 223 patients diagnosed with various cardiovascular conditions (172 with 
significant coronary lesions and 51 with other clinical manifestations but no 
without coronary lesions). TCA compounds are primary metabolites potentially 
affected by a number of internal and external factors. For this reason, it is 
important to consider the influence of cardiovascular risk factors when proposing 
metabolites of the TCA cycle as potential biomarkers for clinical diagnosis. 
 This led us to examine the relevance of three risk factors (hyperchole-
sterolemia, obesity and smoking habit) to cardiovascular disease through their 
influence on the levels of TCA metabolites in serum from patients with coronary 
lesions. Considering these risk factors proved crucial in order to explain the 
variability of the target TCA metabolites in patients with coronary lesion as 
compared to control individuals. In this study, the statistical analysis was based 
on ROC curves the figures of merit of which were used to assess the 
discriminating capabilities of TCA metabolites. 
 Malic acid and α-ketoglutaric acid led to models with high specificity and 
acceptable sensitivity for discriminating between patients with and without 
coronary lesions, with provision for obesity —a risk factor that influences the 
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levels of both metabolites. In any case, the α-ketoglutaric acid model was less 
robust than the malic acid model. 
 
Chapter 11 
 The platform for targeted analysis used in this chapter was intended to 
enable the quantitative determination of peptides of clinical interest. The 
platform used on-line coupled SPE and tandem mass spectrometry with direct 
infusion to facilitate the development of fast, highly sensitive and selective 
methods. Its applicability was assessed by determining the antimicrobial peptide 
cathelicidin in human serum, using the selective reaction monitoring (SRM) 
mode with three transitions confirmed by in silico fragmentation of the target 
peptide. The need for an internal standard was avoided by using a dual cartridge 
configuration to confirm quantitative retention of cathelicidin.  
 The automated SPE device used, in combination with a polymeric 
divinylbenzene resin as sorbent, proved efficient in desalting and deproteinizing 
samples. This is of paramount importance in clinical analysis of biofluids, which 
frequently involve deproteination with organic solvents. The analytical process 
took only 12 min per sample. The limits of detection and quantitation were 2.5 
and 8.25 µg/L, respectively (0.20 and 0.66 pg on column), and testify to the high 
efficiency of the SPE–MS/MS system. Repeatability and within-laboratory 
reproducibility were 2.4% and 2.7%, respectively, and reflected the high precision 
of the method. 
 Since cathelicidin takes part in the immune response, where it operates 
in the first line of defence, the analytical method was validated by application to 
serum samples from intensive care patients (n = 17) and healthy donors (n = 23). 
Although the levels of cathelicidin in intensive care patients were higher than 
those in healthy donors, the differences were not statistically significant. 
 This approach can be useful to analyze other peptides such as clinical 
biomarkers and target proteins —following enzymatic hydrolysis to representa-
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tive peptides. Thus, with little or no change, it could be applied to any other 
peptide with considerably reduced costs per analysis as compared with immuno-
assay. Furthermore, this new approach can be fully automated without the need 
for a robotic workstation, and also a higher selectivity is obtained because cross-
reactivity is absent.  
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 La investigación que constituye esta Tesis se ha centrado en el desarrollo 
de aplicaciones basadas en análisis metabolómico global y orientado en el área 
clínica, destacando la utilidad de la espectrometría de masas para ambas 
estrategias. Las innovaciones metodológicas constituyen otro de los aspectos que 
caracterizan la investigación. Las conclusiones más destacadas de la investigación 
pueden resumirse en los siguientes puntos:  
- Las innovaciones desarrolladas para mejorar algunos aspectos 
débiles del análisis global, que han llevado a concluir que: 
1) Biofluidos poco convencionales como el sudor constituyen una 
nueva fuente de muestras que debe considerarse en investigación 
clínica. Las ventajas del sudor en esta área están soportadas en 
su muestreo no invasivo y en su composición simple. La identifi-
cación en sudor de una amplia variedad de familias de meta-
bolitos mediante análisis por LC–QTOF confiere a la exploración 
de este biofluido un interés muy particular. 
2) El análisis de sudor mediante LC–QTOF tras una simple dilución 
como única etapa de preparación de la muestra es una opción 
muy adecuada para obtener una instantánea del metaboloma del 
sudor, aunque también pueden utilizarse otros protocolos de 
preparación de la muestra cuando el análisis se oriente a un 
cierto grupo de metabolitos. 
3) El uso de un sistema automatizado de SPE acoplado a un equipo 
de LC–QTOF permite mejorar la detección de metabolitos 
mediante combinación de diferentes sorbentes. Una configura-
ción en serie en la que se acoplan dos sorbentes con mecanismos 
de retención complementarios ha demostrado ser una alternativa 
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competitiva para analizar metabolomas complejos mediante una 
única plataforma, en este caso LC–MS/MS. 
4) La aplicación del fraccionamiento en fase gaseosa (GPF) en 
estudios metabolómicos ha demostrado ser una excelente estra-
tegia para incrementar el número de metabolitos identificados en 
una muestra dada. De hecho, mientras el modo “auto MS/MS” 
convencional de adquisición de datos proporcionó información 
para sólo el 48–57% de las potenciales entidades detectadas, los 
métodos basados en GPF, mediante la combinación de cuatro 
rangos para seleccionar iones precursores, proporcionaron infor-
mación para al menos el 80% de todas las entidades detectadas.  
- La aplicación de diferentes plataformas analíticas globales para 
estudios en nutrimetabolómica o en determinadas enfermedades 
(aterosclerosis o cáncer de pulmón), han conducido a las siguientes 
conclusiones:   
5) Los perfiles metabolómicos obtenidos mediante una plataforma 
basada en LC–QTOF utilizando suero de individuos sometidos a 
diferentes dietas permitió establecer las diferencias metabólicas 
asociadas a cada dieta. El uso de una etapa de preparación de la 
muestra para dividir los componentes del suero en sus fracciones 
polar y no polar resultó una estrategia muy útil para estudiar de 
forma separada las dos fracciones. Los principales efectos meta-
bólicos de las dietas se adscribieron al metabolismo de los lípi-
dos. 
6) La comparación de los perfiles del suero de pacientes con 
aterosclerosis reveló la presencia de 13 compuestos (bilirrubina y 
ácidos cólico y desoxicólico, entre otros) cuyos niveles son dife-
rentes dependiendo de que se trate de pacientes con angina 
estable, infarto agudo de miocardio (AMI) e infarto de miocardio 
sin elevación del segmento ST (NSTEMI). La bilirrubina ha de-
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mostrado ser uno de los metabolitos con mayor influencia para 
discriminar entre episodios de angina estable y de AMI/NSTEMI. 
Esta estrategia es también adecuada para la búsqueda de 
biomarcadores, como lo ha puesto de manifiesto el desarrollo de 
un panel de compuestos para la predicción del infarto de 
miocardio con una especificidad del 85.1% y una sensibilidad del 
80.8%.  
7) En un intento de solventar la principal limitación en el diagnós-
tico del cáncer de pulmón y conseguir su detección en un estadio 
temprano, se han propuesto dos paneles de marcadores para la 
predicción de este tipo de cáncer utilizando sudor. Los dos 
paneles incluyen maltotriosa y ácido nonanedioico en combi-
nación con γ-GluLeu o MG(22:2). Ambos paneles mejoran de 
forma significativa la capacidad de metabolitos independientes 
para la discriminación entre pacientes con cáncer de pulmón y 
controles. El primer panel se caracteriza por un 100% de 
especificidad y un 63.6% de sensibilidad. Por tanto, la posibilidad 
de falsos negativos es del 0%. El segundo panel proporciona 
valores de sensibilidad y selectividad por encima del 81.0%.  
- El desarrollo y aplicación de diferentes plataformas analíticas orien-
tadas ha permitido extraer las siguientes conclusiones: 
8) El método desarrollado para el análisis de fosfolípidos permite la 
identificación de 81 de estos compuestos en suero. La aplicación 
de esta plataforma para analizar muestras de pacientes 
ateroscleróticos ha permitido encontrar un grupo de cuatro 
fosfolípidos —lysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) and 
SM(d18:2/14:0)— que diferencia de forma significativa los 
pacientes con angina estable de los diagnosticados con NSTEMI. 
El panel construido con estos cuatro metabolitos tiene una 
capacidad de predicción en el conjunto de entrenamiento del 
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70.7 y del 66.0% para pacientes con angina estable y con 
NSTEMI, respectivamente. Además, la curva ROC obtenida para 
el modelo presenta un área bajo la curva (AUC) de 0.715 y 0.747 
para los conjuntos de entrenamiento y de validación, respecti-
vamente, con un 66.0 y 70.0% de sensibilidad y especificidad, 
respectivamente.   
9) Se ha desarrollado, asimismo, un método para determinar 
aminoácidos en suero utilizando la plataforma SPE–LC–MS/MS, 
cuya aplicabilidad se ha demostrado mediante análisis de 
muestras de pacientes ateroscleróticos diagnosticados con angina 
estable o infarto agudo de miocardio. Los resultados ponen de 
manifiesto que la lisina y la treonina se afectan por la isquemia, 
siendo el efecto más pronunciado en mujeres que en hombres. La 
influencia de la obesidad, un factor de riesgo clave en enferme-
dades cardiovasculares, es más significativo para valina y 
metionina, ambas incrementadas en individuos obesos. 
10) Se ha desarrollado un método basado en GC–MS para el análisis 
de compuestos implicados en el ciclo de los ácidos tricarboxílicos 
(TCAs), que se ha aplicado a muestras de suero de pacientes con 
lesiones coronarias y de individuos control. Se ha estudiado la 
influencia en esta enfermedad de tres factores de riesgo tales 
como hipercolesterolemia, obesidad y hábito de fumar. La con-
clusión del estudio es que estos factores deben tenerse en cuenta 
cuando se propongan metabolitos del ciclo de los TCA como 
potenciales biomarcadores. El análisis estadístico reveló que los 
ácidos málico y α-cetoglutárico conducen a modelos de pre-
dicción independientes, con buena especificidad y aceptable 
sensibilidad para la discriminación entre pacientes con y sin en-
fermedades coronarias.  
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11) Se ha demostrado la utilidad de una plataforma simple, como la 
que resulta del acoplamiento SPE–MS/MS, para analizar pépti-
dos mediante su aplicación a la determinación de catelicidina. El 
péptido se detectó mediante tres transiciones, confirmadas por 
fragmentación in silico. La aplicación del método a pacientes de 
una unidad de cuidados intensivos y a individuos sanos reveló 
que no existían diferencias significativas entre ambos grupos, 
aunque los niveles en los individuos control fueron ligeramente 
más bajos. 
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 The research conducted in this Doctoral work was aimed at developing 
applications based on targeted and untargeted metabolomics analysis in the 
clinical field, with special emphasis on the usefulness of mass spectrometry for 
both strategies. Also, the research has introduced some methodological inno-
vations. 
The most salient conclusions drawn from this work can be summarized 
as follows: 
- Innovations alleviating the weaknesses of untargeted analysis: 
1) Unconventional biofluids such as sweat can be effective new 
sources of samples for use in clinical research. The greatest 
advantages of sweat samples are their simple composition and 
the fact that they can be obtained non-invasively. Also, this 
biofluid is potentially useful for identification of metabolites 
from a wide variety of families by LC–QTOF analysis. 
2) The only sample preparation step required to analyze sweat by 
LC–QTOF is dilution. This facilitates obtaining a representative 
snapshot of its metabolome. However, alternative sample pre-
paration protocols can be used to address specific groups of 
metabolites. 
3) The joint use of automated SPE and LC–QTOF with combina-
tions of different SPE sorbents improves metabolite coverage. A 
serially arranged combination of two SPE sorbents possessing 
complementary retention mechanisms seems to be a competitive 
choice for analyzing complex metabolomes with a single plat-
form.  
4) The use of gas phase fractionation (GPF) in metabolomic studies 
has proved an effective strategy for increasing the number of 
   
494 
Mass spectrometry for the identification and  
quantitation of metabolomic biomarkers in clinical analysis 
 
metabolites that can be identified in a given sample. In fact, the 
conventional “auto MS/MS” mode of data acquisition provided 
MS/MS information for only 48–57% of the potential entities 
present, whereas using GPF-based methodology over four dif-
ferent ranges to select precursor ions increased the proportion to 
at least 80% . 
- Use of untargeted analytical platforms in nutrimetabolomics studies 
and research on specific (atherosclerosis and lung cancer) diseases: 
5) Metabolomic profiling with an LC–QTOF platform of serum from 
individuals under different diets allowed metabolic differences 
between diets to be established. Using a sample preparation step 
to split serum components into a polar and a non-polar fraction 
proved useful towards examining polar and non-polar com-
pounds separately. The main metabolic effects of intervention 
diets were found to be associated to lipid metabolism.  
6) A comparison of serum profiles from atherosclerotic patients 
suffering from different cardiovascular diseases revealed the 
presence of 13 compounds including bilirubin, cholic acid and 
deoxycholic acid, the levels of which differed between patients 
with stable angina, acute myocardial infarction (AMI) and non-
ST elevation myocardial infarction (NSTEMI). Bilirubin was 
among the most useful metabolites to discriminate between 
stable angina and AMI/NSTEMI events. This strategy is also 
useful for biomarker identification (e.g., a marker panel allowed 
myocardial infarction to be predicted with 85.1% specificity and 
80.8% sensitivity). 
7) Two marker panels for predicting lung cancer from sweat 
samples were established that overcome the main shortcoming of 
lung cancer diagnosis: the difficulty of detection at an early stage. 
The two panels involve maltotriose and nonanedioic acid in 
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combination with γ-GluLeu or MG(22:2). Both were found to 
substantially improve the discrimination capacity of independent 
metabolites between lung cancer patients and controls. One 
panel features 100% specificity and 63.6% sensitivity, and hence 
a 0% false negative rate; the other has specificity and sensitivity 
above 81%. 
- Development and use of different targeted analytical platforms: 
8) The proposed method for phospholipids enabled the identifica-
tion of 81 phospholipids in serum. Using this platform to analyze 
samples from atherosclerotic patients allowed the identification 
of a group of four phospholipids accurately discriminating 
between patients with stable angina and others diagnosed with 
NSTEMI, namely: lysoPC(20:5), PC(18:1/18:2), PC(18:0/20:4) 
and SM(d18:2/14:0). A panel including these four metabolites 
exhibited a disease prediction capability in the training set of 
70.7 and 66.0% for stable angina and NSTEMI patients, 
respectively. Also, the area under the ROC curve (AUC) for the 
model was 0.715 for the training set and 0.747 for the validation 
set, and the resulting sensitivity and specificity 66.0 and 70.0%, 
respectively. 
9) A method for determining amino acids in serum by SPE–LC–
MS/MS was successfully developed and validated on athero-
sclerotic patients diagnosed with stable angina or acute myo-
cardial infarction. Lysine and threonine levels were found to be 
affected by ischemic events (particularly in females). Obesity, 
which is a major risk factor for cardiovascular disease, was 
especially influential on valine and methionine, which were 
found at increased levels in obese individuals. 
10) A GC–MS method for determining the compounds involved in 
the tricarboxylics acid (TCA) cycle in serum was developed and 
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applied to patients with coronary lesions and control individuals. 
The role of the risk factors hypercholesterolemia, obesity and 
smoking habit in the disease was studied, and the influence of the 
three factors found to be essential with a view to identifying 
potential biomarkers among metabolites of the TCA cycle. Statis-
tical analysis revealed that malic acid and α-ketoglutaric acid 
lead to independent prediction models with high specificity and 
acceptable sensitivity for discriminating between patients with 
and without coronary lesions.  
11) The usefulness of SPE–MS/MS for analysing peptides in bio-
fluids was demonstrated by developing an automated platform 
for assessment and quantitative analysis of cathelicidin. The ana-
lyte was detected by using three different transitions that were 
confirmed by in silico peptide fragmentation. Application of this 
method to intensive care unit patients and healthy individuals 
revealed the absence of significant differences between the two 
groups and also that the control individuals had slightly lower 
concentration levels of the target analytes. 
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Cholesterol oxidation products in milk: 
Processing formation and determination 
 
M. Calderón-Santiago, A. Peralbo-Molina, F. Priego-Capote,  
M. D. Luque de Castro* 
Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, 
and Institute of Biomedical Research Maimónides (IMIBIC), Reina Sofía Hospital, 
University of Córdoba, E-14071, Córdoba, Spain 
Abstract 
Cholesterol oxidation products (oxysterols) are commonly present in foods 
derived from animals. The main limitations for analysis of these products are 
associated with the long sample preparation protocols that require 
saponiﬁcation. In this research, a protocol was optimized for determination of 
oxysterols in milks under the process to obtain given commercial milk products. 
UHT milks, powder milks, condensed milk, and evaporated milk were selected 
for this study. The levels of the different oxysterols are discussed attending to the 
type of milk. UHT and skimmed powder milks provide the highest concentration 
of oxysterols. Particularly, high concentrations were found for 7β-
hydroxycholesterol (up to 205.6 ng/mL), 5-cholesten-3β-ol-7-one (up to 21.8 
ng/mL), cholesterol 5α,6α-epoxide (up to 14.9 ng/mL), and 25-
hydroxycholesterol (up to 5.1 ng/mL). An increase in cholesten-3β-ol-7-one and 
cholesterol 5α,6α-epoxide, resulting from the skimming process, was also 
observed. Additionally, two different heating modes, microwave-assisted and 
conventional heating, have been mimicked to study their inﬂuence on the 
 
European Journal of Lipid Science 
and Technology 
114 (2012) 687–694 
 
                                                                                                                         
503 
Annex I  
formation of oxysterols in milk. Both heating protocols contributed to the 
formation of oxysterols but short periods of microwave irradiation (60 s) can lead 
to levels of oxysterols similar to conventional heating for 5 min. 
Practical applications: The results of the research described in this article, 
supported by previous studies in the ﬁeld, allow to advice about the strong 
inﬂuence of microwave heating of milk on the formation of toxic oxides from the 
lipid fraction. Although conventional heating can be more tedious and time 
consuming, it seems to be healthier. 
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Global metabolomics profiling of human 
serum from obese individuals by liquid 
chromatography–time of flight/mass 
spectrometry to evaluate the intake of 
breakfasts prepared with heated  
edible oils 
 
C. Ferreiro-Vera, F. Priego-Capote, M. Calderón-Santiago, M. D. Luque de 
Castro* 
Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, 
and Institute of Biomedical Research Maimónides (IMIBIC), Reina Sofía Hospital, 
University of Córdoba, E-14071, Córdoba, Spain 
Abstract 
The metabolic proﬁle of human serum after intake of breakfasts prepared with 
different heated vegetable oils has been studied. Four oils (olive and sunﬂower 
oils, pure and enriched with natural and artiﬁcial oxidation inhibitors) were 
subjected to a simulated heated process prior to breakfast preparation. A 
metabolomics global proﬁling approach performed on post-basal serum samples 
revealed statistical differences among individuals based on breakfast intake, and 
identiﬁed compounds responsible for such differences. Serum samples obtained 
in basal state (control samples) and 2 and 4 h after programmed intakes were 
analyzed by LC–TOF/MS. The resulting ﬁngerprints were compared and 
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differences between basal and post-basal states evaluated, observing that the 
intake of different breakfasts altered the metabolic signature of serum. Analysis 
models based on PLS algorithms were developed to discriminate individuals in 
post-basal state for each intervention breakfast. Then, Volcano tests enabled to 
detect signiﬁcant molecular entities explaining the variability associated to each 
breakfast. It is worth emphasizing the importance of fatty acids, their derivatives 
and phospholipids for tentative identiﬁcation. 
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High-resolution mass spectrometry to 
evaluate the influence of cross-breeding 
segregating populations on the phenolic 
profile of virgin olive oils 
 
V. Sánchez de Medina1,2,3, M. Calderón-Santiago1,2,3, M. El Riachy4, F. Priego-
Capote*1,2,3, M. D. Luque de Castro*1,2,3 
1Department of Analytical Chemistry, Annex Marie Curie Building, Campus of 
Rabanales, University of Córdoba, E-14071, Córdoba, Spain 
2University of Córdoba Agroalimentary Excellence Campus, ceiA3, Campus of 
Rabanales, 14071, Córdoba, Spain 
3Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofía University 
Hospital, University of Córdoba 
4Lebanese Agricultural Research Institute, Tal Amara, Lebanon 
Abstract 
BACKGROUND: The growing demand of high quality virgin olive oils (VOOs) has 
increased the interest in olive breeding programs. Cross-breeding is considered, 
within these programs, the best strategy to generate new cultivars as an attempt 
to improve the present cultivars. In this research, the phenolic profile of VOOs 
from target crosses (Arbequina×Arbosana, Picual×Koroneiki and 
Sikitita×Arbosana) and their corresponding genitors (Arbequina, Arbosana, 
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Koroneiki, Picual and Sikitita) has been evaluated using a targeted metabolomics 
approach.  
RESULTS: The phenolic profiles were obtained by LC–QqTOF targeted analysis 
of thirty-seven phenols or compounds involved in the main pathways for their 
biosynthesis. Statistical multivariate analysis by Principal Component Analysis 
(PCA) was applied to study the influence of the genotype on phenols composition. 
Phenolic compounds with the highest contribution to explain the observed 
variability associated to genotype were identified through fold change algorithms 
(cut-off>2.0) and t-test analysis.   
CONCLUSION: A total of nine phenols (viz. quercetin, ligstroside aglycon (p-
HPEA-EA), demethyloleuropein aglycon, oleuropein aglycon (3,4-DHPEA-EA), 
hydroxypinoresinol, hydroxytyrosol, phenolic acids such as p-coumaric acid, 
ferulic acid and protocatechuic acid) contributed to explain the observed 
variability with 99% confidence (p<0.01). 
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Quantitative determination and 
confirmatory analysis of N-acetylneu-
raminic and N-glycolylneuraminic acids in 
serum and urine by solid-phase extraction 
on-line coupled to liquid chromatography–
tandem mass spectrometry 
 
F. Priego-Capote*, M. Orozco-Solano, M. Calderón-Santiago, M. D. Luque de 
Castro 
Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, 
and Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofía 
University Hospital, University of Córdoba, E-14071, Córdoba, Spain 
Abstract 
N-acetylneuraminic acid (Neu5Ac) and N-acetylglycolylneuraminic acid 
(Neu5Gc), two acylated derivatives of 9-C carboxylated monosaccharides, are 
involved in a number of biological processes as modulators of glycoconjugates. A 
partially automated method is here presented for determination of these sialic 
acids in the two most important biofluids for clinical analysis: serum and urine. 
For this purpose, a solid-phase extraction (SPE) workstation was on-line 
connected to an LC–MS/MS triple quadrupole mass detector. Hydrolysis to 
release sialic acids bound to glycoconjugates and derivatization were the two 
steps implemented as sample preparation prior to SPE–LC–MS/MS analysis. 
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Following thorough optimization of the SPE and LC–MS/MS conditions, the 
analytical method was validated using the standard addition approach to assess 
the presence of matrix effects. The proposed method affords detection limits of 
0.03 ng/mL and 0.04 ng/mL for Neu5Ac and Neu5Gc, respectively. The 
precision (expressed as relative standard deviation) was 1.7 and 4.6% for within-
day variability, and 4.8 and 7.2% for between-days variability. Accuracy, 
estimated using spiked (between 1 and 50 ng/mL) and non-spiked samples of 
both biofluids, ranged from 95.2 to 99.6%. The method was applied to human 
serum and urine of healthy volunteers, thus showing its suitability for application 
in both clinical and research laboratories. 
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Influence of the genotype on the fatty acids 
composition of virgin olive oils along the 
ripening process 
 
V. Sánchez de Medina1,2,3, M. Calderón-Santiago1,2,3, M. El Riachy4, F. Priego-
Capote*1,2,3, M. D. Luque de Castro*1,2,3 
1Department of Analytical Chemistry, Annex Marie Curie Building, Campus of 
Rabanales, University of Córdoba, E-14071, Córdoba, Spain 
2University of Córdoba Agroalimentary Excellence Campus, ceiA3, Campus of 
Rabanales, 14071, Córdoba, Spain 
3Maimónides Institute for Research in Biomedicine of Córdoba, Reina Sofía University 
Hospital, University of Córdoba 
4Lebanese Agricultural Research Institute, Tal Amara, Lebanon 
Abstract 
The composition of fatty acids (FAs) is one of the most critical aspects that affects 
the quality of virgin olive oil (VOO), which is related to the balance of 
concentrations of saturated, monounsaturated and polyunsaturated FAs. The aim 
of this research was to study the influence of the ripening stage of olive fruits and 
genotype on the composition of esterified FAs (EFAs) and non esterified FAs 
(NEFAs) present in VOOs from advanced selections obtained by crosses between 
Arbequina, Picual and Frantoio cultivars. For this purpose, a method based on 
gas chromatography with flame ionization detection (GC–FID) was used to 
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estimate the percent of each type FAs. Statistical unsupervised analysis was 
carried out by Principal Component Analysis (PCA) to find clustering of samples 
attending to the ripening stages. Discrimination was observed for VOO samples 
associated to early and advanced ripening stages according to the concentration 
of FAs. Statistical analysis by ANOVA test allowed evaluating the contribution of 
ripening and genotype to explain the variability in the concentration of EFAs and 
NEFAs with p-value<0.05. Linoleic acid (C18:2) was the FA most influenced by 
the genotype; practically along the complete ripening process (from yellow or 
yellowish–green to black color). Furthermore, the highest genetic variability in 
FAs composition was observed in the ripening stage in which the fruit color is 
reddish or light violet, since five EFAs (C16:0, C16:1, C18:1, C18:2 and C18:3) 
were significant to explain this effect. Therefore, the interval that lasts this 
ripening stage is the most appropriate to compare genotypes in olive breeding 
programs according to FAs composition. 
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The dual trend in histatins research 
 
M. Calderón-Santiago, M. D. Luque de Castro* 
Department of Analytical Chemistry, Annex Marie Curie Building, Campus of Rabanales, 
University of Córdoba, E-14071, Córdoba, Spain 
 
Abstract 
We review histatins (Hsts) in order to encourage development of analytical 
platforms to clarify obscure points in knowledge of this family of antimicrobial 
and antifungal peptides. To explain the present interest, we outline the number 
and the nature of Hsts and their known functions (i.e. antimicrobial action, 
wound closure, biomarkers of stress, satiety, body mass and incipient 
Alzheimer_s disease, and diagnosis and treatment of addiction, including to 
cocaine). The two aspects of research on Hsts (i.e. their natural effects on living 
organisms and their potential use for medical applications, including as 
biomarkers) make it necessary to develop new analytical methods. The variety of 
matrices in which Hsts exist (e.g., saliva and tooth-surface-protein pellicle) make 
it essential to develop new sample-preparation steps and to improve 
identiﬁcation and quantitation steps as analytical instrumentation evolves. 
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In this context, metabolomics studies could be of great interest, as contributions 
of analytical chemists could be one of the keys to achieving the role that they 
deserve within ‘‘-omics’’ research. 
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1. Päivi Pöhö, Maarit Kivilompolo, Mónica Calderón Santiago, Sirkku 
Jäntti, Susanne K. Wiedmer and Tuulia Hyötyläinen, Chapter 9: 
Applications, in “Chromatographic methods in metabolomics”, edited by 
Tuulia Hyötyläinen and Susane Wiedner, The Royal Society of Chemistry 
(RSC) 2013. 
 
 
2. Mónica Calderón Santiago, María Dolores Luque de Castro, Chapter 25: 
Use of Lactobacillus spp to degrade pesticides in milk, in “Processing and 
impact on active components in food”, edited by Victor R. Preedy, 
Elsevier 2014. 
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Processing and Impact on Active Components in Food 
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No Patente: P201331228 
 
Método de clasificación, diagnóstico y 
seguimiento de individuos con riesgo de 
padecer cáncer de pulmón mediante el 
análisis de sudor 
 
B. Jurado-Gámez, A. Salvatierra-Velázquez, M. Calderón-
Santiago, F. Priego-Capote, M.D. Luque de Castro 
 
 
Los autores de la presente invención han analizado la concentración de los 
distintos metabolitos del sudor en individuos que no padecen cáncer de pulmón y 
en individuos que padecen cáncer de pulmón. Han encontrado una serie de 
marcadores para el diagnóstico de los individuos con cáncer de pulmón, 
diferenciando los sujetos con cáncer de pulmón de aquéllos que no lo padecen. 
Esto, entre otras cosas, permitiría hacer un cribado inicial para diferenciar 
aquellos individuos que serían susceptibles de ser sometidos a otras pruebas 
diagnósticas, más agresivas o caras, y/o confirmar o apoyar el diagnóstico 
mediante otras pruebas. Así pues, la presente invención proporciona un método 
de obtención de datos útiles para la clasificación, diagnóstico y seguimiento de 
individuos con cáncer de pulmón. 
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1. Human sweat metabolomics for lung cancer prediction 
M. Calderón-Santiago, F. Priego-Capote, B. Jurado-Gámez, M.D. Luque de 
Castro 
V JORNADAS DE JÓVENES INVESTIGADORES DEL IMIBIC 
Córdoba, 2014 
Tipo de evento: Poster en Congreso  Ámbito: Nacional 
2. Study of Coronary Lesions by Analysis of Essential Amino Acids 
and Citric Acid Cycle in Human Serum 
M. Calderón-Santiago, F. Priego-Capote, J.G. Galache-Osuna, M.D. Luque de 
Castro 
XVIII REUNIÓN DE LA SOCIEDAD ESPAÑOLA DE QUÍMICA ANALÍTICA 
Úbeda, Jaén, 2013 
Tipo de evento: Poster en Congreso  Ámbito: Nacional 
3. Determination of Essential Amino Acids and Tricarboxilic Acid 
Cycle Metabolites in Human Serum to Study Coronary Lesions 
M. Calderón-Santiago, F. Priego-Capote, J.G. Galache-Osuna, M.D. Luque de 
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5. Determination of oxysterols in dairy products and study of their 
formation under heating conditions 
M. Calderón-Santiago, A. Peralbo-Molina, F. Priego-Capote, M.D. Luque de 
Castro 
7th Lipidomics Congress (Lipids in all states)  
Anglet-Biarritz (Francia), 2010 
Tipo de evento: Poster en Congreso  Ámbito: Internacional 
6. Determinación de oxisteroles en derivados lácteos mediante 
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estudio de la influencia de la energía microondas en su formación 
M. Calderón-Santiago, A. Peralbo-Molina, F. Priego-Capote, M.D. Luque de 
Castro 
XII Reunión del Grupo Regional Andaluz de la Sociedad Española de Química 
Analítica  
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7. Multiple Reaction Monitoring Verification and Quantitative 
Analysis of Cathelicidin Biomarker in Human Serum After Automated 
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F. Priego-Capote, M. Calderón-Santiago, J.M. Mata-Granados, J.M. Quesada-
Gómez, M.D. Luque de Castro 
58th Annual meeting of American Society of Mass Spectrometry  
SALT LAKE CITY, UTAH, USA, 2010 
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8. Automatic Determination of Cathelicidin in Human Serum by On-
Line Solid-Phase Extraction Liquid Chromatography-Triple 
Quadrupole Mass-Spectrometry with Multiple Reaction Monitoring 
M. Calderón-Santiago, J.M. Mata-Granados, J.M. Quesada Gómez, M.D. Luque 
de Castro 
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Abbreviations 
ACE, automated cartridge exchange 
ACN, acetonitrile 
ACS, acute coronary syndrome 
AMI, acute myocardial infarction 
ANOVA, analysis of variance 
AQUA, absolute quantitation 
AUC, area under the curve 
BCAAs, branched chain amino acids 
BMI, body mass index 
BPC, base peak chromatogram 
BSTFA, bis-(trimethylsilyl)-fluoroacetamide 
BTP, black tea polyphenols 
CAD, coronary arthery disease 
CD, Crohn’s disease 
CE, capillary electrophoresis 
CI, confidence interval 
CoA, coenzyme A 
COX-2, cyclooxygenase 2 
CPK, creatinin phosphokinase 
CVD, cardiovascular disease 
CYP, cytochrome P450 
DG, diglyceride 
EBC, exhaled breath condensate 
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ECG, electrocardiogram 
EI, electron impact ionization 
EIC, extracted ion chromatogram 
ELISA, enzyme-linked immunosorbent assay 
EPA, eicosapentaenoic acid 
ESI, electrospray ionization 
FID, flame ionization detector 
FT-IR, Fourier transformation infrared 
FWHM, full width at half maximum 
GC, gas chromatography 
GPF, gas phase fractionation 
HDL, high density lipoprotein 
HETE, hydroxyeicosatetraenoic acid 
H-FABP, human fatty acid binding protein 
HILIC, hydrophilic interaction liquid chromatography 
HLB, hydrophilic–lipophilic balance 
HMDB, Human Metabolome Database 
HMUFA, high fat content diet with monounsaturated fatty acids 
HO, hemeoxygenase 
HODE, hydroxyoctadecadienoic acid 
HP-921, hexakis (1H, 1H, 3H-tetrafluoropropoxy) phosphazine 
HPD, high pressure dispenser 
HpODE, Hydroperoxyoctadecadienoic acid 
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Abbreviations 
HSFA, high fat content diet with saturated fatty acids 
Ile, isoleucine 
IS, internal standard 
IT, ion trap 
KEGG, Kyoto Encyclopedia of Genes and Genomes 
LC, liquid chromatography 
LDL, low density lipoprotein 
Leu, leucine 
LFHCC, low fat content diet supplemented with oleic acid 
LFHCCn-3, low fat content diet supplemented with omega 3 
LIPGENE, Diet, genomics and the metabolic syndrome: An integrated nutrition,       
agro-food, social and economic analysis 
LLE, liquid-liquid extraction 
LOD, limit of detection 
LOQ, limit of quantitation 
LPC, lysophosphatidylcholine 
LPE, lysophosphatidylethanolamine 
Lys, lysine 
MALDI, matrix-assisted laser desorption ionization 
MANOVA, multivariate analysis of variance 
Met, methionine 
METLIN, Metabolites and Tandem MS Database 
MetS, metabolic syndrome 
MF, molecular feature 
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MG, monoacylglycerol 
MIDAS, autosampler 
MM, mix mode 
MPP, mass profiler professional 
MS, mass spectrometry 
MUFA, monounsaturated fatty acid 
NMR, nuclear magnetic resonance 
NSCLC, non-small cell lung cancer 
NSTEACS, non-ST elevation acute coronary syndrome 
NSTEMI, non-ST elevation myocardial infarction 
NU-AGE, new dietary strategies addressing the specific needs of elderly population 
for a healthy aging in Europe 
OGTT, oral glucose tolerance test 
PA, glycerophosphatidic acid 
pAUC, partial area under the curve 
PC, glycerophosphatidylcholine 
PCA, principal component analysis 
PE, glycerophosphatidylethanolamine 
PG, glycerophosphatidylglyceride 
PGE3, prostaglandin E3 
Phe, phenylalanine 
PLS, partial least squares 
PLS-DA, partial least squares discriminant analysis 
PLTP, plasma phospholipid transfer protein 
 557 
Abbreviations 
PM, personalized medicine 
PS, glycerophosphatidylserine 
PUFA, polyunsaturated fatty acid 
QC, quality control 
QqQ, triple quadrupole 
QTOF, quadrupole–time of flight 
ROC, receiver-operating characteristic 
ROS, reactive oxygen species 
RSD, relative standard deviation 
RT, retention time 
SA, stable angina 
SD, standard deviation 
SFA, saturated fatty acid 
SH, strong hydrophobic 
SM, sphingomyelin 
SPE, solid-phase extraction 
SPME, solid-phase microextraction 
SIM, selected ion monitoring 
SRM, selected reaction monitoring 
T2D, type 2 diabetes 
T2DM, type 2 diabetes mellitus 
TCA, tricarboxylic acid 
TG, triglyceride 
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Thr, threonine 
TIC, total ion current 
TLC, thin-layer chromatography 
TMCS, trimethylchlorosilane 
Trp, tryptophan 
UC, ulcerative colitis 
UHD, ultrahigh definition 
UPLC, ultra performance liquid chromatography 
Val, valine 
VLDL, very low density lipoprotein 
VOC, volatile organic compounds 
 

